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Abstract 
The findings of this project have added to the pool of information reported in the 
literature regarding the application of the nasal route for the delivery of insulin and other 
peptide drugs. The preliminary studies reported in this project were apparently the first 
studies performed to investigate the potential use of chitosan in nasal delivery systems. 
Nasal delivery systems were investigated in rat and sheep models. The efficacy of 
chitosan as a nasal absorption enhancer for insulin was compared to that of several other 
compounds which had been reported in the literature to enhance nasasl drug absorption. 
Erythrocyte haemolysis studies were also performed to evaluate the membrane damaging 
effects of the various compounds tested. 
The grade of chitosan predominantly used was a medium viscosity glutamate salt 
(MVCSN) which was 82% deacetylated and had a molecular weight of about 162,000. 
Other grades of chitosan of similar degree of deacetylation were also investigated for 
comparison with MVCSN (low viscosity grades of chitosan glutamate (LVCSN) and 
lactate (CSN lactate), medium viscosity chitosan hydrochloride (CSN HC1) and high 
viscosity chitosan base (HVCSN)). 
The efficacy of chitosan in enhancing the nasal absorption of both insulin and salmon 
calcitonin, used an an alternative peptide, was demonstrated in rat and sheep models. 
Nasal insulin delivery systems were extensively investigated in rat and sheep models. In 
the rat model, insulin / LVCSN formulations at pH 
-4 were more effective than 
formulations at pH 
-7 in enhancing intranasal insulin absorption which was assessed 
indirectly from the degree of hypoglycaemia following dose administration. The reduced 
absorption in the latter formulation which was in the form of a suspension was attributed 
to complex formation between insulin and LVCSN. In the rat model, the absorption 
enhancing efficacy of MVCSN was second only to that of LPC. This was encouraging 
in view of the severe membrane damaging effects that LPC solutions have been shown to 
cause. In contrast, chitosan solutions have been shown to be relatively non-toxic to 
biomembranes. In the sheep model, a formulation incorporating MVCSN was much 
more effective than a formulation containing LPC in promoting nasal insulin absorption. 
These differences were attributed to the animal models used to investigate nasal 
absorption. 
The degree of nasal absorption enhancement was improved by increasing the solution 
concentration of MVCSN until and optimal concentration was attained (approximately 
0.5% and 0.35% in rat and sheep models, respectively). Further evaluation of nasal 
insulin / chitosan formulations in sheep, suggested that the formulation concentration of 
chitosan was important for its absorption enhancing efficacy and at optimal chitosan 
concentration nasal insulin absorption was limited by the dose concentration of insulin. 
In both rat and sheep models, the nasal administration of hypotonic or isotonic 
formulations of insulin with chitosan did not influence the degree of nasal absorption 
enhancement attained. However, in rats, a hypertonic formulation was shown to further 
improve nasal insulin absorption which was attributed to the combined effects of the 
chitosan and the increased tonicity of the formulation on the nasal membrane. 
The grade of chitosan used in the nasal absorption studies appeared to influence the 
degree of absorption enhancement obtained. In the rat model there was no difference in 
the absorption enhancing efficacy of CSN lactate and MVCSN although the performace 
of HVCSN was marginally reduced. In contrast, in the sheep model, MVCSN was 
more effective than LVCSN and CSN lacate in enhancing nasal insulin absorption 
although there was no difference in the performance of MVCSN and CSN HCL. 
In studies in the rat, MVCSN was shown to have a transient effect on the permeability of 
the nasal mucosa to insulin which lasted about 30 minutes. This supports the claims that 
chitosan is non-damaging to the nasal mucosa. Erythrocyte haemolysis studies showed 
that MVCSN was non-damaging to rat erythrocyte membranes at concentrations which 
were higher than the concentrations used in nasal absorption studies. This was 
encouraging since the other compounds investigated for comparison with chitosan in this 
project were shown to be potent haemolytic agents at concentrations which were much 
lower than the concentrations which were effective for nasal absorption enhancement. 
MVCSN was less damaging to erythrocyte membranes than the other grades of chitosan 
tested. 
This project demonstrated that chitosan enhanced the nasal absorption of insulin in rat 
and sheep models. In the sheep model the bioavailability of nasal insulin, relative to the 
subcutaneous route, was generally less than 5%. However, the hypoglycaemia which 
followed nasal insulin / chitosan dose administration was encouraging and a similar 
degree of efficacy in humans could be feasible for the therapeutic application of nasal 
insulin. 
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CHAPTER 1 
INTRODUCTION 
1.1 Background 
The dramatic increase in the use of peptides and proteins as therapeutic agents is not only 
due to biotechnological advancement but also to the greater understanding of their role in 
physiology and pathology (Banga and Chien, 1988). Many types of peptides and 
proteins find therapeutic application and several examples are given below: 
1) Hormones such as insulin for the treatment of diabetes mellitus, calcitonin for the 
treatment of osteoporosis and erythropoietin to stimulate erythropoiesis in patients with 
renal disease. 
2) Enzymes, including those of thrombolytic or fibrinolytic activity, such as tissue 
plasminogen activator and urokinase. 
3) Coagulation factors, such as factor VIII used in the treatment of haemophilia A. 
4) Lymphokines and cytokines such as interferons, interleukins, tumour necrosis factor 
and granulocyte colony stimulating factors are used as immunomodulators in cancer 
therapy and autoimmune diseases. 
5) Immunotherapeutic agents for example immunoglobulins and antitoxins used to infer 
passive immunisation in the treatment of cancer and vaccines such as Hepatitis B and 
influenza surface antigen preparations used for active immunisation. 
(Gesellchen and Santerre, 1991, Kompella and Lee, 1991, Davis, 1992, Smith et al., 
1993). 
Peptides and proteins may be produced by chemical synthesis but perhaps the greatest 
advancement has been in genetic engineering or recombinant DNA technology. 
Recombinant DNA technology not only allows the production of natural peptides and 
proteins to be optimised and produced on a large scale but also via gene manipulation or 
chemical modification methods there is the potential to develop and produce drugs having 
improved potency and bioavailability with reduced immunogenicity (Gesellchen and 
Santerre, 1991, Smith et al., 1993). 
Although the oral route is generally preferred for the administration of drugs, particularly 
those required in chronic therapies (Lee and Yamamoto, 1990, Smith et al., 1992, Davis, 
1992), it is largely non effective for the systemic delivery of most natural peptide and 
protein drugs (Lee, 1991). The oral bioavailabilityof peptide and proteins is generally 
low due to a number of physical and physiological factors which limit their absorption 
from the gastrointestinal tract. Orally administered drugs must be able to withstand harsh 
chemical and enzymatic degradation in the gastrointestinal tract. Thus, the enzymatic 
barrier is one of the main barriers limiting the gastrointestinal absorption of peptides and 
proteins. Peptide and protein drugs tend to be large molecular weight hydrophilic 
compounds having a low permeability across the gastrointestinal mucosa and those that 
are absorbed must avoid the `first pass' metabolism and clearance predominantly by the 
liver but also by the gut mucosa (Humphrey, 1986, Lee et al., 1991). 
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Due to the unsuitability of the oral route, most peptide and protein therapeutic agents must 
be administered parenterally i. e. by the injection of the dosage form into the body. The 
main routes for parenteral administration are by intravenous (i. v. ), intramuscular (i. m. ) 
or subcutaneous (s. c. ) injection (Banerjee et al., 1991). To maintain therapeutic efficacy, 
peptides and proteins must generally be administered frequently because of their short 
biological half lives. For acute clinical applications, requiring limited injections, 
parenteral administration is acceptable. However, for chronic therapy alternative non- 
parenteral routes which are easily accessible as well as controlled delivery systems would 
be preferable (Kimura, 1984, Banga and Chien, 1988, Eppstein and Longenecker, 1988, 
Illum, 1992). Furthermore, chronic injective therapy requires some patient skill for 
effective self medication and because of the pain of injection, inconvenience and possible 
infection or immunogenicity associated with the use of some drugs, patient compliance 
tends to be low with treatments interrupted or irregular (Pontiroli et al., 1989). There are 
a number of non-parenteral routes other than the oral route which can be exploited for the 
systemic administration of peptide and protein drugs such as transdermal, ocular, buccal, 
rectal, vaginal, pulmonary and nasal routes (Siddiqui and Chien, 1987, Banga and 
Chien, 1988). Of these, the intranasal route is perhaps the most viable and favourable for 
chronic systemic medication using peptides and polypeptides (Chien and Chang, 1985, 
Davis, 1986, Longenecker, 1986). Intranasal delivery systems for a number of 
compounds have been investigated and some of these compounds will be discussed later. 
The emphasis of the project is the development of a nasal delivery system for insulin 
which would be a major break-through in the treatment of diabetes mellitus. 
1.2 Insulin and Insulin therapy 
Insulin is the main drug used for the treatment of diabetes mellitus. Current insulin 
therapy requires that the drug is parenterally injected and hence attention has been focused 
on alternative routes for the administration of insulin (Gizurarson and Bechgaard, 199 1). 
A brief review of insulin and insulin therapy will be given and reference has been made to 
publications by: Hardy (1981), Karam et al. (1986), Kelleher (1988), Pickup (1988 and 
1991), Espinal (1989), Kahn and Shechter (1990), Gizurarson and Bechgaard (1991), 
Kennedy (1991), Owens et al. (1991) and Ilium and Davis (1992). Additional 
information regarding insulin therapy is given in Chapter 7. 
1.2.1 Chemistry of insulin 
Human insulin is a small protein molecule of molecular weight about 5810. It consists of 
two peptide chains, an A chain containing 21 amino acid residues and aB chain 
containing 30 amino acid residues, which are covalently linked via disulphide bridges. A 
disulphide linkage is also present in the A chain. The primary structure of human insulin 
is given in Figure 1.1. There is a species difference in the exact A and B chain sequence 
of amino acids. Human and porcine insulin differ by only one amino acid residue. In 
porcine insulin (molecular weight about 5780) alanine (ALA) replaces threonine (THR) at 
position 30 of the B chain. Human and bovine insulin differ by three amino acids. In 
bovine insulin (molecular weight about 5730) ALA and valine (VAL) replace THR and 
isoleucine (ILE), respectively, at positions 8 and 10 of the A chain and ALA replaces 
2 
THR at position 30 of the B chain. Insulin exists as a compact three dimensional 
structure in which the aliphatic side chains of the A and B chains create a non polar core 
and hydrophilic residues are exposed on the surface of the molecule in addition to a 
number of hydrophobic residues. The basic structure of insulin must be preserved in 
order that it retains its full biological activity and modifications to the basic residues will 
lead to full or partial loss of biological activity. In solution, insulin exists as a monomer, 
dimer or hexamer depending on its concentration, pH and the ionic strength of the 
solution. 
Figure 1.1 The primary structure of human insulin 
S-3: Disulphide bridge 
1.2.2 The biosynthesis and secretion of insulin 
The biosynthesis of insulin begins when the insulin gene codes for the synthesis of the 
rapid turnover single chain peptide preproinsulin in the ribosomes of the rough 
endoplasmic reticulum. Human preproinsulin, of molecular weight about 11,500 
contains 110 amino acids. Pancreatic microsomal peptidases rapidly cleave 
preproinsulin, in the rough endoplasmic reticulum, to the precursor peptide proinsulin. 
Proinsulin, of molecular weight about 9000, is a single chain peptide containing 86 
amino acids. It consists of the insulin A and B chains linked by a 35 amino acid 
connecting or C-peptide. The proinsulin molecules are transported to and packed within 
secretory granules in the golgi apparatus. In these granules proinsulin is enzymatically 
cleaved into insulin and the C-peptide. Proinsulin has a low physiological (insulin-like) 
activity whilst the C-peptide has no physiological activity. Insulin and the C-peptide are 
secreted together in equimolar amounts and small amounts of proinsulin and cleaved 
intermediate peptides will also be present. 
Insulin is secreted in the endocrine pancreas by the B cells of the islets of Langerhans. 
The cells of the islets of Langerhans, are scattered between the acinar cells of the exocrine 
, 
pancreas, from which they are separated by a thin membrane. The secretions of the 
pancreatic acinar cells play a major role in digestion. The islets of Langerhans are highly 
vascularised compared to the acini and are richly innervated by autonomic nerves. Four 
main cell types can be identified in the islets of Langerhans: A (a) cells comprise about 
20% of the islet cell mass and mainly secrete glucagon and proglucagon; B (ß) cells, 
which secrete insulin, C-peptide and proinsulin, make up about 75% of the islet cell 
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mass; D (S) cells comprise 3-5% of the islet cell mass and secrete somatostatin; and F cells 
secrete pancreatic polypeptide and account for less than 2% of the islet cell mass. Insulin 
is stored, in crystal form, within granules in the islet B cells. Each crystal also contains 
zinc atoms. The release of insulin from the cell occurs by exocytosis. In normal adults 
the pancreas contains about 7 mg of insulin and about 2 mg of insulin are secreted daily. 
Insulin secretion is central to the regulation of glucose homeostasis. Many nutrient and 
neurohormonal factors are involved in the regulation of insulin secretion. Secretagogues 
can directly stimulate the pancreatic islets or potentiate its response to other stimulants. In 
addition, substrates can inhibit insulin secretion. Secretagogues include glucose, 
mannose, ribose, leucine, arginine, glucagon, gastrin inhibitory polypeptide, 
cholecystokinin and drugs such as sulphanylureas. Blood glucose concentration is the 
main secretagogue stimulating the release of insulin. However, the mechanisms by 
which the insulin secretory response is activated are unclear although they appear to 
depend on the intracellular concentration of calcium ions. Insulin is degraded 
predominantly in the liver, kidney and muscle. About 50% of insulin reaching the liver 
from the portal vein is degraded before reaching the general circulation. The half-life of 
circulating insulin in normal subjects is about 3-5 minutes. 
1.2.3 The physiological role of insulin 
The main endocrine function of insulin is to promote the storage of ingested nutrients by 
controlling carbohydrate, lipid and protein metabolism. It will indirectly affect every 
tissue in the body although principally it acts in the tissues which are specialised for 
energy storage: the liver, muscle and adipose tissue. Insulin and the other pancreatic 
hormones may also have a paracrine regulatory effect on the surrounding endocrine cells 
of the pancreas. An example of this paracrine effect is the inhibition of glucagon 
secretion by insulin, whilst glucagon stimulates insulin secretion. 
In the liver insulin regulates a number of metabolic pathways. It promotes anabolism by 
increasing glucose utilisation via the glycolytic pathway and increasing the synthesis and 
storage of glycogen from glucose (glycogenesis). Liver glycogen stores are the main 
source of post absorptive glucose. The synthesis of protein, triglycerides and the storage 
of very low density proteins is also increased. Insulin also has a number of anti-catabolic 
effects such as inhibiting the breakdown of stored glycogen (glycogenolysis) and 
decreasing the catabolism of fatty acids, amino acid, proteins and urea. In muscle, 
insulin promotes the synthesis of protein and glycogen. However, muscle glycogen 
stores cannot be used in glucose homeostasis due to the lack of the enzyme glucose-6- 
phosphatase in muscle tissue. The storage of fat, as triglycerides, in the cytoplasm of 
adipose cells is a highly efficient means of energy storage compared to carbohydrates or 
proteins. Insulin promotes the storage of triglycerides in adipose tissue and prevents the 
lipolysis of stored triglycerides. 
1.2.4 Mechanisms of action of insulin 
Insulin elucidates its effects via a sequence of reactions which start when insulin binds to 
4 
a specific cell surface receptor. The insulin receptor is a membrane bound glycoprotein 
consisting of two subunits, one which binds insulin and the second which transduces the 
signals which lead to insulin action. However, the events following the binding of 
insulin to the cell surface receptors are unclear and discussion of these is beyond the 
scope of this text. Many of the effects of insulin action, such as nutrient transport, 
stimulation or inhibition of enzymes, protein phosphorylation or RNA synthesis, occur 
rapidly, within seconds or minutes. Here it is thought that insulin binds to a specific cell 
surface receptor. Other effects of insulin may take many hours. These include the 
synthesis of protein, DNA, or cell growth. These events may be due to insulin binding 
to insulin-like growth factor receptors. 
1.2.5 Commercial sources of insulin 
Commercially, insulin is extracted mainly from porcine pancreas and purified by 
crystallisation. Extractions of insulin from the bovine pancreas are also available but their 
use commercially has declined in the advent of the large scale production of human 
sequence insulins which have an amino-acid sequence identical to that of human insulin. 
Semisynthetic human insulin is produced by the enzyme modification of porcine insulin. 
Biosynthetic human insulins are produced by recombinant DNA technology in 
fermentation processes. There are three main methods by which this can be achieved. 
Human insulin type crb was the first method to be used commercially. Certain strains of 
bacteria are genetically modified by recombinant DNA technology. The human insulin 
nucleotides are inserted into the DNA of the bacteria and separate insulin A and B chains 
are obtained and combined, via disulphide bonding, to produce insulin. Human insulin 
type prb is produced by the enzymic cleavage of proinsulin which has been obtained from 
bacteria genetically modified by recombinant DNA technology. Human insulin type pyr 
is produced from a precursor molecule which has been obtained from a yeast which has 
been genetically modified by recombinant DNA technology. 
Differences in the amino-acid sequence of animal insulins may lead to the formation of 
insulin antibodies when these preparations are administered to humans. Porcine insulin 
tends to be much less immunogenic than bovine insulin due to fewer differences from the 
primary structure of human insulin. Human insulins should be theoretically non- 
immunogenic although problems may arise due to the presence of contaminants. 
Unpurified insulin preparations may contain a number of contaminants including large 
molecular weight material, proinsulin, partially cleaved extraction or insulin bioproducts, 
insulin derivatives and other pancreatic islet hormones. Although many of these are 
biologically inert, relative to insulin, they may add to the immunogenicity of the insulin 
preparation. Insulin preparations can be partly purified by crystallisation methods. 
Repeated recrystallisation will improve the purity of the insulin. Gel filtration on 
sephadex gel columns will reduce or limit the contamination with materials of molecular 
weight higher than that of insulin. Chromatographic methods such as ion exchange 
chromatography will further reduce contamination. Insulin preparations will usually 
contain less than 20 parts per million (ppm) proinsulin. 
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1.2.6 Diabetes mellitus 
Diabetes mellitus describes the clinical syndrome characterised by inappropriate elevated 
blood glucose levels (hyperglycaemia). These arise from a number of disorders rather 
than from a single disease entity. Hyperglycaemia, thus a disruption of the normal 
metabolic feedback mechanisms, occurs due to a deficiency in the secretion of the 
pancreatic hormone insulin, or due to reduced biological effectiveness of the insulin 
produced or a combination of the two. In the western world diabetes mellitus can be 
classified into two main types: Type I or insulin-dependent diabetes mellitus (IDDM); 
and Type II or non-insulin dependent diabetes mellitus (NIDDM). Other forms exist 
such as malnutrition related diabetes mellitus (MRDM) and those associated with certain 
other conditions and syndromes. 
The onset of IDDM is most commonly in childhood. Links between the disease and 
genetic factors are not as marked as with NIDDM. Environmental factors in the 
genetically predisposed individual are thought to play a major role in the development of 
the disease. These environmental factors include certain viral infections such as mumps, 
rubella and coxsackie virus B4 in addition to certain toxins which result in the destruction 
of pancreatic B cells. There is also a strong associations between the disease and an auto- 
immune reaction in which antibodies are produced to components of the pancreatic B 
cells, leading to `self-destruction' of the B cells. 
NIDDM is generally a less severe form of diabetes mellitus which predominantly affects 
middle-aged adults. The majority of patients who develop the disease are obese and this 
criterion is used to sub-classify NIDDM into obese and non-obese types. In NIDDM 
patients, there is usually no significant destruction of pancreatic B cells and often normal 
levels of insulin are secreted. However, NIDDM is usually associated with insulin 
resistance whereby there is a decrease in the response of peripheral tissues to insulin. 
The pancreatic B cells appear to lose the ability to respond to the hyperglycaemia resulting 
from resistance to insulin and hence NIDDM is also associated with insulin deficiency. 
In the untreated state, insulin insufficiency is associated with the acute effects of both 
hyperglycaemia, such as thirst, polyurig and lethargy, and hypoglycaemia, such as 
sweating, palpitations, nausea, confusion and drowsiness, which may lead to eventual 
coma and death. In IDDM, insulin administration is essential to maintain normal blood 
glucose concentrations whereas in NIDDM, the majority of patients can control the 
disease by regulating their diet or a combination of dietary regulation and oral 
hypoglycaemic agents such as sulphonylureas which stimulate the release of insulin from 
pancreatic B cells. Poor diabetic control may lead to the development of chronic 
complications such as retinopathy, neuropathy and nephropathy. 
1.2.7 Current insulin therapy 
Insulin may be administered by intramuscular, intravenous or intraperitoneal injection 
although most commonly it is administered by subcutaneous injection either as a single or 
as multiple daily injections. Ideally, insulin therapy should mimic the normal pulsatile 
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patterns of physiological insulin production (Mattews et al., 1987), i. e. provide a 
constant basal concentration of insulin between meals and a boost of insulin after meals 
(prandial insulin). Close control of insulin concentrations in the diabetic patient will 
require a multiple injection regimen and close monitoring of blood glucose concentrations 
and a strict control of diet. A number of types of insulin are available for subcutaneous 
administration: short acting, intermediate acting and long acting preparations. The insulin 
regimen will usually be prescribed depending on the individuals requirements. However, 
there are many problems associated with subcutaneous insulin treatment such as poor 
compliance, adverse insulin pharmacokinetics, variable and unpredictable subcutaneous 
insulin absorption and lack of adequate feed-back control. Thus, the difficulties in 
achieving a normal physiological profile of insulin by subcutaneous therapy has lead to 
the investigation of new approaches for insulin delivery such as sustained release 
implants and non parenteral methods of insulin delivery including nasal administration. 
Several examples of studies investigating intranasal insulin absorption are given later in 
the text. The development of safe and effective nasal delivery systems for insulin, or 
indeed other drugs which must be given parenterally, is an exciting and demanding 
challenge. Although nasal systems may not totally replace injection regimens, they may 
lower the frequency of injections, allow greater patient control of blood glucose 
concentrations, thus preventing chronic complications, and help to improve the lives of 
millions of diabetics. 
1.3 Intranasal administration of peptide and protein drugs 
Drugs have often been administered nasally for their local or topical action on the nasal 
mucosa (Parr, 1983). These include compounds administered for the treatment of nasal 
allergies, nasal decongestants and anti-infective preparations. Some of the compounds 
administered for topical treatment have resulted in side-effects due to their absorption into 
the systemic circulation. 
The intranasal route for the systemic delivery of drugs has been shown to be effective for 
a large number of compounds. Extensive reviews of the many compounds administered 
intranasally to man and animals, including peptides and polypeptides, have been given by 
Chien and Chang (1985 and 1987), Chien et al. (1989) and Fisher (1990 and 1994). 
Examples of some of the compounds which have been administered nasally will be given 
later in the text. The nasal route has also been implicated as a potential site for the 
delivery of drugs to the brain (Gopinath et al., 1978). 
The nasal route is an ideal alternative to parenteral or oral administration for chronic 
systemic delivery of therapeutic drugs. The accessibility of the nasal route facilitates self 
medication thus improving patient compliance compared to parenteral routes (Pontiroli et 
al., 1989). The nasal cavity has a relatively large absorptive surface area and the high 
vascularity of the nasal mucosa ensures that absorbed compounds are rapidly removed. 
Drugs absorbed into the rich network of blood vessels pass directly into the systemic 
circulation and thus avoid hepato-gastrointestinal first-pass metabolism (Chang and 
Chien, 1984, Chien and Chang, 1985). Thus, the nasal route offers potential advantage 
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for the systemic delivery of peptide and polypeptide drugs which are susceptible to 
degradation by the chemical and enzymatic systems of the gastrointestinal tract or first- 
pass clearance in the liver. The nasal mucosa has a high permeability compared to other 
mucosal surfaces (Davis, 1992). The plasma pharmacokinetic profile following 
intranasal absorption is similar to that obtained by bolus iv injection for many compounds 
(Illum, 1992). This has implications particularly in drug replacement therapy in that there 
is the opportunity to design drug dosing regimens to mimic the normal pulsatile secretion 
pattern of peptides and polypeptides. The efficacy of pulsatile delivery compared to 
continuous delivery has been demonstrated for a number of peptide and polypeptide 
hormones such as insulin, human growth hormone and luteinising hormone-releasing 
hormone (LHRH). Parenteral administration by s. c and i. m. routes, often results in the 
formation of a drug depot at the site of injection and with slow absorption from the depot 
tends to result in sustained delivery rather than pulsatile delivery (Eppstein and 
Longenecker, 1988). In addition to non-parenteral routes for drug delivery, the 
development of parenteral controlled delivery systems for pulsatile delivery, biofeedback 
or self-regulated delivery and site-specific or targeted delivery is another expanding field 
of biomedical research (Banerjee et al., 1991). 
Despite the potential of the nasal route, there are a number of factors which limit the 
intranasal absorption of peptide and protein drugs for systemic delivery. Thus, the 
bioavailability achieved following intranasal dose administration tends to be 
uneconomically low compared to parenteral routes and poorly reproducible (Eppstein and 
Longenecker, 1988, Lee and Yamamoto, 1990). This is reflected in the fact that very 
few intranasal peptide and protein preparations are currently available for systemic 
medication. The normal physiology of the nasal cavity presents a number of barriers to 
peptide and protein drug absorption. These barriers include the physical removal from 
the site of deposition in the nasal cavity by the mucociliary clearance mechanisms, 
enzymatic degradation in the mucus layer and nasal epithelium and the selective 
permeability of the nasal epithelium (Chien and Chang, 1987, Banga and Chang, 1988, 
Eppstein and Longenecker, 1988, Lee and Yamamoto, 1990, Ilium, 1992). The 
development of nasal drug delivery systems requires an understanding of the structure 
and function of the nasal cavity, the intranasal barriers which limit peptide and protein 
absorption and the strategies by which these barriers may be overcome. 
The nasal route has also been implicated as a potential site for the delivery of drugs to the 
brain (Gopinath et al., 1978). The significance of the intranasal delivery of drugs to the 
brain will be briefly discussed since it will not be considered elsewhere in this text. The 
free movement of many substances from blood to the cells in the central nervous system 
is limited by the blood brain barrier. The blood brain barrier is formed by the `high- 
resistance tight junctions' between the cells in the brain capillary endothelium (Rubin and 
Porter, 1989). The blood brain barrier severely restricts the delivery of many therapeutic 
drugs to the brain, particularly hydrophilic drugs such as peptides and polypeptides. The 
problems of drug delivery to the brain may possibly be overcome by utilisation of the 
nasal route. This also has implications as a portal of entry of pathogenic bacteria and 
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viruses to the central nervous system (Gopinath et al., 1978). It has been suggested that 
compounds delivered to the brain may be absorbed from the nasal olfactory mucosa into 
the cerebrospinal fluid (CSF) occupying the perineural space. The CSF in the perineural 
space is continuous with that in the subarachnoid space surrounding the brain and the 
cerebral ventricles. The CSF in the subarachnoid space is separated from the brain by a 
fragile membrane, the pia mater, which unlike the blood brain barrier does not constitute 
a significant barrier to absorption. Absorption into the CSF may occur through the 
perineural sheath, a connective tissue sheath which follows the path of the olfactory nerve 
fibres from the perineural space to the olfactory submucosa. It has also been suggested 
that absorption from the olfactory mucosa to the brain may be via olfactory neurones 
which enter the olfactory bulb in the cranial cavity (Faber, 1937, Yoffey and Courtice, 
1956, Gopinath et al., 1978, Sakane et al., 1994). 
The potential of the nasal route for the delivery of compounds to the brain has been 
demonstrated using a number of compounds such as an aqueous solution of potassium 
ferrocyanide / iron ammonium citrate (Faber, 1937), colloidal gold particles (Gopinath et 
al., 1978), progesterone (Kumar et al., 1982), taurine (Lindquist et al., 1983), 
hydrophilic and lipophilic muramyl peptides (Fogler et al., 1985), wheat germ agglutinin 
conjugated to horseradish peroxidase (Shipley, 1985), vasotocin (Pavel, 1986), 
aluminium lactate (Perl and Good, 1987), 3,3-bis(4-pyridylmethyl)-l-phenylindolin-2- 
one (Hussain et at, 1989) and sulphisomidine (Sakane et al., 1994). Sakane et al. (1995) 
demonstrated a relationship between drug molecular weight and its direct absorption from 
the nasal cavity to the CSF, in rats, using fluorescein isothiocyanate-labelled dextran. 
For dextrans up to a molecular weight of at least 20000 Da, intranasal absorption into the 
CSF was shown to decrease as molecular weight increased. Nasal absorption of 
compounds, such as dyes, proteins and vaccinia virus, into the lymphatic system via the 
respiratory and olfactory nasal mucosa has also been reported (Yoffey and Drinker, 
1938a, Yoffey et at., 1938b, Yoffey and Sullivan, 1939, Yoffey and Courtice, 1956). 
The lymphatic system eventually drains into the venous system and thus offers an indirect 
route for the entry compounds into the systemic circulation. However, it is the 
respiratory region of the nasal cavity which is important for the systemic delivery of 
drugs administered intranasally. 
1.4 Structure and function of the adult human nasal cavity 
The nasal cavity is the main airway by which ambient air enters the body. Nasal 
breathing is of extreme importance since it functions to condition inspired air before 
passing to the delicate alveolar tissue in the lungs, a function which will be lost or 
impaired if totally reliant on breathing via the mouth. Inspired air is conditioned in the 
nasal cavity by cleaning, warming and humidifying and the structure of the nasal cavity is 
well adapted to these functions. Many sources of reference have been used during this 
review of the structure and function of the adult human nasal cavity including: Proctor et 
al. (1973), Mygind (1978 and 1993), Berglund and Lindvall (1982), Cole (1982), 
Proctor (1982 and 1985), Tos (1982), Widdicome and Wells (1982), Proctor and Chang 
(1983), Schreider (1986), Olsson and Bende (1986), Chien and Chang, (1987), Sleigh et 
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al. (1988), Chien et al. (1989), Su, (1991), O'Donoghue et al. (1992), Fawcett and 
Raviola (1994). Additional reference sources are given in the text. 
1.4.1 The gross anatomy of the adult human nasal cavity 
The nasal cavity is located mainly within the skull although projects, in-part, anteriorly 
into the external nose which consists of a bone and cartilaginous skeleton covered by 
connective tissue and skin. The nasal septum, composed of cartilage and bone, divides 
the nasal cavity into two approximately equal halves. Each half of the cavity begins 
anteriorly at the nares or nostrils of the external nose and extends, approximately 10-14 
cm, posteriorly to the nasopharynx. At the nasopharynx, the septum ends and two 
halves of the airway join together. Each half of the nasal cavity has a medial wall, 
formed by the nasal septum, a roof, a floor, which is parallel with the hard palate, and a 
lateral (outer side) wall which is formed by the bones and cartilage skeleton of the skull. 
A midline- and cross-section of the adult human nasal cavity is shown in Figures 1.2 and 
1.3, respectively. 
The nasal cavity can be divided into three functional regions: the vestibular-, the 
respiratory- and the olfactory regions. The anterior part of the vestibular region begins 
just inside each of the nares and terminates at a ridge of cartilage called the internal ostium 
or nasal valve approximately 1.5-2 cm from the pares. Beyond the internal ostium lies 
the main part of the nasal cavity in which the respiratory and olfactory regions are 
located. The total volume of the nasal cavity is approximately 15-20 cm3 with a total 
surface area of about 150 cm2. The vestibule has a surface area of about 20 cm2 and a 
cross-sectional area which narrows from about 0.9 cm2 to 0.3 cm2 at the internal ostium 
which is the narrowest part of the nasal cavity. Each side of the main nasal cavity 
extends about 5 cm from the floor to the roof and approximately 10 cm from the internal 
ostium to the nasopharynx. The width of the cavity varies between 0.1-0.3 cm, due to 
the presence of the turbinates which are described below, and has a cross-sectional area 
of about 0.14 cm2. The surface area of the main nasal cavity is about 130 cm2 of which 
about 10-20 cm2 is occupied by the olfactory region and the remainder is occupied by the 
respiratory region. 
In the main nasal cavity, bony scroll-like inward projections in the lateral wall form the 
turbinates or conchae. Each of the turbinates is attached at the upper end to the lateral 
wall and projects downwards in the cavity. The turbinates, which are covered in soft 
spongy tissue, increase the surface area of the cavity. It is because of the turbinates that 
the lateral wall is often described as folded or uneven although the remainder of the wall 
is fairly fiat. The scroll-like passages or spaces formed by the overhanging turbinates, 
between the turbinate and the lateral wall, are called meatuses. From the main nasal 
airway, the meatuses extend laterally and upwards and then medially to form a simple 
scroll. There are three turbinates termed the inferior-, middle- and superior turbinates 
each having a corresponding meatus. The inferior turbinate, the largest of the three 
turbinates, lies just above the nasal floor and begins at the internal ostium. The middle 
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turbinate is situated further into the nasal cavity and the superior turbinate is located deep 
in the nasal cavity. 
The main nasal airway extends upwards from the floor of the nasal cavity to the middle 
turbinate and from the nasal ostium to the posterior of the turbinates. The passage above 
the middle turbinate in which the olfactory region is located and the meatuses are 
generally free of inspirational air flow. Air filled cavities within the bones of the skull, 
referred to as the paranasal sinuses, open into the nasal cavity. The paranasal sinuses are 
evaginations in the bones of the skull surrounding the nasal cavity which are lined with 
mucosa which is continuous and identical with that lining the nasal cavity. This can have 
important implications during nasal infections which may spread to the sinuses resulting 
in localised pain or headache. The sinuses consist of paired maxillary and frontal 
sinuses, a labyrinth of about 20 ethmoidal sinuses and a number of sphenoidal sinuses 
which open directly or indirectly into the nasal cavity. In addition a palatine sinus may 
also be present. The nasolacrimal duct (tear duct) opens into the anterior of the inferior 
meatus. 
Figure 1.2. Midline-section (lateral wall) of the adult human nasal cavity- 
Adapted from Mygind (1978) and Proctor (1982) 
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BC. Buccal cavity, NV. nasal vestibule, NS. nasal septum, IT. inferior turbinate, MT. middle turbinate, 
ST. superior turbinate, SS. sphenoidal sinus, OET. orifice of eustacean tube, NP. nasopharynx. Cross- 
sections through the nasal cavity at positions A, B and C are shown in Figure 1.3 
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Figure 1.3. Cross-section of the adult human nasal cavity 
Adapted from Mygind (1978) 
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NS. nasal septum, IT. inferior turbinate, MT. middle turbinate, ST. superior turbinate, MS. maxillary 
sinus. Cross-sections through the nasal cavity: A. Internal osteum, B. Middle of nasal cavity, C. 
Posterior of nasal cavity 
The anatomy of the nasal cavity is well adapted to the function of conditioning inspired 
air. The slit-like nasal airway (1-5 mm wide) is narrowest at the internal osteum and 
widest at the nasopharynx. At the internal osteum the high resistance to airflow and the 
relatively high linear velocity of the air stream (12-18 m/sec compared to about 1 m/sec in 
the trachea) combined with the bending of the air stream (almost a 90° bend) and 
turbulence facilitates the impaction of the majority of particles carried in the inspired air 
stream in the anterior of the nasal cavity from where they are mainly removed by 
mucociliary clearance. In the main part of the nasal cavity the cross-sectional area of the 
nasal cavity increases and the linear velocity of the air stream is reduced. The narrowness 
of the airway, the increased surface area combined with the reduced air velocity optimise 
the contact between the inspired air and the nasal mucosa where air is warmed and 
humidified and gases and vapours are absorbed. In the posterior of the nasal cavity, the 
air stream bends about 90° as it passes to the nasopharynx and the air stream increases in 
velocity resulting in the impaction of particles in the posterior of the nasal cavity from 
where they are removed by mucociliary clearance. 
1.4.2 
, 
Nasal mucosa 
The nasal vestibule is lined with stratified squamous epithelia which is continuous with 
the facial skin and is in-part keratinised particularly close to the pares. Long stiff hairs or 
vibrissae, sebaceous glands and sweat glands are abundant in the anterior portion of the 
vestibule. The vibrissae play a defensive role by filtering large particles from inspired 
air. Posteriorly, the vibrissae and sebaceous / sweat glands become sparse and a 
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transitional band of non-ciliated cuboidal or columnar epithelium replaces the stratified 
squamous epithelium and extends into the anterior of the main nasal cavity. Ducts from 
anterior serous cells located in the respiratory mucous open in the upper part of the 
vestibule and release watery or serous fluid secretions. The main nasal cavity is lined 
with mucous membrane which is continuous with that of the paranasal sinuses, 
nasopharynx and nasolacrimal ducts. The mucous membrane is composed of two layers, 
an epithelium and a tunica propria separated by a basement membrane, and is anchored to 
the underlying bony or cartilagenous skeleton. The respiratory and olfactory regions of 
the main nasal cavity have respiratory and olfactory mucosa, respectively. 
1.4.2.1 Olfactory mucosa 
The olfactory mucosa is a specialised region of the nasal cavity which contains the 
receptors for the sense of smell. The olfactory mucosa is confined to the roof of the nasal 
cavity and the upper part of the nasal septum. The epithelial cells are columnar 
pseudostratified which tend to be taller than those of the respiratory mucosa and of which 
there are three main types: olfactory cells, sustentacular cells and basal cells. The 
olfactory cells are the receptor cells for the sense of smell. These cells are bipolar 
neurones which are distributed between the sustentacular or supporting cells. The apex 
of the bipolar neurone is tapered into a dendritic process which extends to the epithelial 
surface and terminates in a bulbous expansion called the olfactory bulb or knob which 
lies above the apical epithelial surface. The olfactory bulb contains numerous basal 
bodies from which non-motile cilia extend and lie parallel to the apical epithelial surface. 
These cilia, except at the base, do not have the typical 9+2 axonemal structure and tend 
to be much narrower and longer than typical cilia. These modified cilia increase the 
surface area of the receptor cell. Pinocytotic vesicles are present on the apical surface of 
the olfactory cells. The base of the olfactory cell tapers to form an un-myelinated nerve 
axon which extends just below the basal lamina into the connective tissue and joins with 
neighbouring axons to form small bundles of nerve fibres which become surrounded by 
Schwann cells. These ensheathed bundles, known as fila olfactoria, join with other 
bundles to form the olfactory nerves which penetrate the bones of the skull in the roof of 
the nasal cavity before passing into and synapsing in the olfactory bulb of the brain 
(Gopinath et al., 1978). 
The sustentacular cells are rich in organelles and are thought to provide both metabolic 
and physical support to the olfactory cells. At the apical surface of the sustentacular cells, 
microvilli project into the mucus and pinocytotic vesicles are present. Basal cells lie close 
to the basal lamina between the olfactory and sustentacular cells into which basal cells are 
are able to differentiate. Processes from the basal cells sheath the olfactory cell axons for 
a small portion of its length. Brush cells having large microvilli on the apical surface may 
also be present in small numbers. These may be involved in sensory reception and in- 
particular the sneeze reflex. 
Underlying the olfactory mucosa and separated by a basal lamina, the lamina propria 
consists of connective tissue with subepithelial pigment and lymphoid cells, glands, 
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vascular and nerve tissue. The branched tubuloalveolar olfactory glands of Bowman 
continually secrete a serous fluid on to the epithelial surface via ducts. Air-borne 
odorants dissolve in this serous fluid prior to detection by the epithelial receptor cells. 
There is a rich sub-epithelial capillary plexus and a deeper lying venous plexus and 
lymphatic system although the vasculature of the olfactory mucosa is not as rich as in the 
respiratory mucosa. Trigeminal nerve fibres are present along with the olfactory nerves. 
1.4.2.2 Respiratory mucosa 
The respiratory mucosa lines most of the nasal cavity and resembles that of the trachea 
and bronchi. The respiratory epithelium is mainly a ciliated columnar pseudostratified 
epithelium but stratified cuboidal or simple cuboidal epithelia may also be present 
particularly over the more exposed regions such as parts of the turbinates. The 
respiratory epithelium is composed of five main cell types: ciliated columnar cells, non- 
ciliated columnar cells, goblet cells, basal cells and brush cells. Ciliated columnar cells 
are the most abundant cell type and occur in groups which are interspersed with non- 
ciliated cells. Goblet cells which secrete mucus glycoproteins, are abundantly but 
unevenly distributed in the respiratory epithelium. The ratio of ciliated cells to goblet 
cells is approximately 5: 1. The density of goblet cells is lower on the nasal septum than 
the turbinates and the distribution is lower on the middle turbinate than the inferior 
turbinate. The distribution in the mucosa of the paranasal sinuses is similar to that on the 
septum. The density of goblet cells tend to increase in an anterior to posterior direction 
on the septum and turbinates. Basal cells are undifferentiated intermediate cells which 
can mature into columnar or goblet cell types. Unlike the other cell types, these cells do 
not reach the apical surface of the epithelium. Brush cells have a brush border of 
microvilli up to 2 gm long and may have an absorptive function in the regulation of the 
fluid balance in the mucus layer. Microvilli are abundant on the apical surface of both 
ciliated and non-ciliated cells. Up to 500 microvilli each about 1-2 tm long and 0.1 tm 
in diameter may be found. Macrophages, leucocytes and clusters of lymphocytes may 
also migrate throughout the epithelium. 
1.4.3 Junctional complexes between epithelial cells 
Epithelial cells in the nasal mucosa are generally in close apposition and adjacent cells are 
extremely adherent. Cohesion at the apices of epithelial cells occurs in specialised 
regions collectively referred to as the junctional complex. The junctional complex consists 
of three regions: zonula occludens, zonula adherens and macula adherens and under light 
microscopy appears as a dark band or terminal bar near the apex of the epithelial cells. 
The zonula occludens is often referred to as the tight junction and is the region of the 
junctional complex which is closest to the apical cell surface. The zonula occludens is a 
zone or band which circumferentially extends round the lateral cell membrane. The lateral 
membrane between adjacent cells appear to converge and fuse at close intervals. The 
molecular nature of these bands is not fully understood and the literature tends to be 
controversial. The zonula occludens controls the diffusion of ions and molecules 
between cells and constitutes a barrier to the movement of macromolecules across the 
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epithelium by this route. The number of sites of fusion in the tight junction determines 
the permeability of the epithelium by the paracellular route. Leaky epithelia, present in 
some kidney tubules, contain few sites of contact whereas intestinal epithelia contains 
many sites and is highly impermeable. The human nasal epithelia has been described as 
non-uniform by Inagaki et al. (1985) with connections of goblet-goblet and goblet- 
ciliated cells being weak, thus the epithelium is relatively `leaky', compared to the 
connections of ciliated-ciliated cells. 
In contrast to the zonula occludens, the zonula adherens and the macula adherens do not 
constitute a barrier to the movement of molecules between cells and are both cell adhesion 
devices. The zonula adherens lie just below the zonula occludens and consist of a 
circumferential, adhesive filled, space between adjacent lateral cell membranes. The 
macula adherens is typically located just below the zonula adherens and forms a 
discontinuous band of disc shaped plaques around the lateral membrane. The 
intercellular space is filled with an adhesive material. Filaments from both the zonula 
adherens and the macula adherens extend into the cytoplasm and anchor the cytoskeleton 
to the cell surface. An additional junctional specialisation between lateral cell membranes 
is the gap junction where the intercellular space is reduced to narrow channels through 
which metabolites and ions can diffuse between cells and in this way function in the 
electrical coupling of cells throughout the epithelium 
1.4.4 The basal lamina and lamina propria 
The basal lamina (basement membrane) separates the epithelium from the underlying 
lamina propria and consists of two layers; a low density lamina lucida adjacent to the 
epithelium and an underlying and more dense lamina densa. The basal lamina consists of 
collagen fibres, glycoproteins and proteoglycans. The collagen in the lamina densa is 
cross-linked forming a layer which is flexible but has high tensile strength. Collagen 
fibres also anchor the lamina densa to the collagen fibres of the lamina propria. The basal 
lamina supports the epithelial layer. Large molecules crossing the epithelium may be 
passively filtered on the basis of size, shape (mainly due to the network of collagen 
fibres) and electrostatic charge (mainly due to the proteoglycan heparan sulphate which 
carries a strong anionic charge). 
The lamina propria (tunica propria) underlying the basal lamina anchors the mucosa to the 
underlying skeletal structures and in addition provides support to the mucosa. The lamina 
propria consists of a loose type connective tissue of extracellular ground substance with 
moderately abundant and loosely interwoven collagen fibres and proteoglycan and related 
substances. The ground substance is a hydrated gel consisting mainly of water, 
proteoglycans (chondroitin sulphates, heparin sulphate, heparin, keratan sulphate and 
hyaluronic acid) and electrolytes. Embedded in the connective tissue are glands, 
subepithelial cells, vascular and nervous tissue. There are numerous branched and 
tubuloalveolar glands regularly distributed throughout the connective tissue layer of the 
respiratory mucosa. These discharge their mucus or serous secretions onto the surface of 
the nasal vestibule (anterior serous nasal gland) or respiratory epithelium (seromucous 
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glands) via short ducts. The paranasal sinuses contain much fewer glands which are 
mainly confined round the orifices of the sinus. The main mucosa of the paranasal 
sinuses is almost devoid of glands. Subepithelial cells consist of fibroblasts and 
fibrocytes, which secrete extracellular material (fibrils and ground substance), histiocytes 
which contain very active substances such as hydrolytic enzymes in cytoplasmic vesicles 
(lysosomes). Macrophages, leucocytes, lymphocytes, plasma cells and mast cells have 
also been identified in the connective tissue of the nasal mucosa. 
1.4.5 Vasculature of the nasal cavity 
The nasal mucosa, particularly that of the respiratory region, is highly vascular, having 
an extensive blood supply and lymphatic drainage system. The main blood supply is via 
branches of the maxillary artery and facial artery arising from the external carotid artery 
and the ophthalmic artery derived from the internal carotid artery. Branches of the major 
nasal arteries anastomose in the basal regions of the lamina propria forming a deep 
network or plexus. Branches from the arterial plexus ascend through the mucosa giving 
rise to arterioles which terminating in a subepithelial capillary plexus just below the 
epithelial layer or supplies the subepithelial glands and tissues. Blood drains from the 
respiratory mucosa into venous plexuses. Fine networks of small vessels tend to be 
located in the superficial regions of the lamina propria whereas networks of larger vessels 
tend to be located in the deeper layers. The venous plexuses drain into larger veins in the 
anterior and posterior of the nasal cavity. Rich superficial venous or cavernous plexuses 
consisting of tortuous networks of large anastomosing veins are abundant over the 
regions of the inferior and middle turbinates and over part of the septum. The venous 
plexuses, especially the cavernous plexuses and others which are located in the regions of 
main inspirational air flow, also receive blood directly from the arteries via arteriovenous 
anastamoses. Arteriovenous anastamoses enable blood to be shunted to the venous 
system thus by-passing the capillary network and therefore are extremely important for 
the regional regulation of blood flow due to mechanical, thermal, psychological or 
chemical stimulation. The plexus has the ability to engorge with blood resulting from 
vasoconstriction of the deeper veins and vasodilation of arterioles which supply the 
plexus via the capillary networks. The engorgement of the plexus with blood may lead to 
a swelling of the mucosa which can temporarily occlude the airway and make the tissue 
appear erectile. This occlusion of the airways is thought to occur cyclically and 
alternately between the two sides of the nasal cavity as a function to prevent the drying- 
out of the mucous membrane on any one side. Nasal veins do not have valves and thus 
there is a postural variation in blood pressure and flow dynamics. 
Relatively large capillaries adjacent to the basal lamina and smaller capillaries around the 
glands contain. pores or fenestrations, each closed by a very thin pore diaphragm, 
between the peripheral endothelial cells. The fenestrations facilitate rapid fluid transport 
processes in the nasal mucosa. Other small non-fenestrated capillaries are also present in 
the lamina propria and these capillaries tend not to be associated with the epithelial surface 
or glands. The superficial capillary network and those supplying the glands join to form 
venules which drain into larger superficial veins. The endothelial basal lamina of the 
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superficial nasal blood vessels is characteristically porous. This renders the arterioles and 
venules particularly susceptible to vasoactive agents carried in the blood since they lack 
an internal elastic membrane and thus the endothelial basal lamina is continuous with the 
basal lamina of the underlying smooth muscle cells. The superficial fenestrated 
capillaries supply the mucous layer covering the epithelium with moisture for the 
humidification of inspired air. The superficial venous networks especially the erectile 
cavernous plexuses in the mucosa enables inspired air to be heated before passing to the 
delicate tissues of the lower respiratory tract. Blood tends to flow from the rear of the 
cavity countering the flow of inspired air and thus provides rapid and efficient heat 
exchange. The regional blood flow in the cavernous sinusoids can be controlled in terms 
of flow speed and volume to provide efficient temperature conditioning of inspired air. 
The lymph vessels also form a rich plexus in the respiratory mucosa. The lymph vessels 
of the respiratory region of the nasal cavity predominantly drain into upper deep cervical 
lymphatic vessels and into upper deep cervical and retropharyngeal lymph nodes before 
entering veins at the base of the neck. The lymph vessels absorb and thus drain away the 
tissue fluid which passes through the capillary walls and which collects in the tissue 
spaces of the nasal mucosa. The removal of tissue fluid ensures that the airway is kept 
clear. 
1.4.6 Nervous innervation of the respiratory mucosa 
The nerve supply to the respiratory mucosa is via an integration of sensory and motor 
nerves of the somatic and autonomic branches of the peripheral nervous system. The 
trigeminal nerve is the major sensory nerve of the facial region and branches of its fibres 
are distributed throughout the mucous membranes of the nasal cavity and the paranasal 
sinuses. The trigeminal nerve is composed of mainly somatic sensory fibres with a 
general somatosensory function (receive sensory information from the mucosa of the 
nasal cavity and paranasal sinuses). Autonomic parasympathetic and sympathetic fibres 
provide motor innervation of the nasal mucosa. The integration of sensory, secretomotor 
and vasomotor functions enables the main functions of the nasal cavity, i. e. conditioning 
inspired air by warming, humidifying and cleaning, to be performed. 
Various reflexes are associated with the nasal mucosa. Since man is generally regarded 
as an obligate nasal breather then some of these reflexes function to protect the lower 
respiratory tract from irritants. Stimulation of sensory receptors, usually nerve endings, 
in the nasal mucosa give rise to sensory sensations which via the central nervous system 
elicits a response reaction in the nasal mucosa. This may involve sneezing or allergic 
reactions to sensory irritants for example pollutant gases such as sulphur dioxide and 
inert dust which may cause localised pain or discomfort sensations. However, the 
respiratory mucosa in humans has limited somatosensory function and has poor capacity 
for the localisation and discrimination of sensory stimuli. The respiratory mucosa will 
respond to mechanical and chemical stimuli but lacks thermoreceptors so does not 
respond to hot or cold air. Sensory stimulation as a result of breathing unconditioned air, 
resulting in secretomotor and vasomotor reflexes via parasympathetic and sympathetic 
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pathways, is suggested to be via thermoreceptors in the nasal vestibule (Cauna, 1982). 
Exercise also initiate a nasal reflex by decreasing nasal resistance to air flow thus 
facilitating nasal breathing to meet the demand for increased respiration. This occurs by 
graded vasoconstriction of nasal blood vessels. 
The nasal blood vasculature receives vasomotor innervation from both sympathetic and 
parasympathetic nerves. The nerves form a plexus of nonmyelinated nerve fibres in the 
lamina propria. Sympathetic nervous innervation causes vasoconstriction whereas 
parasympathetic stimulation results in vasodilation. Normally, vessels of the cavernous 
plexuses are kept partially constricted by constant sympathetic stimulation. In contrast, 
vessels are not continually innervated by parasympathetic stimulation. As previously 
mentioned, the vasomotor tone can result in rapid changes not only in the volume and 
speed of blood flow in the nasal mucosa but also airflow through the nasal cavity. When 
the venus plexuses are engorged with blood then airflow through the nasal cavity is 
reduced. Secretomotor innervation of nasal glands is via parasympathetic nerves and 
there is no direct sympathetic innervation. However, glandular secretion is influenced by 
their blood supply and thus indirectly affected by sympathetic fibres. 
1.4.7 Nasal mucus secretion 
A thin layer of clear nasal fluid or mucus forms a continuous cover over the surface of the 
nasal mucosa. Mucus is a mixture of secretions derived from a number of sources. 
These include mucous secretions from goblet cells and subepithelial mucous glands, 
serous secretions from subepithelial serous glands, secretions from lacrimal glands 
(tears), tissue fluid transudate and condensed water from expired air. Normal mucus is 
hypertonic compared to plasma and has a pH between about 5.5-6.5. Mucus is 
composed of 95-97 % water with 2.5-3 % mucus glycoproteins or mucins, and the 
remainder consists of electrolytes (up to about 2%), proteins and other macromolecules. 
Sloughed cells and micro-organisms may also be present as well as lipids and DNA 
which may be derived from damaged cells. Water movement across the nasal epithelium 
into the nasal lumen is thought to occur by passive diffusion as a result of the osmotic 
gradient set-up by active ion transport. The hypertonicity of mucus is probably due to 
active ion transport in combination with water evaporation from the mucosal surface. 
Mucus glycoproteins constitute 70-80% of the dry-weight of mucus and are composed of 
a single polypeptide chain to which are attached sugar side chains. Mucus glycoproteins 
may be acidic or neutral in nature. Acid glycoproteins are predominate in human mucus 
and contain sialic acid and/or sulphate groups. Neutral glycoproteins contain large 
amounts of fucose but may also contain small amounts of sialic acid. The glycoproteins 
give mucus characteristic rheological (visco-elastic) properties which are related to its 
function of providing a protecting coating to the nasal epithelium and facilitating 
mucociliary clearance of materials deposited in the nasal cavity. 
The protein content of mucus is in the form of immunoglobulins, albumin, lactoferrin, 
lysozyme and other enzymes and protease inhibitors. IgA is the major immunoglobulin 
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in nasal mucus and accounts for up to 50% of the total protein content. The 
immunoglobulins and nasal immunology are mentioned later. Lactoferrin, an iron 
binding protein, and the enzyme lysozyme (muraminidase) may have antimicrobial 
activity against many airborne microbes (Rodwell, 1988). Lysozyme has optimal activity 
at slightly acidic pH and thus is suited to the normal pH of the nasal cavity (Tachibana et 
al., 1986). However, lysozyme activity may be reduced during cases of acute common 
cold, acute rhinitis or acute sinusitis where nasal pH is often alkaline. Lysozyme and 
proteolytic enzymes such as acid hydrolases and peroxidases present predominantly in 
the lysosomal granules of macrophages and neutrophils are able to digest phagocytosed 
foreign antigenic material. In addition, these and other cells may discharge the contents 
of their granules outside of the cell and directly into mucus and these may act in breaking 
down materials for example inflammatory products which are not ingested and in the 
activation of chemical mediators and proenzymes (Hamaguchi et al., 1986, Roitt et al., 
1987). Hochstrasser (1983) suggests that proteolytic mucus lysosome enzymes are 
inactivated and compensated by the antiproteolytic capacity of normal nasal mucus. It 
was reported that in cases of common cold, the number of granulocytes, mainly 
neutrophils infiltrating nasal secretions was increased and there was a corresponding 
increase in the amount of neutrophilic lysosomal enzymes present in mucus 
(Hochstrasser, 1983). However, the trypsin-like protease activity of these enzymes did 
not increase due to the increase in serum antiproteases such as a 1-antityrpsin. This was 
thought to be a protective mechanism to prevent irreversible, protease induced damage to 
the nasal mucosa (Hamaguchi et al., 1986). Amylase, an enzyme which hydrolyses 
starch and glycogen, has been demonstrated in the secretory granules of submucosal 
serous glands and has been speculated to be involved in controlling secretion fluidity 
(Tachibana et al., 1986b). 
1.4.8 Nasal enzymes 
The nasal mucosa contains a variety of enzymes which are present in nasal secretions, on 
the surface of or in the cytosol of epithelial cells, where they may be free or membrane 
bound, and in the lamina propria where they are particularly associated with glandular 
tissue. Much of the literature relates to studies in animals although Sarkar (1992) 
considered that despite inter-species variations, the profile of nasal drug metabolising 
enzymes in humans will be similar. The enzymes identified in nasal mucosa include 
monooxygenases, reductases, transferases, esterases and proteases (Irwin et al., 1995). 
Monooxygenase enzymes include cytochrome P-450-dependent monooxygenases which 
are particularly abundant in the olfactory region and may function in the 
biotransformation and removal of odorant compounds thus ensuring that the acuity of 
olfaction does not decrease due to the build-up of a high background odour (Dahl et al., 
1982). The cytochrome P-450-dependent monooxygenases are thought to be important 
as a first line defensive mechanism against inhaled xenobiotics, particularly 
environmental pollutants, volatile chemicals and odorous chemicals, which are 
biotransformed into nontoxic compounds which may then be excreted (Hadley and Dahl, 
1983). However, biotransformations of some inhaled compounds into chemically 
19 
reactive metabolites have been implicated as a cause of nasal lesions or tumours in animal 
species (Bond, 1986, Brittebo et al., 1986). Mucociliary clearance and swallowing of 
chemically reactive metabolites in mucus may also have implications in the induction of 
tumours in the alimentary tract as well as in the upper respiratory tract (Dahl et al., 1985). 
Studies by Bond et al. (1988) indicate that there is an uneven distribution of xenobiotic 
metabolising enzymes along the respiratory tract and presumes that the balance of 
activating and inactivating enzymes will determine whether a compound will be 
carcinogenic in a particular tissue. 
Various types of proteolytic enzymes are present in nasal mucosal membranes and are 
also a constituent of nasal secretions and are mentioned later in the text. However, these 
have not been isolated and characterised in the nasal cavity and their presence is based on 
studies with model peptide drugs such as enkephalins, substance P, insulin and 
proinsulin (Lee and Yamamoto, 1990). Proteolytic enzymes may exhibit exopeptidase or 
endopeptidase activity. Exopeptidases cleave the terminal N or C bonds in peptide chains 
and include aminopeptidases and angiotensin-converting enzyme (dipeptidyl peptidase 
and dipeptidyl carboxypeptidase). Endopeptidases such as endopeptidase-24.11 (neutral 
endopeptidase) cleave the internal peptide bonds (Kashi and Lee, 1986, Lee and 
Yamamoto, 1990). Aminopeptidases are the principal proteolytic enzymes in the nasal 
cavity (Audus and Tavakoli-Saberi, 1991). Stratford and Lee (1986) identified a number 
of aminopeptidases in nasal mucosa homogenates in the albino rabbit. Aminopeptidase N 
and A were shown to be membrane bound whereas aminopeptidase B was a cytosolic 
enzyme. Leucine aminopeptidase and lysosomal aminopeptidase were also identified. 
Compared to various other mucosae (buccal, rectal and vaginal) the overall subcellular 
distribution of aminopeptidases in the nasal mucosa are the most similar to those in ileal 
mucosa. Membrane bound aminopeptidase activity accounted for almost half of the total 
enzyme activity compared to 20% in ileal mucosa and 80% in buccal, rectal and vaginal 
mucosa (Lee and Yamamoto, 1990, Ilium, 1992). However, the subcellular distribution 
of aminopeptidases in different mucosae will vary depending on the peptide substrate 
used in the aminopeptidase assay (Irwin et al., 1995). The evolutionary development of 
proteolytic enzymes in the nasal cavity is probably a protective mechanism against the 
invasion of foreign peptidagenous and proteinaceous materials (Hussain et al., 1990). 
1.4.9 Nasal immunology 
Large numbers of microorganisms enter the nasal cavity either with inspired air or via 
direct finger contact with the nostril. Rhinoviruses, which are responsible for the 
common cold may also reach the nasal cavity via the nasolacrimal duct (Mygind and 
Winther, 1987). The relatively thin mucosal lining covering most of the nasal cavity 
constitutes a weak mechanical barrier to the entry of potentially pathogenic microbes and 
protection against most infectious agents is provided by a number of innate and adaptive 
immune mechanisms (Weir, 1977, Brandtzaeg, 1988). Innate immune mechanisms are 
non-specific to the microbial antigen and in most instances will be sufficient to prevent 
manifestation of the disease. These include the physical barrier of the nasal mucosa, 
mucociliary clearance, anti-microbial agents (e. g. lysozyme, protease enzymes) and 
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phagocytic cells (predominantly macrophages and neutrophils). A number of soluble 
factors such as complement and interferon are also involved (Weir, 1977, Mygind and 
Winther, 1987). If innate immune mechanisms are breached then an antigen specific 
adaptive immune response such as immunoglobulin (antibody) production and cell- 
mediated immune mechanisms via activated lymphocytes will be initiated (Mygind and 
Winther, 1987). Nasal associated lymphoreticular tissue (NALT) is located in the 
submucosa in the nasopharyngeal area (tonsils) and is ideally positioned to encounter 
environmental antigens (McGhee and Kiyono; 1993). NALT represents an inductive site 
for the adaptive mucosal immune system in the upper respiratory tract and hence 
possibilities exist to exploit NALT in the development of vaccines. Studies in rats 
indicate that of the airway associated lymphoid tissue, NALT may be the major IgA 
inductive site. 
IgA is the major immunoglobulin in nasal mucus. There are two types of IgA, one an 
IgA monomer (7S monomer) passes directly into nasal secretions from the blood and the 
second and predominant type, secretory IgA (mainly an 11 S dimer containing a joining or 
J chain), is secreted locally in the nasal mucosa. The IgA's can bind to and neutralise 
viral antigens thus preventing their colonisation of the nasal mucosa. IgG may also be 
present in nasal mucus the source of which appears to be from the blood although 
subepithelial cells containing IgG have been demonstrated. IgD, IgE and IgM have been 
detected in mucus as a result of transudation or local production. IgE producing cells and 
mucosal mast cells containing IgE may be present in allergic individuals. 
1.4.10 Mucociliary transport 
Mucociliary transport is the movement of mucus by cilia. Cilia are fine, contractile 
projections on the apical surface of the columnar epithelial cells and there are 
approximately 200-300 cilia per cell each cilium being between 5-10 µm long and 0.1-0.3 
µm wide. The respiratory cilia have the characteristic 9 plus 2 axonemal structure. The 
density of ciliated cells increases posteriorly in the nasal cavity. Mucus consists of two 
fluid layers: a viscid gel layer (mucus or epiphase) floats on a less viscid sol layer 
(periciliary fluid layer or hypophase) immediately adjacent to the epithelial surface. 
Mucus is not present as a uniform sheet but forms droplets, flakes and plaques. Mucus 
is transported by the symmetric beating action of cilia. During the cyclic beating of the 
cilia, contact of the ciliary tips with the viscid gel layer is sufficient to generate a 
propulsive force on the mucus. During mucus transport the gel layer is propelled 
whereas the sol layer remains stationary. The synchronous beating of cilia in the nasal 
mucosa generates metachronal waves over the surface of the nasal mucosa. In patches or 
fields of mucosa, the cilia beat frequency and direction of beat may vary, although the 
cilia in each patch will display metachrony. Ciliated regions of mucosa are also 
interspersed will non-ciliated cells. Mucus is transported by a combination of several 
metachronal waves which overcomes any irregularities or variations in the beat frequency 
or direction between the patches of cilia and allows the continued transport of mucus over 
non-ciliated regions. Although the overall transport of mucus is generally towards the 
nasopharynx, the pattern of transport of mucus droplets, flakes or plaques across the 
21 
surface of the nasal mucosa may exhibit numerous directional changes due to regional 
variations in the frequency and direction of each metachronal field. 
The nasal cilia beat frequency (CBF) is about 10 Hz (range 4.5 to 11.9 Hz), based on in 
vitro studies using nasal biopsies obtained from healthy volunteers (Duchateau et al., 
1985). Measurements were performed at 30°C. However, in the same study the average 
temperature in the inferior turbinate of 6 healthy subjects was found to range between 
29.2-34.2°C and thus CBF may increase posteriorly in the nasal cavity with increasing 
temperature of the mucosal surface in this direction. Mucus is continually transported, at 
about 5 mm per minute, over the surface of the respiratory mucosa. The depth of the sol 
layer must be regulated to ensure efficient mucus transport and transport rates will be 
reduced if the sol layer becomes too deep or too shallow. Microvilli, on the epithelial cell 
surface, may contribute to the overall fluid regulation in the mucus layers via transport 
mechanisms. In the nasal cavity, the mucus layer is generally renewed every 15 minutes 
by transport posteriorly towards the nasopharynx, from where it is removed into the 
stomach by swallowing. In addition, in the anterior regions of the inferior turbinates, 
mucus may also be transported in an anterior direction towards the nares and removed as 
it drains into the vestibular region of the nasal cavity by blowing or wiping the nose. 
Mucociliary transport is an important physiological defence mechanism referred to as 
mucociliary clearance. The majority of particles and gases which are inhaled via the nose 
are removed before passing to other parts of the respiratory system. Any particles or 
gases which adhere to or dissolve in the mucus layer will be cleared from the nasal cavity 
by mucociliary transport. However, less soluble gases and small particles may evade the 
mucociliary clearance mechanism and penetrate further into the respiratory tract. 
1.5 Animal models for intranasal drug absorption studies 
A prerequisite for the development of nasal delivery systems, for testing in human clinical 
trials is that they are first evaluated and optimised in animal models (Ritschel, 1987). 
Ideally, nasal drug absorption in the animal model will correlate with nasal absorption in 
humans. Thus, results from animal studies can be reliably extrapolated to humans. 
However, the results obtained from absorption studies will often be influenced by the 
animal model employed and extrapolation to absorption in humans should be approached 
with caution. Nevertheless, animal models are invaluable in pharmaceutical research, not 
only for preclinical evaluation of new drug compounds but also for optimising the 
various formulation factors which will influence drug absorption. Various animal models 
have been used in intranasal drug absorption studies using species such as mice, rats, 
guinea pigs, rabbits, dogs, sheep and monkeys (Chien et al., 1989, Gizurarson, 1990, 
Ilium, 1995). Attention will be focused on the rat and sheep nasal models which have 
been extensively utilised throughout this project. However, comparative characteristics 
of the nasal cavities of man and several animal species are given in Table 1.1. Reviews 
of the animal models used in intranasal drug absorption studies, to which reference has 
been made in the following text, have been given by Chien et al (1989), Gizurarson 
(1990) and Ilium (1995). 
22 
1.5.1 The rat model 
The rat is widely used in intranasal drug delivery studies. Rats are relatively inexpensive 
animals which are easy to maintain, handle and use experimentally. They breed easily 
and reach maturity quickly and hence tend to be readily available commercially. Several 
strains of rat are available and they are usually used in the weight range 200-300 g (4-5 
months old). The structure of the rat nasal cavity will be briefly discussed before 
describing the various experimental rat models which have been employed for nasal drug 
delivery studies. 
1-5J. 1 Structure of the rat nasal cavity 
The description of the rat nasal cavity is based upon Hebel and Stromberg (1976), 
Schreider and Raabe (1980), Gross et al., (1982), Proctor and Chang (1983), Schreider 
(1986), Young (1986), Popp et al., (1986), Fisher (1990) and Uraih and Maronpot 
(1990). A midline section of the rat nasal cavity is shown in Figure 1.4. The rat nasal 
cavity is incompletely separated by the nasal septum, in the posterior ventral region, 
allowing the two halves of the nasal cavity to join at the beginning of the nasopharyngeal 
duct leading to the nasopharynx. 
In the main part of the nasal cavity two pairs of turbinates project from the lateral wall of 
the nasal cavity. The nasoturbinate projects ventrally from the roof of the nasal cavity 
leaving the dorsal meatus between the roof and nasoturbinate which extends the length of 
the cavity. The maxilloturbinate projects dorsally in the ventral region of the nasal cavity. 
Between the floor of the nasal cavity and the maxilloturbinate is the ventral meatus which 
is the main passage for inspired air and extends to the nasopharyngeal duct. A middle 
meatus is positioned between the naso- and maxilloturbinates. The turbinates, 
particularly the nasoturbinate, have a hook-like arrangement with a laterally pointing 
curve. In the posterior of the nasal cavity is the ethmoid recess, lying ventral to the 
posterior of the dorsal meatus, which contains a complex arrangement of turbinates 
referred to as endoturbinates (positioned near to the nasal septum) and ectoturbinates 
(positioned near to the lateral wall). The dorsal, middle and ventral meatus communicate 
medially at the common meatus which extends along the length of the nasal cavity 
between the nasal septum and the turbinate bones. Folds of accessory cartilage, referred 
to as the atrioturbinates, project from the vestibule to the naso- and maxilloturbinate and 
these separate the common meatus from the ventral, middle and dorsal meatus in the 
anterior of the respiratory region although there is communication between the two via a 
slit between the cartilages which diminishes posteriorly. Paired paranasal sinuses are 
present in the rat although the literature contains conflicting reports of their number and 
size. Ethmoid, frontal, sphenoid and maxillary sinuses have been reported. A feature 
not found in humans is the vomeronasal organ of Jacobson consisting of paired blind 
epithelial tubes running along the ventral region of the nasal septum from the vestibule, to 
which it communicates via a short lateral duct, to the nasopalatine duct (incisive canal) 
which connects the nasal and oral cavities. The function of the vomeronasal organ is not 
clear although it may be involved in olfaction. 
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The mucosa lining the rat nasal cavity contains three distinct types of epithelium: stratified 
squamous, respiratory and olfactory. The proportion of the total nasal surface area 
occupied by the various epithelia types was determined by Gross et al. (1982) using two 
groups of rats, weighing 115 g and 288 g. The percentage composition of the epithelial 
types were 3-4 % stratified squamous epithelium, 44-47 % respiratory and 50-52 % 
olfactory. Simple squamous stratified epithelium, which is in-part keratinised, lines the 
vestibule, the anterior of the naso- and maxilloturbinate regions and the floor of the 
ventral meatus up to the nasopalatine duct. Some vibrissae may be present originating 
from hair follicles in the underlying lamina propria. Generally, in contrast to humans, the 
lamina propria consisting of a simple collagenous matrix is devoid of hair follicles and 
glands. However, ducts originating from glands underlying the anterior respiratory 
epithelium, particularly the nasal septum, discharge serous secretions into the vestibule. 
Respiratory epithelium occupies much of the turbinates, nasal septum, the anterior part of 
the ethmoid recess and the maxillary sinus. Exceptions are the upper posterior region of 
the dorsal meatus. The lateral walls of the vomeronasal organ are also lined with 
respiratory mucosa. Five types of cell are found in the respiratory epithelium: ciliated, 
non-ciliated, goblet, basal and brush cells. The lamina propria of the respiratory region 
contains a rich vascular system, abundant tubuloalveolar serous and mucous glands and 
nerve endings originating from the trigeminal nerve which regulate vascular tone and 
glandular secretions. The lateral wall between the naso- and maxilloturbinates contains 
large venous sinuses referred to as swell bodies. Smaller venous sinuses are also found 
in the region of the maxilloturbinates and the ventral region of the nasal septum. The 
distension and collapse of the swell bodies give the nasal mucosa erectile properties and 
regulates the pattern of air-flow in the cavity depending on factors such as temperature, 
humidity and carbon dioxide concentration in inspired air. A cyclical alteration in air 
conductivity in the rat nasal passages (nasal cycle), similar to that in the human nasal 
passage, has been demonstrated by Bolsen-Moller and Fahrenkrug (1971). Olfactory 
mucosa lines most of the ethmoid recess including the exo- and endoturbinates and the 
upper posterior region of the dorsal meatus. A small isolated patch of specialised 
olfactory mucosa, referred to as the Septal organ of Rodolfo-Masera, is located in the 
ventral region of the nasal septum posterior to the vomeronasal organ. This is thought to 
be part of a chemosensitive alert system and may also function in monitoring inspired air 
for odours. The vomeronasal organ is also lined medially with specialised olfactory 
epithelia. The olfactory epithlium contains bipolar olfactory cells, columnar sustentacular 
cells and basal cells. 
The structure of the rat nasal cavity is generally more complex than that of the human 
nasal cavity due to the complexity of the nasal turbinates. However, the epithelial 
structure is similar in the human and the rat nasal cavity although the proportion of 
respiratory and olfactory epithelia differ in the two species. In humans, the olfactory 
epithelium occupies about 10% of the total surface area of the nasal cavity compared to 
about 50% in rats. These differences in structure and function of the rat nasal cavity 
reflects the greater importance of olfaction in the rat. The absolute dimensions of the rat 
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nasal cavity are much smaller than in humans which is obvious from the size difference 
between the two species. However, if the surface area of the nasal cavity is corrected for 
body weight or total body area, the nasal surface area in the rat is between about 10-40 or 
3-7 times larger, respectively, than the surface area of the human nasal cavity. Again, 
these dimensions reflect the greater importance of olfaction in the rat. 
Figure 1.4. Midline-section (lateral wall) of the rat nasal cavity 
Adapted from Fisher (1990) 
NP 
IT 
NV. nasal vestibule, NT. nasoturbinate, MT. maxilloturbinate, ET. ethmoidturbinates, NP. nasopharynx, 
ND. nasopalatine duct, BC. buccal cavity, IT. incisor tooth. 
1.5 1.2 Rat models for intranasal drug delivery studies 
Two main types of experimental nasal rat model are generally described in the literature, 
the in situ (nasal perfusion) model, the in vivo (surgical) model. 
The in situ, nasal perfusion, model was described by Hirai et al. (1981 a). The technique 
is performed under terminal anaesthesia with the rat usually positioned ventral surface up. 
The trachea is cannulated, using plastic tubing, to maintain the patency of the airway 
during the experimental period. A second cannula is inserted into the oesophagus and 
positioned at the posterior of the nasal cavity. The nasopalatine duct is sealed, usually 
using a cyanoacrylate adhesive, to prevent drainage of the drug solution from the nasal 
cavity into the oral cavity. The oesophageal cannula is connected to a reservoir 
containing the drug solution and is continually stirred. The drug solution will usually be 
maintained at 37°C. A peristaltic pump is used to circulate drug solution from the 
reservoir and through the nasal cavity. The perfused drug solution passes out of the 
nostrils and is recollected in the reservoir via a funnel. The drug solution will be 
continually recirculated through the rat nasal cavity and a sample of the perfusate will be 
periodically taken from the reservoir and analysed for drug content. The amount of drug 
absorbed is evaluated by measuring the disappearance of drug from the perfusate. 
However, the disappearance of drug from the perfusate does not necessarily indicate 
nasal absorption since drug instability, e. g. degradation of peptide and protein drugs by 
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nasal proteolytic enzymes, and aggregation of the drug compound may reduce the 
concentrations of drug in the perfusate. Perfusate drug concentrations may also decrease 
due to systematic losses such as adsorption to cannula tubing (Gibson and Olanoff, 
1987). Evaporation from the drug reservoir may also be problematic with this technique. 
Use of the in situ model allows the evaluation of drug absorption as a function of time. 
However, both the rate of perfusion and the perfusate volume have been shown to 
influence the rate of drug absorption and so must be carefully controlled (Hussain et 
al., 1985, Huang et al., 1985). The rate of absorption of phenobarbital was shown to 
increase as the perfusion rate increased (between 1.0-2.0 ml/min) although was 
independent of perfusion rate above 2 ml/min. A linear relationship was shown to exist 
between the in situ rate constants of absorption and the reciprocal of the volume of 
perfusate and the authors showed that the rate constants agreed well with rate constants 
calculated from in vivo absorption studies. 
The best indication of drug absorption into the systemic circulation is from the direct 
measurement of drug concentrations in the blood requiring periodic blood sampling. 
Alternatively, the appropriate biological response evoked by the drug may be monitored 
for example hypoglycaemia or hypocalcaemia following insulin and calcitonin 
absorption, respectively. In addition, the measurement of drug concentrations in samples 
other than blood, such as urine, may be used as an indication of absorption. 
Measurement of the biological response may be useful for screening the efficacy of 
absorption from nasal delivery systems if an assay method for the drug is not available or 
is complicated, time consuming and expensive. The in situ model has also been used to 
investigate the degradation of drugs by nasal enzymatic systems. Examples of the use of 
the in situ model will be given later in the text. 
The in vivo surgical model, also performed under terminal anaesthesia, was also 
described by Hirai et al. (1981 a). Rats are positioned ventral surface up, the trachea and 
oesophagus are cannulated and the nasopalatine duct is sealed as previously described for 
the preparation of the in situ model. The oesophageal cannula was then sealed using 
cotton and adhesive to prevent the drainage of the nasal dose into the oesophagus and 
stomach. Dose solution is usually administered to the nasal cavity via one nostril, using a 
micropipette, and the nostril sealed with adhesive to prevent dose drainage from the nasal 
cavity. The in vivo method of dose administration is more comparable to dose 
administration in humans in contrast to the perfusion technique. Intranasal absorption is 
usually assessed by analysing blood samples collected periodically from the caudal (tail) 
vein, femoral artery / vein, carotid artery or the dorsal aorta. 
Fisher et al. (1985) simplified the in vivo model and found that the results obtained were 
comparable to those obtained using the model described by Hirai et al. (1981 a). In the 
simplified model, the oesophagus was not cannulated but was occluded by tying it to the 
tracheal cannula and neither the nasopalatine duct nor the nostrils were sealed. However, 
considerable drainage of the dose into the trachea was observed if the nasopalatine duct 
and nostrils were not sealed and the animals were positioned ventral surface down. A 
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simplified rat model has also been reported by Lau-Cam et al. (1991) which did not 
require surgery and hence was suggested to be a less stressful and more physiological 
means of investigating intranasal drug absorption. The absolute bioavailability of 
propranolol administered via the nasal route (100 µl volume) was shown to be very 
similar in the model to that obtained following surgical preparation of animals as 
described by Hirai et al. (1981a) and Fisher et al. (1985). However, as rats are obligate 
nasal breathers then the air flow through the nasal cavity may influence dose distribution 
and therefore the area for absorption (Chandler, 1994). This may have important 
implications when drugs are used which are absorbed to a lesser extent than propranolol 
or smaller dose volumes are administered. Mayor and Illum (1994) have shown that the 
use of anaesthetic agents, particularly long acting anaesthetics, such as pentobarbitone 
sodium, resulted in the increased nasal absorption of insulin in rats. This was suggested 
to be mainly due to impaired mucociliary clearance in anaesthetised rats. Drainage and 
mechanical removal of dose from the nasal cavity will also be prevented by anaesthesia. 
A reduction in the rate of mucociliary clearance in the rat trachea by anaesthesia has 
previously been demonstrated (Patrick and Stirling, 1977). Anaesthesia has also been 
shown to decrease the mucociliary clearance rate in sheep trachea (Landa et al., 1975). 
Dose volume is an important consideration in nasal absorption studies and most often 
dose volumes between 20-50 µl will be administered. Chandler et al. (1991a) 
investigated the effect of dose volume on dose distribution in the rat nasal cavity using 
histological techniques. Doses of 20,50 or 100 µl of I% polyoxyethylene-9-lauryl ether 
(Laureth-9) solution, an agent known to cause damage to epithelial membranes, were 
administered to one nostril and tissues were fixed for histological examination after 5,20 
or 60 minutes. The tissue damaging effects of a 100 µl dose of Laureth-9 were observed 
on both sides of the nasal cavity after 5 minutes although the damage was more severe on 
the dosed side. Tissue damage, especially on the undosed side, was increased with 
increasing contact time. Following contact for 5 minutes, the 50 µl dose severely 
damaged the dosed side of the nasal cavity but there was only slight damage around the 
septum on the undosed side. However, damage to the undosed side of the nasal cavity 
increased with increased contact time. In contrast, damage to the nasal tissue induced by 
a 20 µl dose was confined to the dosed side of the nasal cavity irrespective of contact 
time. Thus, dose volume should be carefully controlled during nasal absorption 
experiments particularly when comparing formulations. Investigation of nasal absorption 
from powder delivery systems is difficult in the rat, compared to larger species, due to 
the narrowness of the nares and the difficulty in accurately administering small quantities 
of powder. However, Bjork and Edman (1988) investigated the nasal absorption of 
insulin from lyophilised powder formulations in the rat administering about 1 mg of 
powder., 
1.5.2 The sheep model 
In biomedical research, the sheep is commonly used as an animal model although 
relatively few studies employing the sheep as an animal model for intranasal absorption 
studies have been reported. An important feature of the sheep model for intranasal 
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absorption studies is that the animals are conscious, although sheep may be sedated 
during dose administration, and hence normal patterns of mucociliary clearance should 
not be disrupted. Thus, compared to small animal models, nasal absorption in the sheep 
model will allow better prediction of nasal absorption in humans. The manageable size of 
the sheep combined with their passive and tolerant nature enable them to be easily 
handled in nasal absorption studies. They are generally readily obtainable throughout the 
year at the specific weights required. The large nostril size of the sheep, enables both 
liquid and powder nasal delivery systems to be evaluated and doses comparable to those 
administered to humans can be given to sheep. Chien et al. (1989) suggests that the 
sheep model is suitable and practical for evaluating parameters involved in the nasal 
delivery of drug from a more sophisticated formulation. The paired external jugular veins 
which pass down the neck on either side of the trachea are easy to locate, and can be 
readily cannulated by non surgical procedures for the purpose of serial blood sampling. 
Sheep can be repeatedly used in drug absorption studies provided an adequate wash-out 
period is allowed between successive dose administrations. The washout period should 
take into account the pharmacokinetic profile of the drug and replenishment of blood 
volumes in sheep 
1.5.2.1 Structure of the sheep nasal cavity 
The description of the sheep nasal cavity is based upon May (1964) and Hare (1975). A 
midline section of the sheep nasal cavity is shown in Figure 1.5. The nasal cavity of the 
sheep is pyramidal shape with the apex located in the anterior of the cavity. The nasal 
septum incompletely separates the nasal cavity in the posterior, ventral region of the 
cavity, although the separation may be completed by a thick fold of the mucosal lining, 
extending from a plate of the septal cartilage, which contains a rich submucosal venous 
plexus. If the separation is incomplete, the two sides of the cavity will join to form a 
common, nasopharyngeal meatus at the floor of the nasal cavity close to the 
nasopharynx. Two major scroll-like turbinate bones, the dorsal turbinate and the more 
complex ventral turbinate, project inwards from the lateral wall and extend, antero- 
posteriorly, across most of the nasal cavity. The ventral turbinate bone occupies most of 
the lateral wall of the cavity and is separated into upper and lower regions (ventral and 
dorsal plates), which are arranged in coils. A series of smaller ethmo-turbinates are 
located in the superior part of the nasal cavity and the largest of these, at the posterior of 
the superior region, is the middle turbinate. 
There are three major meatuses in the nasal cavity created by the turbinates. The dorsal 
meatus, between the dorsal turbinate and the cavity roof, is long and narrow and extends 
the whole length of the nasal bone. The ventral meatus, between the cavity floor and the 
ventral turbinate. Between the dorsal and ventral turbinates is the middle meatus which is 
divided, posteriorly into dorsal (olfactory) and ventral (respiratory) parts by the middle 
turbinate. The ventral meatus is the largest and least restricted of the passages providing 
a direct communication between the nares and the nasopharynx. Ethmoidal meatuses, 
small, narrow, passages between the ethmoid bones in the postero-ventral part of the 
nasal cavity, are also found. The three meatuses communicate medially at the common 
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meatus, a narrow slit-like passage extending between the floor and roof and between the 
septum and turbinates. The common meatus is narrow dorsally and widens ventrally. 
The vomeronasal organ consisting of two blind-tubes, about 7 cm long and 0.3-0.4 cm 
wide, are positioned on either side of the nasal septum, at the level of the nasal floor, and 
enter the oral cavity. There are five paranasal sinuses in sheep (frontal, maxillary, 
palatine, sphenoid and ethmoidal) which are embedded in the various bones of the skull. 
Each sinus is connected, either directly or indirectly, to the nasal cavity. The mucosa of 
these sinuses is continuous with that of the nasal mucosa. 
Stratified squamous epithelia containing numerous serous glands lines the vestibule just 
inside the Hares. In the main part of the nasal cavity there is a transition from stratified 
squamous epithelia to pseudostratified columnar epithelium. The reddish coloured 
mucosa of the respiratory region, containing an abundance of mucus secreting goblet 
cells and numerous subepithelial tubuloalveolar glands which are mainly serous in nature, 
occupies the majority of the nasal cavity. The postero-superior regions of the nasal 
cavity, the ethmoturbinates, dorsal turbinate and adjacent region of the nasal septum are 
lined with the yellow coloured mucosa of the olfactory region containing olfactory cells 
(bipolar neurones), sustentacular cells and basal cells. There are numerous serous 
secreting tubuloalveolar glands and also sensory nerve endings. The nasal mucosa, 
particularly that of the respiratory region, has a rich vascular system with abundant small 
arteries, veins, capillary plexuses and venous plexuses. 
Figure 1.5. Midline-section (lateral wall) of the sheep nasal cavity 
Adapted from Gizurarson (1990) 
NV. nasal vestibule, NT. dorsal turbinate, MT. middle turbinate, ET. ethmoidal turbinates, VT. ventral 
turbinate, NP. nasopharynx, 
The nasal cavity of the sheep is more complex than that of humans due to the complexity 
of the nasal turbinates. However, as in the rat, the epithelial structure of the sheep nasal 
cavity is similar to that in humans. The absolute dimensions of the sheep nasal cavity are 
much larger than in humans which is probably related to a function of the nasal cavity in 
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sheep for the dissipation of heat through through water vaporisation. 
1.5.2.2 The sheep model for intranasal absorption studies 
Sheep models have been used and described by Longecker et al. (1987) and Ilium et al. 
(1989). Sheep are usually used in the conscious state although a sedative may be 
administered immediately prior to dose administration to facilitate the handling of the 
sheep and to prevent or limit sneezing during dose administration. A low dose of 
ketamine, administered intravenously, has been used to induce sedation and typically the 
sedative effects of the ketamine last about three minutes. Although long acting 
anaesthetics have been shown to reduce mucociliary clearance in sheep (Landa et al., 
1975) sedation should have very little overall effect on mucociliary clearance. 
Cannulation of the jugular vein allows serial blood samples to be collected (Hecker, 
1983) and intravenous ketamine for induction of anaesthesia to be administered. Since 
the jugular veins are bilateral, intravenous drug doses, for reference purposes, may be 
administered into one jugular vein and blood samples collected from the contralateral 
jugular vein. Jugular vein cannulae may remain indwelling in sheep for several weeks 
provided that their patency is maintained by regularly flushing in with an isotonic solution 
containing anticoagulant (typically heparinised normal saline). This will allow cross-over 
studies to be performed. Intranasal doses may be administered using various devices 
which should be inserted to a depth of about 7-10 cm into the sheep nostril to allow doses 
to be administered to the main part of the nasal cavity. The sheep provides a convenient 
model to investigate nasal delivery systems prior to their evaluation in human clinical 
trials. 
Table 1.1. Comparative characteristics of the nasal cavity of man and 
animal species 
Species Nasal Surface Length Bend to Turbinate Clearance Equivalent 
[Weight volume area (cm) nasopharynx complexity half-life nasal volume 
(kg)] (ml) (cm2) (min) (µl) * 
Man 20 160 7.5 90° Single 15 150 
[70] scroll 
Rat 0.4 14 2.3 15° Double 5 13 
[0.25] scroll 
Sheep 114 327 18 30° Double 42 307 
[60] scroll 
Dog 20 221 10 30° Branching 20 207 
[10] (complex) 
Monkey 8 62 5.3 80° Single 10 58 
[7] scroll 
Rabbit 6 61 5.2 50° Branching 10 58 
[3] (complex) 
Guinea pig 0.9 27 3.4 30° Double 7 25 
[0.6] scroll 
Mouse 0.03 2.8 0.5 15° Double 1 3 
[0.03] scroll 
Adapted from Gizurarson (1990) and Ilium (1995). 
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1.6 Intranasal absorption of peptide drugs 
It is recognised that the intranasal route has great potential for the delivery of peptide and 
protein drugs for systemic medication. However, a number of factors affect intranasal 
drug absorption. These are often referred to as the barriers to drug absorption. These 
will be described below along with the approaches which may be used to overcome these 
barriers. 
1.6.1 Barriers to peptide and polypeptide drug absorption 
The most significant barriers to intranasal peptide and protein drug absorption are: 
i) Deposition and clearance from the nasal cavity 
ii) Penetration of the mucus layer and the epithelial membrane 
iii) Enzymatic degradation 
1.6.1.1 Deposition and clearance of drugs from the nasal cavity 
Particles which are deposited in the nasal cavity will tend to be rapidly cleared by 
mucociliary mechanisms with a half life of clearance of about 15-30 minutes (Ilium et al., 
1987). Thus, for drugs administered intranasally, mucociliary clearance will tend to limit 
the time available for drug formulations deposited in the nasal cavity to be absorbed 
across the nasal mucosa. This may be an important factor for peptide and protein drugs 
which do not tend to exhibit optimal absorption characteristics (Schipper et al., 1991, 
Ilium; 1992). The site of deposition and clearance of drug formulations administered to 
the nasal cavity will depend largely on the delivery system and the type of administration 
device used (Chien and Chang; 1987, O'Hagan and Illum; 1990). The type of 
administration device will influence the size of the particles administered to the nasal 
cavity since it will determine droplet size if aerosol devices are involved. Particle size is 
an important determinant for the site of deposition of inhaled compounds in the nasal 
cavity (Phalen, 1984). For non-spherical particles this will depend on the equivalent 
aerodynamic diameter of the particles which relates the tendency of the particles to settle 
to that of spherical particles of unit density. Inhaled aerosolized particles of aerodynamic 
diameter less than 1 gm will tend to pass through the nasal cavity to the lower respiratory 
tract. Particles of diameter greater than about 10 µm will tend to be entirely deposited in 
the nasal cavity and will be trapped in the mucus layer. The proportion of particles 
between 1-10 µm deposited in the nasal cavity will be influenced by several other factors 
such as the velocity of the air stream and the turbulence of air flow. Larger particles tend 
to deposit more anteriorly and smaller particles more posteriorly in the nasal cavity. 
The fate of particles administered intranasally from a delivery device will be influenced by 
a number of factors such as particle size, size distribution, density, shape and 
hygroscopicity, respiratory patterns, nasal pathology and the delivery device employed. 
The nasal deposition of particles administered from a delivery device such as a nasal 
spray will be mainly by inertial impact with sedimentation and diffusion being of less 
importance (Chien and Chang; 1987). Several studies have evaluated the deposition of 
compounds from nasal delivery systems and are detailed below. In most of these 
studies, tracer compounds radiolabelled with 99mtechnetium were used allowing the fate 
of the compounds administered to the nasal cavity to be easily followed by gamma 
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scintigraphy. 
Aoki and Crawley (1976), studied the nasal distribution and clearance of radiolabelled 
human serum albumin (HSA), administered as spray or drops, in human volunteers. 
Drops were shown to be deposited over the main part of the nasal cavity 2 minutes after 
administration and changes in the volume or concentration of the HSA solution did not 
affect the pattern of distribution. Spray was shown to be mainly deposited beyond the 
nasal cavity in the pharynx and although the size of the spray droplets were not given it is 
likely that most were considerably less than 10 gm in diameter otherwise a significant 
proportion of droplets would be expected to deposit in the nasal cavity. Mygind and 
Vesterhauge (1978) used a plastic cast of the human nose to investigate the intranasal 
distribution of toluidine blue dye administered as an aerosol or as drops. Aerosol 
administered from a metered dose pump proved to be the best administration device 
delivering a constant dose which was evenly distributed over both the septal and lateral 
walls of the nasal cavity and covered a large surface area. A metered dose aerosol tended 
to distribute the dye as a narrow band predominantly on the anterior septal wall with little 
distributed on the lateral wall. Administered as two actuations of the metered dose 
aerosol per `nostril', one directed into the upper part of the nose and one in the lower part 
of the nose, improved the distribution of dye. Spray delivered from a plastic bottle 
nebulizer was variable with fairly even distribution obtained provided that the bottle was 
squeezed vigorously and hence this device would be unsuitable for the delivery of 
accurate drug doses. Drops, administered from a drop-bottle, were poorly distributed 
tending to deposit on a very small surface area of the nasal cast predominantly in the 
anterior third of the nasal cavity. 
Hardy et al. (1985) administered radiolabelled albumin solutions as drops or a spray to 
human volunteers. Spray was deposited mainly in localised regions in the anterior of the 
nasal cavity and was slowly cleared to the pharynx predominantly along the inferior 
meatus. This slow clearance was attributed to the dose predominantly depositing in the 
non-ciliated regions of the nasal cavity. Administration of drops resulted in more 
extensive spread in the nasal cavity, due to mucociliary transport, which was more 
pronounced when three drops (90 µl volume) were administered rather than one drop (30 
µl). Three drops were sufficient to cover most of the walls of the nasal cavity. 
Approximately 40% of the total dose, following administration as spray or drops, was 
cleared within about 10 minutes although overall drops were cleared much faster than 
spray since drops tended to deposit in the ciliated regions. In a study in human 
volunteers, approximately 80% of the total dose of insoluble radiolabelled teflon particles 
(median aerodynamic diameter of 3.2 p. m) were deposited in the nasal cavity with much 
of the rest remaining in the dose actuator (Newman et al., 1987). The majority of the 
particles were distributed on a single area in the anterior of the nasal cavity and failed to 
penetrate much beyond the internal osteum. Aerosol distribution was not improved by 
administering two actuations of the metered dose aerosol per `nostril' as proposed by 
Mygind and Vesterhauge (1978) following studies using a human nasal cast and this was 
attributed to the wider nasal passages of the nasal cast compared to the human nose in 
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vivo. Liversidge et al. (1988) found that the dosage form (either spray or drop) and site 
of administration (either dorsal or ventral surface of the nostril) influenced the nasal 
distribution and clearance of radiolabelled diethylenetriamine pentacetic acid (DTPA) in 
dogs. Greatest deposition on the turbinates and the slowest clearance was achieved by 
administration of drops to the dorsal surface, just inside the nostril, during inhalation. 
This is of significance since the turbinate mucosa having a high surface area and 
vascularity should theoretically provide the optimal surface for drug absorption. A drop 
of DTPA administered to the ventral surface resulted in low turbinate deposition and rapid 
clearance from the nasal cavity. Administration of a spray to both surfaces resulted in 
turbinate deposition which was intermediate between that of drops administered to the 
ventral and dorsal surfaces and was cleared fairly rapidly. 
Harris et al. (1986) investigated the relationship between intranasal deposition, clearance, 
in vivo absorption and biological response in human volunteers. Solutions containing 
desmopressin, a synthetic derivative of the posterior pituitary hormone arginine 
vasopressin, and radiolabelled HSA were administered from metered-dose pumps 
(dosing 50 or 100 µl per actuation) or as drops using either a plastic catheter tube or a 
single dose pipette each administering 200 µl. The doses of desmopressin administered 
from each delivery device was 300 µg. Deposition and clearance were followed by 
gamma scintigraphic detection of radiolabelled HSA and the intranasal absorption of 
desmopressin was assessed directly from plasma desmopressin concentrations or 
indirectly from its biological response (coagulating activity). Drops from both devices 
tended to be deposited in the posterior of the nasal cavity close to the nasopharynx and 
were cleared rapidly (50% of the dose cleared within about 20 minutes). Sprays tended 
to be deposited in the anterior of the nasal cavity and spray droplets were cleared at a 
relatively slower rate (50% clearance of 100 pl (2 x 50 µl) or 200 µl (2 x 100 p1) spray 
dose was 240 minutes or 120 minutes, respectively). The faster clearance of drops 
compared to sprays supports the findings of Hardy et al. (1986). Desmopressin was 
absorbed to a greater extent following the administration of sprays and the 100 µl dose 
performed better than the 200 µl dose. The studies indicated a relationship between 
deposition, clearance and intranasal absorption and the importance of nasal spray volume 
and concentration. In a later study in humans, the effects of concentration and dose 
volume on the nasal bioavailability and biological response of desmopressin (300 pg 
doses), administered from a metered dose spray, were evaluated (Harris et al., 1988). 
Bioavailability and enhanced biological response were significantly greater after 
administering 2x 50 µl compared with 1x 50 µl and 1x 100 µl doses. Based on these 
studies, Harris et al. suggested that the bioavailability of drugs administered to the nasal 
cavity may be increased by increasing their residence time in the nasal cavity. 
Subsequently, the effect of viscosity on patterns of deposition and clearance of nasally 
administered solutions containing desmopressin and radiolabelled HSA methylcellulose, 
as a viscosity enhancing agent, were investigated in humans (Harris et al., 1988b). 
Methylcellulose was assessed as a spray from a metered dose pump at concentrations of 
0,0.25 and 0.50% (mean diameters of the spray droplets were 51.3 pm, 81.3 µm and 
200 µm respectively) or as drops from a catheter tube at concentrations of 0 or 0.5% 
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(viscosity had no affect on the size of drops). Sprays tended to be deposited in the 
anterior of the nasal cavity and there were no apparent differences in the initial pattern of 
deposition of the 0% and 0.25% solutions but the initial deposition of the 0.5% solution 
was shifted anteriorly probably due to the considerable increase in particle size at this 
concentration. Administration of sprays resulted in 50% clearance in 65,75 and 43 
minutes at concentrations of 0%, 0.25% and 0.50%, respectively. Drops were deposited 
more evenly over the nasal cavity and pharynx although the initial deposition was more 
localised for the 0.5% solution and solution viscosity did not affect clearance with 50% 
of the administered dose being cleared after about 20 minutes. To explain the results, it 
was suggested that viscosity had a maximal effect on the retention time which was related 
to the droplet size. The effect of solution viscosity in relation to the intranasal absorption 
of desmopressin was later assessed in human volunteers (Harris et al., 1989). 
Desmopressin solutions containing 0% or 0.25% methylcellulose were administered 
intranasally from a metered dose pump. The authors reported that the addition of 
methylcellulose resulted in slower and sustained absorption although this claim is not 
convincing from the published results. The previous study by this group (Harris et al., 
1988b) had shown that there was only a small difference in the rate of clearance of 
solutions containing either 0% or 0.25% methylcellulose. It would be interesting to 
evaluate nasal absorption and biological effect when the differences in clearance rates are 
much more pronounced. 
Pennington et al. (1988) also investigated the influence of solution viscosity, using 
hydroxypropyl methylcellulose (HPMC) as the viscosity enhancer, on the deposition and 
clearance of nasal sprays containing radiolabelled DTPA, in humans. Three solutions 
containing either 0.6%, 0.9% or 1.25% HPMC (kinematic viscosities of 36,120 and 430 
mm2. S-1, respectively), were compared and each formulation was found to be deposited 
in the anterior of the nasal cavity, predominantly in the atrium, with no significant 
differences in the pattern and area of deposition. The half lives of clearance of the 
solutions (0.6%, 0.9% and 1.25%) were reported as 1.0,1.7 and 2.2 hours, respectively 
and clearance was mainly along the inferior meatus to the pharynx. Clearance rates were 
not significantly different due to large inter-subject variation, although the results indicate 
that increasing formulation viscosity increases the residence time of the dose in the nasal 
cavity and thus may be a means by which the therapeutic efficacy of nasal spray 
preparations are prolonged. The clearance pattern following the administration of the 
0.6% solution was biphasic which was suggested to be due to a relatively fast clearance 
of dose which is deposited in the ciliated posterior regions and the slower clearance of 
dose which is deposited in the less sparsely ciliated or non-ciliated anterior regions. 
Particles deposited in non-ciliated regions will be cleared by a very slow drag from 
contiguous mucus which will usually transport particles in an anterio-posterior direction 
although movement anteriorly may also occur where they may be removed by blowing, 
wiping or sneezing (Proctor et al., 1973). The differences observed in the clearance of 
the more viscous solutions may be due to the formation of a continuous film on the nasal 
mucosa which will tend to be slowly dragged from the site of deposition in contrast to 
less viscous solutions which may be film forming but these are likely to break up due to 
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mucus drag and be transported at faster rates (Pennington et al., 1988). 
Ilium et al. (1987) investigated the deposition and subsequent clearance of three 
radiolabelled microsphere powder systems (albumin, starch and DEAE-dextran 
microspheres) and two control systems (commercially available sodium cromoglycate 
powder or solution formulation) in human volunteers. Initial deposition of the powders, 
administered from a nasal insufflator, was mainly in the anterior part of the nasal cavity 
with little of the dose being deposited in the turbinate regions. In contrast, the nasal 
solution, administered from a spray pump, was deposited throughout the nasal cavity 
from the atrium to the nasopharynx. Both the control systems were rapidly cleared from 
the nasal cavity with half times of clearance of about 15 minutes. The microsphere 
formulations were cleared much slower from the nasal cavity with clearance half times for 
albumin and starch microspheres of about 3 hours. At this time, approximately 60% of 
the DEAE-dextran formulation remained in the nasal cavity. The slow clearance of the 
microsphere from the nasal cavity was proposed to be due to a combination of their 
mucoadhesive properties and also due to deposition in the non-ciliated anterior regions of 
the nasal cavity. The control powder, despite being deposited in the anterior of the cavity 
was rapidly cleared probably because it did not exhibit mucoadhesive properties. 
Wolff et al. (1993) investigated the effect of varying the site of deposition on nasal 
clearance in anaesthetised (ketamine anaesthetic) rhesus monkeys. Radiolabelled sulphur 
colloid solution administered to the turbinate region of the nasal cavity, using a catheter 
tube, was shown to be cleared more rapidly than that administered to the anterior regions 
with 27 ± 4% and 87 ± 7%, respectively, of the dose being retained in the nasal cavity 
after 30 minutes which may be due to initial deposition in predominantly ciliated and non- 
ciliated regions, respectively. 
The clearance of drug formulations from the nasal cavity may be reduced in patients with 
pathological conditions such as chronic sinusitis, nasal polyposis and infection such as 
the common cold which tend to impair mucociliary function (Lee et al., 1984, Chien and 
Chang; 1987). Lee et al. (1984) investigated the effects of nasal polyposis, causing 
obstruction of the nasal airway, on the deposition and clearance of radiolabelled HSA 
solution administered intranasally using a spray applicator (mean droplet diameter 51 
µm). The pattern of deposition and clearance in patients with nasal polyposis was 
compared with that of normal healthy volunteers. The pattern of deposition of HSA 
solution did not differ between normal subjects and those will nasal polyposis with 
deposition in the anterior region of the nasal cavity. However, clearance was 
considerably slower in patients with nasal polyposis and clearance did not improve 
following polypectomy which suggested that the physical obstruction of the polyps to 
mucus flow was not responsible for the slow clearance which was presumed to be due to 
defects in ciliary action, mucus secretion or a combination of the two. Thus, pathological 
conditions are an important consideration if the nasal route is to be utilised for systemic 
drug delivery since inappropriate drug absorption (too great or too little) may be achieved 
depending on the distribution of the drug at the absorption site. It may not be an 
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appropriate alternative to parenteral administration if controlled blood concentrations are 
required (Lee et al., 1984). 
1.6.1.2 Penetration of the mucus layer and epithelial membrane 
The mucus layer protects the underlying epithelial membrane and is vital for the 
mucociliary clearance mechanism as outlined above. The mucus layer presents the first 
physical barrier to drugs deposited in the nasal cavity. Drugs must penetrate the mucus 
layer, particularly the viscous gel layer, to reach the epithelial cell membrane before the 
mucociliary clearance mechanism removes the deposited drug from the nasal cavity. The 
role of nasal mucus as a diffusional barrier for peptide and polypeptide drug absorption 
has not been established (O'Hagan and Ilium, 1990, Lee et al., 1991). It has been 
suggested that mucus is a selective barrier to macromolecules (Edwards; 1978). Kearney 
and Marriott (1987) showed that the rate of transport of tetracycline across rat small 
intestinal epithelium was significantly increased if the layer of endogenous mucus was 
removed which was attributed to mucus as a diffusional barrier to drug transport rather 
than due to binding of the drug with mucus glycoproteins. However, since the thickness 
of the mucus layer in the nasal cavity is about one hundredth of that of the intestines, then 
the mucus layer may not present a serious diffusional barrier for drugs. There are 
possibilities that drugs may interact with mucus particularly the mucus glycoproteins 
which tend to be negatively charged due to the sialic acid and sulphate groups of the acid 
glycoproteins (anionic polyelectrolytes). 
The mucolytic agent N-acetyl-L-cysteine, has been shown to improve the intranasal 
absorption of human growth hormone in rats (O'Hagan et al., 1990) with bioavailability, 
relative to a subcutaneous dose, improved from about 7% to 12%. N-acetyl-L-cysteine 
finds clinical application in the treatment of bronchopulmonary diseases by reducing the 
viscosity and tenacity of mucus thus facilitating its removal. Thus, improved absorption 
may be due to a reduction in the intermolecular interactions of growth hormone with 
mucus glycoprotein chains (Ilium, 1992). However it is not known if N-acetyl-L- 
cysteine has a direct effect on the permeability of the nasal epithelial membrane (Lee, 
1991). Ilium (1992) suggests that relative to many of the other factors which limit nasal 
absorption, mucus does not constitute a very significant barrier. 
Following its passage through the mucus layer, for absorption to take place the drug 
molecule must be able to traverse the epithelial membrane. The nasal epithelium is a 
highly efficient barrier to the absorption of peptide and protein drugs. Absorption across 
epithelial membranes, irrespective of the mucosal site in which they are located is 
proposed to occur by either transcellular or paracellular routes. In the transcellular route, 
molecules pass directly through cells by passive diffusion or by active processes which 
may involve carrier mechanisms. Alternatively transcytosis may occur whereby 
molecules are taken up in vesicles by endocytosis at the cell surface and cross the cell 
discharging their contents into the intercellular space. In the paracellular route, which 
may also be referred to as transport via aqueous channels or pores, molecules pass 
through the tight junctions and spaces between adjacent cells. Aqueous pores in the cell 
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membrane have also been described (Harvey, 1975, Gardner, 1984). However, there is 
no anatomical evidence to support the existence of aqueous pores in the cell membrane 
and the likely candidate are the intercellular tight junctions (Fisher, 1994). The properties 
of the drug molecule and the characteristics of the cellular barrier will determine whether 
or not molecules are able to cross the barrier by transcellular or paracellular routes (Raub 
et al., 1993). McMartin et al. (1987) proposed that in nasal mucosa, there are two 
mechanisms for the transport of compounds. One, a fast mechanism which is dependent 
on the lipophilicity of the compound and the second, a slower mechanism which is 
dependent on the molecular weight of the compound. Lipophilic compounds tend to 
readily diffuse across biological membranes since they are able to partition into the lipid 
environment (bilayer) of the cell membrane and diffuse into and traverse the cell in the 
cell cytoplasm. Drugs may also diffuse in the cell membrane, crossing the cell from the 
apical to the basolateral surface (Raub et al., 1993). 
A number of lipophilic drugs, some of which are mentioned below, have been shown to 
be completely or almost completely absorbed after intranasal administration, relative to 
the intravenous route. Absorption of the ß-adrenoceptor antagonist propranolol has been 
shown to be rapid and complete following intranasal administration in rats, dogs and 
humans with blood concentrations similar to those following intravenous administration 
(Hussain et at., 1979,1980a, 1980b). In vitro studies, using sheep nasal mucosal 
tissue, showed that propranolol was transported at a rate approximately five times that of 
mannitol which has a similar molecular weight but is less lipophilic (Wheatley et at., 
1988). It was suggested that propranolol traverses the nasal membrane by the trancellular 
route and mannitol by the paracellular route both by passive processes. The absorption 
of naloxone, a narcotic antagonist, buprenorphine, an opiate analgesic and testosterone, a 
natural steroid hormone, were 101%, 95% and 99% (25 µg dose) respectively in rats 
(Hussain et at., 1984). The bioavailability of 17a-ethinyloestradiol, a synthetic steroid, 
was shown to be 80%, 85% and 84% at dose concentrations of 1.75,3.5 and 7 µg/kg, 
respectively (Bawarshi-Nassar et at., 1989). The difference in bioavailability of the nasal 
route compared to the intravenous route was attributed to metabolism in the nasal 
mucosa. 
The correlation between lipophilicity and nasal absorption has been demonstrated using 
several compounds. The lipophilicity of a compound may be indicated by the partition 
coefficient which measures the partitioning or distribution of molecules between organic 
and aqueous solvents. The greater the value of the partition coefficient then the higher is 
the lipid solubility of the compound. Hussain et al. (1985) and Huang et al. (1985) 
demonstrated the effect of lipid solubility in rats using a series of barbiturates at pH 6.0. 
The intranasal absorption of the barbiturates was greater as the chloroform/water partition 
coefficient increased. However, a fifty-fold difference in the partition coefficient resulted 
in only a four-fold difference in the extent of absorption. The pH is an important 
consideration since at pH 6.0 the barbiturates are almost entirely in their non-ionised form 
(pKa 7.6). Generally unionised molecules will tend to partition from aqueous into 
organic phases whereas ionised molecules tend to remain in aqueous phases where they 
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are hydrated and highly soluble (Florence and Attwood, 1988). Thus, unionised 
molecules will tend to be more readily absorbed across mucosal membranes than ionised 
species. Most drugs are weak electrolytes, containing ionisable groups, which will tend 
to diffuse across lipid membranes mainly in their unionised, lipid soluble, form. The 
ionised, hydrophilic form will remain in aqueous phases. The pH will influence the ratio 
of ionised and unionised species as given by the Henderson-Hasselbach equation below: 
pH = pKa + (log ionised / log unionised) 
Where pKa is the negative logarithm of the dissociation constant of the drug 
Acidic drugs will tend to be predominantly unionised and basic drugs predominantly 
ionised at pH values below their pKa. The pH dependency of the absorption of weak 
electrolytes is the basis of the pH-partition hypothesis. The intranasal absorption of 
aminopyrine, a weakly electrolytic lipophilic compound, has been shown to follow the 
pH-partition theory (Hirai, 1981 a). However, the same authors showed that although 
salicylic acid was absorbed to a greater extent in the unionised form, there was 
considerable absorption of the ionised species and clearly does not follow the pH- 
partition theory. Similarly, benzoic acid was absorbed to a greater extent in its ionised 
form but the compound was also absorbed when it was almost fully ionised (Hussain et 
al., 1985). Kaneo (1983) investigated the intranasal absorption of hydralazine, an 
antihypertensive basic drug, in rats (in-situ model) showing that the absorption of 
hydralazine increased linearly as values of pH and the fraction of the unionised species 
increased. Minimum absorption was demonstrated when the compound was fully 
ionised (pH « pKa) and it was suggested that the presence of aqueous channels in the 
nasal membrane allowed the absorption of the ionised species. Fisher (1990) considered 
that these results may be explained if absorption occurs via both lipoidal (transcellular) 
and aqueous (paracellular) routes. The unionised species will cross the membrane via the 
lipoidal route and the ionised species will cross the membrane via the aqueous route. 
Gibson and Olanoff (1987) showed that the intranasal rate of uptake of steroids in rats 
increased as the octanol/water partition coefficient increased and was found to be pH 
independent. The same authors investigated the nasal absorption of alkanoic acids 
(decanoic (C10), octanoic (C8) and hexanoic (C6) acids), each having a pKa value of 
4.85, over the pH range 2.5 to 10. The nasal absorption rates of each compound were 
similar and did not correlate to the partition coefficient (partition coefficient increased in 
the order C6<C8<C10) although absorption rates were pH dependent with maximum 
values between pH 4.5-5.0. Maximum absorption rates would be expected to occur at 
pH values less: than the pKa value when the compound is largely unionised. The 
apparent right shift in the peak absorption rates as a function of pH together with the lack 
of correlation to partition coefficient was suggested to be due to the presence of an 
aqueous boundary layer over the lipid membrane. Thus, it is the aqueous layer rather 
than the lipid membrane which, under certain circumstances, influences the nasal 
absorption of charged compounds. Fisher (1990) points out that these compounds do 
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not follow the classical pH-partition theory and the reasons may be due to absorption via 
lipoidal and aqueous routes. Corbo et al. (1989b) in a study in rabbits, demonstrated that 
the rate and extent of absorption of progesterone and its monohydroxy, dihydroxy and 
trihydroxy derivatives decreased as the lipophilicity decreased. These findings were 
inconsistent with previous absorption studies in rabbits using progesterone and its 
hydroxy derivatives (Chien et al., 1988, Corbo et al., 1989a) where the extent of 
absorption was shown to be a hyperbolic function of the nasal mucosa partition 
coefficient (the degree of partitioning of the compound into excised samples of rabbit 
nasal tissue) rather than the octanol/water partition coefficient. The bioavailability of 
progesterone was lower than that of its less lipophilic monohydroxy derivative. Corbo et 
al. (1990) studied the barrier properties of nasal, rectal and vaginal membranes and found 
that the nasal membrane had the highest in vitro transport of mannitol (model hydrophilic 
compound) and progesterone (model lipophilic compound). The in vitro transport of 
progesterone and its hydroxy derivatives was shown to decrease as lipophilicity 
decreased and although the nasal membrane was found to have `hydrophilic character' it 
was found to be primarily lipophilic in nature. Gibson and Olanoff (1987) concluded that 
for non-ionised molecules the nasal membrane is essentially a modified lipophilic 
transport barrier. 
Although lipophilicity has been demonstrated to be of some importance in the intranasal 
absorption of several compounds, McMartin et al. (1987) suggested that the correlation 
between absorption and lipophilicity (indicated by charge and hydrophobic balance) was 
weak compared to the correlation between absorption and molecular weight. However, it 
was pointed out that the relatively weak correlation of charge and polarity may be 
consequential of the relationship with molecular weight since lipophilic compounds at the 
lower end of the molecular weight range were studied. 
Hydrophilic, polar compounds are thought to be absorbed by the paracellular route via 
the intercellular tight junctions and the spaces between cells (aqueous pores). The 
presence of aqueous pores has been described by several authors (Hirai et al., 1981, 
Kaneo, 1983, Hayashi et al., 1985, McMartin et al., 1987, Tengamnuay and Mitra, 
1988, Fisher et al., 1992). Gibson and Olanoff (1987) dismissed the presence of 
aqueous pores in the nasal membrane since the in-situ absorption of mannitol, over a 60 
minute period was shown to be negligible. Mannitol has been shown to slowly permeate 
the ovine nasal membrane in vitro over a 60 minute period (Wheatley et al., 1988) and 
Corbo et al. (1989) showed that mannitol was readily absorbed in vitro over a 24 hour 
period. 
A correlation between molecular weight and intranasal absorption has been demonstrated 
using of a variety of compounds (McMartin et al., 1987). The nasal membrane was 
found to be readily permeable to hydrophilic compounds up to a molecular weight of 
about 1000. This molecular weight dependency suggests that transcyctosis is not 
responsible for the absorption of these compounds since endocytotic vesicles would be 
unlikely to restrict compounds of molecular weight less than than several hundred 
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thousand. Absorption via membrane pores and carrier systems was also thought to be 
unlikely since permeation of compounds of molecular weight of Z 1000 would disrupt the 
ion concentration gradients and therefore the internal environment of the cell. Also, this 
method would require that compounds are absorbed across the cell membrane into the 
cytoplasm containing a variety of peptidases which would probably destroy peptide 
drugs. Thus, it is likely that small hydrophilic compounds are absorbed via the aqueous 
pores. 
The nasal membrane has been reported to be richer in water channels of smaller pore size 
compared to the jejunum or rectum and water influx across the nasal membrane was 
shown to be three times greater than that in the jejunum and six times greater than in the 
rectum (Hayashi et al., 1985). Transport of water across the numerous glands in the 
nasal mucosa may effect drug absorption through solvent drag (Kotani et al., 1983). In 
the study by Hayashi et al. (1983), inulin (molecular weight 5200) was used as a non- 
absorbable marker although Fisher et al. (1987) showed that inulin was significantly 
absorbed and dextran (molecular weight 70000) was absorbed to some extent following 
intranasal administration. Kotani et al. (1983) also found that inulin and fluorescein 
isothiocyanate-labelled dextran (molecular weight 20000) were not absorbed nasally and 
concluded that they were suitable for use as volume indicators in nasal perfusion studies. 
Volume indicators allow changes in perfusate volume, which may occur due to water 
transport, to be assessed since this, as well as drug absorption, will alter perfusate drug 
concentration. In the studies mentioned above, the conflicting results for inulin and 
dextran absorption may be explained by the different times allowed for contact between 
the drug and the nasal mucosa in the respective studies. Kotani et al. (1983) and Hayashi 
et al. (1985), using in vivo and/or in situ rat models, evaluated absorption over a period 
of 1 hour compared to 6 hours in the in vivo study by Fisher et al. (1987) suggesting that 
a contact time of more than 1 hour is required to achieve significant absorption of inulin. 
Nasal absorption may also be influenced by molecular shape allowing linear and flexible 
compounds such as dextran and to a lesser extent inulin to pass `end-on' through pores 
which are narrower than values predicted from their molecular radii (Fisher, 1990). 
Fisher et al. (1987) investigated the effect of molecular size on the intranasal absorption 
of a range of water soluble compounds in the rat finding that there was a direct correlation 
between the log of the molecular weight and the log of the proportion absorbed. Maitani 
et al. (1989) studied the effects of molecular weight and charge on intranasal absorption 
in rabbits using two dextran derivatives of various molecular weights. However, the 
dextrans were not absorbed without coadministration of the bile salt sodium glycocholate 
as an absorption enhancer. The absorption of a neutral dextran decreased as dextran 
molecular weight increased supporting the inverse relationship between molecular weight 
and intranasal absorption. In contrast, the absorption of polycationic dextrans increased 
with molecular weight for dextrans of molecular weight less than 10000 which was 
suggested to be due to the increased binding of the polycation to the negatively charged 
mucus. However, O'Hagan and Illum (1990) argue that there was no significant 
difference between the absorption profiles of the charged and neutral dextrans at 
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molecular weights below 10000. In addition, absorption of the dextrans was not 
achieved without the use of sodium glycholate which has been proposed to function by 
producing aqueous pores or reverse micelles in the nasal membrane (Gordon et al., 
1985). Fisher et al. (1992) investigated the intranasal absorption of a homologous series 
of water soluble fractionated di-iodo-L-tyrosine-labelled dextrans in rats. The dextrans 
had similar physicochemical properties, being inert and having a uniform charge, and the 
size range of each of the 13 dextrans was small. This was in contrast to the 5 water 
soluble compounds used in the previous study (Fisher et al., 1987) which were 
differently charged, some being pharmacologically active, some metabolised and the 
larger compounds were heterogeneous. An inverse relationship between dextran 
molecular weight and intranasal absorption was demonstrated. Hosoya et al. (1993) 
investigated the in vitro permeability of rabbit nasal, buccal and various gastrointestinal 
mucosa, to fluorescein isothiocyanate-labelled dextrans of molecular weight 4400-71200. 
It was shown that the nasal mucosa had the lowest membrane resistance and the highest 
permeability to the dextrans which suggested that the nasal mucosa was a `leaky' 
structural barrier. The higher permeability of the nasal mucosa was attributed partly to 
the shorter diffusion path since the thickness of the nasal mucosa (337 ± 35 µm) was 
approximately half that of the jejunal (740 ± 26 µm) and upper colonic (710 ± 25 gm) 
mucosae. The permeability of each mucosa was shown to decrease with increasing 
molecular weight. 
Peptides are generally poorly absorbed following intranasal administration which may be 
attributed to their polar nature and hence the production of more lipophilic peptide 
prodrugs (drug precursors) could be useful in improving peptide bioavailability. The 
effects of polarity have been investigated using a model amino acid; L-tyrosine having 
three polar functional groups, each of which may influence nasal absorption (Hussain et 
al., 1985, Huang et al., 1985b). In situ perfusion studies in rats were used to investigate 
the effect of structural modifications of L-tyrosine on nasal absorption. Preliminary 
studies showed that the intranasal absorption of L-tyrosine, existing in its zwitterionic 
form over the pH range studied, was concentration dependent but pH independent and 
occurred by a carrier-mediated process. Derivatives of L-tyrosine were used to study the 
effect of the different polar functional groups on nasal absorption. Increasing the 
lipophilicity of L-tyrosine by O-acyl esterification did not improve absorption which was 
attributed to the polarity of the carboxylic and/or amino groups since the O-acyl 
derivatives also existed in zwitterionic form. N-acetyl-L-tyrosine, used to mask the 
amino group, had a similar partition coefficient to L-tyrosine and was absorbed at a 
similar rate. Carboxylic acid esters of L-tyrosine, used to mask the carboxylic group, 
were found to be more lipophilic than L-tyrosine and were absorbed at a faster rate. The 
rate of absorption of a carboxylic acid ester was shown to be four times faster than an 0- 
acyl ester having a partition coefficients of the same order of magnitude suggesting that 
the enhanced nasal absorption of the carboxylic acid esters of L-tyrosine was due to 
masking the negative charge on the carboxylate moiety. Carboxylic acid esters were 
shown to be hydrolysed in the perfusion medium although the rate of disappearance of 
the compound from the perfusate was an order of magnitude less than that accountable 
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for by absorption. Hussain et al. (1985), suggested that the intranasal absorption of the 
polar quaternary ammonium compound clofilium tosylate, an antiarrhythmic drug, does 
not support the concept of low peptide absorption due to their polar nature. Clofilium 
tosylate was shown to be nasally absorbed in the in vivo rat model which was suggested 
to occur by simple diffusion (Su et al., 1984, Su and Campanale, 1985). However, the 
drug caused mild tissue necrosis, even with lowest dose tested, which may account for 
the nasal absorption observed for this compound. 
The intranasal absorption of peptides is generally low without co-administration with 
absorption enhancing compounds with bioavailabilities obtained in the region of 1-2% 
when administered as simple solutions (O'Hagan and Ilium, 1990). Several peptides 
have been shown to be absorbed without the use of enhancers. The intranasal absorption 
of thyrotropin-releasing hormone (TRH), a tripeptide neurotransmitter, has been shown 
to be approximately 20% relative to the intravenous route in rats (Sandow and Petri, 
1985). The synthesis of lipophilic analogues of TRH and other peptides has been 
proposed as a means by which their transmembrane permeability may be enhanced 
(Muranishi et al., 1991). However, it was also pointed out that the biological activity of 
these derivatives may be reduced compared to the parent compound. Su et al. (1985b) 
demonstrated the intranasal absorption of pentapeptide drugs in rats using two enkephalin 
analogues (metkephamid and DADLE). Metkephaniid (molecular weight 661) was 
completely absorbed (bioavailability relative to the intravenous route 102%) but DADLE 
(molecular weight 570) was absorbed to a lesser extent (bioavailability relative to 
subcutaneous route 59%), the difference explained as being due to metkephamid having 
greater stability and less susceptibility to enzymatic degradation. The effect of peptide 
dose on the intranasal absorption of metkephamid was investigated. The amount of 
metkephamid absorbed was directly proportional to the dose administered and the results 
suggested that the compound was rapidly absorbed by diffusion. Faraj et al. (1990), 
based on published reports and their own studies, point out that although there is 
variation between peptides in the fraction of the dose absorbed, peptide absorption is 
rapid. The initial rate of peptide absorption was suggested to be as rapid as the 
absorption of lipophilic compounds such as propranolol, although the total amount of 
peptide absorbed was said to be usually small and self limited. Assuming that peptides 
are absorbed via aqueous pores, it was speculated that the self limiting step was due to 
blockage of the pores by peptides or their hydrolysis products. 
1.6.1.3 Enzymatic degradation 
The low bioavailability of peptides administered via the nasal route can be attributed in 
part to poor transport across the nasal mucosa but enzymatic degradation in the nasal 
cavity may also constitute a significant barrier to peptide absorption. As previously 
discussed, intranasal drug absorption avoids the `first pass' metabolism associated with 
poor bioavailability via the oral route but proteolysis before, during or following 
intranasal absorption also appears to limit intranasal peptide drug absorption. The nasal 
route was initially regarded as being devoid of the enzyme systems which limit oral 
absorption but Zhou (1994) considered that proteolytic activities are the most important 
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barriers preventing the intranasal absorption of peptide drugs. The various enzyme 
systems associated with the nasal cavity have previously been reviewed. Peptide drugs 
are most likely to be susceptible to the exopeptidases, cleaving peptides at their N and C 
termini, or endopeptidases, cleaving the internal peptide bonds, which are present in the 
nasal cavity. The importance of in vivo peptide degradation by nasal enzyme systems has 
not been fully elucidated (O'Hagan and Ilium; 1990, Ilium; 1992). Various studies have 
investigated peptide degradation during in situ or in vitro animal studies the results of 
which generally indicate that for many peptides, particularly smaller peptides, enzymatic 
degradation is likely to be a significant barrier to their absorption. Many studies have 
investigated the stability of peptides in vitro following incubation of peptides with nasal 
homogenates. However, with these studies there is an over exposure of peptides to the 
various enzymes present in the nasal tissue, since the homogenates will contain enzymes 
which are liberated from all mucosal cells and also those from subcellular fractions 
including the cell cytosol and lysosomal enzymes. Homogenate studies may be useful 
for comparing overall peptide degradation at various mucosal sites and to assess the 
likelihood of degradation of specific peptides at these sites. However, they do not take 
into account the susceptibility of peptides during absorption relative to the normal 
structural organisation of enzymes (Kashi and Lee; 1986, Ilium; 1992). 
Hirai et al. (1981) showed that insulin was rapidly degraded in rat nasal homogenates 
with approximately 50% and 9% of the insulin remaining after incubation for 10 and 60 
minutes respectively. Hayakawa et al. (1889) investigated the hydrolysis of various 
concentrations of insulin in rabbit nasal homogenates. As insulin concentration was 
increased from 5 to 100 µl the susceptibility to proteolysis was shown to decrease 
(indicated from the increasing half life of degradation) and this apparent self-stabilisation 
was attributed partly due to self-association of insulin as concentration increased but also 
due to saturation of the proteases by insulin since the rate of proteolysis increased as the 
protein content of the tissue homogenate increased. At a tissue protein content of 10 
mg/ml, the half lives of hydrolysis of 5 and 100 µM insulin were 9 minutes and 429 
minutes, respectively. The vasopressin analogue desmopressin (DDAVP), a 
nonapeptide, was shown to be degraded by enzymes in rabbit nasal homogenates 
(Critchley, 1989). Hussain et al. (1985) investigated the in situ absorption of the 
dipeptide L-tyrosyl-L-tyrosine in rats finding that it underwent extensive hydrolysis in the 
nasal perfusate which was attributed to the presence of peptidase enzymes in the nasal 
cavity since the compound was stable in the perfusate medium. The dipeptides L-glycyl- 
L-tyrosine and L-glycyl-L-tyrosinamide and the more lipophilic dipeptide ester, L- 
tyrosyl-L-tyrosine methyl ester, were also shown to be rapidly hydrolysed demonstrating 
that the enzymatic hydrolysis was not specific for L-tyrosyl-L-tyrosine. The poor 
bioavailability. of intranasally administered peptides was attributed to enzymatic 
hydrolysis in the nasal cavity during the absorptive process. 
Kashi and Lee (1986), investigated the hydrolysis of pentapeptides in rabbit nasal 
homogenates using various enkephalins. Methionine enkephalin and leucine enkephalin 
were shown to be rapidly hydrolysed (half lives of degradation were approximately 16 
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minutes and 20 minutes respectively) which was attributed mainly to aminopeptidases 
with contribution from dipeptidyl peptidase and dipeptidyl carboxypeptidase. [D-Alal 
Met-enkephalinamide, being resistant to aminopeptidase mediated cleavage, was much 
less susceptible to hydrolysis (half life of degradation of about 162 minutes). Chun and 
Chien (1995) investigated the effect of pH on the degradation of methionine enkephalin in 
rabbit nasal mucosal extracts reporting that the fastest degradation of methionine 
enkephalin occurred at about pH 7 indicating optimal activity of enkephalin-degrading 
enzymes at this pH. 
The enzymatic degradation of leucine enkephalin has also been investigated using an in 
situ rat perfusion model (Hussain et al., 1985, Hussain; 1989, Faraj et al., 1990). The 
disappearance of leucine enkephalin from the nasal perfusate (half life of about 30 
minutes) was shown to be almost entirely due to its hydrolysis in the perfusate rather than 
to absorption from the nasal cavity. Leucine enkephalin was also shown to be rapidly 
hydrolysed in buffer solution which had been pre-circulated through the rat nasal cavity 
indicating that active nasal enzymes were extracted into the buffer. The hydrolysis of 
leucine enkephalin was also demonstrated in rats using an in vivo-in situ technique, in 
which small volumes of drug solution were administered to the nasal cavity which was 
washed-out at appropriate time intervals and the nasal washings collected and analysed 
for drug and metabolite content, which was suggested to simulate the use of nose drops 
in humans. The rate and extent of formation of the metabolite depended on the 
concentration of leucine enkephalin with greater conversion of the parent compound to 
metabolite at lower concentrations suggesting that the enzymes which hydrolyse leucine 
enkephalin become saturated at higher drug concentrations. Using the same in vivo-in 
situ technique, it was found that the hydrolysis of leucine enkephalin was reduced by the 
inclusion of di- or tripeptides which were suggested to compete for peptidase enzymes in 
the nasal cavity. The same research group observed the hydrolysis of leucine enkephalin 
(half life of disappearance was about 40 minutes) in human nasal washings 
demonstrating the presence of loosely bound peptidase enzymes in the human nasal 
cavity (Hussain et al., 1990). Irwin et al. (1994) investigated the degradation of leucine 
enkephalin and its metabolite des-tyrosine leucine enkephalin in sheep nasal washings 
and mucosal homogenate preparations finding that the half life of degradation was 40 and 
12 minutes for leucine enkephalin and 13 and 7 minutes for des-tyrosine leucine 
enkephalin respectively. With reference to leucine enkephalin, this study outlines the 
greater exposure of peptides to enzymes in studies involving nasal homogenates. Irwin 
et al. (1995) demonstrated the hydrolysis of di-, tri- and tetrapeptides in sheep nasal 
homogenates. Each of the peptides investigated was shown to be degraded following 
incubation with the nasal homogenates but there was considerable variation in their 
susceptibility to degradation. 
1.6.2 Overcoming the barriers to peptide or protein drug delivery 
The various absorption barriers must be overcome in order to achieve an effective degree 
of absorption of peptide and protein drugs via the nasal route. Much attention has been 
focused on the use of compounds, in the form of absorption enhancing agents, which 
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will promote the absorption of peptide and protein drugs administered nasally and these 
are discussed below. An alternative approach is to modify the structure of peptides and 
protein drugs in order to improve their absorption characteristics although investigation of 
such systems is limited. Hashimoto et al. (1989) synthesised palmitoyl derivatives of 
insulin which were more lipophilic than native insulin. Following intravenous 
administration to rats, a monopalmitoyl derivative resulted in a hypoglycaemic response 
which was similar in magnitude but more prolonged than that following the intravenous 
administration of native insulin. In contrast, a dipalmitoyl derivative was less effective in 
lowering plasma glucose concentrations following intravenous administration. However, 
both the mono- and the dipalmitoyl derivatives were much less effective than native 
insulin in lowering plasma glucose concentrations following intramuscular 
administration. Asada et al. (1992 and 1995) showed that the transport of insulin across 
intestinal membranes was improved by chemical modification with fatty acids which 
enhanced lipophilicity of the insulin. However, as lipophilicity was increased the 
pharmacological availability was decreased although several of the derivatives exhibited 
pharmacological activity similar to that of native insulin. Insulin derivatives were shown 
to be more stable in small intestine mucosal homogenates. This suggests that the stability 
of peptide and proteins, administered by non-parenteral routes, may be improved by the 
use of chemically modified derivatives. 
Many compounds have been investigated as absorption enhancers for peptide and protein 
drugs. These compounds are usually classified into a number of enhancer systems based 
on the way in which they principally act on the mucosa and promote drug absorption. 
However, compounds may enhance drug absorption via a combination of several 
mechanisms. The classification system is generally used for all compounds which are 
used as enhancers via non-parenteral routes. The main types of enhancer system are: 
(i) bile salts and derivatives such as sodium deoxycholate, sodium glycocholate and 
sodium taurodihydrofusidate; (ii) surfactants such as sodium lauryl sulphate and 
polyoxyethylene-9-lauryl ether; (iii) chelating agents such as ethylenediaminetetraacetic 
acid (EDTA), citric acid and salicylates; (iv) fatty acids such as sodium caprylate and 
sodium laurate; (v) enzyme inhibitors such as bestatin and amastatin (vi) novel enhancer 
systems such as bioadhesives, cyclodextrins and chitosan. (Lee and Yamamoto; 1990, 
O'Hagan and Illum; 1990, Ilium; 1991). 
1.6.2.1 Bile salts 
The common naturally occurring bile salts are steroids which are synthesised in the liver 
from cholesterol. Bile salts are amphipathic molecules possessing distinct nonpolar and 
polar regions. In aqueous solution at low concentration, bile salts exist as monomers but 
above the critical micellar concentration, bile salts will self associate to form colloidal 
aggregates referred to as micelles. In bile salt micelles, the hydrophilic groups are 
exposed to the aqueous medium and surround a core formed by the nonpolar 
hydrophobic groups and as a consequence the whole structure is water soluble. Micelles 
consisting of only bile salts are referred to as simple micelles. However, mixed micelles 
are formed if other lipids are solubilised into the core structure of simple micelles. Bile 
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salts have surface active (surfactant) properties enabling them to solubilise lipids. This is 
of biological importance in the digestion and absorption of dietary lipids (Gordon et al., 
1971, Carey and Small; 1972, Shiau; 1987). 
Hirai et al. (1978) showed that a solution formulation containing I% sodium glycocholate 
enhanced the intranasal absorption of insulin in dogs. In a later study several bile sodium 
salts (taurocholate, cholate, deoxycholate, glycocholate, chenodeoxycholate) were shown 
to be equally effective in enhancing the nasal absorption of insulin in rats (Hirai et al., 
1981b). The absorption promoting effect of bile salts was suggested to be due not only 
to the increase in membrane permeability, i. e. a direct effect on the nasal mucous 
membrane, but also due to their inhibitory effect on proteolytic enzymes since sodium 
glycocholate significantly inhibited the enzymatic hydrolysis of insulin in rat nasal tissue 
homogenates (Hirai et al., 1981c). Moses et al. (1983) showed that coadministration of 
1% sodium deoxycholate enhanced the intranasal absorption of insulin in human 
volunteers. However, following nasal administration, a solution containing sodium 
deoxycholate was reported to cause mild nasal irritation and slight nasal congestion which 
lasted about 15 minutes. The same study group investigated the effect of dihydroxy bile 
sodium salts (deoxycholate, glycodeoxycholate, taurodeoxycholate, ursodeoxycholate, 
chenodeoxycholate) and trihydroxy bile sodium salts (cholate, glycocholate and 
taurocholate) on the nasal absorption of insulin in human volunteers (Gordon et al., 
1985, Flier et al., 1985). In contrast to the work reported by Hirai et al. (1981b), the bile 
salts differed in their absorption promoting efficacy and the bile salts glycocholate, 
taurodeoxycholate, deoxycholate and chenodeoxycholate appeared to be the most 
effective. Sodium deoxycholate was shown to be only slightly effective at a 
concentration of 2.5 mM, 50% effective at 6 mM and maximally effective at 12 and 24 
mM. The optimal effect of deoxycholate was exhibited at a concentration well above the 
critical micellar concentration of approximately 3 mM. Each of the bile salts investigated 
in the study resulted in local nasal irritation (burning sensation in the nose lasting for up 
to 5 minutes) although the degree of irritancy did not correlate with enhancing activity 
since ursodeoxycholate was inactive but resulted in the most irritation. The taurine and 
glycine conjugates tended to be less irritative. 
Longenecker et al. (1987) showed that the bile salt `derivative' sodium 
taurodihydrofusidate (STDHF), at a concentration of 1 %, enhanced the nasal absorption 
of insulin in sheep (bioavailability approximately 16%). Absorption enhancement 
appeared to occur only in the presence of micelle formation and it was suggested that 
solubilization of insulin in STDHF micelles plays a major role in its activity as an 
absorption promoter. An erythrocyte haemolysis assay showed that STDHF was less 
haemolytic indicating that it caused less membrane damaging effects, than sodium 
deoxycholate and much less haemolytic than the surfactant polyoxyethylene-9-lauryl ether 
(Laureth-9). STDHF (I%) was shown to improve intranasal insulin bioavailability from 
0.9% to 5.2% in rabbits and from 0.3% to 18.0% in rats (Deurloo et al., 1989, Verhoef 
et al., 1989). The above studies illustrate the difference in intranasal insulin absorption 
with the animal model employed since the bioavailability obtained by coadministration of 
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the formulation containing 1% STDHF was greater in the anaesthetised rat model than in 
the conscious rabbit model (sedated during dose administration) although there were no 
significant differences between the animal models in the absence of the enhancer. 
STDHF was shown to induce ciliostasis at concentrations of 0.3% and above although it 
was less ciliostatic than sodium deoxycholate or Laureth-9 (Hermens et al., 1990). A 
formulation of insulin with 1% STDHF decreasd cilia beat frequency from 100% to about 
20% after 10 minutes. The authors suggested that long-term application of irreversibly 
ciliostatic formulations should be avoided in nasal drug delivery. 
Maitani et al. (1986) showed that bile salts at 3% w/v enhanced the intranasal absorption 
of (i-interferon in rabbits and that sodium glycocholate and sodium cholate were more 
effective than sodium deoxycholate in promoting absorption. Sodium glycocholate at 
0.5% was shown to increase the bioavailability of intranasally administered methionyl- 
human growth hormone from less than 1% to between 7-8% (Daugherty et al., 1988). 
Aungst et al. (1988) investigated the effect of sodium glycocholate on insulin absorption 
in the rat following nasal, rectal, buccal and sublingual administration finding that insulin 
absorption was improved in the order nasal > rectal > buccal > sublingual. Tengamnuay 
and Mitra (1990) showed that a bile salt-fatty acid mixed micellar solution (15 mM 
sodium glycocholate with 5 mM linoleic acid) was marginally more effective than the bile 
salt alone in promoting intranasal insulin absorption in the rat. Bile salt-lipid mixed 
micelle formulations have been shown to improve the intestinal absorption of normally 
poorly absorbed non peptide drugs such as streptomycin and gentamicin in animal 
models (Muranishi et al., 1979). The absorption of gentamicin was also shown to be 
improved via the nasal route in human volunteers following coadministration with I% 
sodium glycocholate (Rubinstein, 1983) and in rabbits by coadministration with several 
different bile salts (Duchateau et al., 1986). In a later study in rabbits, Duchateau et al. 
(1987) showed that bile salts effectively improved the nasal bioavailability of phenol red. 
Duchateau et al. (1986) showed that dihydroxy bile salts, particularly deoxycholate, were 
more ciliotoxic than trihydroxy bile salts. Ciliotoxicity is an important consideration in 
intranasal drug delivery since absorption enhancers should not affect the normal 
mucociliary clearance mechanisms. However, it is not clear how impairment of cilia 
function may manifest in vivo although increased susceptibility and recurrence of 
respiratory infections are known to result in patients with `immotile' cilia syndrome 
(Hermens et al., 1990). 
The mechanism by which bile salts enhance drug absorption has not been fully elucidated 
although it appears that there may be a combination of effects (O'Hagan and Ilium; 
1990). Several mechanisms by which bile salts enhance drug absorption have been 
proposed. Gordon et al. (1985), in nasal absorption studies with insulin, proposed that 
bile salts act by forming transmembrane channels or as mobile carriers for insulin due to 
the formation of reverse micelles. In reverse micelles, the hydrophilic surface of the bile 
salt faces inwards and the hydrophobic surface faces outwards towards the lipid 
environment of the membrane. The different degrees of potency of the bile salts was 
suggested to be due to their ability to penetrate the membrane, and self-associate to form 
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reverse micelles. The formation of insulin / bile salt mixed micelles, resulting in the 
complete solubilization of insulin, was speculated to move down an aqueous 
concentration gradient through the nasal epithelial cells, into the intercellular space and 
into the blood circulation. The authors favoured the channel type mechanism rather than 
the mobile carrier since absorption enhancement became saturated at bile salt 
concentrations of approximately 12 mM probably indicating local membrane saturation. 
The reverse micelles were suggested to stack end-to-end and span the lipid bilayer with 
ionised polar groups projecting into the aqueous environment on either side of the 
membrane. Thus, the stacked reverse micelles form a temporal aqueous pore through 
which solubilised insulin can be transported. It has also been suggested that ion-pairing 
between anionic bile salts and the positive residues on peptides and proteins would render 
them more lipophilic and hence increase membrane permeability (Lee; 1990). Passive 
diffusion of bile salt micelles into hamster intestinal mucosa has been demonstrated in 
vitro (Gordon et al., 1971). Maitani et al. (1991) demonstrated the permeability of rabbit 
nasal mucosa to bile salts by investigating their effect on membrane potential. The nasal 
membrane, carrying a net negative charge, became slightly more negatively charged by 
pretreatment with bile salt solution due to the penetration of the bile salt into the nasal 
mucosa. Uchida et al. (1991a and 1991b) showed that bile salts increased the membrane 
permeability to water soluble compounds and suggested that this is due to the formation 
of a temporal pore in the membrane. Gordon et al. (1985), proposed that pores may 
form in the lipoidal membrane, thereby enhancing transcellular transport. Alternatively, 
formation of an intercellular `pore' would increase permeability via the paracellular route. 
Lee (1990) suggests that the rapid nature of bile salt induced absorption enhancement of 
water soluble compounds would tend to favour a mechanism involving the paracellular 
route. 
The mechanism of absorption enhancement of bile salts may in part be due to their ability 
to chelate calcium ions similar to the mode effect of EDTA which is thought to chelate 
calcium and magnesium ions in the regions of the tight junctions, thus opening the tight 
junctions and promoting absorption via the paracellular route (Murakami et al., 1984). In 
the study investigating the rectal absorption of ampicillin in rats, formulations containing 
calcium chloride were shown to decrease the absorption enhancing efficacy of sodium 
deoxycholate although the presence of magnesium ions had no affect suggesting that the 
bile salt binds membrane calcium ions but not magnesium ions. Shiga et al. (1987), in a 
study investigating colonic absorption, also suggested that the absorption enhancing 
mechanism of sodium taurocholate is by chelated depletion of metal ions in regions of the 
tight junctions similar to that of EDTA. Bile salts (deoxycholate, taurodeoxycholate, 
glycocholate) have also been shown to be potent mucolytic agents resulting in a decrease 
in the viscosity and elasticity of human bronchial mucus (Martinet al., 1978). The effect 
on mucus was more prominent as bile salt concentration increased and at the highest 
concentration investigated (20 mM), liquefaction of gelled mucus occurred. For 
intranasally administered compounds to reach the nasal epithelium, they must first 
penetrate the mucus layer which will be facilitated if the consistency of mucus is 
adversely affected. 
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Hirai et al. (1981c) demonstrated that bile salts inhibit the enzymatic degradation of 
insulin in the nasal mucosa suggesting this as a possible mechanism by which they 
promote absorption. Lee and Kashi (1987) showed that bile salts were more potent as 
inhibitors of aminopeptidase activity at concentrations above their critical micellar 
concentration. However, no correlation existed between aminopeptidase inhibition and 
the rank order of absorption enhancing potency suggesting that the inhibition of 
proteolytic enzymes is not a principal mechanism. 
Several studies have shown that bile salts have a membrane damaging effect which may 
be another reason for their effectiveness as absorption promoters. Chadwick et al. 
(1979) showed that dihydroxy bile acids (deoxycholic acid and chenodeoxycholic acid) 
induced fluid secretion, increased mucosal permeability and resulted in mucosal damage 
during in vivo perfusion of the rabbit colon. Hirai et al. (1981 c), using scanning electron 
microscopy, showed that nasal villi were slightly denuded at the tip 2 hours after the 
administration of 1% sodium glycholate although complete recovery had occurred by 24 
hours. Bile salts (glycholate, cholate, taurocholate) were also shown to cause membrane 
damage (assessed by measuring protein release from the nasal mucosa and erythrocyte 
haemolysis) although the extent of the damage was reported to be mild compared to many 
of the other compounds investigated. However, it must be pointed out that the 
concentrations of the compounds used in the study were much lower than the 
concentrations which had been demonstrated to promote insulin absorption. Shao and 
Mitra (1992) showed that 15 mM sodium deoxycholate caused the greatest membrane 
damage (protein release), while STDHF, cholate, glycocholate and taurocholate, in 
descending order, exhibited less membrane damaging effects. Hersey and Jackson 
(1987) using in vitro techniques, showed that 0.5% sodium deoxycholate caused a rapid 
4 to 5 fold increase in nasal permeability which was accompanied by extensive 
histological damage to the epithelium suggesting that bile salts work by removing the 
epithelial layer which constitutes a major barrier to drug absorption. Damage to the nasal 
epithelium would obviously cause concern particularly during chronic therapy. Merkus 
et al. (1993) showed that the dihydroxy bile salts deoxycholate and taurodeoxycholate 
caused much greater morphological damage to rat nasal mucosa following 5 minutes 
exposure than did glycocholate after 10-15 minutes exposure (all assessed at a 
concentration of I%). The study also showed that there was a good correlation between 
morphological damage and arrest of cilia beat frequency which was suggested to be a 
valuable tool in the search for safe absorption enhancing compounds. Clearly, 
ciliotoxicity would tend to prolong the residence time of the formulation in the nasal 
cavity and may be another factor for the absorption enhancing efficacy of bile salts. 
1.6.2.2 
. 
Surfactants 
The term surfactant or surface-active agent applies to compounds which tend to 
accumulate at the boundary between two phases resulting in a modification of the surface 
energy of the interface (Florence and Attwood, 1988, Hills, 1988). In solution, 
surfactants will lower the surface and interfacial tension of water and promote the 
association into micelles and foam formation (Schott, 1995). Many compounds display 
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surfactant properties including the bile salts previously mentioned and fatty acids such as 
phospholipids. The efficacy of saponin, a sapogenin glycoside, in promoting the nasal 
absorption of insulin was demonstrated as early as 1932 by Collens and Goldzieher. The 
potency of surfactants in enhancing the intranasal absorption of insulin has been 
demonstrated in dogs (Hirai et al., 1978) and in rats (Hirai et al., 198 lb). In dogs, the 
non-ionic surfactant Laureth-9 and saponin, at concentrations of 1 %, increased the 
intranasal absorption of insulin. In rats, various compounds with surfactant activity 
including bile salts were investigated. The absorption enhancing efficacy of a range of 
non-ionic polyoxyethylene 
-ether and -ester surfactants were evaluated and it was shown 
that the esters did not perform as well as the ethers. Of the ether type surfactants, those 
with an hydrophile-lipophile balance (HLB) of between 8-14 were shown to be more 
effective and this group included Laureth-9 (HLB 11.5) which caused a decrease in 
plasma glucose concentrations of about 60%. An increasing value of HLB corresponds 
to increasing hydrophilic character (Helenius and Simons; 1975). Hirai et al. (1981b) 
also showed that anionic surfactants, such as sodium laurylsulphate and potassium 
laurylsulphate, saponin and surfactin (a peptidelipid) effectively promoted the nasal 
absorption of insulin but the efficacy was lower than that of Laureth-9. Laureth-9 was 
shown to be a more potent enhancer with a maximal absorptive effect observed at a 
concentration of about 0.3% compared to about 0.5% for both saponin and the bile salt 
sodium glycocholate. 
Salzman et al. (1985) investigated the efficacy of a nasal insulin formulation containing 
Laureth-9 in normal volunteers and in Type I diabetic patients. In fasted subjects, insulin 
was rapidly absorbed from nasal formulations containing I% Laureth-9 and in normal 
volunteers and diabetic patients, plasma glucose concentrations were lowered to 50% of 
basal values in about 45 and 120 minutes, respectively. Following a meal, an insulin 
formulation containing 1% Laureth-9 was more effective in controlling postprandial 
hyperglycaemia than formulations containing 0.1 % or 0.25 % Laureth-9. The absorption 
profile of insulin and subsequent control of postprandial hyperglycaemia following 
intranasal administration of the insulin / Laureth-9 formulation simulated more closely 
endogenous insulin secretion compared to a subcutaneous dose of insulin. However, the 
degree of nasal irritation, although highly variable between subjects, increased with 
increasing concentration of Laureth-9. 
Several other studies have assessed surfactants, mainly Laureth-9, as an absorption 
enhancer for insulin. Pontiroli et al. (1986) reported that Laureth-9 enhanced the 
absorption of insulin and glucagon in normal subjects following intranasal 
administration. Aungst and Rogers (1988) showed that 5% Laureth-9 promoted the 
nasal, buccal and rectal absorption of insulin in rats. Formulations of insulin with 
Laureth-9 were also shown to markedly improve intranasal insulin absorption in rats 
(Chandler et al., 1991b, Jabbal Gill et al., 1994b). Chandler et al. (1991b) administered 
an insulin dose of 8 IU/kg in a formulation containing 1% Laureth-9 and reported an 87% 
decrease in blood glucose concentrations 60 minutes after dosing. Insulin was not 
absorbed nasally without the presence of absorption enhancers. Jabbal Gill et al. (1994b) 
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administered 4 IU/kg insulin with 0.9% Laureth-9 and blood glucose concentrations were 
shown to decrease to about 55% of the basal value compared to 86% for the insulin 
control solution. Duchateau et al. (1987) reported that 1% Laureth-9 improved the 
absolute bioavailability of phenol red in rabbits from about 22% to 87%. Laureth-9 at a 
concentration of 1% (17 mM) has been shown to enhance the absorption of recombinant 
methionyl human growth hormone (Met-hGH) across the rat nasal mucosa (Daugherty et 
al., 1988). The bioavailability of Met-hGH, compared to an intravenous dose varied 
between about 60-80% depending on the dose administered. This was a marked 
improvement on the bioavailability of 7-8% achieved using the bile salt sodium 
glycocholate. 
Surfactants are able to modify the properties of biological membranes and alter their 
permeability or transport characteristics (Gibaldi and Feldman; 1970). However, the 
mechanism of absorption enhancement of surfactants such as Laureth-9 appears to 
correlate with the damage that it causes to the integrity of the nasal mucosa. Surfactants, 
including bile salts, have been shown to have membrane solubilising properties and have 
been used to extract membrane components for biochemical study (Helenius and Simons; 
1975, Florence; 1981). The solubilization and subsequent disruption of membrane 
integrity by surfactants appears to be at the centre of many of the observed biological 
effects caused by these compounds (Florence; 1981). 
Hirai et al. (1981c) investigated the possible mechanisms for the enhanced nasal 
absorption of insulin by surfactants. Surfactants, such as polyoxyethylene ethers, 
including Laureth-9, sodium lauryl sulphate and saponin, were shown to have a potent 
haemolytic or protein releasing effect on biomembranes indicating the disruption of the 
integrity of the membranes which correlated well with their absorption enhancing 
potency. For polyoxyethylene ethers it was found that the degree of membrane damage 
decreased as the value of HLB either increased or decreased from a value of 11.5 (the 
HLB value of Laureth-9). In rat nasal homogenates, the activity of leucine 
aminopeptidase decreasd as the concentration of Laureth-9 increased although it had only 
a slight inhibitory effect on the degradation of insulin. At concentrations of 0.27 %, non- 
ionic surfactants resulted in less than about 23% inhibition of leucine aminopeptidase 
compared to about 98% for the ionic surfactant sodium laurylsulphate and 85-87% for 
bile salts. The recovery of the nasal membrane from the hyperabsorptive state induced by 
1% Laureth-9 was also assessed by intranasally administering Laureth-9 solution to 
conscious rats followed by the intranasal administration of 10 IU/kg insulin solution to 
anaesthetised rats at various time intervals. Insulin absorption was shown to decrease as 
the time interval between surfactant and insulin administrations increased. The recovery 
from the hyperabsorptive state following the administration of the bile salt sodium 
glycocholate (I%) was faster than that following the administration of Laureth-9 
indicating the greater membrane disturbing effects of the latter. Scanning electron 
microscopy confirmed these findings by showing that the membrane damage caused by 
Laureth-9 was significant at 2 hours and had not recovered by 24 hours whereas sodium 
glycocholate caused only slight membrane damage at 2 hours and there was complete 
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recovery by 24 hours. Following the intranasal administration of Laureth-9 or sodium 
glycocholate solutions 3 times daily for one month, Laureth-9 was shown to be more 
irritative, causing a morphological change in the nasal microvilli, compared to sodium 
glycocholate, which resulted in no morphological change. The studies of Hirai et al. 
(1981 c) appear to indicate that absorption enhancement by surfactants such as Laureth-9, 
sodium lauryl sulphate and saponin is due mainly to disruption of the nasal membrane. 
Longenecker (1986) and Longenecker et al. (1987) showed that Laureth-9 was a highly 
potent haemolytic agent finding that it was approximately 20 and 100 fold more 
haemolytic than sodium deoxycholate and STDHF, respectively. Laureth-9 at a 
concentration of 0.3%, was shown to cause rapid and irreversible ciliostasis of human 
nasal cilia (Hermens et al., 1990). Daugherty et al. (1988), using histological 
techniques, showed that nasal solutions containing 1% Laureth-9 severely disrupted the 
cellular permeability barrier. In the rat nasal cavity, the entire epithelial monolayer was 
shown to be removed at certain locations, as early as 30 minutes after dose 
administration, and was accompanied by multifocal necrosis, inflammation and 
exudation. In comparison, sodium glycocholate was reported to be less destructive on 
the integrity of the epithelial lining. Laureth-9 was found to cause severe disruption of 
the rat nasal mucosa after only 5 minute exposure (Ennis et al., 1990). This was 
confirmed by Chandler et al. (1991a) who demonstrated that 1% Laureth-9 caused 
epithelium disruption, cell loss and reduction in epithelium height after 5 minutes 
exposure and became worse as contact time was increased. Jabbal Gill et al. (1994b) 
have also demonstrated damage to the rat nasal membrane in rats using histological 
techniques. Sodium lauryl sulphate and Laureth-9, at a 1% concentration, were shown to 
severely disrupt the integrity of the rat nasal epithelium which was generally accompanied 
by an increase in the permeability of the mucosa to a range of polyethylene glycols (PEG) 
of molecular weight about 600 to over 2000 daltons (Donovan et al., 1990). In contrast, 
0.1 % Laureth-9 caused only slight damage to the nasal mucosa. It was suggested that the 
surfactant may alter or extract membrane proteins and lipids resulting in severe disruption 
of the integrity of the membrane at higher concentrations which correlates with their 
ability to improve absorption. 
In view of the severity of the epithelial damage caused by surfactants such as Laureth-9 
and sodium lauryl sulphate, at concentrations which are required to significantly improve 
drug absorption, it is unlikely that these compounds will be successfully exploited for 
nasal delivery systems for peptide and protein drugs. However, surfactants remain a 
useful research tool against which alternative enhancers can be assessed (O'Hagan and 
Ilium; 1990). 
1.6.2.3 Chelating agents 
Compounds such as EDTA, salicylic acid and citric acid have metal ion chelating 
properties. Critchley (1989) showed that the absorption of desmopressin was 
significantly improved in rats by coadministration of a formulation containing 1% EDTA. 
Values of bioavailability calculated after administering either control solution or solution 
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containing EDTA were approximately 16% and 59% respectively. In contrast, Aungst 
and Rogers (1988) showed that the degree of enhancement of insulin absorption by 
coadministration of 5% EDTA or sodium salicylate was low via the nasal and buccal 
routes compared to the rectal route. EDTA was shown to increase the permeability of 
rabbit nasal mucosa in vitro (Uchida et al., 1991a and 1991b). Adjei et al. (1992) 
showed that EDTA improved the nasal absorption of leuprolide acetate, a luteinizing 
hormone releasing hormone agonist, in rats. Following coadministration of EDTA with 
cyclodextin, the bioavailability of leuprolide acetate was 47% compared to 37% following 
coadministration of cyclodextin alone and only 13% for a control solution of leuprolide 
acetate. Yamamoto et al. (1993) investigated the effects of sodium salicylate and EDTA 
on the nasal absorption of phenol red and a series of fluorescein isothiocyante dextrans 
(FITC-dextrans, having mean molecular weights of 4400,9400 and 71200) in rats. 
Sodium salicylate was shown to be ineffective in promoting the nasal absorption of 
phenol red and the FITC-dextrans and EDTA only effectively enhanced the nasal 
absorption of the 4400 molecular weight FITC-dextran. Citric acid has also been 
proposed as a calcium ion chelating agent for transepithelial transport following in vitro 
studies (Cho et al., 1989). Citrate (0.1,1.0 and 10 mM) was shown to significantly 
decrease the transepithelial electrical resistance across a cell monolayer. This was 
assumed to be an indication of the citrate opening tight junctions in the epithelium thereby 
enhancing paracellular solute transport. 
The absorption enhancing activity of chelating agents is related to their ability to open 
intercellular tight junctions by chelating divalent cations thereby increasing transport by 
the paracellular route (Murakami et al., 1984). Divalent cations, particularly Ca2+ and 
Mgt+, are important for maintaining both the structure and rigidity of cell membranes and 
ciliary activity (Cassidy and Tidball, 1967). The integrity of epithelial tight junctions is 
dependent on extracellular Ca2+ and following exposure to absorption enhancers, the 
ability of Ca2+ to restore the mucosal barrier function has been used to indicate a 
paracellular mechanism (Lee et al., 1991c). Although the chelation of divalent cations is 
associated with the opening of tight junctions, the site of action of the chelating agents is 
not known. Lee et al. (1991c) suggested that chelating agents act on other elements of 
the junctional complex rather than directly on the tight junction itself. One such junctional 
element is the Ca2+ dependent cell adhesion molecule uvomorulin. In addition to 
increasing the size of intercellular spaces, chelating agents may also increase water influx 
via the intercellular space. Increasing water influx may increase the absorption of 
hydrophilic solutes by a solvent-drag mechanism, increasing blood flow at the site of 
absorption or increasing the concentration gradient. 
If the chelating agent decreases ciliary activity thereby mucociliary clearance, then the 
residence time of the dose at the site of delivery will be increased. Batts et al. (1989) 
demonstrated that 0.1 % EDTA irreversibly halted mucociliary transport over the frog 
palate following one or two 10 minute applications. However, in the presence of an 
excess of calcium ions, sufficient to saturate the chelation sites of EDTA, the compound 
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was well tolerated. In a later study, 0.1 % EDTA was shown to be non-ciliotoxic to 
explants of chick embryo (Batts et al., 1990). Furthermore, EDTA did not affect mucus 
rheology which is another factor, in addition to a direct action on cilia, which could 
influence mucociliary clearance. The differences observed between the frog palate and 
the chick embryo trachea were explained as being due to the differences between the two 
models. In the frog palate, the cilia beat in response to mechanical stimulation and are 
otherwise inactive. In contrast, the cilia of higher vertebrates beat in the absence of 
stimulation and appear to maintain a basal activity. In addition, the activity of the cilia of 
the frog palate are apparently more dependent on an extracellular source of calcium than 
chick embryo trachea. Batts et al. (1991) also evaluated the effect of EDTA on nasal 
clearance in human volunteers using a modified saccharin test with concomitant gamma 
scintigraphy (Batts et al., 1991). A solution of 0.1 % EDTA (0.3 ml) was administered to 
the volunteers, as drops, one hour prior to the administration of a radiolabelled saccharin 
solution by spray (0.1-0.2 ml ejection volume). The deposition and subsequent clearance 
of the radiolabel was monitored by gamma scintigraphy. The time of perception of a 
sweet taste, indicating the presence of saccarin in the nasopharynx, was also recorded. 
EDTA was shown to be well tolerated by the nasal mucosa and did not significantly alter 
the rate of nasal spray clearance. However, the authors suggested possible explanations 
for the lack of toxicity of EDTA in the human study. The calcium concentrations in nasal 
secretions may be sufficiently high to complex with EDTA and reduce ciliotoxicity. In 
addition, EDTA may bind to mucus glycoproteins thereby preventing toxic amounts from 
reaching the cilia over the experimental period. 
1.6.2.4 Fatty acids and fatty acid derivatives 
Fatty acids are organic compounds which are the principal component of most lipids and 
consist mainly of straight chains of an even number of carbon atoms. Mishima et al. 
(1987) investigated the effect of medium chain fatty acid salts; sodium caprylate (C8), 
sodium caprate (C 10) and sodium laurate (C 12) on the intranasal absorption of insulin in 
rats. Sodium caprate at 1% was shown to be the most effective and resulted in a 10-fold 
increase in insulin absorption compared to an insulin solution without enhancer. Optimal 
absorption enhancement was shown at a sodium caprate concentration of 1%. 
Bioavailabilities, relative to a subcutaneous dose, for 1% sodium caprylate, caprate and 
laurate salts were in the region of 15%, 50% and 30% respectively. 
Acylcarnitines have also been used to enhance drug absorption. These are a class of fatty 
acid derivatives consisting of a fatty acid connected to a quaternary amine which carries a 
free carboxyl group (O'Hagan and Ilium; 1990). Endogenous acylcarnitines, formed 
from carnitine and the fatty acyl group of acyl coenzyme A, are important in the transport 
of long chain fatty acids across the mitochondrial membrane and are thus important in the 
regulation of fatty acid metabolism (Fix et al., 1986). Fix et al. (1986) showed that 2% 
palmitoylcarnitine was highly effective in promoting the rectal absorption of somatostatin 
analogue, gentamicin, cefoxitin, theophylline and methyldopa in rats. LeCluyse et al. 
(1991) showed that the efficacy of acylcarnitines as absorption promoters for cefoxitin 
administered rectally was dependent on their fatty acid chain length. Acylcamitines with 
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chain lengths between 2-8 carbon units were ineffective compared to those containing 12- 
18 carbon units and palmitoylcarnitine (C16) resulted in maximal absorption 
enhancement. The presence of 1% palmitoylcarnitine in solution formulations has been 
shown to increase the bioavailabilitiy of human growth hormone, relative to a 
subcutaneous dose, from about 7% to 22% following intranasal administration in rats 
(O'Hagan et al., 1990). 
Lysophospholipids are another class of fatty acid derivatives which have been shown to 
be potent absorption enhancers for a variety of drugs. Lysophospholipids are formed 
naturally in biological membranes by the action of phospholipase enzymes on membrane 
phospholipids (Stafford and Dennis; 1988). They are usually found at low concentration 
in most biomembranes although cellular damage and inflammatory processes can cause 
activation of phospholipase enzymes and increased production of lysophospholipids 
which have been shown to be able to stimulate macrophage production (Yamamoto and 
Ngwenya; 1987, Stafford and Dennis; 1988). Lysophospholipids are ampiphilic 
compounds consisting of a large polar head group and one long chain acyl group joined 
to a glycerol backbone (Stafford and Dennis; 1988). The polar head group is commonly 
a choline or ethanolamine moiety attached to the glycerol backbone via a phosphate ester 
although other moieties such as glycerol, serine and inositol are possible. The non-polar 
long chain acyl group consists of a saturated or unsaturated hydrocarbon chain which is 
attached to the glycerol backbone via an ester linkage. The length of the acyl chain may 
vary but most naturally occurring lysophospholipids are 16 or 18 carbon units in length. 
Lysophosphatidylcholine (LPC, lysolecithin) generally describes a group of compounds 
which each contain a choline moiety but which differ in the length of the acyl side chain. 
Naturally occurring LPC which is commercially derived from egg yolk 
phosphatidylcholine will usually contain a mixture of LPCs of different side chain length 
such as stearoyl (C 18) and palmitoyl (C 16). Relatively pure LPC homologues having 
specific side chain lengths and degrees of saturation can be derived synthetically. 
Several studies have demonstrated the absorption promoting efficacy of LPC for drugs 
delivered via the nasal route. Hansen et al. (1988) showed that 0.5% lauroyl-L-a-LPC 
enhanced to intranasal absorption of insulin in rabbits but was found to irritate the nasal 
mucosa in human volunteers. Didecanoyl-L-a-LPC, administered as a microemulsion, 
was non-irritant to the volunteer's nasal mucosa and enhanced the intranasal absorption 
of insulin in rabbits. Ilium et al. (1988) showed that LPC enhanced the intranasal 
absorption of gentamicin from a liquid formulation in the anaesthetised rat model but was 
less effective in the conscious sheep model. These differences were explained as the 
difference between the in vivo rat model, where mucociliary clearance is impaired, and 
the conscious sheep model which is physiologically more relevant since mucociliary 
clearance mechanisms are not impaired. However, the incorporation of LPC in a 
lyophilised powder formulation of gentamicin and starch microspheres improved the 
bioavailability of gentamicin from about 10% to 57% following nasal administration to 
sheep. Similar increases in nasal drug absorption by coadministering LPC with starch 
microspheres were demonstrated by Farraj et al. (1989) and Critchley et al. (1994). A 
55 
powder formulation of LPC with starch microspheres increase the absolute bioavailability 
of insulin from about 5% to 13% in sheep (Farraj et al., 1989). LPC in a solution 
formulation resulted in only a slight improvement in insulin bioavailability from about 1% 
to 2%. Critchleyet al. (1994) showed that 0.2% LPC increased the nasal absorption of 
desmopressin in the rat model with absolute bioavailability improved from approximately 
16% to 26%. In sheep, LPC had only a slight effect on desmopressin absorption 
improving the nasal bioavailability from about I% to 3% compared to an improvement 
from about 5% to 10% in a powdered starch microsphere formulation. 
In a later study, 0.5 % LPC was shown to improve the nasal absorption of insulin (16.7 
IU/kg) in rats (Ilium et al., 1989). In the study, an LPC composed mainly of a mixture 
of palmitoyl (72%) and stearoyl (24%) components was shown to be as effective as LPC 
palmitoyl or LPC stearoyl. Chandler et al. (1994) investigated the efficacy of a range of 
synthetic LPC homologues in promoting intranasal insulin (8 IU/kg) absorption in rats. 
It was found that coadministration of LPCs which possessed 10 or more carbon groups 
in their fatty acid chain were effective enhancers although LPC caproyl (C6) did not 
appreciably promote insulin absorption. At equimolar concentrations (11.9 mM), it was 
shown that LPC decanoyl (C 10) and LPC stearoyl (C18) were equally effective in 
promoting insulin absorption but that LPC caproyl (C6) was not significantly different to 
a control insulin formulation (without enhancer). The absorption enhancing efficacy of 
three concentrations of LPC decanoyl (15.2,11.9 and 5 mM), in terms of lowering blood 
glucose concentrations, increased as LPC concentration decreased although the rate of fall 
of glucose concentrations decreased with decreasing LPC concentration. However, 
blood samples were only collected up to 40 minutes and so this may not fully reflect the 
efficacy of the various concentrations of LPC particularly since glucose concentrations 
after coadministration of insulin with 5 mM LPC reached a plateau or were levelling off at 
40 minutes in contrast to the glucose concentrations which were still falling at the 40 
minute time point when 11.9 mM LPC was coadministered. Lysophosphatidylglycerol 
(LPG) at 0.0625% and 0.5% was shown to be equally effective in promoting the nasal 
absorption of insulin despite an approximately 10-fold difference in the LPG 
concentration. The extent of insulin absorption was shown to be similar to that obtained 
with LPCs containing 10 or more carbon groups on the fatty acid chain. 
LPC at 0.2% was shown to be more effective in enhancing the absorption of human 
growth hormone (hGH), via the nasal route, than 1% palmitoylcarnitine (O'Hagan et al., 
1990). In studies in rats, the presence of LPC increased the bioavailability of 1 mg/kg 
hGH, relative to a subcutaneous dose, from about 7% to 29%. Fisher et al. (1991) 
further investigated the effect of LPC on the intranasal absorption of hGH in three animal 
species finding that the co-administration of LPC with hGH consistently increased hGH 
absorption. Bioavailability of hGH was improved from about 2% to about 18% in rats 
with 0.5% LPC (1 mg/kg hGH) and in sheep from 0.2% to about 16% with 0.585% 
LPC (0.308 mg/kg hGH) and the amount of hGH absorbed was shown to be 
proportional to the concentration of LPC in the nasal solution. In rabbits, a concentration 
of 0.2% LPC (0.308 mg/kg hGH) increase bioavailability from about 1% to 73%. 
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The mechanisms by which fatty acids and fatty acid derivatives act as absorption 
enhancers are not fully understood. Mishima et al. (1987) demonstrated the membrane 
damaging activity of medium chain fatty acid salts by investigating their haemolytic 
activity. Sodium laurate was shown to have the highest haemolytic potency resulting in 
approximately 75% haemolysis at 0.1 % compared to only about 4% haemolysis for 0.1 % 
sodium caprate although at 0.5% both compounds resulted in a similar degree of 
haemolysis (approximately 68-74%). In contrast, sodium caprylate resulted in only 
about 2% haemolysis at concentrations up to 1%. Mishima et al. (1987) also investigated 
the ability of the fatty acid salts to sequest calcium ions finding that sodium caprylate, 
sodium caprate and sodium laurate (concentration of 1M) were able to bind 0.02,0.35 
and 0.42 M of calcium ions respectively, compared to about 1.08 M for the same 
concentration of EDTA. The sequestration of ions was shown to increase with increasing 
alkyl chain length of the fatty acid salts. The fatty acid salts were also shown to inhibit 
leucine aminopeptidase activity in rat and rabbit nasal homogenates in the order; sodium 
laurate > sodium caprate > sodium caprylate. The results are not conclusive, suggesting 
that absorption enhancement may involve a combination of factors including damage to 
the nasal membrane, sequestration of ions and hence the opening of tight junctions and 
inhibition of proteolytic enzymes in the nasal mucosa. 
The damaging effects of acyl carnitines on erythrocyte membranes have been 
demonstrated by Cho and Proulx (1969 and 1971). The acyl carnitines were generally 
shown to be potent haemolytic agents on rat and human erythrocytes (Cho and Proulx; 
1969). Haemolytic potency was shown to decrease as the fatty acid chain length of the 
acyl carnitine decreased with little or no haemolytic activity for chain lengths of C 10 and 
below. The haemolytic action of the acyl carnitines coupled with their ampiphilic nature 
suggests that absorption enhancement is due to a surfactant-like effect on mucosal 
membranes (O'Hagan and Ilium, 1990). Fix et al. (1986) demonstrated that 
enhancement of the rectal absorption of sodium cefoxitin by palmitoyl carnitine was 
reversible within 60-120 minutes indicating no gross mucosal damage. Furthermore, 
histological examination of intestinal or rectal tissue showed that even after prolonged 
exposure to I% palmitoyl carnitine there was only slight alteration in the mucosal 
structure. Significant rectal absorption enhancement was observed at concentrations of 
palmitoyl carnitine which did not alter mucosal structure. LeCluyse et al. (1991) 
investigated the relationship between in vivo enhancement of drug absorption and in vitro 
perturbation of brush border membranes from rat intestine by acyl carnitines of varying 
chain length (C2-C 18). Acyl carnitines of chain length less than 12 carbon units were 
ineffective in enhancing cefoxitin absorption and did not result in a decrease in the lipid 
order of brush border membranes used as an indication of the membrane perturbing 
effects. Acyl carnitines of chain length 12-18 carbon units effectively promoted cefoxitin 
absorption and decreased lipid order. However, the membrane perturbing effects 
differed among the C 12-C 18 acyl carnitines and did not correlate with their absorption 
enhancing efficacy. The authors concluded that the acyl carnitines must possess a critical 
chain length, above 10 carbon units, in order to partition into the membrane and must 
perturb the membrane lipid order beyond a threshold value (15-20%) to effectively 
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enhance absorption. Richardson et al. (1989) showed that the intravaginal administration 
of 1% palmitoyl carnitine to ovariectomised rats resulted in moderate epithelial damage 
which was suggested as a partial mechanism for enhanced gentamicin absorption. 
Although the thickness of vaginal epithelia was reduced compared to control animals by 
treatment with palmitoyl carnitine the damage was not as severe as that following 
administration of Laureth-9 and LPC which both resulted in extensive cell loss. The 
literature suggests that acyl carnitines, like other fatty acid `derivatives', act as absorption 
enhancers due to their surfactant-like effect on mucosal membranes which may also result 
in epithelial disruption. However, other mechanisms such as enzyme inhibition and 
calcium ion chelation may also be involved to some extent. 
Lysophospholipids, being ampiphilic surface-active agents probably act as absorption 
enhancers by a mechanism similar to that of the surfactants (O'Hagan and Ilium; 1990). 
LPC has been demonstrated to be a potent haemolytic agent (Cho and Proulx; 1971, 
Weltzien et al., 1977, Weltzien; 1979, Martin et al., 1992, Jabbal Gill et al., 1994a, 
Chandler et al., 1995). Martin et al. (1992) showed that LPC caused 50% haemolysis at 
a concentration of 0.07 mM (pH 6 and 8) and 0.09 mM (pH 7). Jabbal Gill et al. 
(1 994a) demonstrated that LPC was a more potent haemolytic agent than other surfactants 
such as Laureth-9 and GDC causing 100% haemolysis at a concentration as low as 0.04 
mM (0.002%). Chandler et al. (1995) compared the membrane activity of three LPC 
homologues (stearoyl C18, decanoyl CIO and caproyl C6). LPC caproyl, investigated 
up to concentrations of 20 mM did not result in erythrocyte haemolysis (results corrected 
for background haemolysis). LPC decanoyl was haemolytic at concentrations greater 
than about 5 mM (0.21%) and resulted in approximately 50% haemolysis at a 
concentration of 20 mM. In contrast, LPC stearoyl was a potent haemolytic agent 
resulting in 50% haemolysis at 0.01 mM and approximately 100% haemolysis at 
concentrations above 0.02 mM (0.00 11 %). Thus decreasing the length of the LPC fatty 
acid side chain decreased the haemolytic activity and supported the findings of Weltzien 
(1977). 
Previously, Chandler et al. (1994) showed that at concentrations of 11.9 mM LPC 
stearoyl and LPC decanoyl were equi-effective in promoting intranasal insulin absorption 
in the rat but that LPC caproyl was ineffective which together with the results from the 
haemolysis studies suggests that disruption of the nasal membrane is a prominent 
mechanism for the absorption enhancing efficacy. LPC caproyl did not promote insulin 
absorption, even at a concentration of 17.6 mM (0.625%) and lacked haemolytic activity. 
In contrast, LPC stearoyl was shown to be a potent haemolytic agent at a concentration 
well below that which enhanced insulin absorption. However, other mechanisms may be 
involved since LPC decanoyl was also shown to be an effective enhancer at a 
concentration (5.0 mM) at which it was not haemolytic. The enhancing efficacy along 
with haemolytic activity increased with increasing concentration of LPC decanoyl. As 
pointed out by Chandler et al. (1995), care must be taken when extrapolating the results 
from studies using a model membrane system, such as erythrocyte haemolysis studies, to 
the effects on the nasal membrane. 
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Chandler et al. (1991b), using histological techniques, showed that 0.625% LPC 
(stearoyl//palmitoyl mixture) caused severe damage to rat nasal mucosa. The thickness of 
the nasal epithelium was reduced in parts to a thin layer of squamous cells and cells were 
lost from the epithelium and were observed in the nasal lumen mixed with large quantities 
of mucus. In further histological studies in the rat, Chandler et al. (1994) evaluated the 
nasal membrane damaging effects of formulations containing insulin and LPC caproyl or 
LPC decanoyl at equimolar concentrations (11.9 mM). LPC caproyl, which did not 
promote insulin absorption, showed signs of slight membrane interaction but this was 
regarded as comparable to that which resulted from administration of a control solution of 
insulin. Membrane disruption following the administration of LPC decanoyl was only 
marginally increased compared to LPC caproyl. However, LPC decanoyl promoted 
insulin absorption to a similar extent as the LPC stearoyl/palmitoyl mixture which was 
shown to severely disrupt the nasal epithelial membrane. In addition, LPG at 0.5% was 
shown to cause membrane damage which was comparable to that caused by LPC 
stearoyl/palmitoyl mixture but that 0.0625% LPG resulted in only slight membrane 
damage, comparable in that caused by the control solution of insulin, despite enhancing 
the absorption of insulin to a similar extent as 0.5% LPG. Thus, it appears that drug 
absorption is possible without severe membrane disrupting effects by careful selection of 
the lysophospholipid and the concentration used. 
Martin et al. (1978) showed that LPC had mucolytic activity and that the viscosity of 
mucus decreased with increasing LPC concentration. In contrast, phosphatidylcholine 
showed no mucolytic activity. At concentrations of 6 and 20 mM, mucus viscosity was 
decreased in the region of 50% and 80% respectively. Thus, mucolytic activity may be 
an important contribution to the absorption enhancing mechanism of lysophospholipids. 
The mechanisms by which fatty acids and fatty acid derivatives acts as absorption 
enhancers has not been fully elucidated although membrane perturbation appears to be an 
unfortunate feature of these compounds. This would severely limit the use of these 
compounds for commercial application. 
1.6.2.5 Enzyme inhibitors 
The exact nature of the nasal enzymatic barrier in vivo and the extent to which it affects 
intranasal peptide delivery has not been fully elucidated. However, in vitro and in situ 
studies indicate that enzymatic degradation may constitute a significant barrier to peptide 
absorption in the nasal cavity particularly for smaller peptides (Ilium, 1992). Enzyme 
inhibitors have been extensively shown to inhibit the degradation of peptides in mucosal 
homogenates but few studies have reported the use of enzyme inhibitors to improve the 
bioavailability of peptides. 
Several of the classes of compounds previously mentioned, such as bile salts, surfactants 
and fatty acids, have been shown to possess enzyme inhibitory action which may 
contribute to their overall efficacy as absorption enhancers. However, enzyme inhibition 
does not appear to be the main mode of action of these compounds. Aprotinin is a 
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protease inhibitor which has been used to prevent the proteolytic degradation of proteins 
and polypeptides during purification from biological fluids (Hewlett; 1990). Aprotinin 
will inhibit a variety of enzymes belonging to the serine protease group, such as trypsin, 
chymotrypsin, plasmin and kallikrein, by binding to the active site of the enzyme. The 
oral absorption of vasopressin in rats was shown to be increased by coadministration 
with aprotinin which was attributed to the inhibition of proteolytic enzymes, such as 
trypsin, in the gastrointestinal tract thereby preventing or limiting the degradation of 
vasopressin (Saffran et al., 1988). Morimoto et al. (1992) showed that aprotinin 
enhanced the nasal absorption of salmon calcitonin in rats. However, in the same study, 
the same concentrations of aprotinin did not enhance the intranasal absorption of 
vasopressin and desmopressin. A later study reported that aprotinin improved the 
bioavailability of salmon calcitonin after nasal administration from 5.4% to 7.5% at pH 4 
and from 3.2 to 6.9% at pH 7 respectively (Morimoto et al., 1995). 
Bestatin is an enzyme inhibitor which has been investigated as an absorption enhancer. 
Bestatin has been reported to specifically inhibit aminopeptidase B and leucine 
aminopeptidase in vitro and furthermore it has been shown to have low toxicity following 
intraperitoneal injection (300 mg/kg) in mice (Umezawa et al., 1976). Critchley (1989) 
reported that bestatin (10 µg/ml) increased the bioavailability of desmopressin, compared 
to a control solution, by 8%. However, following nasal administration to rats, bestatin at 
a concentration of 0.015% did not enhance the absorption of hGH (O'Hagan et al., 
1990). Hanson et al. (1986) showed that bestatin did not improve the nasal absorption of 
salmon calitonin in rats. This was recently confirmed in studies by Morimoto et al. 
(1995). O'Hagan et al. (1990) also studied the effects of amastatin, a potent inhibitor of 
leucine aminopeptidase and a less potent inhibitor of aminopeptidase A, at a concentration 
of 0.015%. Amastatin was shown to improve intranasal hGH absorption in rats, relative 
to a subcutaneous dose, from about 7% to 29%. Critchley (1989) also demonstrated that 
puromycin, which had been shown to inhibit the degradation of enkephalin in vitro by 
Barclay and Phillipps (1978), improved the bioavailability of desmopressin, compared to 
a control solution, by 4%. In situ studies have shown that boroleucine, an a- 
aminoboronic acid derivative, is 100 and 1000 times more effective than bestatin and 
puromycin, respectively in preventing the degradation of leucine-enkephalin in nasal 
perfusate (Hussain et al., 1989). Furthermore, in contrast to bestatin and puromycin, 
boroleucine was shown to be a potent but reversible inhibitor of nasal aminopeptidase 
enzymes (Hussain et al., 1990). However, effective absorption promotion using a- 
aminoboronic acid derivatives has not been demonstrated. Bacitracin, a less potent 
inhibitor of aminopeptidase activity than bestatin or puromycin which has been used as an 
antimicrobial agent, has been shown to enhance the nasal absorption of two analogues of 
growth hormone releasing hormone (GH-RH) in rats (Raehs et al., 1988). This may 
indicate that there are additional mechanisms involved in the absorption enhancing 
efficacy of this compound. In vitro studies showed that bacitracin irreversibly arrested 
cilia motility within one hour after exposure for 20 minutes. Differences in the 
absorption promoting efficacy of enzyme inhibitors appears to be also dependent on the 
characteristics of the drug molecule. In the study by Morimoto et al. (1992), the 
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inhibition of trypsin activity in the nasal mucosa was reported to be useful for enhancing 
the absorption of salmon calcitonin but not for the absorption of vasopressin or 
desmopressin. Likewise, in studies in rats, bestatin was reported by Critchley (1989) to 
increase the nasal absorption of desmopressin but Morimoto et al. (1995) showed that it 
was ineffective for the nasal delivery of salmon calcitonin. 
Despite the limited number of studies performed, the degree of absorption promotion of 
peptide drugs by coadministration with enzyme inhibitors does not appear to have the 
same magnitude as that demonstrated by utilising other enhancing systems. Although 
enzyme inhibition may be an important factor contributing to the mechanism of action of 
some absorption promoting compounds, enzyme inhibition alone does not appear be a 
sufficient factor to increase the bioavailability of intranasally administered drugs. 
1.6.2.6 Other absorption enhancers 
Cyclodextrins 
Cyclodextrins are cyclic oligosaccharides which have been used to improve the physical 
and chemical properties of drug molecules in solution through the formation of inclusion 
complexes (Irie et al., 1992). During the formation of peptides / cyclodextrin inclusion 
complexes, the hydrophobic residue of the peptide guest molecule penetrates into the 
`cavity' of the cyclodextrin host molecule (Irwin et al., 1994). This will reduce the 
concentration of free drug in solution and may have a significant effect on aqueous 
solubility and chemical stability. The poor water solubility of lipophilic drugs can be 
overcome by the formation of guest-host complexes (Rao et al., 1990). The common 
types of cyclodextrin are a- ((Y-CD), ß- (3-CD) and y-cyclodextrin (y-CD) containing 6,7 
or 8 glucopyranose units, respectively, which are linked forming a torus-shaped, apolar, 
electron-rich hydrophobic cavity (Jabbal Gill et al., 1994a). Chemically modified 
cyclodextrins are also available, such as hydroxy-propyl-p-cyclodextrin (HP-f3-CD) and 
dimethyl-ß-cyclodextrin (DM-0-CD), which have improved solubility characteristics 
compared to the parent compound (Yoshida et al., 1988). 
DM-13-CD was shown to significantly enhance the nasal absorption of 170-estradiol, 
compared to a suspension of 1713-estradiol, in both rats and rabbits (Hermens et al., 
1990). Compared to a suspension of 1713-estradiol, coadministration with DM-ß-CD 
improved the absolute bioavailability of estradiol from about 23% to 67% in rats and 25% 
to 95% in rabbits. The effect of DM-ß-CD as a solubilising agent for the poorly water 
soluble estradiol was attributed as an important mechanism for its absorption enhancing 
efficacy. DM-ß-CD has surfactant activities, in-contrast to the underivatized parent ß-CD, 
which may also. be important mechanism for its absorption enhancing properties. DM-fl- 
CD was shown to have only a minor effect on the cilia beat frequency on human adenoid 
tissue and the authors suggested that the formulation containing DM-p-CD is 
biocompatible and suitable for chronic nasal administration. The same study group 
investigated the effect of various cyclodextrins on the intranasal absorption of insulin in 
rats (Merkus et al., 1991). All cyclodextrins were investigated at concentrations of 5% 
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with the exception of p-CD which owing to its lower solubility was investigated at 1.8 %. 
DM-ß-CD was the most effective giving rise to an insulin bioavailability of about 110% 
compared to an intravenous dose. Coadministration with a-CD was less effective 
(absolute bioavailability approximately 28%) and n-CD, HP-ß-CD and y-CD were 
ineffective (absolute bioavailabilities of about 2.9,1.2 and 0% respectively). The 
influence of the cyclodextrins on ciliary beat frequency was investigated using chick 
embryo tracheal tissue and both DM- 3-CD and a-CD were shown to induce ciliostasis 
30-40 minutes after exposure. The ciliostatic effect of DM-ß-CD appeared to be 
reversible (reversibility of ciliostasis induced by a-CD was not evaluated). The cilia beat 
frequency, 60 minutes after exposure to ß-CD, HP-ß-CD and y-CD was reduced to 63, 
78 and 77% respectively. In a later study in rabbits, DM-f3-CD was shown to be more 
effective as a nasal absorption enhancer for insulin when coadministered in a powder 
formulation rather than in a liquid formulation (Schipper et al., 1993). The insulin / DM- 
t3-CD formulation which had previously been shown to result in complete insulin 
absorption in the rat was ineffective when tested in the rabbit giving rise to an insulin 
bioavailability of approximately M. This was attributed to substantial inter-species 
differences in the absorption enhancing effect of DM-ß-CD. However, the administration 
of a powder formulation of insulin and DM-[3-CD improved insulin bioavailability to 
about 13%. 
Jabbal Gill et al. (1994a) showed that cyclodextrins may be useful as protective agents 
against the potential damage induced by absorption enhancers used in nasal delivery 
systems. Using rat erythrocytes as a model biomembrane, enhancers were shown to be 
potent haemolytic agents in the order LPC > Laureth-9 > GDC. The two cyclodextrins 
investigated, HP-f3-Cl) and y-CD, showed low degrees of haemolysis. By combining 
the cyclodextrins with the enhancers it was possible to reduce or prevent haemolysis. As 
the haemolytic potency of the enhancer increased, greater concentrations of cyclodextrins 
were required to prevent haemolysis. The coadministration of cyclodextrins without 
absorption enhancers did not dramatically improve insulin absorption compared to a 
control solution. The enhancers, LPC, Laureth-9 and GDC, were shown to increase 
insulin absorption but in the presence of cyclodextrins, with the exception of Laureth-9 in 
which the enhancing effect was maintained, that of LPC and GDC was considerably 
reduced. However, sustained absorption of insulin was observed following 
coadministration of GDC with y-CD. Histological studies, evaluating Laureth-9, GDC 
and the cyclodextrins, did not consistently correlate with insulin absorption results. 
However, the histological results complemented the findings of the haemolysis studies 
and the enhancer / cyclodextrin combinations were observed to cause the least damage to 
the rat nasal epithelium. Enhancer/ cyclodextrin combinations may provide the necessary 
activity and safety required for nasal drug delivery systems. 
Shao et al. (1992) investigated the possible mechanisms of action of cyclodextrins in 
promoting the nasal absorption of insulin by using a rat in situ perfusion method. 
Concentrations of 5% were used with the exception of p-CD which was used at 1.8%. 
The relative effectiveness of the cyclodextrins in promoting insulin absorption was 
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reported to be in the order y-CD < HP-ß-CD < 3-CD < a-CD < DM-f 
-CD. The 
absorption enhancing efficacy of the cyclodextrins correlated with the release of both 
protein and phospholipid from the nasal membrane, indicating the degree of membrane 
damage, which was measured in the perfusate. The magnitude of cyclodextrin induced 
damage, in terms of solubilising membrane components, was further evaluated by 
measuring enzymic activity of membrane-bound 5'-nucleotidase (5'-ND) and intracellular 
lactate dehydrogenase (LDH) following perfusion of DM-13-CD or HP-13-CD. It was 
shown that the activity of 5'-ND and LDH was considerably increased by perfusion with 
DM-ß-CD confirming the findings that DM-13-CD induces relatively more membrane 
damage. In contrast, HP-ß-CD resulted in only minimal disruption of the epithelial 
membrane. The membrane disrupting effect of DM-ß-CD was shown to depend on the 
cyclodextrin concentration with less membrane disruption observed with 1.8% DM-p-CD 
compared to 5% DM-f3-CD. Cyclodextrins were also shown to be able to dissociate 
insulin hexamers into smaller aggregates which by increasing the diffusion of insulin 
across the nasal membrane may provide an additional mechanism for the absorption 
enhancing efficacy of cyclodextrins. In addition to membrane disruption, other factors 
may contribute to the absorption enhancing properties of the cyclodextrins. Complex 
formation with drug molecules may improve the aqueous solubility of some drugs and 
may also protect the drugs to some extent from proteolytic degradation. Cyclodextrins 
may also have a direct inhibitory effect on proteolytic enzyme activity. Irwin et al. (1994) 
demonstrated that the stability of leucine enkephalin in nasal enzymic systems (mucosal 
homogenates or nasal wash fluid) was improved by ß-CD. However, y-CD did not 
stabilise leucine enkephalin which was attributed to the larger cavity diameter of the y-CD 
resulting in less complexed peptide. 
Bioadhesive systems 
Rapid mucociliary clearance of drug formulations which are deposited in the nasal cavity 
is thought to be an important factor for the low bioavailability of drugs administered 
intranasally (Ilium et al., 1987). Increasing the residence time of the drug formulation in 
the nasal cavity will increase the time of contact between the drug and the nasal mucosa 
which may increase drug absorption. The clearance of solutions administered in the form 
of a spray from the nasal cavity has been shown to decrease as solution viscosity is 
increased by the inclusion of hydroxypropyl methylcellulose and has been suggested as a 
possible means by which the therapeutic effect of nasal spray preparations may be 
increased (Pennington et al., 1988). 
Several approaches have been used to increase the residence time of drug formulations in 
the nasal cavity. Compounds which increase the viscosity of solution formulations may 
be used to prevent drainage of the formulation and slow-down mucociliary clearance 
from the nasal cavity. Compounds having bio- or mucoadhesive properties, enabling 
them to interact with the mucus layer, have also been used in solution or powder delivery 
systems to increase the residence time of drug formulations in the nasal cavity. 
Bioadhesion involves intimate contact between- and interpenetration of the bioadhesive 
and the mucus layer with the formation of chemical bonds (Duchene et al., 1988, Gu et 
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al., 1988). The bioadhesive properties of a compound will depend on the nature of the 
compound and on the nature of the surrounding media. Viscosity enhancers and 
bioadhesives used in drug delivery systems are usually polymeric materials. Many of the 
compounds used have both bioadhesive and viscosity enhancing properties when in 
solution. 
Morimoto et al. (1985) used carbopol, a derivative of polyacrylic acid which forms 
aqueous gels at low concentrations, to enhance the intranasal absorption of insulin and 
calcitonin in rats. Carbopol has been used to increase the viscosity of solutions and has 
also been reported to have excellent mucoadhesive properties (Smart et al., 1985, 
Duchene et al., 1988, Junginger; 1990). Park and Robinson (1987) suggest that the 
bioadhesive properties of carbopol are due to the formation of hydrogen bonds between 
carbopol carboxy groups and suitable groups in the mucus. In the study by Morimoto et 
al. (1985) both 0.1% and 1.0% carbopol promoted insulin absorption. However, 
absorption with 1.0% carbopol was slower than that observed using 0.1 % carbopol 
which was attributed to an optimum concentration / viscosity of the gel base. Thus, at 
concentrations above the optimum, the increased viscosity slows down the release of 
insulin from the gel base. Carbopol at a concentration of 0.1 % also increased calcitonin 
absorption. Morimoto et al. (1987) showed that carbopol gel at concentrations of 0.05, 
0.1 and 0.5%, were ineffective in promoting the intranasal absorption of nifedipine in 
rats. However, sustained absorption of nifedipine was observed by coadministration in a 
gel composed of 0.05% carbopol in 50% PEG. 
Critchley (1989) showed that coadministration of 2% carbopol improved the nasal 
bioavailability of desmopressin from about 16% to 78% in rats but it had no effect on 
gentamicin absorption which was suggested to be due to an interaction between positively 
charged gentamicin and negatively charged carbopol. In addition, DEAE dextran, a 
cationic polymer exhibiting viscosity enhancing and mucoadhesive properties, was 
shown to improve desmopressin absorption (absolute bioavailability of 60%). The 
difference in the performance of carbopol and DEAE dextran was suggested to be due to 
DEAE dextran (a polycation) becoming tightly bound to the mucus layer (containing 
negatively charged binding sites) due to electrostatic interactions which create a barrier to 
drug release. Binding may also occur between the polycation and anionic sites on the 
mucosal surface which are a common feature of membranes (Quinton and Philpott; 
1979). Chu et al. (1991) described a carbopol sustained release gel system for intranasal 
drug delivery. The formulation was of low viscosity for ease of spray administration to 
the nasal cavity but formed a highly viscous gel on contact with the moist nasal mucosa 
due to the change in solvent composition. The authors reported a correlation between 
viscosity and bioavailability following the evaluation of nasal formulations of propranolol 
in dogs which was suggested to be due to the increased residence time of the viscous 
formulations in the nasal cavity. 
Carboxymethylcellulose is another compound which has been reported to have excellent 
bioadhesive properties (Duchene et al., 1988, Junginger; 1990). However, a liquid 
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formulation containing I% carboxymethylcellulose did not promote nasal insulin 
absorption in the rat despite having a similar viscosity to the carbopol formulation which 
had been shown to promote insulin absorption (Morimoto et al., 1985). This suggested 
that viscosity and bioadhesive properties were not the only factor which affected insulin 
absorption. The authors suggested that water absorption from the gel base (water influx) 
would allow the movement of hydrophilic and macromolecular compounds through 
intracellular channels. Thus, polyacrylic acid was suggested to promote drug absorption 
via the paracellular route rather than through the transcellular route. Junginger (1990) has 
suggested that carbopol may bind calcium ions thus opening intracellular tight junctions 
in the nasal mucosa. Cellulose ethers such as methylcellulose and 
hydroxypropylmethylcellulose (HPMC) have been shown to improve the nasal 
absorption of desmopressin in the rats (Critchley 1989). The study was intended to 
investigate the effect of viscosity enhancing agents rather than bioadhesives although the 
bioadhesive properties of methylcellulose and HPMC have been described as excellent 
and satisfactory respectively (Junginger; 1990) and hence it is difficult to distinguish 
between viscosity and bioadhesive effects. Critchley (1989) showed that the absolute 
bioavailabilities of desmopressin from formulations containing 2% methylcellulose 
(viscosity at 37°C 185.2 mPas) or 2% HPMC (viscosity at 37°C 20.6 mPas) were 
approximately 28% and 51 % respectively. The lower absorption for the methylcellulose 
formulation was attributed to its higher viscosity which would limit the spreading of the 
solution in the nasal cavity resulting in a longer path length for diffusion of the drug. 
Harris et al. (1988b) in a study in humans, showed that the addition of 0.25% 
methycellulose to a solution of desmopressin resulted in an increase of the residence time 
of the formulation in the nasal cavity. However, this was not accompanied by an 
increase in the bioavailability of desmopressin compared to a control solution although 
slower and more prolonged absorption was reported from the methylcellulose 
formulation (Harris et al., 1989). 
Nagai et al. (1984) investigated powder dosage forms of insulin for nasal administration 
in dogs. Various excipients were evaluated in this study including the viscosity 
enhancing agents hydroxypropylcellulose (HPC) and neutralised carbopol prepared as 
blends of excipient and freeze-dried insulin. The use of neutralised carbopol resulted in 
the sustained absorption of insulin which was explained as being due to the excipient 
forming a viscous gel incorporating insulin on contact with the nasal mucus which 
adhered to the mucosa and increased the residence time of the formulation in the nasal 
cavity. Insulin was absorbed to about the same extent as in the neutralised carbopol 
formulation by using HPC although the effect was not sustained which may be due the 
HPC forming a less viscous gel in the nasal cavity and also being a poorer bioadhesive 
material. Freeze-dried formulations containing insulin and carbopol resulted a dramatic 
lowering of plasma glucose concentrations, used as an indication of insulin absorption, 
following nasal administration in the dogs and it was found that greater sustainment of 
insulin absorption was observed by increasing carbopol concentration. The excipients 
used in the study were reported to be non-irritant to nasal mucosa following 
administration to human volunteers. 
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Bioadhesive microsphere powder delivery systems for intranasal drug delivery have been 
extensively investigated. The retention of powdered microsphere systems (albumin, 
starch and DEAE dextran) in the nasal cavity following administration to human 
volunteers has been investigated by Ilium (1986) and Ilium et al. (1987). The retention 
of the microsphere systems in the nasal cavity was attributed to the microspheres 
imbibing water, swelling and forming a gel like layer on contact with the nasal mucosa. 
The three microspheres systems were described as having good bioadhesive properties 
with binding suggested as being via hydrogen bonds for albumin and starch 
microspheres and ionic bonding for DEAE dextran. A study in rats evaluated degradable 
starch microspheres (mean diameter of 45 µm) for the nasal delivery of insulin finding 
that the bioavailability of insulin, compared to an intravenous dose was about 30% (B jörk 
and Edman; 1988). Ilium et al. (1988) showed that the bioavailability of intranasally 
administered gentamicin administered as a powder with degradable starch microspheres 
(mean diameter 48 µm) was approximately 10% compared to about I% for a simple 
solution of gentamicin. The nasal dose of starch microspheres was 2.5 mg/kg. The 
absolute bioavailability of gentamicin was further improved to approximately 57 % by a 
combination of starch microspheres and LPC. Although the bioavailability of gentamicin 
from a nasal solution with LPC was not given the absorption profile was very much 
similar to that of the simple gentamicin solution. The same study group showed that the 
starch microsphere delivery system improved the absorption of insulin in sheep (Farraj et 
al., 1990). The absolute bioavailability of insulin administered with starch microspheres 
(2.5 mg/kg) was 4.5% compared to about I% for a solution of insulin without absorption 
enhancers. The absorption of insulin was further improved by the coadministration of 
LPC with starch microspheres with an absolute bioavailability of about 13% and 
bioavailability relative to the subcutaneous route of almost 32%. The coadministration of 
LPC with insulin in a solution formulation resulted in an absolute bioavailability of about 
2%. However, the dose of LPC administered to sheep from the solution formulation was 
considerably less (0.02 mg/kg) than from the powder formulation (0.2 mg/kg). A 
combination of LPC and starch microspheres (2.5 mg/kg) has also been shown to 
improve the nasal absorption of hGH (Ilium et al., 1990) and desmopressin (Critchley et 
al., 1994) in sheep. For hGH, bioavailabilities, relative to the subcutaneous route, by 
coadministration with LPC as a solution, or in the form of powders with starch 
microspheres or LPC / starch microspheres were 0.1%, 2.7% and 14.4%, respectively. 
For desmopressin, bioavailabilities, relative to intravenous route, were 4.7% with starch 
microspheres and 9.6% with LPC / starch microspheres. 
It has been reported that degradable starch microspheres are biocompatible and do not 
induce serious histopathological changes to nasal mucosa (Björk et al., 1991). Starch 
microspheres were administered twice daily to the left nostril of rabbits (10 or 20 mg 
doses) for 2,4 or 8 weeks. The right, undosed, nostril of each animal was used for 
control purposes. There were no macroscopic alterations in the nasal mucosa (such as 
changes in the mucosal architecture, inflammatory reaction or ulcerations) due to the 
administration of starch microspheres and scanning electron microscopy showed that 
nasal epithelial cells and cilia remain intact. The authors concluded that starch 
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microspheres have negligible effects on nasal mucosa. In the study by Björk et al. 
(1991) the dose of starch microspheres administered to rabbits was 5 or 10 mg/kg for 10 
or 20 mg doses, respectively, which is much higher than the doses of about 2.5 mg/kg 
which were shown to effectively promote drug absorption in the studies by Ilium et al. 
(1988,1990), Farraj et al. (1990) and Critchley et al. (1994). 
B jörk et al. (1992) showed that that the administration of 10 mg degradable starch 
microspheres into each nostril of 15 healthy volunteers once daily for eight days was well 
tolerated and there was no significant changes in mucociliary transport within this period. 
In vitro studies using a cell model, originating from a human intestinal epithelial (Caco-2) 
cell line, showed that degradable starch microspheres pre-applied to the mucosal side of 
the cell monolayer increased the transport of both mannitol and insulin (applied at later 
stages) across the cell layer (Artursson; 1990). The effect of the starch microspheres on 
the permeation of mannitol and insulin was shown to be reversible. Transmission 
electron microscopy showed that the cells and cilia of the cell monolayer following 
exposure to starch microspheres were intact but that the intracellular tight junctions were 
opened to a higher degree. The tight junctions were shown to be closed again after 180 
minutes. Thus, the opening and closing of the tight junctions correlated with the 
reversible effect of starch microspheres on the permeation of mannitol and insulin 
indicating absorption via the paracellular route. In a recent paper by this study group, 
starch microspheres coated with insulin were shown to induce a pulsed delivery of 
insulin across Caco-2 cells in vitro which lasted for 1-2 hours (Björk et al., 1995). The 
pulsed delivery correlated with a reversible separation of the intracellular tight junctions. 
The effect on tight junctions was thought to involve hydration of the starch microspheres 
since prehydrated microspheres had no effect on transport across the cell monolayer. The 
hydration capacity of the starch microspheres is 8-10 times their own dry volume and 
thus on hydration the mean diameter increases from 20 µm to 45 µm. Hydration of the 
microspheres was suggested to cause a hydrostatic pressure within the intracellular space 
that results in the structural separation of the tight junctions. 
Other types of microsphere have also been investigated. In studies in rats, powder 
formulations incorporating insulin and dextran microspheres (Sephadex) or DEAE- 
dextran microspheres (DEAE-Sephadex) have been investigated as systems for nasal 
delivery (Ryden and Edman; 1991 and 1992). Sephadex was shown to promote insulin 
absorption, assessed from the lowering of plasma glucose concentrations, although 
DEAE-Sephadex had no affect on glucose concentrations and these results were shown to 
correlate with the in vitro release characteristics of insulin from the microsphere systems. 
However, Sephadex appeared to be less effective in promoting insulin absorption in rats 
than the starch microspheres used previously (Björk and Edman, 1988). Dextran 
microspheres which were coated with insulin were show to be more effective in terms of 
promoting insulin absorption in the rat than when insulin was loaded into the 
microspheres (Pereswetoff-Morath and Edman; 1995). Incomplete or slower release of 
insulin contained within the microspheres is expected since moisture must penetrate into 
the microspheres for complete swelling of the dextran matrix prior to dissolution and 
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diffusion of the insulin into the nasal cavity. In contrast, insulin coated onto the surface 
of the microspheres can begin to dissolve on contact with the moist nasal mucosa. 
Bioadhesive microspheres prepared from human serum albumin have been reported to 
sustain the absorption of propranolol administered intranasally to dogs (Vyas et al., 
1991). Ilium et al. (1994) have investigated hyaluronic acid ester (Hyaff 11) 
microspheres for the nasal delivery of insulin in sheep. These are derived from 
hyaluronic acid, a natural water-retaining and lubricating polysaccharide found in high 
concentrations in soft body tissues (Benedetti; 1994). The Hyaff 11 microspheres (mean 
diameter 10 gm) were shown to effectively promote insulin absorption to a degree similar 
to that obtained by Farraj et al. (1990) in sheep using a starch microsphere powder 
system. The bioavailability of intranasally administered insulin increased as the dose of 
Hyaff 11 microspheres was increased (For doses of 0.25,0.50,1.0 and 2.0 mg/kg 
Hyaff 11 microspheres values of bioavailability, relative to a subcutaneous dose, were 
7.7,10.0,11.5 and 14.5% respectively). The mechanism of action of these 
microspheres is unclear. However, some degree of bioadhesiveness, an appropriate size 
range and the ability to release the drug from the microspheres in vivo were considered as 
factors. The effect of Hyaff 11 microspheres on intracellular tight junctions was not 
known. 
1.6.3 General problems in the development of nasal delivery systems 
The main barriers preventing the use of the nasal route for the delivery of the majority of 
peptide and protein drugs are rapid clearance or degradation of the administered drug 
formulation from the nasal cavity and/or poor absorption of the drug across the nasal 
epithelium. The very low bioavailabilities obtained severely restricts the commercial 
exploitation of the nasal route for the delivery of the majority of peptide and protein 
drugs. Exceptions are compounds, such as calcitonin nasal spray developed by Sandoz 
Pharma, which, although poorly absorbed via the nasal route (bioavailability of 
approximately 1 %) are marketable owing to their high potency and relatively low 
molecular weight. Thus, therapeutic plasma concentrations of these drugs can be 
achieved at relatively low doses. By using absorption enhancers, used here as a `loose- 
term' to describe any compound which can modulate nasal absorption, it may be possible 
to commercially exploit the nasal route for many other peptides and proteins. Ideally, the 
absorption enhancer should be rapid-acting, result in transient and reversible modulation' 
of the absorptive properties or physiology of the nasal mucosa and not be absorbed 
systemically. The degree of absorption enhancement should be predictable and 
reproducible. Ultimately the compound must be safe for nasal administration particularly 
as many nasal preparations of peptide and protein drugs would be used in chronic 
therapeutic regimens which could require one or more daily doses. A full evaluation of 
the safety of potential enhancers must be made before it is possible to exploit such 
compounds on a commercial basis. However, many of the enhancers investigated have 
been shown to cause damage to the nasal mucosa at the concentrations required to 
promote nasal absorption. Thus, research groups are continually investigating novel 
materials or better use of existing materials to fit the criteria of the ideal absorption 
enhancer. The novel use of chitosan, a versatile biomaterial that finds many commercial 
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applications (Sandford 1989), as an absorption enhancer in nasal drug delivery systems 
appears promising based on various published reports and the findings of this project. A 
review of chitosan is presented below. 
1.7 Chitosan 
1.7.1 Sources of chitosan 
Certain fungi contain chitosan as part of their cell walls although it is seldom found in 
nature (Arcidiacono et al., 1989). Commercially it is obtained by the N-deacetylation of 
chitin, a biopolymer widespread in nature. The abundance of chitin is second only to 
cellulose to which it is structurally similar. Chitin is a major component of the cuticular 
or exoskeletal structures of most invertebrates. It is found in the cell walls of most fungi 
and yeasts and is synthesised by some unicellular organisms (Jeuniaux et al., 1988). It is 
estimated on a global basis that krill, marine crustacea of the order Euphausiacea, can 
potentially provide the highest yield of annually accessible chitin (Brine, 1984). 
However, commercially, the highest yields of chitin, per total dry weight of material, are 
obtained from the calcified cuticles (shells) of decapod crustaceans mainly crabs and 
shrimp (also prawn, lobster and crayfish). These provide a readily available source of 
chitin as part of the waste material from shellfish processing plants. Reliability of the 
source for chitin production is ensured because of the seasonal harvesting of shellfish 
(Sandford, 1989). In several countries, including the USA, Japan, Norway, Italy and 
India, shellfish waste is commercially exploited for the production of chitin or chitosan 
(Nicol, 1991). The processing of shellfish waste currently satisfies the demand for chitin 
and chitosan. However, with increasing commercial applications for chitin and chitosan, 
alternative sources may be required in the future. With advances in biotechnology, 
microbially produced chitin and chitosan would appear an attractive alternative to that 
derived from shellfish. The cell walls of certain fungi such as the Mucorales contain both 
chitin and chitosan (Shimahara, 1989). Microbial derived chitosan can be prepared more 
readily than chitosan derived from shellfish waste. Also, with genetic manipulation of 
microorganisms there is the potential for the production of a more consistent and well 
defined material (Arcidiacono et al., 1989). 
In nature, chitin usually exists as a complex with other materials. In fungi, chitin forms a 
complex with other polysaccharides such as glucans or mannans and may constitute up to 
about 45 % of the total dry weight of organic matter. In the calcified cuticle of crustacea, 
it is tightly associated with proteins, inorganic salts mainly calcium carbonate, lipids, 
pigments and trace metals (Jeuniaux 1971, Austin 1988). Cuticular chitin may contribute 
between about 58-85 % of the total dry weight of organic matter and the protein 
constituent may, range from about 10-32 %. Although chitin is responsible for much of 
the structural integrity of the cuticle it is the overall chitin complex to which many of the 
mechanical and physical properties can be attributed. Chitin is prepared by removing 
other materials from the chitin complex. The method of preparation may considerably 
alter the chemical and physical properties of chitin. In addition there is a species variation 
in the properties of chitin. Thus a range of chitins exist which vary depending on the 
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species, method of preparation and application requirements and may therefore be better 
described as chitin isolates (Brine 1981 & 1981b, Austin, 1988). 
1.7.2 Structures of chitin and chitosan 
Chitin is a polymer which consists mainly of unbranched chains of I 
-1,4 linked-2- 
acetamido-2-deoxy-D-glucopyranose which can also be referred to as poly N-acetyl-D- 
glucosamine. Chitin is structurally similar to cellulose (t-1,4 linked-D-glucopyranose). 
The difference is that the cellulose hydroxyl group at carbon position 2 (C2) is replaced 
by an acetamido group in chitin. The disaccharide repeating unit of chitin is 
C 16H26010N2" 
Chitosan is the deacetylated derivative of chitin and consists mainly of poly [(3-1,4 
linked-2-amino-2-deoxy-D-glucopyranose] also referred to as poly-D-[glucosamine]. In 
chitosan an amine group replaces the chitin acetamido group at C2. The disaccharide 
repeating unit of chitiosan is C12H2208N2. These structures represent idealised 
structures, but the N-acetylation of chitin is usually incomplete and chitosan will be partly 
N-acetylated. Thus chitin and chitosan exist as copolymers of N-acetyl-D-glucosamine 
and glucosamine. It is not fully established if naturally occurring chitin, existing as part 
of a complex, is partially deacetylated or whether deacetylation results from hydrolysis 
during chitin extraction and purification (Roberts 1992). The pure homopolymer chitin is 
often denoted as chitin [1.0] and pure chitosan as chitosan [0.0] where the figure in 
brackets gives the mole fraction of N-acetyl-D-glucosamine residues. Thus, chitosan 
[0.15] would denote chitosan having 85% decetylation. The structures of chitin and 
chitosan are shown in Figure 1.3. 
1.7.3 Preparation of chitosan 
Chitosan is produced by the alkaline deacetylation of chitin which is itself produced 
commercially, from the shells of crustaceans. Chitin must first be isolated from the other 
materials, mainly proteins, with which it forms a complex. Several methods are used to 
extract and purify chitin but these will usually involve deproteination, demineralisation 
and removal of lipids and pigments. The methods employed in the production of chitin 
will often depend on the commercial application of the chitin. Muzzarelli (1977) outlines 
a number of methods for the isolation of chitin. The raw chitinous starting material i. e. 
crab, prawn or lobster shells will usually first be washed, crushed and dried prior to 
deproteinisation commonly using aqueous sodium hydroxide which may partially 
deacetylate the chitin if strong alkaline treatment is used (Roberts 1992). Residual amino 
acids in the chitin may subsequently affect the properties of the chitosan. 
Demineralisation will often involve treatment with hydrochloric acid but this will often be 
accompanied by' some deacetylation and depolymerisation and less harsh agents such as 
EDTA have been shown to result in less denatured chitin although there is incomplete 
removal of inorganic salts (Shimahara and Takiguchi, 1988). Pigments, mainly 
carotenoids, may also be extracted with ethanol or acetone or destroyed with bleaching 
agents (Roberts 1992). 
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Deacetylation of the processed chitin to produce chitosan occurs by hydrolysis of the C2 
acetamido group. Most commercially produced chitosans will not be 100 % deacetylated 
since extreme conditions are usually required if the degree of deacetylation is to exceed 
about 85 %. Typically chitosans are produced which are 75-85 % deacetylated. The 
acetamido group can be hydrolysed by alkaline or acidic treatment. However acidic 
hydrolysis will be accompanied by considerable hydrolysis of glycosidic links leading to 
depolymerisation (Muzzarelli 1977, Roberts 1992). The characteristics of the chitosan 
product will depend largely on the acidic treatments used during the initial isolation of the 
chitin since this will considerably determine the degree of depolymerisation. Resistance 
of the chitin acetamido group to hydrolysis is increased by the trans arrangement of the 
C2-C3 substituents (Horton & Lineback 1965). Recent publications describe the kinetics 
of depolymerisation and the prediction and control of depolymerisation of chitosan by the 
use of nitrous acid for the reliable manipulation of the chitosan molecular weight (Allan 
and Peyron, 1995a &b). The degree of deacetylation of chitin can be controlled to some 
extent by regulating the conditions under which the chitin is treated, mainly the 
concentration of alkali used (commonly aqueous NaOH) and the temperature and duration 
of the treatment. Increasing the temperature and / or the duration of the treatment will 
increase the degree of deacetylation but result in considerable chain degradation 
(Muzzarelli 1977). Increasing the concentration of aqueous alkali allows lower 
temperatures and / or treatments of shorter duration to be used. For example an acid 
soluble chitosan (approximately 60 % deacetylated or above) may be obtained with either 
5% NaOH at 150 °C for 24 hours, 40 % NaOH at 100 °C for 18 hours or 50 % NaOH at 
100 °C for 1 hour. The latter treatment gave a product which was 82 % deacetylated. 
Increasing the duration of the treatment resulted in considerable chain degradation. If the 
degree of acetylation of the final chitosan end product is to be carefully controlled for its 
commercial application, then often the best way to achieve this is to re-acetylate either 
highly deacetylated chitosans (typically 5% acetylated) or moderately deacetylated 
chitosans (typically 15-40 % acetylated) to the required acetyl content. 
The chitosan end product obtained will depend on subsequent treatment following 
deacetylation. Acid soluble chitosan flakes are produced if the deacetylated chitin is 
dried. These may then be milled into a chitosan powder which can be dry-blended with 
organic acids (e. g. acetic, formic, lactic and adipic acids) to produce self dissolving 
chitosan/acid blends. The purity of the chitosan end product may be improved by 
dissolution of the deacetylated chitin in acid followed by filtration to remove extraneous 
substances then precipitation, washing and drying to obtain the purified acid soluble 
chitosan in its free amine form. Alternatively, drying (e. g. spray-drying) after the 
filtration step will yield chitosan salts (chitosonium acid salts), the nature of which will 
depend on the acid used for dissolution (Sandford, 1989). Water soluble chitosan salts 
are produced if acids such as acetic, lactic, hydrochloric, formic and glutamic acid are 
used in the dissolution step (Muzzarreli, 1977, Lang and Clausen, 1989). 
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Figure 1.6. Structure of chitin and chitosan 
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1.7.4 Solubility and solution properties of chitosan 
Chitosan, in its free amine form (-NH2), is insoluble in water at neutral or alkaline pH 
but will dissolve under suitable acidic conditions (Sandford 1989). During dissolution, 
the free amine groups become protonated forming cationic amine groups (-NH3+). Since 
chitosan is a weak base salts (polyelectrolytes) are formed with acids (Roberts, 1992). 
The solubility of the chitosan salt is dependent on the nature of the anion involved. In 
addition, particularly with slightly soluble salts, solubility will be influenced by molecular 
weight, degree of N-acetylation and the temperature. The amount of acid present will 
also influence solubility since a minimum amount of acid is required to protonate the 
amine groups. Thus, more acid is required to solubilise 5% chitosan compared to 1% 
chitosan (Pronova Biopolymers, Chitosan Product literature). Chitosan is soluble in 
dilute solutions of mineral acids although solubility is limited by the concentration ratio of 
chitosan : acid. Increasing the concentration of acid (e. g. with HCl) may cause 
precipitation of the chitosan. Hydrochloride salts of chitosan are soluble whereas the 
nitrate and phosphate salts are slightly soluble and the sulphate salt is insoluble at room 
temperature (Muzzarelli, 1977). Chitosan is soluble in solutions of most organic acids 
and forms soluble salts such as acetate, formate, glutamate, lactate, malate and pyruvate. 
The water solubility of chitosan in salt form will be influenced by the degree of 
acetylation and distribution of acetyl groups of the chitosan (Rinaudo & Domard, 1989, 
Aiba, 1991). Water soluble chitosans tend to have degrees of acetylation between 0 and 
30%. Chitosans having degrees of acetylation between 30 and 70% will usually be 
soluble in dilute acids. However, water solubility of these chitosans will mainly depend 
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on both the degree and distribution of acetyl groups since this will affect the 
intermolecular associations that occur between acetyl regions. In addition, glucosamine 
residues being hydrophillic in nature will become charged at acid pH which will increase 
the interaction with the solvent. An irregular arrangement of acetyl groups along the 
length of the chitosan chain (referred to as block type copolymers) tends to decrease 
chitosan solubility since associations between acetyl regions of chitosan chains will be 
increased resulting in aggregation 
. 
In contrast, solubility will tend to be increased in 
chitosans having a regular arrangement of acetyl groups (referred to as random type 
coploymers) since associations between chains, and hence aggregation will tend to be 
reduced. Chitosans which are more than 70% acetylated tend to be refered to as partially 
deacetylated chitins. These chitosans will not usually be soluble in water but are usually 
soluble under suitable acid conditions. 
In an acid medium a chemical equilibrium reaction will be established as given below 
(Rinaudo & Domard, 1989). 
Glc-NH2 + AH t* G1c-NH3+ + A- 
The reaction directly depends on the pKa. Chitosans will usually be soluble below pH 
5.5-6. For polyamines, the ease of dissociation of conjugate acid groups (-NH3+) is 
increased by the presence of adjacent NH3+ groups thereby increasing the dissociation 
constant of the conjugate acid (Ka) and decreasing pKa (Roberts, 1992). Thus, the pKa 
depends on the charge density of the polymer which is proportional to the degree of 
deacetylation and on the degree of neutralisation of the acid. For samples having the 
same fraction of NH3+ groups neutralised, values of pKa will decrease with an increase 
in the degree of deacetylation of the chitosan. Values of pKa in the literature range from 
about 6.3 to 7 (Muzzarelli, 1985, Roberts, 1992). However, these measurements do not 
take into account the effect of charge density of the chitosan. The intrinsic pKa of 
chitosan was reported to be 6.5 using Katchalsky's equation and extrapolating to zero 
charge (Rinaudo & Domard, 1989). Measurment of intrinsic pKa takes into account the 
degree of acetylation and the degree of neutralisation of the chitosan. 
The solution properties of chitosan will depend on the degree of N-acetylation and 
molecular weight of the chitosan and on the ionic strength and pH of the solvent 
(Rinaudo & Domard, 1989, Roberts, 1992). The rheological behaviour of chitosan can 
be used to predict the conformation of chitosan in solution (Lang and Kienzle-Sterzer, 
1982). The flow properties of polyelectrolytic polysaccharides depends on the overall 
molecular conformation and on the degree of hydrogen bonding or electrostatic repulsion 
between neighbouring chain segments. 
Ionic strength (salt concentration) strongly influences the molecular configuration of 
chitosan in solution. In solutions of low ionic strength, chitosan tends to adopt an 
extended, rodlike, configuration due to the electrostatic repulsion between charged 
glucosamine groups resulting in a stiffening of the chitosan chain. Thus, decreasing the 
degree of deacetylation would tend to reduce the degree of chain stiffening (Anthonsen et 
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al., 1993). At low ionic concentration, solution viscosity is increased due to the increase 
in intramolecular repulsion between charged groups resulting in an elongated 
conformation and enlargement of the hydrodynamic volume (Muzzarelli, 1977). As ionic 
strength increases the chitosan chain will tend to become more flexible and adopt a 
random coil conformation due to the shielding of charged glucosamine groups by the salt 
counter-ions resulting in a reduction in the electrostatic repulsion between the charged 
groups. This will decrease the hydrodynamic volume of the chitosan molecule, thereby 
reducing solution viscosity. The stiffness of the chitosan molecular backbone increases 
with an increase in the degree of ionisation of the chitosan amino groups and with a 
decrease in the ionic strength of the media (Kienzle-Sterzer et al., 1984). Chain 
flexibility will also increase with temperature, thus solution viscosity will tend to decrease 
(Roberts, 1992). The degree of ionisation of chitosan will depend on the concentration 
and degree of deacetylation of the chitosan and on the pH and ionic strength of the 
solvent. At high ionic strength, a decrease in the degree of deacetylation will tend to 
favour an extended chain conformation since the bulky N-acetyl groups have a steric 
effect and will also interfere with intramolecular hydrogen bonding (Anthonsen et al., 
1993). Chitosan can be precipitated out of solution by an increase in the concentration of 
electrolytes such as NaCl and KCl or by the addition of concentrated HCl 
. 
Precipitation 
with electrolytes is due largely the increase in ionic concentration rather than the 
accompanying decrease in pH. Phosphate salts and polyphosphoric acid or its salts will 
also precipitate chitosan. 
At low ionic concentration, a reduction in pH will drive the equilibrium reaction (given 
above) to the right favouring the presence of Glc-NH3+ (Filar and Wirick, 1977) Thus, 
chitosan molecules will tend to stiffen and adopt an extended configuration resulting in an 
increase in solution viscosity. Once the chitosan molecule has adopted the extended 
conformation further decrease in pH will tend to have very little effect on solution 
viscosity although high concentrations of acids such as HCl can precipitate chitosan from 
solution resulting in a dramatic decrease in viscosity. Conversely, an increase in pH 
favours the presence of free amine groups and the chitosan molecule will tend to adopt a 
random coil conformation resulting in a decrease in solution viscosity. Above a certain 
pH chitosan will precipitate out of solution due to the reduction in the solubility of 
chitosan as free amine groups predominate. The susceptibility of chitosan to changes in 
solution pH will be highly dependent on the degree of deacetylation and concentration of 
the chitosan. A low degree of deacetylation will tend to improve the stability of chitosans 
at higher pH. In contrast, high concentration will tend to decrease chitosan stability at 
higher pH. The magnitude of the viscosity change can be reduced by using a more 
highly ionised acid or by increasing ionic concentration. At higher ionic concentration, 
the effects of pH tend to be masked due to the shielding of charged moieties by salt 
counter-ions. 
Chitosan solutions behave as non-Newtonian fluids since the viscosity of chitosan will 
vary depending on the rate of shear applied (Lang and Kienzle-Sterzer, 1982). Chitosan 
solutions display shear thinning properties with viscosity decreasing as shear rate 
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increases although at low shear rates chitosan solutions will show Newtonian behaviour. 
Solution viscosity will increase with increases in chitosan molecular weight and degree of 
ionisation of amine groups of chitosan and a decrease in the ionic concentration of the 
solution which will each increase the hydrodynamic volume of chitosan. Viscosity will 
also decrease with heating chitosan solutions (Rinaudo and Domard, 1989). 
A reduction in the viscosity of chitosan solutions tends to occur with aging due to 
degradation. Degradation may be due to a number of factors such as hydrolysis, free 
radical oxidation / reduction reactions and microbial attack. The stability of chitosan in 
solution may be influenced by a number of factors such as the presence of other 
excipients, particularly preservatives which would prevent microbial growth, pH and 
storage temperature. The degradation of chitosan in solution during storage is accelerated 
by increasing the storage temperature. Chitosan is degraded by lysozyme which is an 
important property in the utilisation of chitosan for pharmaceutical and medical 
applications (Nordtveit et al., 1994). Biodegradation of chitosan by lysozyme is 
influenced by the degree of deacetylation of chitosan with initial degradation rates tending 
to increase with the degree of acetylation. Degradation is dramatically reduced when the 
degree of deacetylation is high since lysozyme enzymes act on acetyl groups. Thus, the 
pure homopolymer chitin will be the most susceptible to lysozyme. 
Chitosan displays a number of useful solution and chemical properties which have been 
exploited commercially and these have been comprehensively reviewed by Muzzarelli 
(1977) and Roberts (1992). The commercial applications of chitosan are detailed in 
Section 1.7.7. Chitosan, being a polyelectrolyte, will react with negatively charged 
polyelectrolytes usually forming insoluble complexes (Muzzarelli, 1977, Mireles et al., 
1991, Roberts, 1992). Mireles et al. (1991) showed that complex formation with 
polyanions such as polyacrylic acid was influenced by solution pH although for polymers 
such as pectin, alginate and carrageenan complex formation was independent of pH. For 
each of these polyanions, complex formation was found to be independent of the ionic 
concentration of the solution. Electrostatic interaction between polyanionic COO- or S03- 
groups and polycationic NH3+ groups were attributed as the main cause of complex 
formation. Chitosan-polyanion complex formation was proposed as a means of 
obtaining large floculating molecules possessing both positive and negative charge 
characteristics. These could find potential application in the food industry. Rha et al. 
(1985) reported the biotechnological application of chitosan-polanion capsules for cell 
entrapment or immobilisation. 
Chitosan 
-has the ability to form complexes with transition metal and post-transition metal 
ions (but not with alkali and alkaline earth metal ions) and has been extensively reviewed 
by Muzzarelli (1973 and 1977) and Roberts (1992). Comparison of published data 
proves difficult due the different methods of investigation and/or conditions used by 
different research groups (e. g. differences in the mode of agitation or in the physical 
nature of the chitosan) and inadequate characterisation of the chitosans used. The 
capacity of chitosan to adsorp metal ions depends largely on the concentration of 
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accessible amine groups of the chitosan. This will depend on the degree of deacetylation 
of the chitosan and to some extent on the crystal structure of the chitosan. 
1.7.5 Physicochemical characterisation of chitosan 
The term chitosan can be applied to a family of polymers which usually contain both N- 
acetyl-D-glucosamine and D-glucosamine subunits. Thus, as no definite structure exists 
for chitosan, it is necessary to characterise chitosans usually in terms of their degree of 
N-acetylation and molecular weight since these will influence the properties and potential 
uses of the individual chitosans ((Rinaudo & Domard, 1989, Roberts, 1992). Various 
analytical methods used to characterise the degree of acetylation and molecular weight of 
the chitosans are described below. In addition to the characteristics of the polymer, for 
medical and pharmaceutical application, chemical and microbiological purity levels should 
be standardised (Knapczyk et al., 1989b). Measurement of the content of residual 
protein, colour, moisture, ash, nitrogen, heavy metals and percentage of insoluble 
materials are reviewed by Knapczyk et al. (1989b) and Roberts (1992). 
1.7.5.1 Measurement of the degree of N-acetylation of chitosan 
The degree of N-acetylation and N-deacetylation of chitosan are inversely related and may 
be determined by measurement of the proportion of the amide or amine functional group 
in the chitosan. Alternatively other analytical methods may be employed. 
Determination of the N-acetyl content 
Infra-red spectroscopy (IR) 
Infra-red spectroscopy (IR) is frequently used to analyse chitosan since it is a relatively 
rapid technique for determining N-acetyl content and the instrumentation is widely used 
in analytical laboratories (Roberts, 1992). Also, if an internal reference peak is used to 
correct for variation in the amount of material in the beam, then the purity of the material 
does not have to be determined. This method can be used to analyse insoluble samples of 
chitosan. Several methods of IR have been reported in the literature which vary in the 
absorbance band ratio selected for measurement and also on the choice of standardisation 
method allowing a correlation between the degree of acetylation and absorbance to be 
determined (Rinaudo & Domard, 1989). Each method has limitations over the range of 
values of N-acetylation which can be measured. Sannan et al. (1979) used a band ratio 
(in cm-1) of 1554/2878, Miya et al (1980) used 1655/2867 and Miya et al (1985) used 
1554/897 (references reported by Aiba, 1986). However, Aiba (1986) showed that 
different results were obtained for the same chitosan depending on which of the above 
band ratios were used. Another disadvantage of this technique is that hydroxyl bands of 
polysaccharides and /or linked water molecules appear near 1640 cm-1 thus, these may be 
confused with the bands attributed to the N-acetyl group (Domard, 1987). 
Ultra-violet spectroscopy (UV) 
Muzzarelli and Rocchetti (1986) reported a method using first derivative ultra-violet 
spectroscopy (UV) at 199 nm to measure N-acetyl content of chitosan although 
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quantitative results were not given. N-acetyl-D-glucosamine solutions were used for 
calibration. Aiba (1986) measured N-acetyl content of chitosan using conventional UV 
and found that there was a better correlation of the results obtained to those of a colloid 
titration method (measures free amino group) than those obtained by IR. The uv 
absorbance at 220 nm of chitosan samples and acetylglucosamine oligomers was found to 
be linear. Thus, an average of the molar absorption coefficients of N-acetyl-D- 
glucosamine and di-N-acetyl-D-chitobiose(177 and 173, respectively) were used to 
determine the N-acetyl content of the chitosan samples. The molar absorption coefficient 
of glucosamine at 220 nm was found to be negligible. This technique is only suitable for 
chitosan samples which are soluble in dilute acidic solutions. 
Circular dichroism (CD) 
Domard (1987) describes circular dichroism (CD) as an easy and precise method for 
determining the N-acetyl content of chitosan samples. CD spectra of N-acetyl-D- 
glucosamine and its oligomers show two CD bands one close to 190 nm and the second, 
arising from the n-1t* transition, close to 211 nm whereas in a fully deacetylated chitosan, 
glucosamine residues show only one CD band centred near 185 nm. In acidic solution, 
the CD band attributed to glucoseamine residues disappears due to protonation of the 
amine group. Thus, in dilute acid media, the CD spectrum will show only the bands 
attributed to the N-acetyl group. The band arising from the n-n* transition in the range 
200-250 was used to deduce the N-acetyl content of chitosan samples using chiotobiose, 
which is readily available commercially, for reference. The transition state is independent 
of ionic strength and pH of the chitosan solution and only small amounts of sample are 
required to prepare solutions for analysis. Domard (1987) found that the results 
following measurement of N-acetyl content by CD gave good agreement with those 
reported by Miya et al. (1980) using IR. 
High-field nuclear magnetic resonance spectroscopy (NMR) 
High-field nuclear magnetic resonance spectroscopy (NMR) has been described as a 
simple and rapid technique which can be applied routinely to measure the proportion and 
distribution of N-acetyl groups in chitosan samples (Varum et al., 1991 a and b). In the 
method using 1 H-NMR described by Varum et al. (1991 a), limited depolymerisation of 
the chitosan samples with nitrous acid (attacks D-glucosamine units but not N-acetyl-D- 
glucosamine units) was performed to reduce solution viscosity, improve solubility and 
narrow the line widths of the signals. Solutions of chitosan were prepared in D20 and 
1 H-NMR spectra recorded at either 99.6 MHz (to confirm that the relative areas of the 
peaks observed represented the relative occurrence of chitosan) or 500 MHz (to identify 
the resonances of the spectrum and thus, determine the degree of N-acetylation). By 
calculating the proportions of the four possible diads that occur in chitosans (G1cNAc- 
G1cNAc, G1cNAc-GIcN, GlcN-G1cNAc, GIcN-G1cN where G1cNAc and G1cN represent 
the N-acetyl-D-glucosamine and D-glucosamine units, respectively) the distribution of the 
acetylated residues can be determined. A method using 13C-NMR to measure the 
acetylation sequences of chitosan has also been reported ((Varum et al., 1991b). 
Advantages of this technique are that small sample weights are required for analysis and 
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measurement is not influenced by the water content of the chitosan. However, NMR is 
only suitable for chitosans having a degree of N-acetylation above 5% and like IR relies 
on the production of good quality films of chitosan (Rinaudo & Domard, 1989). 
Gel permeation chromatography (GPC) 
Aiba (1986) used gel permeation chromatography (GPC) with UV detection at 220 nm to 
analyse chitosan samples prepared in dilute acetic acid. The peak area were found to be 
dependent on the degree of N-acetylation, the technique was reproducible and a linear 
relationship existed between the peak areas and the concentration of chitosan or 
acetylglucosamine oligomers. Calibration with acetylglucosamine oligomers was found 
to be unsuccessful and thus, chitosan samples of known degree of N-acetylation (fairly 
consistent values obtained following analysis by IR, UV and colloid titrimetry) were 
used. The results obtained by GPC were shown to be fairly consistent with those 
determined by colloid titrimetry and IR using the methods of Miya et al. (1980 & 1985). 
Aiba (1986) concluded that GPC was a reliable technique for the determination of the 
degree of acetylation of chitosan and furthermore, molecular weights could also be 
measured concurrently. Roberts (1992) points out an unusual feature of the study by 
Aiba (1986) in that the calibration samples had the same retention time regardless of 
molecular weight. 
Hydrolytic techniques 
In this technique the amount of acetic acid liberated by acidic or alkaline hydrolysis of the 
N-acetyl groups of chitosan is quantified and used to calculate the degree of N- 
acetylation. Rutherford and Austin (1978) used 50% NaOH high temperature to 
hydrolyse the chitosan followed by acidification with phosphoric acid and fractional 
distillation. The volume of acetic acid in the distillate was determined by titrimetry and 
this was related to the % N-acetyl content of the chitosan sample. Niola et al (1993) 
reported a method using acid hydrolysis (sulphuric and oxalic acid mixture) at high 
temperature. The acetic acid produced was separated from the reaction mixture and 
quantified by HPLC. This technique can be applied to chitosan samples regardless of 
degree of N-acetylation and solubility. 
Determination of the amine group content 
Acid-base titrimetrv 
Roberts (1992) described an acid-base titrimetry method (first reportedby Broussignac in 
1968) in which the chitosan was dissolved in a known excess of acid and titrated 
potentiometrically with NaOH giving a titration curve with two inflection points. The 
difference between the two inflection points on the abscissa corresponded to the amount 
of acid required to protonate the amine groups from which the proportion of amine 
groups hence the degree of N-acetylation was determined. Since there is a tendency for 
chitosans to precipitate in the neutral pH range titration methods are imprecise, sometimes 
erroneous and often uneasy to use (Domard and Rinaudo, 1989). Hayes and Davies 
(1978) titrated solutions of chitosan hydrochloride with sodium hydroxide. The titration 
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was followed by three methods; either potentiometrically; or by using phenolphthalein as 
an indicator; or with silver nitrate using 2,7-dichlorofluorescein as an indicator. Values 
of N-acetyl content were shown to be in close agreement using each of the three 
titrimetric methods. 
Colloid titration 
Colloid titration is based on the reaction between cationic and anionic polyelectrolytes in 
aqueous solution where neutralisation of electrical charge proceeds stoichiometrically 
(Roberts, 1992). With knowledge of the concentration of ionic groups in the anionic 
polyelectrolytes, the concentration of ionic groups in chitosan (cationic polyelectrolyte) 
can be calculated from the relative volumes at the end point. The end point is detected 
using a dye such methylene blue (3.1) or toluidine blue (3.2) which undergo a metameric 
colour change in the presence of free anionic polyelectrolyte. Aiba (1986 & 1991) used 
colloid titrimetry to determine the degree of N-acetylation of samples of chitosan finding 
that the results obtained were generally in agreement with those obtained using UV. 
Metachromatic titration 
In metachromatic titrimetry, the absorbance (at Xm. ) of a dye showing polyelectrolyte 
induced metachromasy will decrease with increase in concentration of added 
polyelectrolyte until a minimum value is obtained where further additions of 
polyelectrolyte will not affect absorbance (Roberts, 1992). The intersection of a plot of 
Absorbance versus volume of polyelectrolyte solution added indicates the point at which 
an equivalent number of dye ions and charged groups on the polyelectrolyte are present. 
Gummow and Roberts (1985) reported a quantitative method for the determination of 
either the concentration of a chitosan of known structure or the amine group content of 
chitosan of unknown structure to be elucidated using an anionic dye (sodium 2'-hydroxy- 
1,1'-azo-naphthalene-4-sulfonate). 
Other methods 
Domszy and Roberts (1985) reported a method in which the free amine groups of 
chitosan react with an excess of salicylaldehyde (in a 1: 3 mole ratio), in methanol/ acetic 
acid, to give a yellow Schiff's base (N-salicylidenechitosan). The salicylaldehyde 
remaining at the end of the reaction period was determined by spectroscopy. A method 
using dye adsorption was reported by Maghami and Roberts (1988). In this technique 
the amine groups of chitosan which have been protonated with acid act as sites for the 
adsorption of anionic dyes. At equilibrium there is a 1: 1 stoichiometry for the interaction 
between the protonated amine groups of chitosan and the sulphonic acid groups on the 
dye thus the quantity of dye adsorbed will depend on the ionic charge of the dye. The 
quantity of dye adsorbed at equilibrium can be determined from the initial and final 
concentrations in the reaction mixture and therfore the proportion of amine groups in the 
chitosan sample determined. The results have been shown to compare reasonably well 
with those obtained by IR. This technique can be used with chitosans which are not fully 
soluble. A drawback to this method is that aggregation of the dye can lead to erroneous 
calculation of the degree of N-acetylation. A colorimetric assay was described by Hayes 
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and Davies (1988) which was an adaptation of a technique reported by Ride and Drysdale 
(1972) for estimation of fungal chitin in the presence of plant tissues. Deamination of 
glucosamine units with nitrous acid yields 2,5-anhydromannose which can be measured 
colorimetrically. Techniques using picric acid adsorption and reaction with 2,4- 
dinitrofluorobenzene have also been described (refer to Roberts, 1992). 
Nanjo et al. (1991) described an enzymatic method for determining the degree of N- 
acetylation of chitosan. Chitosan was completely hydrolysed to D-glucosamine and N- 
acetyl-D-glucosamine using chitosanolytic enzymes and chitosanase and the subsequent 
monosaccharides determined by colorimetric assays or HPLC. HPLC was found to be 
the best method for quantitative analysis in terms of its simplicity and rapidity although its 
application is limited due to interference by impurities in the chitosan samples or in the 
enzyme preparations. The results obtained for this technique agreed reasonably well with 
those obtained by colloid titration. 
Determination of degree of acetylation based on the overall composition 
Elemental analysis has been used to calculate the degree of N-acetylation of chitosan 
(Aiba, 1986 & 1991). Aiba showed that for some of the chitosan samples studied, the 
degree of N-acetylation calculated by elemental analysis compared well with other 
methods although there were inconsistencies with some of the chitosan samples tested. 
The nitrogen content of pure chitin and pure chitosan is 6.89% and 8.69%, respectively 
(Roberts, 1992). Thus, with knowledge of the nitrogen content of the sample the degree 
of N-acetylation can be determined. The use of the nitrogen / carbon ratio may be 
preferable due to the presence of moisture and residual inorganic materials in chitosan 
samples (the ratio is 0.194 and 0.146 for pure chitin and chitosan respectively). Since 
the nitrogen and carbon content of proteins will be very different to that of chitosan, 
residual protein must not be present in the chitosan sample. Other methods such as gas 
chromatography and pyrolysis have been reported (Hayes and Davies, 1988, Roberts, 
1992). 
1.5.2 Determination of the molecular weight of chitosan 
The physicochemical properties of chitosan in solution will be influenced by the average 
molecular weight and the molecular weight distribution of the chitosan (Beni et al., 1993). 
A reliable method for the measurement of molecular weight is essential for quality 
assurance of the product on a commercial basis (Muzzarelli et al., 1987). However, 
precise determination of chitosan molecular weight remains difficult due to polymer- 
polymer or polymer-solvent interactions and difficulty in determining the concentrations 
used (Rinaudo & Domard, 1989). 
Measurement of intrinsic viscosity 
Measurement of intrinsic viscosity ([il]) is a rapid and relatively simple method for the 
determination of the molecular weight of polymers (Roberts & Domszy, 1982). Intrinsic 
viscosity and molecular weight (M) are related by the Mark-Houwink relationship given 
below. 
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[ii] 
=K Ma 
Where K and a are empirical constants which are independent of molecular weight but 
depend on the degree of N-acetylation of the chitosan, the solvent system used and the 
temperature (Roberts & Domszy, 1982, Maghami & Roberts, 1988, Wang et al., 1991, 
Roberts, 1992). Values of K and a are usually determined from a plot of log [ri] versus 
molecular weight for a number of homologous chitosan fractions having a narrow 
molecular weight distribution. Conveniently values of K. and a can be obtained for 
chitosan from the literature (Rinaudo & Domard, 1989). However, careful selection of 
values of K and a is required to match the particular chitosan-solvent systems used in the 
viscometry (Wang et al., 1991). A disadvantage of viscometry is that it is not an absolute 
technique for determining chitosan molecular weight since it relies on pre-determination 
of the constants 
.K and a and there are wide 
discrepancies in the literature for these values. 
However, viscometry remains a popular and precise method of analysis of chitosan not 
only for the determination of chitosan molecular weight but also to investigate the 
behaviour of chitosan in solution. 
Laser light scattering s ectophotometry (LLS) 
Static laser light scattering spectrophotometry (LLS) has been used to study the molecular 
weights of chitosan (Muzzarelli et al., 1987). An advantage of using LLS is that it does 
not require the use of reference materials and thus, provides an absolute measurement of 
molecular weight. However, this technique has been reported to generally overestimate 
chitosan molecular weights due to aggregation of chitosan chains which occurs on 
standing (Rinaudo & Domard, 1989, Roberts, 1992) although problems of aggregation 
were not apparent in the study reported by Muzzarelli et al. (1987). LLS also requires 
that a precise determination of the concentration dependence of the refractive index 
(dn/dc) for chitosan obtained (Rinaudo & Domard, 1989, Roberts, 1992). Values of 
dn/dc reported in the literature appear to depend on the chitosan and/or the solvent used. 
This technique also requires that several Zimm plots are obtained from which molecular 
weights are determined (Beri et al., 1993). LLS cannot determine molecular weight 
distribution of chitosan unless time consuming fractionation of the sample is performed. 
LLS has been coupled to GPC to improve the accuracy of molecular weights 
determinations (Domard and Rinaudo, 1984). However, coupling GPC to multiple-angle 
laser light scattering (MALLS) allows molecular weights and molecular weight 
distributions to be determined (Beri et al., 1993). 
Gel permeation chromatography (GPO 
Gel permeation chromatography (GPC) or size exclusion chromatography (SEC) is 
frequently used to measure the molecular weight and molecular weight distribution of 
polymers and has been applied to chitosan (Roberts, 1992). In GPC, separation of 
molecules is based on molecular size with larger molecules eluting first since smaller 
molecules are able to move in and out of the pores in the column matrix (Freifelder, 
1982). To determine the molecular weight of chitosan by GPC requires that there is no 
interaction (either attraction or repulsion) between the gel and the chitosan (Rinaudo & 
Domard, 1989, Roberts, 1992, Terbojevich et al., 1993). Since many conventional gel 
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matrices tend to be negatively charged then adbsorption of cationic chitosan to the gels 
due to electrostatic attraction may cause problems in measuring molecular weights by this 
method. Wu (1988) described a method to measure the molecular weight distribution of 
chitosan by high-performance liquid chromatography (HPLC) using a conventional gel 
(Glycophase-G/CPG) columns which were preconditioned by injection of chitosan to 
deactivate any residual active sites on the column. Rinaudo and Domard (1989) reported 
that a cationic silica gel (porous silica beads grafted with quaternary ammonium groups) 
and an eluent containing a low molecular weight electrolyte (0.05ammonium acetate) to 
suppress repulsion between chitosan and the gel gave a good determination of molecular 
weight using light scattering detection. 
Beri et al. (1993) reported that SEC coupled to multiple-angle laser light scattering 
detection (MALLS) was an accurate, reliable and reproducible technique for the 
determination of molecular weight and molecular weight distribution in the molecular 
weight range 10,000-500,000. For chitosans having molecular weights above 100,000 
the technique could also be used to determine the conformation of chitosan in solution. 
Terbojevichet al. (1993) reported a high-performance GPC method for determining the 
molecular weight distribution of chitosan. A difficulty encountered by this method was 
that calibration with sodium polystyrene sulphonate standards was not possible under the 
conditions required for the elution of chitosan. Since chitosan standards of narrow 
molecular weight distribution are not commercially available, attempt was made to 
produce calibration standards by fractionation of chitosan. However, this was not 
successful and hence calibration was performed with chitosan fractions having a broad 
molecular weight distribution. Hasegawa et al. (1994) reported a method for determining 
the molecular mass distribution of chitosan using pullulan standards. Dextrans have 
frequently been used as calibration standards in conventional GPC studies although this 
is likely to lead to erroneus molecular weight values for chitosan, particularly 
overestimation of values, since the difference in the conformation of the two polymers in 
solution leads to difference in their behaviour on the column during GPC (Beri et al., 
1993). An additional source of error using conventional GPC is due to changes in 
elution volume if the column is overloaded which will affect the values of molecular 
weight obtained. By coupling GPC to laser light scattering the pitfalls associated with 
using secondary calibration techniques such as the use of dextrans and possible potential 
problems due to column overloading are avoided. 
Sedimentation equilibrium 
Sedimentation equilibrium is a technique which has been widely used to determine the 
molecular weight and molecular weight distribution of solutes and has been used to 
measure the molecular weight of chitosan (Errington, 1993, Errington et al., 1993, 
Aspden, 1996). This technique was also used in this project details of which are given in 
Chapter 10. However, this technique is intricate and time consuming and furthermore, 
great care in sample preparation is required since errors in polymer concentration 
measurement can affect the accuracy of molecular weight measurments (Beri et al., 
1993). 
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1.7.6 Commercial applications of chitosan 
Chitosan is a versatile material that has many potential commercial applications 
(Sandford, 1989). These include applications in industrial waste management, paper 
technology, agriculture, food, cosmetics and biotechnology as well as biomedical and 
pharmaceutcal uses. 
1.7.6.1 Industrial waste management 
Increased public awareness of environmental pollution by heavy metals and potentially 
other toxic materials such as pesticides which through accumulation via the food chain 
can have serious impact on ecological systems and ultimately on health has led to a 
demand for the purification of industrial effluent prior to their discharge or reuse (Knorr, 
1991). However, conventional methods for removing heavy metals from industrial 
waste waters by using methods such as precipitation, oxidation, filtration, 
electrochemical treatment, ion exchange and evaporation tend to be either ineffective at 
removing all traces of metal ion contamination or expensive particularly if contaminating 
levels of metal ions are low (Volesky, 1987). Chitosan has excellent chelating properties 
for many potentially harmful metals and thus, the use of chitosan may provide a 
commercially viable alternative to the use of conventional purification methods 
(Muzzarelli, 1977, Sandford, 1989). Chitosan has been shown to chelate metals such as 
copper, nickel, chromium, cadmium, manganese, cobalt, lead, mercury, zinc, uranium 
and silver. Treatment of industrial waste effluent to remove metal ions does not require 
the use of highly processed and purified chitosans which would considerably reduce the 
cost of their application (Coughlin et al., 1990). The use of chitin and chitosan to remove 
contaminants such as dyestuffs from processing effluents has also been reported (Knorr, 
1991). Chitosan has flocculant properties and thus may be used to clarify waste water in 
preference to synthetic polymer flocculants which may contain hazardous monomers 
(Sandford, 1989). In Japan, clarification of waste water is the largest single use of 
chitosan. 
1.7.6.2 Paper and textile technology 
Use in paper manufacture has been described as the greatest potential application of chitin 
and chitosan (Nicol, 1991). Muzzarelli (1977) reviewed chitosan as a paper and textile 
additive. Adding chitin and chitosan to pulp increases the strength of paper, speeds up 
the rate of water drainage from pulp and increases the quantity of fibres retained when 
manufacturing sheets of paper. This enables the use of cheaper, weaker fibres without 
reducing quality and considerably reduces the cost of beating the paper pulp. Paper 
containing chitin and chitosan is also easier to print on. Chitin and chitosan also increase 
the wet strength of paper which has implications in the manufacture of disposable 
nappies, shopping bags and paper towels. Chitosan has been used as a thickener and 
fixing agent in the preparation of printing pastes. Domszy and Roberts (1986) 
investigated ionic interactions between chitosan and oxidised cellulose which have 
obvious implications in the paper industry. In the textile industry the use of chitin to 
improve cellulose fibres has been investigated. Also, plastic fibres have been prepared 
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using chitosan. The use of chitosan as a sizing agent for fabrics is reported to have 
advantages over conventional agents such as starch and gums and one of the main 
features of this is the resistance of chitosan to laundering. Applications of chitosan in the 
dying and printing of textiles is also an important applcation. 
1.7.6.3 Azriculture 
There are a wide variety of potential applications of chitosan in agriculture including use 
as an animal feed, to coat seeds (e. g. wheat, rice and peas) and as a fertiliser (Sandford, 
1989). The use of chitinous material as a feeding supplement for animals such as cattle 
(Patton & Chandler, 1975), rats (Landes & Bough, 1976) chickens (Austin et al., 1981), 
hens and rabbits (Hirano et al., 1990) and fish (Kono et al., 1990) has been investigated. 
Landes and Bough (1976) showed that the addition of up to 5% chitosan in the diet of 
rats had no adverse effects. However, growth reductions were observed in animals fed a 
diet containing 10-15% chitosan and this was accompanied by alteration of the tissue 
composition of liver. Hirano et al. (1990) reported that a hen fed a high dose of chitosan 
(20 g/day) suppressed appetite due to aggregation of chitosan in the upper small intestine 
although the animal made full recovery within one week of stopping the dietary intake of 
chitosan. Chitosan is used at low concentration to recover proteinaceous material from 
food processing waste waters which is subsequently used as animal feed although the 
chitosan content of the feed will usually be low (less than 0.1 %). 
Chitosan has been shown to be fungicidal against many pathogenic fungi except those in 
which chitosan is present as a component of the cell wall (Allan & Hadwiger, 1979). 
This has implications for the use of chitosan for pre- and post harvest protection of crops. 
Increased crop yields have been reported after coating wheat seeds with chitosan 
(Sandford, 1989). Cuero et al (1991) demonstred that chitosan inhibited the growth and 
toxin production of the mould Aspergillus flavus in preharvest maize which was 
suggested to be due to chitosan chelating essential metal ions which are required by fungi 
for normal growth. The use of chitosan as a postharvest protection against fungi which 
are a major cause of food spoilage during shipping and storage is encouraging in view of 
public concern about the use of chemical pesticides. Leuba and Stossel (1986) 
investigated the antifungal activity and interaction of chitosan with biological membranes. 
Chitosan was shown to reduce fungal growth, disturb the membrane function of a 
filmentous fungus at acid pH and cause agglutination of sheep erythrocytes in vitro which 
may have implications for the agglutination of yeasts. As well as a direct action on fungal 
growth, chitosan may also have an indirect effect by inducing the accumulation of 
phytoalexins (low molecular weight anitmicrobial agents) and proteinase inhibitors, 
increase in cell wall phenolic compounds, deposition of calloses and changes in 
membrane permeability in plant cells. Due to their film forming and gelling properties 
and their mechanical robustness, use of chitosans for the controlled release of 
agrochemicals has been suggested, thus, overcoming the potential problems of leaching, 
degradation and evaporation of conventional fertilisers and pesticides which often 
requires that they are applied in excess (Teixeira et al., 1990). 
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1.7.6.4 Cosmetic applications 
Chitin, chitosan and their derivatives may have many commercial applications in 
cosmetics ranging from preparations for the skin and hair to preparations for oral hygiene 
and tooth care (Lang & Clausen, 1989). Muzzarelli (1989) reports a number of potential 
applications of water soluble modified chitosans (carboxymethyl- and carboxybutyl 
chitosan) in cosmetics. The moisturising, protective and smoothing properties of these 
chitosans due to their hydrophillic nature and film forming properties make them ideal for 
use in skincare products. Due to their antibacterial action, they can also be used in 
mouthwashes and liquid soaps for personal hygiene. The film forming properties of 
chitosan are well suited for its inclusion in haircare products such as setting lotions, 
blow-dry lotions and hair sprays and for use in nail varnishes (Lang & Clausen, 1989). 
The viscosity enhancing properties of chitosan enable it to be used in cosmetic gels and 
emulsions and being a substantive and conditioning polymer due to its polycationic nature 
they can be generally used in hair care (shampoos and hair conditioners) and skin care 
products. The use of chitosan in cosmetics is limited by its insolubility at neutral and 
alkaline pH and in the presence of anionic detergents. However, water soluble chitosan 
derivatives which are compatible with anionic detergents may enable the more widespread 
use chitosan in cosmetics. 
1.7.6.5 Food applications 
Chitosan is a non toxic biomaterial which is endogenously present at low concentration in 
foods such as prawns, soft-shelled crabs, cheeses, mushrooms and yeasts (Arai et al., 
1968). In Japan it is already used as an ingredient in foods such as biscuits and noodles 
(Nicol, 1991). Chitosan has many potential uses in the food industry. The chelating / 
flocculating properties of chitosan have been exploited for the clarification or fining of 
beverages such as apple or carrot juices and are reported to be as effective as, yet easier to 
use than, conventional silica sol/gelatin/bentonite treatment (Knorr, 
, 
1991). As well as 
reducing turbididty, chitosans have also been shown to reduce microbial counts in apple 
juice at ambient temperature which has important implications with consumer demant for 
less processed foodstuffs. As previously mentioned, chitosan is effective for the 
recovery of proteinaceous material in food (cheese, meat, poultry, fruitcake, shellfish) 
processing plants which may subsequently be used for animal feed. The emulsifying 
properties of chitosan are also being investigated in products such as mayonnaise and 
peanut butter (Nicol, 1991). Chitosan has also been shown to improve the stability of 
food emulsions susceptible to freeze-thaw breakdown (International Commission on 
Natural Health Products, 1995). The use of chitin and chitosan in the baking of bread 
were reported by Knorr (1982). Microcrystalline chitin was shown to increase specific 
loaf volume in breads. Chitosan films may be used to coat fruit and vegetables to 
preserve freshness and to prevent the growth of fungi which will may improve their 
shelf-life and also considerably reduce post-harvest losses during shipment and storage. 
Tough, non-toxic and biodegradable films for foods, such as sausages, and food 
packaging may also utilise chitosan and furthermore the chitosan component of these 
films may help to prevent the growth of bacteria which cause food-poisoning (Knorr, 
1991, Nicol, 1991). 
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1.7.6.6 Biotechnology applications 
In biotechnology, chitosan has important applications for the immobilisation of cells and 
enzymes and in the purification and recovery of biologicals (Muzzarelli, 1985, Sandford, 
1989). The immobilisation of whole cells is a practical method of obtaining biocatalytic 
systems and is of particular use when multi-enzyme systems are required or enzyme 
isolation is too expensive (Protan Laboratories, Inc., 1987a). Chitosan ionotropic gels 
(gel formation requires the presence of a counterion) used for the entrapment of whole 
cells have advantages over conventional gels (e. g. calcium alginate, widely used for the 
entrapment of plant and microbial cells), since they are stable in phosphate buffers and in 
the presence of sodium and potassium ions. Unlike gels such as agarose and kappa- 
carrageenan they are gel forming at room temperature. Chitosan has been used to 
immobilise a wide variety of enzymes which have important applications in 
biotechnology (Muzzarelli, 1985, Protan Laboratories, Inc., 1987b). Enzymes may be 
immobilised using three general techniques; entrapment and ionic and absorptive binding; 
crosslinking chitosan solutions; and crosslinking insolubilised chitosan. Enzyme 
immobilisation using crosslinked chitosan systems are the preferred methods. 
Glutaraldehyde is commonly used to crosslink solutions containing chitosan and enzyme. 
Glutaraldehyde crosslinks the amino groups of the chitosan and enzyme via a reaction 
involving the formation of Schiff bases (aldimine bonds) which results in the formation 
of a gel which can be washed and collected as a granular moist product (90% water). A 
simpler technique is via crosslinking insolubilised chitosan. Glutaraldehyde is added to 
chitosan flakes in water resulting in crosslinked chitosan which following washing and 
air drying is insoluble in acid solutions. The crosslinked chitosan is suspended in buffer 
containing the enzyme and more glutaraldehyde is added resulting in the formation of 
complex between the chitosan and the enzyme which can be collected by filtration after 
washing and air drying. The crosslinking of the enzyme can be easily controlled and the 
ease of preparation, the high enzyme loading and the production of a dry product has 
advantages over other techniques. 
Applications of chitin and chitosan in chromatography have also been reported including 
chromatographic techniques for the immobilisation of enzymes, separation of nucleic 
acids and amino acids, separation of wheat germ agglutinin and removal of coloured 
substances from foods such as tea, coffee and apple juice (Muzzarelli, 1977). Takeda 
(1978) reported that powdered chitin as an adsorbent in thin-layer chromatography was 
as good as, or superior to that of crystalline cellulose, silica gel and polyamide layers for 
the separation of phenols, amino acids, nucleic acid derivatives or inorganic ions. 
1.7.6.7. Biomedical and pharmaceutical applications 
Chitosan has many biomedical applications which make use of its non-toxic and 
biodegradable properties and also its physical, mechanical and bioactive properties (Olsen 
et al. 
, 
1989, Sandford, 1989). Knapczyk et al. (1989b) described specifications of 
chitosan for biomedical and pharmaceutical application. Knapczyk et al. (1989a) 
investigated some biomedical properties of chitosan, with a view to determining `is 
chitosan really a drug or an excipient ? ', and concluded that chitosan was an excipient 
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with specific biomedical properties. 
Cell binding 
The cell binding properties of chitosan have led to its application as haemostatic, 
bacteriostatic and spermicidal agents (Olsen et al., 1989). As a haemostatic agent, 
chitosan is able to coagulate blood via agglutination of red blood cells which is 
independent of the normal blood clotting cascade. The agglutination is predominantly 
due to the interaction of the negatively charged neuraminic acid residues on the red cell 
membrane with positively charged chitosan. Malette et al. (1983) investigated the 
haemostatic activity of chitosan, in vivo, in dogs. The study looked at blood loss from 
porous vascular grafts (grafts sewn into the infrarenal aorta) pre-soaked in either saline 
solution, as a control, or chitosan solution. The control animals suffered immediate 
exsanguination (mean blood loss approximately 440 ml) and all animals died. In 
contrast, blood loss from grafts treated in chitosan solution was dramatically reduced 
(mean blood loss 44 ml) due to the plugging of the interstices of the graft by the chitosan 
coagulum and all animals survived. In the surviving animals killed up to a period of four 
months after the study, it was found that the graft material was encased in abundantly 
vasular smooth muscle which penetrated the graft and linked the outer layers to the inner 
subepithelial layers indicating healing. The potency of chitosan as a haemostatic agent is 
reported to be molecular weight dependent with the coagulum formed by lower molecular 
weight chitosan (35,000) being `less firm' than that formed by chitosans of higher 
molecular weight (600,000 & 1,500,000) (Olsen et al., 1989). Chitosan derivatives have 
also been investigated as blood anticoagulants although compared to heparin the 
anticoagulant potency of these derivatives appears to be low (Muzzarelli, 1977, 
Nishimura and Tokura, 1987b). Dutkiewicz et al. (1990) investigated the coagulating 
properties of chitosan derivatives in vitro, finding that the clotting time of whole blood 
depended on the chemical modification of the polyaminosaccharide structure. The 
clotting time in the presence of the chitosans was significantly higher than that of the 
control. 
Cell activation 
Chitin and chitosan have been shown to possess immunological properties which is 
thought to be due to their ability to activate certain cell type (Muzzarelli, 1985). The role 
of chitin and chitosan in cell activation is thought to be as an adjuvant since there is no 
evidence to suggest that they have antigenic properties. Although chitosan has been 
reported to activate a number of cell types, it is the activation of macrophages which is 
believed to be most important for its immunomodulating properties (Nishimura et al., 
1984 and 1985). Macrophage activation leads to the production of various superoxides 
and cytokines. The production of cytokines is known to influence the activities of other 
cell types such lymphocytes, fibroblasts and endothelial cells. The cytolytic and 
cytostatic activity of macrophages against leukaemia and carcinoma cells was reported. It 
was shown that a 70% deacetylated chitosan had the greatest immunoadjuvant and 
antitumour activities in mice and guinea pigs. This chitosan was reported to be digested 
by lysozyme more slowly than the chitosan derivatives tested. Macrophage activation 
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with chitosan (80% deacetylated) in the form of biodegradable multi-porous beads and 
multi-porous microspheres has been described (Nishimura et al., 1986 & 1987a). 
Stimulation of the production of interleukins and colony stimulating factor by 
macrophages was also demonstrated. This research group also discussed the possibilities 
of the use of these chitosan preparations as carriers for drugs such as antitumour drugs. 
Otterlei et al. (1994) investigated the effect of the neutral solubility and molecular weight 
of chitosan on its immunomodulating properties. 
Wound healing 
Chitin and chitosan have been investigated as wound healing accelerators (Muzzarelli, 
1977). Knapczyk et al. (1989c) reported that chitosan in the form of a powder and 
solution exhibited no irritant and allergic effects on healthy or damaged skin. The 
mechanism of action of these materials as wound healing promoters has not been fully 
elucidated and there are several mechanisms by which chitosans could improve or modify 
wound healing (Olsen et al., 1989). The N-acetylglucosamine subunit of chitosan is a 
major component of dermal tissue and its presence in scar repair tissue is essential. 
Furthermore, glycoproteins, which are the predominant proteins in the initial phases of 
wound healing, contain abundant N-acetylglucosamine. Thus, chitinous material may 
provide a source of N-acetylglucosamine through their degradation by lysozymes which 
are present in wound fluid. The oral administration of N-acetylglucosamine has also 
been reported to accelerate wound healing and improve the tensile strength of scar tissue. 
In addition, since glycosaminoglycans, to which chitosans have similar structural 
characeteristsics, play an important role in the structural organisation of collagen in the 
wound giving structure and strength to newly formed collagen, it is possible that 
chitosans provide a recognised environment for wound healing to occur similar to that of 
glycosaminoglycans. The activation of cells such as macrophages by chitosan, thereby 
stimulating the inflammatory response through modulation of the activity of other cells or 
via the secretion of regulatory substances, may also be important for the wound healing 
process. Muzzarelliet al. (1988) report normal regeneration of the dura mater in cats by 
the application of chitosan (86.8% deacetylated). The role of chitosan was suggested to 
be as a primer on which normal tissue architecture is organised similar to the actions of 
glycosaminoglycans. Through its wound healing properties, chitosan could find 
application as an artificial skin which would be of particular benefit in the treatment of 
extensive skin loss occuring as a result of burns (Chandy and Sharma, 1990). 
Several application of chitosan in bone healing, treatment of periodontal bone loss and 
dentistry have been reported (International Commission on Natural Health Products, 
1995a). Malette et al. (1986) demonstrated the use of chitosan to enhance the 
regeneration of. leg bone in dogs. Studies by Borah et al. (1992) showed that N-acetyl 
chitosan induced bone growth in large metacarpal / fibular defect areas in rabbits which 
alleviated the need for surgical bone grafting. Reconstruction of the periodontium using 
chitosan ascorbate, thus, avoiding more complicated and less tolerable treatments was 
reported by Muzzarelli(1989). Ina patient exhibiting severe periodontitis, a chitosan gel 
was used to fill large pockets neighbouring the teeth and prevent dental mobility. Ito 
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(1991) also reported the application of chitosan as a bone-filling paste for dental 
treatment. 
Biomedical membranes and ophthalmology 
The use of chitosan in the preparation of artificial kidney membranes has been suggested 
(Muzzarelli, 1977). Chandy and Sharma (1990) reviewed the biomedical applications of 
chitosan membranes. A prerequisite for the use of materials as artificial kidney 
membranes is high tensile strength, selective permeability and blood compatibility. The 
use of albumin blended chitosan membranes for this role has been suggested owing to 
their superior permeability and blood compatibility properties compared to chitosan and 
standard cellulose membranes. The application of chitosan in ophthalmology (e. g. 
contact and intraocular lenses) has utilised the mechanical strength of chitosan, its 
wettable, non-abrasive and non-allergenic properties and its ability to allow oxygen and 
carbon dioxide to permeate to and from the cornea, respectively (International 
Commission on Natural Health Products, 1995b). Markey et al. (1989) described the 
use of chitosan and chitosan blends for the preparation of bandage contact lenses 
primarily for use in the protection of an acutely traumatised eye such as in intraocular 
surgery or a chronically compromised cornea. These materials were reported to exhibit 
properties desirable in a bandage lens. 
Hypocholesterolaemic / hypolipidaemic agent 
The potential use of chitosan as a hypocholesterolaemic agent was demonstrated in rats 
by Sugano et al. (1978) and later by Nagyvary et al. (1979) and Kobayashi et al. (1979). 
The hypolipidaemic activity of chitosan has also been demonstrated (Nagyvary et al., 
1979). In rats fed a high cholesterol diet containing 2-5% chitosan for a period of 20 
days plasma cholesterol concentrations were shown to be reduced by 25-30% without 
influencing food intake and growth of the animals (Sugano et al., 1980). The liver 
concentration of cholesterol and triglycerides was also shown to decrease by a dietary 
supplement of chitosan. The hypocholesterolaemic activity of chitosan was similar to that 
of cholestyramine, an aromatic polymer used as a bile salt sequestrant in the treatment of 
hypercholesterolaemia. Dietary chitosan was shown to increase the faecal excretion of 
exogenous and endogenous cholesterol. Jennings et al. (1988) demonstrated the 
hypocholesterolaemic activity of a diet containing 5% chitosan in rats and in contrast to 
feeding cholestyramine, chitosan did not have deleterious effects on the intestinal 
mucosa. LeHoux and Grondin (1993) showed that a diet containing 7.5% chitosan 
maintained adequate cholesterol homeostasis in rats fed a high cholesterol diet. In rats 
fed with cholestyramine there were changes in the weight or appearance of the liver, 
however, there were no such changes in chitosan fed rats. Hirano et al. (1990) 
confirmed the hypocholesterolaemic activity of a dietary intake of chitosan in hens and 
rabbits. The hypocholesterolaemic and hypolipidaemic activity of chitosan has mainly 
been attributed to the disruption and/or inhibition of micelles in which cholesterol, fatty 
acids or monoglycerides are normally incorporated in the upper intestine, thus preventing 
their absorption (Sugano et al., 1978 & 1980, Nagyvary et al., 1979, Furda, 1983). 
Dietary chitosan has been shown to impair iron absorption in rats, probably as a 
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consequence of chelation, resulting in depression of haemoglobin levels although there 
appeared to be little effect on the absorption of other metal ions (Gordon & Besch- 
Williford, 1984). However, liver iron levels were not significantly lower than those in 
control animals and the authors suggested that impaired iron utilisation may partially be 
attributed to residual EDTA used to prepare the chitosan sample. The hypolipidaemic 
application of chitosan is currently utilised in the USA in a dietary supplement (Fat 
BinderTM, Genesis Research Corporation, IL, USA). Deuchi et al. (1995) investigated 
the effect of viscosity and degree of deacetylation of chitosan on faecal fat excretion in 
rats fed a high fat diet. It was shown that as the viscosity, hence molecular weight, or 
degree of deacetylation of the chitosan preparation increased, fat digestability decreased 
(i. e. faecal fat excretion increased). A supplement of ascorbic acid with chitosan in the 
diet significantly reduced fat absorption possibly due to the increase in the charge of the 
chitosan at reduced pH. 
1.7.6.8 Applications in Pharmaceutical delivery systems 
The pharmaceutical application of chitosan is receiving wide interest particularly for oral 
drug delivery. Studies on the use of chitin and/or chitosan in directly compressed tablets, 
in sustained release preparations of water soluble drugs and in ground mixtures 
containing poorly soluble drugs has been described (Nagai et al., 1984). The gel 
forming property of chitosan in tablet formulations at low pH was suggested as a 
promising vehicle for the sustained release of water soluble drugs in the gastrointestinal 
tract. In dogs, the oral bioavailability of the poorly soluble drug phenytoin (used in the 
treatment of epilepsy) was improved by co-grinding with chitosan which correlated with 
the in vitro dissolution profile of the phenytoin-chitosan ground mixture. Brine (1989) 
evaluated controlled release solid dose forms incorporating chitosan for drug delivery. 
Technical feasibility in the use of chitosan in a direct compression / sustained release 
matrix for the highly water soluble drug chlorpheniramine maleate (and in a controlled 
release wet granulation formulation for aspirin was demonstrated. Machida et al. (1989) 
reported the sustained absorption of prednisolone in dogs from buoyant oral dosage 
forms utilising chitosan. Buoyant formulations were suggested as a means of increasing 
the resisence time of orally administered dose forms in the stomach. The sustained 
release formulations utilised a chitosan granule, containing internal cavities, which was 
layered in a chitosan membrane. By changing the composition of the granules and/or the 
thickness of the chitosan membrane, the release properties of the drug were controlled. 
Knapczyk et al. (1989c) reported that the efficiency of treatment of vaginal fungal 
infections (vaginitis mycotica) with the antifungal agent clotrimazole was improved by the 
use of chitosan. A single application of a vaginal tablet composed of clotrimazole with 
chitosan was as effective as four applications (normally applied over a period of 12-14 
days) of a commercial preparation of clotrimazole. Later, Knapczyk (1992) reported on 
the properties of tablets for buccal and vaginal delivery of antimycotic compounds. The 
proportion of chitosan in the tablet, the degree of acetylation of the chitosan and the 
addition of other excipients was shown to influence the properties of the tablet. Miyazaki 
et al. (1990) utilised the film-forming properties of chitosan to investigate oral drug 
delivery systems. Films which were prepared from chitosan and diazepam (0.5: 1 ratio) 
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and loaded into hard gelatin capsules were shown to be as effective as a commercial tablet 
preparation. 
Duoxian et al. (1991) examined the properties of chitosan-alginate microcapsules which 
were suggested for the sustained release of pharmaceuticals. The use of chitosan gel 
microspheres (chitosan gel core crosslinked with glutaraldehyde) in controlled release 
preparations for the antitumour drug 5-fluorouracil have also been reported (Ouchi et al. 
(1991). Imai et al. (1991) showed that the rate of absorption of the acidic drug 
indomethacin (anti-inflammatory) was improved following the oral administration of a 
`kneaded mixture' containing a complex of indomethacin and low molecular weight 
chitosan which correlated with its increased in vitro dissolution rate. The use of chitosan 
or modified chitosan in pH-sensitive controlled-release cationic hydrogel systems have 
also been described (Amiji and Patel, 1994). These systems were suggested to be 
suitable for the selective delivery of drugs to different regions of the gastrointestinal tract. 
The use of chitosan (93% deacetylated) hydrogels as an ointment base for drugs such as 
lidocaine hydrochloride and clotrimazole has also been described (Knapczyk, 1993). Gel 
stability was reduced when less extensively deacetylated chitosans (66% deacetylation) 
were used which suggested to be due to the possible interactions with the drug. Polk et 
al. (1994) suggested the use of chitosan-alginate microcapsules for the delayed-release of 
protein drugs. Capsules prepared from high molecular weight chitosan or a combination 
of high and low molecular weight chitosan were shown in vitro to be the most effective in 
reducing the release of albumin during the first four hours. Increasing the alginate 
content of the capsules also decreased the release of albumin. The pH of the 
extracapsular fluid was shown to strongly influence the release profile with low release at 
low pH and high release towards neutral pH. The authors suggested the application of 
these capsules for the selective delivery of proteins to the neutral environment of the 
intestines. Alamelu and Rao (1994) investigated a potential delivery device for the 
lipophilic drug dapsone using liposomes sequestered in chitosan gel. In vitro studies 
demonstrated that the liposome-chitosan gel matrix provided a stable slow release system 
for dapsone (tested in phosphate buffer and mouse plasma). In contrast, the release of 
the hydrophillic marker bromothymol blue was more rapid. Akbuga and Durmaz (1994) 
investigated the release of furosemide from chitosan microspheres prepared using a 
water-in-oil emulsion technique with a view of evaluating candidate systems for drug 
delivery. Ritthidej et al. (1994) investigated the application of chitosan as a disintegrant 
in paracetamol tablets, finding that the tablets containing chitosan disintegrated faster than 
those containing the commonly used excipients corn starch and microcrystalline cellulose. 
Collagen-chitosan composite membranes for the controlled release of propranolol have 
been reported (Thacharodi and Rao, 1995. These authors showed that transdermal 
patches incorporating chitosan were successful for the delivery of propranolol. 
Crosslinked chitosan microspheres have also been investigated for the controlled release 
of drugs administered by parenteral injection (Jameela and Jayakrishnan, 1995). In vitro 
drug release was found to be controlled by altering the degree of crosslinking. In vivo, 
no significant biodegradation of placebo chitosan microspheres was observed following 
intramuscular injection in rats. However, the in vivo release profile of drug was not 
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reported. 
1.7.6.9 Novel application of chitosan in nasal delivery systems 
A universal characteristic of cell membranes is their predominantly net negative charge 
due to the presence of anionic radicals which are covalently linked to the molecular matrix 
of the membrane (Quinton and Philpott, 1973). These authors investigated the role of the 
fixed anionic sites in the cell membrane by looking at the effect of cationic polymers on 
membrane-membrane interactions, membrane structural rigidity and membrane 
permeability. The cationic polymers, poly-L-lysines, protamine and histone, were 
shown to produce similar changes in the structure of rabbit gall bladder. Induction of the 
fusion of cell membranes was reported which was suggested to be due to the 
neutralisation of the negative surface charge on the membrane or the formation of 
polymeric cation bridges which crosslink opposed membrane surfaces. The cationic 
polymers were reported to alter the morphology of membrane processes such as 
microvilli which was suggested to be due to the loss of membrane rigidity as a result of 
disruption of the ionic and hydrogen bonds which normally impair a degree of stiffness 
to the membrane. The cationic polymers were reported to increased membrane 
permeability. The authors suggested that the intermolecular interactions involving fixed 
anions which are critical to molecular rigidity are also critical to the molecular 
organisation and hence permeability properties of the membrane. Granger et al. (1986) 
also investigated the role of fixed anionic sites on the integrity of the rat intestinal 
capillary wall by looking at the effect of neutralising the negative charge of these sites by 
using polycations such as protamine sulphate, poly-L-lysine or polyethyleneimine. The 
polycations, administered by intravenous infusion, resulted in increased transmembrane 
efflux of proteins across the intestinal capillary wall. This was attributed to neutralisation 
of fixed anionic sites on the capillary wall although the authors also suggested that other 
mechanisms may be involved since polycations have been shown to distort the kidney 
glomerular basement membrane structure, thus, altering porosity. Increased nasal 
absorption of polycationic dextran derivatives compared to neutral dextran derivatives 
was reported following coadministration with sodium deoxycholate in rabbits (Maitani et 
al., 1989). It was suggested that the positive charges of the polycationic dextrans were 
available to interact and form complexes with the negatively charged nasal mucosa 
thereby increasing absorption through increased intimate contact with the nasal 
membrane. 
The novel application of chitosan to improve the nasal absorption of polypeptides such as 
insulin and calcitonin was reported by Illum (1992). Later, Ilium et al. (1994) published 
the results of nasal absorption studies in rat and sheep models. Some of these results 
were generated, as part of this project. Chitosan glutamate solutions were shown to 
greatly enhance the nasal absorption of insulin in both species. Histological examination 
following exposure of the rat nasal mucosa to 0.5% chitosan for a period of 60 minutes 
showed that there were no significant changes in normal nasal morphology. Rentel et al. 
(1993) demonstrated that chitosan glutamate enhanced the in vitro absorption of a 
vasopressin analogue (molecular weight 1412) across the rat intestinal mucosa from a 
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suspension formulation. 
The mechanism (s) by which chitosan enhances nasal absorption has not been elucidated. 
Ilium et al. (1994) suggested that the mucoadhesive properties of chitosan may contribute 
to the mechanism of absorption enhancement although other factors such as the effect of 
chitosan on the gating properties of epithelial tight junctions may be involved. As 
detailed above, neutralisation of the fixed anionic sites on cell membranes has been 
shown to influence membrane permeability. The mucoadhesive properties of chitosan 
were reported by Lehr et al. (1992). It was suggested that mucoadhesion probably 
results from an ionic interaction between the positively charged amino groups in chitosan 
and the negatively charged sialic acid residues in mucus. Fiebrig et al. (1994) 
demonstrating the interaction between chitosan and pig gastric mucin, a major component 
of gastric mucus, using the technique of sedimentation in an analytical ultracentrifuge. 
Chitosan is also a viscosity enhancing agent and the viscosity of chitosan solutions is a 
function of its molecular weight and concentration as well as on the properties of the 
solvent used (Filar and Wirick, 1977). The mucoadhesive and viscosity enhancing 
properties of chitosan may both contribute to increasing the residence time of the drug 
formulation in the nasal cavity, thereby increasing the time available for absorption. 
Artursson et al. (1994) examined the effect of chitosan on the permeability of Caco-2 
monolayers derived from a human intestinal epithelial cell line using C14-labelled 
mannitol as the model drug. Chitosan resulted in an increase in the rate of mannitol 
absorption which was shown to be concentration and pH dependent. Mannitol 
absorption was highest at the lowest pH tested (4.0) and tended to increase with an 
increase in chitosan concentration reaching a plateau between 0.25% to 0.5% chitosan. 
The pH-dependency in absorption was attributed to the change in the degree of ionisation 
of the chitosan molecule hence in its molecular configuration. At lower pH values, the 
chitosan molecule tends be more ionised, adopting an uncoiled elongated configuration 
(Filar and Wirick, 1977) resulting in closer contact with the Caco-2 monolayer. A 
solution of 0.5% chitosan (pH 4.0) applied to the Caco-2 monolayer for a period of 60 
minutes was shown to induce changes in the distribution of cytoskeletal filamentous actin 
which is thought to be directly or indirectly associated with proteins in the tight junction. 
Thus, it was suggested that chitosan affected the permeability of tight junctions. A recent 
publication reported that 1.5% chitosan glutamate, increased the permeability of a Caco-2 
cell monolayer in terms of a decrease in TER (Borchard et al., 1996). However, 0.5- 
1.5% chitosan did not alter the permeability to C14-labelled mannitol and FITC-dextran. 
It was concluded that TER must decrease below a certain threshold value to permit 
paracellular transport of the marker substances. Mechanisms by which chitosan may act 
as an absorption enhancer have also been investigated by Dodane et al. (1996). In Caco- 
2 cell monolayers, chitosan hydrochloride was shown to cause a reversible, dose- 
dependent increase in membrane permeability indicated by the decrease in TER which 
was more pronounced when chitosan was applied to the apical side compared to the 
basolateral side. Changes in TER were observed within 15 minutes after application to 
the apical side even at the lowest concentration of chitosan tested (0.00125%). At this 
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lower concentration, chitosan did not modulate TER at the basolateral side. The effect of 
chitosan on the permeability of the cell monolayer was shown to be reversible with 
complete recovery within 24 hours. Results indicated that the cells remained viable 
during the recovery period after treatment with chitosan. Structural alteration of the 
Caco-2 monolayer, observed using confocal microscopy, showed that the decrease in 
TER correlated with a constriction of actin which changed from a filamentous- to 
globular-type at the cell-cell boundaries. Structural changes in the tight junction 
associated protein ZO-1 were also observed. Following a recovery period of 24 hours, 
the cell monolayer resembled that of the control. It was suggested that chitosan causes a 
transient modulation of the permeability and structure of the Caco-2 cell layer. 
Exploitation of the use of absorption enhancers or excipients in nasal drug delivery 
systems requires that full evaluation of their safety in candidate nasal systems is 
performed. Chitosan is generally considered to be non-toxic having an oral I D50 in mice 
of more than 16 g/kg which is in the same order as that of sugar and salt (Arai et al., 
1968). Other research groups have also demonstrated the safety of chitosan after oral 
administration to animals as previously mentioned (Landes & Bough, 1976, Sugano et 
al., 1978 and 1980, Nagyvary et al., 1979, Kobayashi et al., 1979, Austin et al., 1981, 
Jennings et al., 1988, Knapczyk et al., 1989, Kono et al., 1990, Hirano et al., 1990, 
LeHoux and Grondin, 1993, Deuchi et al., 1995). The oral toxicity of compounds is an 
important consideration in nasal delivery systems since drug formulations administered to 
the nasal cavity will ultimately find their way to the gastrointestinal tract. Ilium et al. 
(1994) reported that 60 minutes exposure of rat nasal mucosa to 0.5% chitosan did not 
cause significant changes in the morphology of the nasal epithelium. Nasal absorption 
studies in rats reported by Ilium et al. (1994) and studies by Artursson et al (1994) and 
Dodane et al. (1996) using Caco-2 cell monolayers suggest that the effect of chitosan on 
the permeability of membranes is transient which provides useful indication that chitosan 
does not cause significant epithelial damage. Aspden et al. (1995a) reported that chitosan 
caused a reversible reduction in mucociliary transport rate (MTR) in the frog palate model 
which was attributed to interaction between chitosan and frog palate mucus rather than 
ciliotoxicity. Aspden et al. (1995b) and Aspden (1996) reported the absence of chitosan 
toxicity when applied to nasal mucosa. Chitosan glutmate was shown to transiently slow 
the MTR of graphite particles in the frog palate model and in the human nasal turbinate 
model. In a study in 10 human volunteers, nasal administration of daily doses of 
chitosan for a period of 7 days did not cause any change in saccharin clearance times. In 
nasal in-situ perfusion studies in rats, perfusion of chitosan was reported to induce 
minimal damage to the nasal membrane compared to that resulting from nasal perfusion 
of a solution of Laureth-9. Raised concentrations of protein in the nasal perfusate were 
recorded after perfusion of chitosan in contrast to concentrations after perfusion of a 
control solution of 0.9% NaCl. However, increased protein concentrations were not 
accompanied by increased concentrations of the membrane bound enzyme 5'-nucleotidase 
and the cytosolic enzyme lactate dehydrogenase, which would be expected if membrane 
damage occurred. The increased protein concentrations were suggested to be due to 
mucus removal from the nasal membrane after complexation with chitosan and 
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compensatory increased mucus production. The effect of chitosan on guinea pig nasal 
cilia beat frequency (CBF) following a once daily nasal dose for 28 days was also 
reported. Chronic dosing of chitosan had no effect on CBF compared to undosed control 
animals. Measurement of CBF has been suggested as a valuable tool for evaluating the 
safety of nasal absorption enhancers (Merkus et al., 1993). 
The data would appear to suggest that chitosan is safe as a nasal absorption enhancer 
although extensive toxicological evaluation would be required before chitosan could find 
commercial application. 
1.8 Project objectives 
The objective of this project was to investigate the novel application of chitosan for the 
nasal delivery of insulin. Utilisation of the nasal route would be a major break-through in 
the treatment of diabetes mellitus. Insulin is also useful as a model peptide to evaluate 
the potential of chitosan for the nasal delivery of other peptide drugs. For comparison, 
nasal chitosan formulations incorporating salmon calcitonin as an alternative peptide were 
also investigated. Chitosan is commercially available at different degrees of 
deacetylation, in a number of viscosity (molecular weight) grades and in different salt 
forms. In this project, a medium viscosity glutamate salt having a degree of deacetylation 
of about 82% was predominantly used although for comparison other grades were also 
tested. 
Two in vivo animal models, an anaesthetised rat model and a conscious sheep model 
were used to investigate the nasal absorption of insulin or salmon calcitonin from 
formulations incorporating chitosan. The appropriate nasal or parenteral control 
formulations were also tested. Preliminary studies were performed to evaluate the 
efficacy of chitosan as a nasal absorption enhancer by comparing its performance with 
that of other compounds which had been reported in the literature to enhance the nasal 
absorption of peptide drugs. Following these preliminary studies, extensive 
investigations were performed with insulin to evaluate various factors influencing the 
nasal absorption enhancing efficacy of chitosan. Nasal salmon calcitonin / chitosan 
formulations were also tested. The project also evaluated potential membrane damaging 
effects of chitosan and various other compounds using an erythrocyte haemolysis assay. 
Characterisation of the chitosans employed was also performed using techniques such as 
sedimentation equilibrium and viscometry. 
i 
95 
CHAPTER 2 
GENERAL MATERIALS AND METHODS 
2.1 Introduction 
The general materials and methods employed in this project are described in this chapter. 
Details of the grades of chitosan used and methods of preparation of chitosan solutions 
and drug formulations are given along with details of the animal models used to 
investigate intranasal drug absorption, methods of analysis and calculation of results. 
Additional materials and methods are given in the relevant chapters. 
The rat nasal model used was based on that originally described by Hirai et al. (1981a) 
and modified by Fisher et al. (1985 & 1987). The validity of the use of the in vivo rat 
nasal model, similar to the model used in this project, was demonstrated by Fisher et al. 
(1985), Critchley (1989) and Chandler (1993). The sheep model, similar to the one used 
in this project, has previously been described by Longecker et al. (1987) and Ilium et al. 
(1989). The methods are described in the following sections: 
2.2 Preparation of chitosan solutions and drug formulations 
2.3 Absorption studies in rats 
2.4 Absorption studies in sheep 
2.5 Measurement of glucose, insulin or calcium concentrations 
2.5 Calculation of results following glucose, insulin or calcium analysis 
2.2 Preparation of chitosan solutions and drug formulations 
General details of the grades of chitosan used and the methods of preparation of chitosan 
stock solutions and drug formulations are described along with details of the 
measurement of formulation pH and osmolality. Insulin was the main drug used during 
this project although salmon calcitonin (S-CT) was also investigated as an alternative 
peptide drug. 
2.2.1 Grades and properties of the chitosans used 
A glutamate salt of a medium viscosity grade of chitosan (MVCSN) was predominantly 
used in this project. Other grades of chitosan were also evaluated for comparison. Each 
grade of chitosan used had a similar degree of deacetylation although different viscosity 
(molecular weight) grades and different salt forms were tested. The grades and 
properties of the various types of chitosan used are given in Table 2.1. 
2.2.2 
.- 
Preparation of chitosan stock solutions 
Chitosan solutions were prepared by weighing the appropriate amount of chitosan into a 
suitable volumetric flask, adding approximately 8/10ths of the final volume of solvent 
and stirring overnight, at room temperature, using a magnetic stirrer. The pH of the 
chitosan solution was measured (refer to Section 2.2.6) and if appropriate adjusted to the 
required pH with HCl. The solution was made up to the final volume with solvent 
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which had been preadjusted to the required pH. Chitosan solutions were then filtered 
through 0.45 µm syringe filters and stored in glass bottles at 4°C prior to use. 
Table 2.1. Grades and properties of the chitosans used 
CHARACTERISTICS OF THE VARIOUS GRADES OF CHITOSANS TESTED IN THIS PROJECT 
Chitosan grade Low viscosity 
chitosan glutamate 
Low viscosity 
chitosan lactate 
Medium viscosity 
chitosan glutamate 
Medium viscosity 
chitosan hydrochloride 
High viscosity 
chitosan 
Synonym LVCSN CSN lactate MVCSN CSN HCL HVCSN 
Product Seacure +G Seacure +I1OL Seacure +210G Seacure +CI Seacure 443 
Batch number P390 004-580-07 004-282-10 012422-01 077-372-05 
Nature of material Spray-dried powder Spray-dried powder Spray-dried powder Spray-dried powder flaked 
Water solubility Soluble Soluble Soluble Soluble Insoluble 
Salt type glutamate lactate glutamate hydrochloride chitosan base 
Salt content (% w/w) 55-65 65-75 55-63 80-90 not applicable 
Degree of deacetylation (% 80-85 82 82 81 75 
Batch viscosity (mug)' 388 1010 
Batch viscosity (CPS)'" 3 7 18 
- 
Batch viscosity (CPS) "" 15 
- 
54 
All grades of chitosan were supplied by Pronova Biopolymer A/S, Drammen, Norway 
" Intrinsic viscosity 
"" 0.5% w/v chitosan in phosphate buffer 
"** 0.5% chitosan in acetate buffer 
2.2.3 Properties of insulin and salmon calcitonin used 
Sodium insulin was used throughout the studies. Each batch of insulin used had a 
specific activity of about 28 IU/mg for pure insulin. However, since the insulin products 
used also contained salts and water, the purity of each batch was measured to ensure that 
formulations contained the correct concentration of insulin, thus correct doses were 
administered. The purity of insulin was determined by spectrophotometry. The 
absorbance of accurately prepared solutions of insulin product (typically 0.5 to 0.8 
mg/ml) were measured at 276 nm using a Hewlett Packard 845A diode array 
spectrophotometer (Hewlett Packard GmbH, Germany) and matching quartz cuvettes 
(Philips quartz cuvettes, Unicam Analytical Supplies, Cambridge, UK). From the 
absorbance readings obtained the purity of the product was calculated with knowledge 
that at 276 nm the absorbance of 1 mg/ml pure insulin is 1.058. The specific activity of 
the insulin product was adjusted according to the degree of purity obtained. In all cases 
the values of purity obtained were in close agreement with values given by the 
manufacturer. Further details of the insulins used are given in the relevant chapters. 
Salmon calcitönin, acetate salt, was used at the specific activity quoted by the 
maufacturer. Further details are given in the relevant chapters. 
2.2.4 Preparation of insulin or salmon calcitonin formulations 
Formulations of insulin or salmon calcitonin for testing in animal models were prepared 
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as described below. Reference solutions for subcutaneous or intramuscular 
administration and control nasal formulations were prepared by diluting a stock insulin or 
salmon calcitonin solution to the required concentration with solvent (e. g buffer or 
NaCl). Nasal test formulations were prepared by mixing appropriate volumes of stock 
insulin or salmon calcitonin solutions with stock solutions of chitosan or enhancers to 
achieve the required concentrations. All stock solutions and solvents used in the 
preparation of nasal formulations were pre-adjusted to the required pH during preparation 
(further details given in relevant chapters). After preparation the final pH was checked 
and formulation osmolality measured as described in section 2.2.5. 
2.2.5 Measurement of formulation osmolality and pH 
Measurements of osmolality and pH were routinely performed during the preparation of 
chitosan solutions and drug formulations. Osmolality is a measure of the tonicity or 
osmotic pressure of the solution (Reich et al., 1995). An Osmol is defined as "the 
weight, in grams, of a solute, existing in a solution as molecules (and/or ions, 
macromolecules, aggregates, etc), which is osmotically equivalent to a mole of an ideally 
behaving nonelectrolyte". Osmolality was measured in units of Osmol/kg. Fluids which 
have the same tonicity as physiological fluids (e. g. 0.9% sodium chloride) are said to be 
isotonic. Those at a higher or lower tonicity than physiological fluids are referred to as 
hypertonic and hypotonic, respectively. The pH measures the hydronium ion 
concentration of a solution and is expressed in terms of the logarithm (log) of the 
reciprocal of the hydronium ion concentration (Niebergall, 1995). This is written 
mathematically as follows: 
pH =log 1 
[H34''] 
Since the log of 1 is zero the above equation can be written: 
pH = 
-log [H3O+] 
2.2.5.1 Measurement of osmolality 
The osmolality of selected solution formulations tested either in animal absorption studies 
or in erythrocyte haemolysis assays were measured using an Osmomat 030 cryoscopic 
osmometer (Gonotec, Berlin, Germany). The instrument determines the total osmolality 
of aqueous solutions by comparing measurements of the freezing points of pure water 
(freezing point 0°C, osmolality 0.000 Osmol/kg) and a standard solution of sodium 
chloride (freezing point 
-0.5557°C, osmolality 0.300 Osmol/kg) with that of the test 
solution. Sample volumes of 50 gl were used. Measurements of single samples were 
performed automatically and the result displayed on a digital display panel. The 
osmometer was first calibrated by performing measurements with pure water and 0.300 
Osmol/kg sodium chloride standard solution (Gonotec). If necessary the instrument was 
adjusted to give reproducible readings of 0.000 and 0.300 Osmol/kg for water and 
sodium chloride calibration solutions respectively. The osmolality of the test solutions 
was measured, at least in duplicate, to obtain reproducible results. 
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2.2.5.2 Measurement of pH 
The pH of solutions was measured during and/or after formulation preparation using a 
Corning 240 pH meter (pH meter) from Ciba Corning Diagnostics Ltd, Sudbury, 
Suffolk, UK. The instrument was calibrated with pH 4.0 and pH 7.0 standard solutions 
prior to determining formulation pH. 
2.3 Absorption studies in rats 
Absorption studies in rats were performed in the Biomedical Services Unit (BMSU), 
QMC, University of Nottingham, UK. In all studies, the rats were under terminal 
anaesthesia. 
2.3.1 Materials 
Heparin (sodium salt, Product H-7005), Sigma Chemical Company Poole Dorset. 
Pentobarbitone sodium BP injection (Sagatal, 60 mg/ml), May & Baker, Dagenham, 
Essex, UK. 
Sodium chloride, 0.9 % w/v, solution (0.9 % NaCI, Steriflex® 0.9% sodium chloride 
intravenous infusion B P), Fresenius Health Care Group, Basingstoke, Hants, UK. 
Ultrapure water ("Elgastat UHP", Elga, High Wycombe, UK) was used throughout. 
Glucose FH/2 tubes (2 ml tubes, containing 2 mg sodium fluoride, 30 I. E. lithium 
heparin), Sarstedt, Leicester, UK. 
All other materials used for the surgical preparation of animals was supplied via 
Danbiosyst UK Ltd, Nottingham, UK. 
2.3.2. The anaesthetised in vivo rat nasal model 
2.3.2.1 Study animals and preparation of rats prior to surgical procedure 
Male Wistar laboratory rats, weighing approximately 250 g, were obtained from the 
BMSU or from the Joint Animal Breeding Unit (JABU), School of Agriculture, 
Nottingham University, UK. All rats were fasted for 16-18 hours prior to the study day 
but were allowed water ad libitum. Food pellets were removed from the cage feeding 
tray and in addition, since rats tend to be coprophagic (faeces eating) then soiled bedding 
was also removed from the cages and replaced with fresh bedding. The tail of each rat 
was uniquely marked with a permanent marker pen. Rats were pre-weighed to ensure 
that the correct doses of anaesthetic and drug solutions were administered. 
2.3.2.2 Implantation of an indwelling needle into the caudal vein of the rat 
The caudal (lateral tail) veins, running along the length of the tail, were used for the 
intravenous administration of anaesthetic and fluid replacement in the rat. To increase 
blood circulation in the tail and to facilitate implantation of a needle in the caudal vein, rats 
were placed in a thermostatically controlled box (`hot box', c/o Dept Pharmaceutical 
Sciences, University of Nottingham, UK), preset at 38 °C, for approximately 10 
minutes. The rat was transferred to a restraining cone and a cannula / needle assembly 
was inserted into the lumen of the caudal vein. The cannula / needle assembly was 
prepared by the insertion of a syringe needle into a 10 cm length of polyethylene cannula 
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tubing. The blunt end of the shaft of a second needle was inserted into the free end of the 
cannula tubing. The cannula / needle assembly was pre-flushed with 0.9 % NaCl prior to 
use to ensure that there were no blockages or leaks. When the needle was correctly 
inserted into the vessel, indicated by blood flow along the cannula, anaesthesia was 
administered as described below. The cannula / needle assembly was secured in place 
using adhesive plaster. 
2.3.2.3 Induction of anaesthesia 
Rats were anaesthetised via the indwelling needle implanted into a caudal vein with 60 
mg/kg pentobarbitone sodium (Sagatal). The pedal withdrawal reflex was used as an 
indication of the induction of general anaesthesia in the rats prior to the performance of 
surgical procedures. Anaesthesia was maintained throughout the experimental period by 
further injections of Sagatal solution via the indwelling needle in the caudal vein. 
2.3.2.4 Tracheal cannulation 
Tracheal cannulation of the anaesthetised animals was performed to maintain the patency 
of the airway throughout the experimental period. During the cannulation, the 
oesophagus was occluded by tying it to the cannula. This was to prevent any possible 
drainage of nasally administered solution formulations into the stomach. The 
anaesthetised rat was placed ventral surface up on a heated table (to maintain the body 
temperature of the animal). The trachea and underlying oesophagus were exposed by 
blunt dissection and two cotton ligatures, of approximate length 20 cm, were passed 
under the oesophagus / trachea. An incision was made in the trachea, between two 
adjacent cartilagenous rings, and a 4-5 cm length of polyethylene cannula tubing inserted, 
caudally (towards the lungs), approximately 1-2 cm into the trachea. The cannula was 
secured in the trachea by tying both ligatures around the cannula, trachea and 
oesophagus. 
2.3.2.5 Carotid artery cannulation 
The carotid artery was used as a convenient and easily accessible vessel from which to 
collect serial blood samples during the experiment. The left common carotid artery, lying 
in close proximity to the trachea was isolated by gently freeing it from the attached 
connective tissue and nerve. Three ligatures were passed under the carotid artery. The 
artery was clamped at the caudal end by attaching a microvessel clip. One of the ligatures 
was tied at the cranial end of the vessel to prevent the back-flow of blood when the vessel 
was cut. An incision was made in the vessel and a length of polyethylene cannula tubing 
of about 20 cm was inserted, caudally into the lumen of the vessel. The cannula was 
secured in the vessel by using the remaining two ligatures. The free end of the cannula 
was clamped with artery forceps and the microvessel clip removed. The artery forceps 
were used to regulate blood flow along the cannula. The cannula was kept patent 
throughout the experiment by flushing with heparinised saline (0.25 mghnl heparin in 0.9 
% NaCl). The site of operation was then covered by a pad of absorbent paper to protect 
the position of the cannula and reduce fluid loss from the site. 
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3.2.6 Dose administration 
Intranasal dose administration 
Intranasal doses were administered at 0.1 ml/kg by instilling the solutions into the right 
nostril of the rat which was positioned ventral surface up. Thus a dose of 25 µl was 
administered to a 250 g rat. The doses were administered via a glass 50 or 100 µl 
microsyringe to which was attached a needle fitted with a 40 mm length of polyethylene 
cannula tubing. The cannula was inserted to a depth of 0.8 cm into the right nostril of the 
animal and the dose gently instilled. After dose administration the cannula tubing was 
carefully withdrawn from the nostril. 
Subcutaneous dose administration 
Subcutaneous doses were administered at 0.25 ml/kg by injecting the solution into the 
nape of the neck using a glass Hamilton 100 µl syringe with suitable needle. 
Intramuscular dose administration 
Intramuscular doses were administered at 0.025 ml/kg by injecting the solution into a 
gluteal muscle of the hind limb to a depth approximately 5 mm using a glass Hamilton 
100 µ1 syringe with suitable needle. Care was taken to ensure that the needle did not 
penetrate blood vessels 
2.3.2.7 Blood sample collection 
All blood samples were collected from the cannulated carotid artery. Prior to the 
collection of each blood sample, the first 1-2 drops of blood were discarded to prevent 
contamination of the sample with heparinised saline. 
During insulin absorption studies, blood samples of about 0.2 ml (10-12 drops) were 
collected for blood glucose analysis into glucose FH/2 tubes at 10 and 5 minutes prior to 
dose administration (-10 and 
-5 minutes) and at 5,10,20,30,45,60,90,120,180 and 
240 minutes post-administration. Blood samples were stored at room temperature prior 
to glucose analysis within approximately 2 hours of collection (refer to Section 2.5). Due 
to limits in the volumes of blood which could be collected from the rat and due to 
problems with cross-reactivity of rat plasma with the insulin radioimmunoassay, insulin 
analysis was not performed. 
During salmon calcitonin absorption studies, blood samples of about 0.2 ml were 
collected into 1.5 ml microcentrifuge tubes containing 0.02 ml of heparinised saline (1 
mg/ml heparin in 0.9 % NaCl) at 10 and 5 minutes prior to dose administration and at 5, 
10,20,40,60,90,120,180,240 and 300 minutes post-administration. Plasma was 
separated by centrifugation at 13000 rpm in a MSE Microcentaur centrifuge (Fisons 
Scientific Equipment, Loughborough, Leicestershire, UK). The plasma was removed 
(approximately 0.1 ml aliquots) and stored frozen at 
-20°C in 1.5 ml microcentrifuge 
tubes prior to calcium analysis (refer to Section 2.5). 
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After the collection of each blood sample the cannula was flushed through with 
heparinised saline. Fluid replacement, equivalent to the volume of blood collected, was 
given to the rats, at suitable time intervals throughout the experiment, in the form of 0.9 
% NaCl via the cannulated caudal vein. Following the completion of serial blood sample 
collection, the rats were killed by an overdose of Sagatal administered via the indwelling 
needle in the caudal vein and the animals disposed of by incineration. 
2.4 Absorption studies in sheep 
Absorption studies in sheep were performed in the facilities of the Joint Animal Breeding 
Unit (JABU), School of Agriculture, University of Nottingham. Studies were performed 
in conscious sheep. However, the sheep were sedated to facilitate dose administration as 
detailed below. 
2.4.1 Materials 
Ketamine hydrochloride (Ketalar®, 100 mg/ml injection, ), Parke Davis Medical, Hants., 
UK. 
Heparinised tubes (4 ml, containing 60 IU lithium heparin) and polystyrene tubes (3.5 
ml), Sarstedt, Leicester, UK. 
All materials for the cannulation or dose administration to sheep were supplied via 
Danbiosyst UK Ltd, Nottingham, UK. 
2.4.2. The conscious in vivo sheep nasal model 
2.4.2.1 Study animals 
Cross-bred (Suffolk & Texel) male and female sheep weighing in the region of 30-60 kg 
were used in the studies. The animals were weighed the day prior to dose administration 
to ensure that the correct doses of ketamine and dose solutions were administered. In the 
various, studies performed in sheep animals were reused allowing at least three weeks 
between successive studies. The sheep were normally housed outside but were brought 
indoors and housed in a well-ventilated barn for the duration of each study. On the day 
of dosing, sheep were enclosed in a pen, in groups of up to 10 animals, to facilitate 
handling. The animals were not fasted prior to dose administration. 
2.4.2.2 Cannulation of the jugular vein 
The external jugular veins, running either side of the neck, were used as a convenient and 
easily accessible site for blood sampling in the sheep. Cannulation of the jugular vein is a 
non-surgical procedure which does not require anaesthesia of the animals. Jugular vein 
cannulation was performed the day prior to the actual dosing study day. An area of skin 
over the position of one of the jugular veins was shaved. The cannula tubing was 
inserted approximately 15 cm into the lumen of the jugular vein, facilitated by the use of a 
needle introducer and guidewire which were subsequently removed, and secured in-place 
with a subcutaneous suture. A bandage was wrapped round the neck of each sheep to 
protect the cannula. The cannula was kept patent by flushing it with heparinised saline 
(25 IU/ml heparin in 0.9% NaCl). The cannula remained indwelling in the jugular vein 
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of each animal for the duration of the study and was removed upon completion of blood 
sample collection. 
2A. 2.3 Dose administration 
The sheep were divided into groups of three or four animals and a different dose 
administered to each group. For the purpose of dose administration, the sheep were 
sedated with an intravenous dose of ketamine hydrochloride (100 mg/ml injection) at 
2.25 mg/kg administered via the jugular vein cannula. This was intended for animal 
restraint, and also as a counter-measure against the animal sneezing during nasal 
administration. The anaesthesia lasted for approximately 3 minutes. 
Nasal dose administration 
Nasal solution formulations were administered at 0.01 ml/kg. The solutions were 
instilled from a1 ml syringe attached to a cannula which was inserted into each nostril to 
a depth of 7-10 cm depending on the weight / size of the animals. The dose solution was 
divided equally between both nostrils. 
Subcutaneous dose administration 
Subcutaneous formulations were administered at 0.0476 mI/kg by injecting the solution 
into the subcutaneous tissue of the flank. To facilitate subcutaneous dose administration 
an area of skin on the flank was shaved. 
2.4.2.4 Blood sampling 
All blood samples were collected from the cannulatedjugular vein of the sheep. Prior to 
the collection of each blood sample the initial 2 ml of blood collected was discarded to 
eliminate traces of heparinised saline. 
During insulin absorption studies, blood samples of 4.0 ml were collected at 15 and 5 
minutes (-15 and 
-5 minutes) prior to insulin dose administration and at 5,10,15,20, 
30,40,50,60,75,90,120,150,180 and 240 minutes post-administration. Blood 
samples were mixed gently in 4 ml heparinised tubes which were kept on crushed ice 
before plasma separation. The plasma was separated by centrifugation at 4°C and 
approximately 3000 rpm. Each plasma sample was divided into two aliquots and stored 
frozen at 
-20°C or -80°C awaiting glucose or insulin analysis, respectively (refer to 
Section 2.5). 
During salmon calcitonin absorption studies, blood samples were collected pre- and post 
administration of formulations at 
-15, -5,15,30,45,60,90,120,150,180,240,300, 
360,420,480 and 600 minutes and plasma separated as described above. Plasma was 
stored frozen at 
-20°C awaiting calcium analysis (refer to Section 2.5). 
2.5 Measurement of glucose. insulin or calcium concentrations 
Glucose, insulin or calcium concentrations in blood or plasma were measured in the nasal 
absorption studies performed in animals as described below. 
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2.5.1 Measurement of blood or plasma glucose concentrations 
Blood or plasma glucose concentrations were measured, in rat and sheep absorption 
studies respectively, using a YSI Model 23 AM Glucose analyser (glucose analyser) and 
YSI Syringepet (syringepet) from Yellow Springs Instruments Co. Yellow Springs, 
Ohio, USA. The glucose analyser used an immobilised glucose oxidase enzyme 
membrane coupled with a highly glucose specific hydrogen peroxide sensor to measure 
glucose concentrations. Glucose in the sample making contact with the glucose oxidase 
membrane and oxygen, supplied by an air supply, is converted to gluconic acid and 
hydrogen peroxide (1-1202). The H202 is oxidised at a platinum anode and the oxygen 
produced by this reaction is reduced to water at the silver cathode. The current produced 
between the anode and cathode is directly proportional to the H202 and thus glucose 
concentration in the sample. The measurement of glucose concentrations is automated 
following the injection of the sample into the instruments sample chamber. Results are 
displayed digitally on a control panel. Samples of 25 pfwere concurrently injected into 
the sample chamber of the glucose analyser using a syringepet (combination syringe and 
pipette). The instrument was calibrated before use and after every 10-15 samples using a 
10 (± 0.1) mmol/l glucose standard solution. The experimental blood or plasma samples 
were mixed with a vortex mixer prior to injection. The measured glucose concentrations 
(mmol/1) were automatically displayed on the control panel of the instrument and were 
recorded manually. 
Basal blood glucose concentrations in rats were typically between 3-4 mmol/l (range 2.8- 
5.1 mmol/1). Basal plasma glucose concentrations in sheep were typically between 3-4 
mmol/l (range 2.8-5.2 mmol/1). 
2.5.2 Measurement of insulin concentrations 
Insulin concentrations in sheep plasma were measured by radioimmunoassay (RIA) using 
a double antibody method validated and routinely used by Dr I Gill, Danbiosyst UK Ltd. 
Some preliminary assays was performed under the supervision of Dr Gill although the 
bulk of the analysis was performed by Dr Gill. The RIA method relies on the competition 
between insulin in the standard solution or test (plasma) sample and 125I-insulin (radio- 
labelled insulin) and a fixed amount of the first antibody raised against insulin in an 
animal model (guinea pig anti-insulin antibody). Competitive binding occurs between the 
radio-labelled and unlabelled insulin and the anti-insulin antibody. If the plasma sample 
contains high concentrations of insulin then the amount of bound unlabelled insulin will 
be high whereas the amount of bound radio-labelled insulin will be low (the amount of 
unbound, radio-labelled insulin will be high). A second antibody, raised against the first 
antibody in a second animal model (donkey anti-guinea pig serum), is added followed by 
polyethylene glycol (PEG) which will precipitate the insulin-antibody complex. 
Following centrifugation the radioactivity in the supernatant or pellet is measured. The 
radioactivity in the pellet will be low and radioactivity in the supernatant will be high if 
plasma concentrations of insulin are high. Insulin standard solutions are used to prepare 
a standard curve from which the insulin concentrations in the test samples can be read. 
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Basal insulin concentrations in sheep were generally below 15 mU/I (range 0.0-35.1 
MU/1). 
2.5.3 Measurement of calcium concentrations 
Plasma calcium analysis was performed following studies to investigate the intranasal 
absorption of salmon calcitonin in rats and sheep. Plasma calcium concentrations were 
measured at Kingsmill Hospital, Mansfield, Nottinghamshire, UK using an ERIS 6170 
selective multitest analyser from Eppendorf (Olympus, Japan). The ERIS tests were 
developed by E Merck, Darmstadt, Germany. The test for calcium (total calcium) is 
based on the reaction of calcium ions in the sample with o-cresolphthalein complexone in 
alkaline solution to form an intense violet colour. The extinction of the colour formed is 
proportional to the concentration of calcium in the sample. The addition of 8- 
hydroxyquinoline eliminates interference by magnesium and iron. The ERIS test uses 7 
tl of plasma and 70 Al of the reagent (o-cresolphthalein complexone 0.05 mmolJl and 8- 
hydroxyquinoline 3 mmol/1). Two standard solutions (2.0 and 3.0 mmol/l calcium 
chloride) are used for the calibration of the instrument. The absorbance of the sample- 
reagent mixture is calculated automatically as the difference between the measurement at 
570 and at 600 nm. Samples (100 µl of rat plasma or 1 ml of sheep plasma which were 
pre-mixed with a vortex mixer prior to use) were dispensed into the appropriate sized 
sample cups which were pre-loaded in sequence into cup holders. Once the cup holders 
were loaded into the instrment, the analysis was fully automated and a printout of the 
measured calcium concentrations (mmol/l) was obtained. 
Basal plasma calcium concentrations in rats and sheep ranged between 1.37-2.35 mmol/l 
and 2.2-2.6 mmol/l, respectively. 
2.6 Calculation of results following glucose. insulin or calcium 
analysis 
2.6.1 Calculation of results following glucose analysis 
For each animal blood or plasma glucose concentrations were expressed as percentages 
of the basal glucose concentration (referred to as blood or plasma glucose concentrations 
(% of basal)), thus taking into account variation in basal values between animals. The 
basal glucose concentration (mmol/1) for each animal was calculated as the mean of the 
two pre-dose values and represented a glucose concentration of 100 %. For each 
formulation group, the mean blood glucose concentration (% of basal) was calculated, 
together with the standard deviations (SD), for each time point. The mean glucose 
concentration (% of basal) versus time curves were plotted for each formulation group. 
For each animal, the minimum blood or plasma glucose concentration (% of basal), Cmin 
and the time taken to reach the minimum concentration, Tmin, was determined and mean 
values of Cmin and Tmin, with SD, were calculated for each formulation group. In some 
instances, the mean values of Cmin with SD were plotted in the form of a column graph 
for each formulation group. To show more clearly correlations between formulation 
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factors such as osmolality, chitosan concentration or transient effect with absorption 
enhancing efficacy, the decrease in % glucose concentration was also calculated for 
individual animals by subtracting the value of Cmin from the basal concentration (100%) 
and mean values calculated, with SD, for each formulation group. These were plotted 
against the formulation variables (refer to Chapters 4 and 7). 
The area under the blood or plasma glucose concentration (% of basal) versus time curve 
(AUC) was determined for each animal, from 0-240 minutes (AUCO-240) using a 
trapezoidal method and a Microsoft Excel programme on a Macintosh computer. For the 
purpose of determining the AUC, blood glucose concentrations above the basal 
concentration were taken as 100 %. The AUCO-240 was subtracted from the total area to 
obtain the area over the curve (AOC). Mean values of AOC, with SD, were calculated 
for each formulation group. The AOC value, representing the total effect of the dose on 
blood glucose concentrations, gave an indication of the efficacy of the formulation for 
nasal insulin delivery. In some instances, the mean values of AOC, with SD, were 
plotted in the form of a column graph for each formulation group. 
In selected studies, an indirect estimate of the rate of insulin absorption was obtained by 
calculating the rate of reduction of glucose concentrations which was obtained from the 
slope of a plot of glucose concentration versus time over the first 30-60 minutes of the 
study. The slope of the plot was determined by linear regression of the data using a 
Cricket Graph programme on a macintosh computer. Some anomalous data points were 
omitted to improve the curve fit. The correlation coefficient, R2, for all curves was above 
0.9. 
In some instances, an estimate of insulin absorption (%) was obtained from the glucose 
data by calculation of values of pharmacological availability as shown below (Li and 
Mitra, 1994). This calculation assumed that insulin absorption, i. e. elevation in insulin 
concentrations, correlated with decreases in glucose concentrations. It was also assumed 
that the subcutaneous injection of insulin had not saturated the glucose lowering 
response. It must be pointed out that values of pharmacological availability should be 
used and quoted with caution. 
Pharmacological availability (%) = AOC(intranasal) x dose(subcutaneous) x 100 
AOC(subcutaneous) x dose(intranasal) 
For calculation purposes, the mean value of AOC(subcutaneous) was used. 
2.6.2 
.1 
Calculation of results following insulin analysis 
For each animal plasma insulin concentrations were determined as mU/l. For each 
formulation group, the mean plasma insulin concentrations were calculated with SD at 
each time point. For individual sheep in each group the maximum plasma insulin 
concentrations (Cmax) and the times at which Cmax occurred (Tm ) were noted and the 
mean values with SD calculated. For each animal the AUCa240 was determined by the 
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trapezoidal method, as above, and the mean values of AUC with SD calculated for each 
formulation group. For each individual animal, the background (basal) plasma insulin 
concentrations, calculated as an average of the concentrations at 
-15 and -5 minutes, was 
subtracted from all subsequent concentrations prior to determining the AUC. Any 
negative value was assumed as zero. In selected studies, an estimate of the rate of insulin 
absorption was obtained by calculating the rate of increase of insulin concentrations 
which was obtained from the slope of a plot of natural log of insulin concentration versus 
time typically over the first 5-15 minutes of the study. The slope of the plot was 
determined by linear regression of the data. Anomalous data points were omitted to 
improve the curve fit. The correlation coefficient, R2, for all curves was above 0.9. 
The bioavailability of insulin from each formulation was calculated relative to the 
subcutaneous dose as given below. 
Relative bioavailability (%) = AUC (intranasal) x dose (subcutaneous) x 100 
AUC (subcutaneous) x dose (intranasal) 
Values of bioavailability were calculated for individual sheep in each nasal formulation 
group prior to determining mean values (± SD). The mean value of AUC following 
subcutaneous administration was used for calculation purposes 
2.6.3 Calculation of results following calcium analysis 
Values of mean plasma calcium concentration (% of basal), Cmin" Tmin and AUCa600 
were determined according to the method used to calculate results following glucose 
analysis (Section 2.6.1). Mean plasma calcium concentration (% of basal) versus time 
curves and mean values of Cmin and AOC (± SD) were plotted for each formulation 
group. In some instances an estimate of salmon calcitonin (S-CT) absorption was 
obtained from the calcium data by calculation of values of pharmacological availability as 
shown below. This calculation assumed that S-CT absorption, i. e. elevation in S-CT 
concentrations, correlated with decreases in glucose concentrations and that the calcium 
lowering response following dose administration was not saturated. 
Pharmacological availability(%) = AOC(intranasal) x dose(intramuscular) x 100 
AOC(intramuscular) x dose(intranasal) 
For calculation purposes, the mean values of AOC(intramuscular) was used. 
2.6.4 Statistical analysis of glucose, calcium or insulin data 
Statistical analysis of glucose (values of Cmin, Tmin, AOC and rates of reduction of 
glucose concentrations) calcium (values of Cmin, Tmin, AOC) and insulin (values of 
Cmax, Tmax, AUC and rates of increase of insulin concentrations) data was performed to 
determine significant differences between the various formulation groups tested. For 
each of the parameters tested, significant differences were evaluated by comparing the 
mean values in each formulation group. A one-way analysis of variance (one-way 
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ANOVA) was the statistical test of choice when comparing the mean data from three or 
more formulation groups. When comparison was made between the mean values from 
only two formulation groups, an unpaired Student's t-test was used. Statistics were 
performed with an Instat 2.03 programme on a Macintosh computer. A brief review of 
the ANOVAand the unpaired Student's t-test is given below. Reference should be made 
to Linton and Gallo (1975) and Bolton (1995) for mathematical details of the statistical 
tests. 
The one-way ANOVA can be used to evaluate the significance between the mean values 
of three or more groups. The ANOVA makes the assumptions that the groups are 
randomly sampled from larger populations having a normal (Gaussian) distribution, that 
groups are independent of each other and that the standard deviations of the populations 
are equal. The ANOVA compares the variability between groups with the variability 
within groups by testing the null hypothesis that the means of the groups are equal. If the 
null hypothesis is rejected then the means of at least two of the groups are not equal (i. e. 
are significantly different). The statistic used to test the null hypothesis in the ANOVA is 
the F value which is a ratio of the variation between groups to that within the group. 
Calculated values of the F statistic are compared to tabulated values at a certain probability 
or P level. All P values were evaluated at a 95% confidence interval, i. e. for samples 
randomly selected from larger populations there is a 95% certainty that the true population 
means lies within the 95% confidence interval. At this level there is a 5% chance of 
randomly obtaining sample means which are significantly different from the population 
mean. Thus, the 5% value is the probability of mistakenly rejecting the null hypothesis. 
The Instat programme automatically calculates the F values and reports the P values. At a 
95% confidence interval, results were interpreted as statistically significance if (P<0.05) 
and not significant if (P>0.05). Lower values of P indicate greater significance. The 
Instat programme interpreted a value of (P<0.01) as `very significant' and a value of 
(P<0.001) as `extremely significant'. 
Rejection of the null hypothesis in the ANOVA indicates that there is significant difference 
between the means of the groups under consideration. However, it does not identify the 
source of the significant differences. Thus, if there were significant differences in the 
ANOVA (P<O. 05), a Tukey-Kramer multiple comparisons test (post-test) was performed 
following the ANOVA to identify significant differences between the individual groups 
tested. In this test the probability of rejecting a true null hypothesis (i. e. the significant 
differences observed are really due to chance) is low (referred to as a Type I error). The 
Tukey-Kramer multiple comparisons test compares the mean values of two groups at a 
time (similar to the student's t-test) and identifies the `q' statistic. The Tukey-Kramer 
multiple comparisons test was pre-selected to be performed automatically by the Instat 
programme if (P<0.05) in the ANOVA test. Calculated values of q were compared to 
tabulated values at a 95% confidence interval. Thus, there was significant difference 
between groups if (P<0.05). 
When there were only two study groups, statistical comparison was made using an 
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unpaired student's t-test. The unpaired student's t-test compares the mean values of two 
data groups with the null hypothesis that the means of the two columns are equal. The t 
statistic was calculated and compared to tabulated values at a 95% confidence interval. 
Thus, P values obtained were significant if (P<0.05). The use of the t-test to compare 
mean values from two groups of data is the most elementary of statistical comparisons. 
If multiple t-tests are performed, i. e. there are more than two data groups requiring 
statistical comparison, the risk of falsely rejecting the null hypothesis is increased since 
the 5% chance of falsely rejecting the null hypothesis (at a 5% significance level) in each 
t-test is multiplied depending on the number of comparisons made. Hence for multiple 
comparisons the ANOVA should be used. 
In each statistical test, either the raw data or mean data with standard deviation (SD) was 
entered in the Instat programme and results calculated automatically. 
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CHAPTER 3 
PRELIMINARY INVESTIGATIONS OF THE EFFICACY OF CHITOSAN 
AND VARIOUS OTHER COMPOUNDS IN ENHANCING THE 
INTRANASAL ABSORPTION OF INSULIN IN THE RAT MODEL 
31 General introduction 
In this chapter the preliminary investigations of the efficacy of chitosan and various other 
compounds in enhancing the intranasal absorption of insulin in the rat model are reported. 
An initial study investigated the effect of a low viscosity glutamate salt of chitosan 
(LVCSN) at two concentrations (0.1 % and 0.5%) and at two values of pH (-4 and 
- 
7) 
on the nasal absorption of insulin. This study was apparently the first ever study 
performed to investigate the nasal absorption of chitosan. As a control an insulin solution 
(pH 
- 
7) without absorption enhancers was administered nasally. In a second study, the 
efficacy of medium viscosity chitosan glutamate (MVCSN) was compared to that of 
various other compounds which had been shown in the literature to promote peptide drug 
absorption. The compounds investigated were: a bile salt, glycodeoxyxholate (GDC); a 
surfactant, polyoxyethylene-9-lauryl ether (Laureth-9); and a lysophospholipid, 
lysophosphatidylcholine (LPC). As controls, buffer solution and an insulin control 
solution were administered nasally. For reference, a subcutaneous dose of insulin was 
administered. 
In the absorption studies, formulations were administered intranasally or subcutaneously 
to rats. Blood samples were collected pre- and post administration of the insulin 
formulations and blood glucose concentrations were measured. Insulin absorption was 
assessed, indirectly, from the decrease in blood glucose concentrations following insulin 
dose administration. 
The studies are reported in the following Sections: 
3.2 Effect of low viscosity chitosan, at pH ~4 or pH ~ 7, on the intranasal 
absorption of insulin in the rat 
3.3 Efficacy of medium viscosity chitosan and various other compounds in 
enhancing the intranasal absorption of insulin in the rat 
Materials and methods used were as described in Chapter 2/ Appendix 1. Additional 
details are given in the relevant sections. 
3.2 Effect of low viscosity chitosan. at pH 
-4 or pH - 7. on 
- 
the intranasal absorption of insulin in the rat 
3.2.1 Aims and objectives 
In a preliminary investigation in an anaesthetised rat model, the effect of a water soluble 
low viscosity grade of chitosan glutamate (LVCSN) on the nasal absorption of insulin 
from liquid formulations was investigated. Insulin doses were administered nasally to 
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rats at 8 IU/kg. LVCSN was evaluated in liquid formulations at two concentrations; 
0.1% and 0.5% w/v, expressed as the concentration of chitosan glutamate salt, and at 
two values of pH: pH 
-4 or pH - 7. At pH -4, the insulin and LVCSN were in 
solution. However, at pH 
- 
7, a suspension was formed (refer to Section 3.2.3). As a 
control, a nasal insulin solution without LVCSN, at pH - 7, was administered. 
3.2.2 Outline of study 
32.2.1 Materials 
Insulin (Semi-synthetic human sodium insulin, specific activity of pure insulin 28 
IU/mg), Nordisk, Gentofte, Denmark. Using spectrophotometry, the purity of the 
material was determined to be 86.5%. Thus, the specific activity of the insulin was 
equivalent to 24.22 IU/mg and this value was used for all subsequent calculations. 
Low viscosity chitosan glutamate (LVCSN), Pronova Biopolymer A/S, Drammen, 
Norway (refer to Table 2.1). 
All other reagents were of analytical grade. 
3.2.2.2 Preparation of insulin formulations 
Insulin formulations were prepared freshly on the morning of each study day. Each 
formulation contained 80 IU/ml insulin (sufficient material to administer a dose of 8 
IU/kg insulin in a volume of 0.1 ml/kg). The formulations containing chitosan contained 
either 0.1 % (1 mg/ml) or 0.5 % (5 mg/ml) LVCSN, expressed as the concentration of 
chitosan glutamate salt. The formulations are listed below. Each formulation was 
prepared in 14.65 mM phosphate buffer of pH 7.4. Formulations prepared at pH -7 
were prepared directly in phosphate buffer. To the formulations at pH -- 4 was added 
HCI, during formulation preparation. Suspensions of insulin / LVCSN were obtained at 
pH 
-7 whereas at pH -4 the insulin and LVCSN were in solution. Each formulation 
was vortex mixed immediately prior to nasal administration to rats. 
Table 3.1. Outline composition of formulations 
Formulation No. Outline composition 
1 Solution: 80 IU/ml insulin, pH-7 (pH 7.4) (control solution) 
2 Suspension: 80 IU/ml insulin with 0.1% LVCSN, pH-7 (pH 7.1) 
3 Suspension: 80 IU/ml insulin with 0.5% LVCSN, pH--7 (pH 6.6) 
4 Solution: 80 IU/nil insulin with 0.1% LVCSN, pH-4 (pH 3.6) d 
5 Solution: 80 IU/ml insulin with 0.5% LVCSN, pH-4 (pH 4.4) 777 
* Concentration of LVCSN expressed as the concentration of chitosan glutamate 
3.2.2.3 Absorption study in the rat model 
Each rat was dosed with 8 IU/kg insulin at a volume of 0.1 ml/kg. A summary of the 
dose groups is given in Table 3.2. In this study there was a slight deviation from the 
times of blood sample collection given in Chapter 2 (additional samples at 15 and 40 
minutes, omitted samples at 30 and 45 minutes). Values of Cmin, Tmin and AOC were 
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not determined in this study since only two rats survived for the full duration of the study 
after administration of an insulin solution containing 0.1 % LVCSN at pH 
-4 and all rats 
dosed with insulin solution containing 0.5% LVCSN at pH 
-4 died prematurely 
probably as a result of severe hypoglycaemia. Thus, meaningful comparison of the 
different dose groups was limited. 
3.2.3 Results and Discussion 
Results are given in Table 3.3 and Figure 3.1. In the study the reduction in blood 
glucose concentrations was used as an indirect assessment of insulin absorption. The 
control solution of insulin (pH 
-7) dosed at 8 IU/kg, resulted in substantial reductions in 
blood glucose concentrations in rats following nasal administration with mean blood 
glucose concentrations decreasing to approximately 48% of the basal concentration 60 
minutes after dose administration (Table 3.3, Figure 3.1). These results were in contrast 
to the results published by Chandler et al (1991b) who administered nasal doses of 8 
IU/kg insulin (from a solution prepared in pH 7.3 buffer) to male rats of a similar 
species, strain and weight as those used in this study. Chandler et al delivered a dose 
volume of 20 µl approximately 0.5 cm into the right nostril of the rat and assessed 
absorption, indirectly from blood glucose concentrations, over a 60 minute period, 
finding that insulin was not absorbed. The reasons for the discrepancy in the results 
between the two studies is not known. However, in this study the dose was delivered 
0.8 cm into the nostril of the rat compared to about 0.5 cm in the study by Chandler et al. 
In the pioneering studies of Hirai et al. (1981 c) the nasal administration of a control 
solution of insulin (10 U/kg) was shown to lower blood glucose concentrations to less 
than 95% of basal values within 1 hour of dosing with maximum hypoglycaemia of about 
90% at 2 hours. Glucose concentrations did not return to basal values until 3-4 hours 
after dose administration. 
Based on the dimensions of cross sections of casts of the rat nasal cavity reported by 
Schreider (1986), the length of the nasal cavity of a 250g rat was 2.3 cm of which the 
external nares occupied the anterior 0.5 cm. Thus, it is possible that in the study by 
Chandler et al (1991b), the nasal dose was delivered to the posterior region of the 
external nares compared to dose delivery to the maxilloturbinate and nasoturbinate 
regions of the nasal cavity in this study. Lower absorption of compounds would be 
expected from the external nares since the epithelium is likely to be stratified squamous 
which may in-part be keratinised and will thus present a more robust barrier to absorption 
than the respiratory epithelium in the nasal turbinate regions. Also, the mucosa of the 
nares will be less vascular than that of the the respiratory region. 
Nasal administration of a suspension of insulin (8 IU/kg) with 0.5% LVCSN (pH - 7) or 
solutions of insulin (8 IU/kg) with 0.1 % or 0.5% LVCSN at pH 4, resulted in decreases 
in blood glucose concentrations which were more pronounced than those resulting from 
the insulin control solution (Table 3.3, Figure 3.1). However, the suspension of insulin 
with 0.1 % LVCSN at pH 77 appeared to be less effective at promoting insulin 
absorption than the control insulin solution. The solution containing 0.5% LVCSN at pH 
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-4 was the most effective formulation and its administration resulted in the premature 
death of all animals in the group probably due to severe hypoglycaemia. At 60 minutes 
following dose administration the mean blood glucose concentration had dropped to 
about 16% of the basal concentration although at this time glucose concentrations were 
probably still continuing to decrease in three out of four animals in the group which died 
prior to collecting the 90 minute blood sample. The premature death of all animals in the 
group was preceded by twitching, muscle spasms, salivation and respiratory depression 
which indicate symtoms associated with severe hypoglycaemia. Of the other dose 
groups, decreases in mean blood glucose concentrations (% of basal concentration) were 
as follows: 61% (0.1% LVCSN suspension pH 
-7), 27% (0.5% LVCSN suspension 
pH 
-7), 44% (0.1% LVCSN suspension pH 
-4) compared to 48% for the control insulin 
solution (Table 3.3, Figure 3.1). 
In this preliminary study in rats, LVCSN enhanced the absorption of insulin. The effect 
of LVCSN was more pronounced at pH 
-4 than at pH -- 7. This was expected in view 
of the fact that at pH 4 the insulin and LVCSN were in solution whereas at pH 7 the 
insulin and chitosan were in the form of a course suspension due to the formation of a 
complex. Chitosan can adsorb proteins from aqueous solution and maximum adsorption 
is reported to occur at the isoelectric point of the protein (Roberts, 1992). Furthermore, 
at a given pH, the degree of adsorption will decrease with an increase in the ionic 
concentration of the medium. Errington (1993) investigated complex formation between 
insulin, having an isoelectric point of about 5.30 to 5.35 (The Merck Index, 1996), and 
medium viscosity chitosan glutamate (Seacure +210) at a pH of about 7. The complex 
was reported to be insoluble and consist of approximately 12 insulin molecules to every 
chitosan molecule. However, it was pointed out that this value represents an empirical 
average since the polydispersity of the chitosan sample, possible crosslinking and 
aggregation of complex particles will influence the values of the insulin: chitosan binding 
ratios obtained. The suspension was reported to become `clear to the naked eye' at a pH 
of about 4.8. Complex formation was attributed to the aggregation of chitosan and 
insulin due to the interaction of the negative carboxyl groups of insulin, at neutral or 
weakly acidic pH, and the positively charged amino groups of chitosan and insulin. At 
acid pH, the amino groups of chitosan and insulin will be strongly charged. However, 
the charge of the carboxyl groups will tend to diminish as pH is lowered which will 
reduce aggregation. Electrostatic repulsion between the positively charged amino groups 
of insulin and chitosan will also prevent aggregation. The amount of insulin which is 
available for absorption will be reduced by the formation of an insoluble complex which 
probably accounted for the reduced insulin absorption observed following the nasal 
administration of these formulations to rats. Furthermore, the absorption enhancing 
properties of chitosan are likely to be affected by complex formation since this will 
decrease the amount of chitosan in solution and will dramatically influence the viscosity 
of the formulation. Since there is a fixed binding ratio between insulin and chitosan, then 
increasing the formulation concentration of either insulin or chitosan would be expected 
to improve nasal absorption since this should increase the concentrations of the respective 
component which is non-complexed. 
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The concentration of chitosan influenced the absorption enhancing efficacy and 
formulations containing 0.5% chitosan (as glutamate salt) either as solutions or 
suspensions, were more effective than those containing 0.1 % LVCSN. In view of the 
unexpected absorption of insulin from the control insulin solution and to fully evaluate 
the absorption enhancing efficacy of the chitosan formulations it was decided that a lower 
dose of insulin (4 IU/kg) would be used in subsequent nasal absorption studies in rats. 
Based on the results of a preliminary nasal absorption study in sheep (refer to Chapter 6), 
showing that medium viscosity chitosan glutamate (MVCSN) was more effective than 
low viscosity chitosan glutamate (LVCSN) in promoting the intranasal absorption of 
insulin, it was decided to focus absorption studies in the rat on the evaluation of 
MVCSN. 
Table 3.2. Summary of formulations and dose groups in the study to investigate the 
effect of LVCSN at pH 
-4 or pH -7 on the intranasal absorption of insulin in rats 
Formulation or Group No. Insulin 
(IU/kg) 
LVCSN 
(mg/kg) 
Dose volume 
(ml/k8) 
1. Insulin control solution 8.0 
- 
0.1 
2. Insulin + 0.1% LVCSN pH-7 (suspension) 8.0 0.1 0.1 
3. Insulin + 0.5% LVCSN pH-7 (suspension) 8.0 0.5 0.1 
4. Insulin + 0.1% LVCSN pH-4 (solution) 8.0 0.1 0.1 
15. Insulin + 0.5% LVCSN pH-4 (solution) 8.0 0.5 0.1 
* Dose of LVCSN expressed as the dose of chitosan glutamate. 
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Table 3.3. Summary of mean blood glucose concentrations following the intranasal 
administration of 8 IU/kg insulin with or without LVCSN at pH -4 or pH -7 In rats 
Mean ± SD (n-3-4) blood glucose concentration (% of basal) 
Time before or 
after dosing (min) 
Insulin control 
(pH 
-7) 
SD 
Insulin/ 0.1 % 
LVCSN (pH 
-7) 
SD 
Insulin/0.5% 
LVCSN (pH 
-7) 
SD 
Insulin / 0.1 % 
LVCSN (pH 
-4) 
SD 
Insulin / 0.5% 
LVCSN (pH 
-4) 
SD 
-10 100.0 0.00 100.0 0.00 100.0 0.00 100.0 100 
0.00 
-5 100.0 0.00 100.0 0.00 100.0 0.00 100.0 
100 0.00 
5 94.5 3.85 102.0 3.27 100.2 3.06 100.5 95.8 8.49 
10 91.4 5.50 94.3 5.17 91.8 5.13 96.1 85.6 7.79 
15 64.6 1.27 86.4 6.15 71.6 16.31 76.5 65.4 13.41 
20 51.8 7.15 77.6 10.60 57.3 15.82 63.8 45.6 14.75 
40 48.6 13.99 67.2 15.56 31.4 3.84 44.1 20.5 10.67 
60 48.2 15.45 64.6 8.02 27.1 7.14 44.2 16.1 11.41 
90 58.3 13.46 61.1 12.96 34.7 14.28 39.9 33.7 
120 62.8 20.05 72.0 24.08 62.0 8.87 43.2 " 
180 79.2 30.74 99.1 31.46 78.0 82.7 
240 79.6 21.43 115.0 32.29 86.1 85.3 " 
* All animals in this formulation group died prematurely 
Figure 3.1. Blood glucose concentration versus time profiles following the 
intranasal administration of 8 IU/kg insulin with or without LVCSN at pH -4 or pH 
-7 in rats 
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-Q- Insulin control solution pH "7 ---0- Insulin + 0.1% LVCSN pH -4 
R Insulin + 0.1% LVCSN pH 
-7 .... l&.... Insulin + 0.5% LVCSN pH -4 
-0-- Insulin + 0.5% LVCSN pH 
-7 
3.3 Efficacy of chitosan and various other compounds in 
enhancing the intranasal absorption of insulin in the rat 
3.3.1 Aims and objectives 
The absorption enhancing efficacy of medium viscosity chitosan glutamate (MVCSN) 
was compared to that of various other compounds which had been shown in the literature 
to promote peptide drug absorption. The compounds investigated were: a bile salt; 
glycodeoxyxholate (GDC), a surfactant; polyoxyethylene-9-lauryl ether (Laureth-9) and a 
lysophospholipid; lysophosphatidylcholine (LPC). As controls, buffer solution and an 
insulin control solution were administered nasally. For reference, a subcutaneous dose 
of insulin was administered. 
3.3.2 Study outline 
3.3 
. 
2.1 Materials 
Insulin (Semi-synthetic human sodium insulin, specific activity of pure insulin 28 
IU/mg), Nordisk, Gentofte, Denmark. Using spectrophotometry the purity of the 
material was determined to be 78%. Thus, the specific activity of the insulin was 
equivalent to 21.84 IU/mg and this value was used for all subsequent calculations. 
Medium viscosity chitosan glutamate (MVCSN), Pronova Biopolymer A/S, Drammen, 
Norway (refer to Table 2.1). 
Glycodeoxycholate, sodium salt (GDC, No. G-3258), Polyoxyethylene-9-lauryl ether 
(Laureth-9, No. P-9641) and Lysophosphatidylcholine (LPC, No. L-4219) from Sigma 
Chemical Company Limited, Poole, Dorset, UK. 
3.3.2.2 Preparation of solution formulations 
Solution formulations were prepared for nasal (Formulations 1-6) and subcutaneous 
(Formulation 7) administration to rats as outlined in Table 3.4. In each of the nasal 
formulations, with the exception of Formulation 1 which did not contain insulin (buffer 
solution used), the insulin concentration was 40 IU/ml (sufficient to administer a dose of 
4 IU/kg insulin in a dose volume of 0.1 ml/kg). The subcutaneous formulation contained 
4 IU/ml insulin (sufficient to administer a dose of 1 IU/kg insulin in a dose volume of 
0.25 ml/kg). With the exception of Formulation 3, the nasal formulations were prepared 
in 14.65 mM phosphate buffer of pH 7.3-7.4. Formulation 3 was prepared in 0.1125 % 
NaCl and adjusted to pH 4 during formulation preparation by the addition of 1M HC1. 
The subcutaneous solution (Formulation 7) was prepared in 0.9 % NaCl. Each 
formulation was freshly prepared on the day of the study. 
3-3 2.3 Absorption study in the rat model 
With the exception of rats dosed with buffer control solution, each rat was dosed nasally 
with 4 IU/kg insulin at a volume of 0.1 ml/kg. The subcutaneous dose was administered 
at 1 IU/kg at a volume of 0.25 mlkg. A summary of the dose groups is given in Table 
3.5. 
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Table 3.4. Outline composition of formulations 
Formulation No. Outline composition 
1 Buffer control solution, pH 7.4 
2 40 IU/ml insulin control solution, pH 7.4 
3 40 IU/ml insulin with 0.5% (5 mg/ml) MVCSN, pH 4 
4 40 IU/ml insulin with 0.9% (9 mg/ml) GDC, pH 7.4 
5 40 IU/ml insulin with 0.9% (9 mg/ml) Laureth-9, pH 7.4 
6 40 IU/mi insulin with 0.5% (5 mg/ml) LPC, pH 7.4 
7 4 IU/ml insulin subcutaneous reference solution 
* Concentration of MVCSN expressed as the concentration of chitosan glutamate 
3.3.3 Results and Discussion 
Results are given in Tables 3.6-3.7 and Figures 3.2-3.3. There was no reduction in 
mean blood glucose concentrations following the nasal administration of the control 
buffer solution (Table 3.6, Figure 3.2). Blood glucose concentrations were actually 
shown to increase over the experimental period which may be due to the affects on 
normal physiology by the use of anaesthetic, the surgical procedure or blood sample 
collection. In contrast, each of the nasal formulations containing insulin resulted in a 
reduction in mean blood glucose concentrations following administration although the 
extent and duration of the hypoglycaemia was variable between the formulation groups 
(Table 3.6, Figure 3.2). The control insulin solution resulted in a small decrease in blood 
glucose concentrations. The hypoglycaemia after dosing the insulin control solution 
tended to be of relatively short duration and glucose concentrations had returned to basal 
values between 45-60 minutes. The coadministration of insulin with either MVCSN or 
the absorption enhancers; GDC, Laureth-9 or LPC, resulted in more substantial and 
prolonged decreases in blood glucose concentrations compared to the insulin control 
solution. Following subcutaneous insulin administration (1 IU/kg), the hypoglycaemia 
was sustained and gluocse concentrations had not recovered to basal values by the end of 
the study period. Insulin was also apparently absorbed nasally at a faster rate following 
the administration of the MVCSN or enhancer formulations compared to the control 
insulin solution as indicated by the lower rates of decrease of glucose concentrations for 
the control solution (Table 3.7). However, after dosing the nasal formulations, the rates 
of reduction of glucose concentrations were marginally lower than those following 
subcutaneous dose administration. 
Lower reductions in glucose concentrations, indicated by higher values of Cmin, and 
AOC (hence pharmacological availability) were observed (Table 3.7, Figure 3.3) 
following the nasal administration of the buffer and insulin control solutions (values of 
Cmin 
- 
97% and 86% and AOC 53 and 1172 % glucose. min, respectively). Values of 
Cmin and AOC show that LPC was apparently the most effective nasal absorption 
enhancer in terms of the extent and duration of the hypoglycaemia which ensued 
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following dose administration. The magnitude of the hypoglycaemia (Cmin) following 
the nasal administration of 4 IU/kg insulin with LPC (- 32%) was similar to that of a 
subcutaneous dose of 1 IU/kg insulin (~ 29%) although the subcutaneous dose resulted 
in more prolonged hypoglycaemia as indicated by the greater value of AOC for the latter 
(8680 and 13379 % glucose. min, respectively). Formulations containing either chitosan 
or GDC were slightly less effective than the LPC formulation in lowering blood glucose 
concentrations. The chitosan and GDC formulations lowered blood glucose 
concentrations to a similar extent (values of Cmin 
- 
43 % and 45 %, respectively) although 
the hypoglycaemia was more sustained following the administration of the chitosan 
formulation (values of AOC 7386 and 4556 % glucose. min, respectively). Laureth-9 
was generally the least effective of the potential absorption enhancers in lowering blood 
glucose concentrations (Cmin 
- 
55%, AOC 3661 % glucose. min) which was surprising 
considering the severe damage caused to the rat nasal membrane by 1% Laureth-9 in the 
studies by Chandler et al (1991). 
Based on the mean values of Cmin, the effectiveness of the formulations in promoting 
insulin absorption were ranked in decreasing order of: LPC > chitosan > GDC > Laureth- 
9» insulin control > buffer control. However, there was no significant difference 
between the performance of the formulations which contained either LPC, chitosan, GDC 
or Laureth-9 when they were compared with a Tukey-Kramer multiple comparisons test 
although each of these formulations was significantly different from the control insulin 
solution Values of AOC followed a similar trend to the values of Cmin and were ranked 
in decreasing order: LPC > chitosan » GDC > Laureth-9» insulin control > buffer 
control. Values of AOC indicate the overall extent and duration of the hypoglycaemia and 
considering the inter-animal variations show that the performance of the LPC formulation 
was only marginally better than the chitosan formulation. However, despite similar 
values of Cmin, the chitosan formulation was apparently much more effective than the 
GDC formulation due to the sustained hypoglycaemia. Comparison of the values of 
AOC using a Tukey-Kramer multiple comparisons test, showed that there was no 
significant difference between the LPC and chitosan formulations but that each of these 
formulations was significantly different from the GDC, Laureth-9 and insulin control 
solutions. The coadministration of either MVCSN or LPC with insulin signifcantly 
increase values of Tmin compared to the control insulin formulation. For LPC, values of 
Tmin were also statistically different from the GDC and Laureth-9 dose groups. 
Assuming that after insulin dose administration the lowering of blood glucose 
concentrations correlates with the absorption of insulin (elevation in blood insulin 
concentrations), then calculation of values of pharmacological availability (refer to 
Section 2.6) provided an estimation of the % absorption of insulin administered nasally 
compared to the subcutaneous route. Estimated absorption was only about 2% for the 
insulin control solution compared to values of approximately 16%, 14%, 8% or 7% 
following coadministration of insulin with LPC, MVCSN, GDC or Laureth-9 
respectively. Thus, compared to the insulin control solution, nasal insulin absorption 
was increased 
-8-fold by coadministration with LPC, -7-fold with MVCSN, -4-fold 
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with GDC and 
-3-fold with Laureth-9. 
The results obtained following the nasal administration of a formulation of insulin (dosed 
at 4 IU/kg) with 0.5% medium viscosity chitosan glutamate are in agreement with those 
reported by Aspden (1996) in terms of values of Cmin although there are discrepancies 
between values of Tmin and AOC obtained in the respective studies. After nasally 
administering the formulations, Aspden reported mean values of Cmin, Tmin and AOC of 
approximately 37%, 120 minutes and 10670 % glucose. min, respectively compared to 
values of about 43%, 47 minutes and 7386 % glucose. min in this study. The values of 
Cmin are in close agreement. However, there is less agreement between values of Tmin 
and AOC. The reasons for this are unclear but, as in the studies of Chandler et al. 
(1991b) previously mentioned, Aspden administered the nasal dose solution only 0.5 cm 
into the rat nasal cavity compared to 0.8 cm in this study. Thus, it is possible that in the 
studies of Aspden, the viscous chitosan solution was delivered to the posterior of the 
external nares hence a longer time was required for chitosan to exert its effect on the more 
robust nasal tissue in this region. Alternatively, slow spread and drainage of the chitosan 
formulation in the rat nasal cavity from the external nares to the respiratory regions, from 
where absorption can readily occur, may also account for the higher value of Tmin 
observed by Aspden. This would also explain the higher values of AOC observed. 
Aspden (1996) also showed that there was very little nasal absorption of insulin from a 
control solution (Cmin 96% compared to 86% in this study) which again may be due to 
deposition and poor absorption of dose from the posterior of the external pares. 
The study demonstrated that insulin was not effectively absorbed via the nasal route 
without coadministration with absorption enhancing compounds. The compounds 
investigated ranked in decreasing order of absorption enhancing potency as follows: LPC 
> chitosan » GDC > Laureth-9. The results are extremely encouraging since MVCSN, 
reported to be non-damaging to the nasal mucosa (Ilium et al., 1994, Aspden, 1996) 
ranked almost as well as LPC and better than either GDC or Laureth-9 which have each 
been shown in various studies to damage the integrity of the nasal membrane (refer to 
Section 1.6.2). 
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Table 3.5. Summary of formulations and dose groups in the study to investigate the 
efficacy of chitosan and various other compounds In enhancing the intranasal 
absorption of insulin in rats 
Formulation or Group No. Insulin 
(IU/kg) 
Enhancer 
(mg/kg) 
Dose volume 
(ml/kg) 
1. Buffer control solution 
- - 
0.1 
2. Insulin control solution 4.0 
- 
0.1 
3. Insulin + 0.5% MVCSN 4.0 0.5 0.1 
4. Insulin + 0.9% GDC 4.0 0.9 0.1 
5. Insulin + 0.9% Laureth-9 4.0 0.9 0.1 
6. Insulin + 0.5% LPC 4.0 0.5 0.1 
7. Subcutaneous insulin reference solution 1.0 
- 
0.25 
* Dose of MVCSN expressed as the dose of chitosan glutamate. 
Table 3.6. Summary of blood glucose concentrations following the intranasal±4 
IU/kg) or subcutaneous (1 IU/k2) administration of insulin with or without MVCSN 
or various other compounds in rats 
Time before Mean ± SD n=3- blood glucose concentration (% of basal 
or after 
dosing (min) 
buffer control 
SD 
Insulin control 
SD 
Insulin/M VCSN 
SD 
Insulin/GDC 
SD 
Insulin/Laureth-9 
SD 
Insulin/LPC 
SD 
Subcut. insulin 
SD 
-10 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 
0.00 100.0 0.00 
-5 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
100.0 0.00 100.0 0.00 
5 100.1 5.70 99.6 3.78 98.0 4.40 95.9 8.93 95.9 5.53 97.3 5.35 91.9 7.66 
10 103.7 5.59 95.0 5.69 87.4 4.32 75.0 7.30 75.9 5.73 66.3 7.70 67.2 11.33 
20 105.4 8.21 86.5 11.97 58.9 2.80 57.1 9.15 58.4 12.38 59.3 8.28 45.1 3.22 
30 108.8 17.32 91.1 17.64 47.5 6.34 49.2 11.66 57.7 20.20 50.8 4.05 44.3 10.97 
45 107.8 7.35 97.0 16.76 44.6 7.97 46.9 16.26 64.5 15.98 41.5 10.06 39.1 4.68 
60 111.2 8.28 100.2 16.05 47.7 9.13 55.5 15.26 71.2 11.98 34.3 6.11 33.2 4.00 
90 117.7 8.92 98.8 11.43 55.5 4.48 67.0 16.95 78.5 7.67 41.0 13.17 41.0 14.16 
120 119.8 14.03 107.7 15.89 64.0 4.85 93.1 18.10 85.8 6.22 53.2 10.30 33.3 7.25 
180 121.6 10.04 124.4 14.70 80.3 5.51 116.4 17.90 104.9 15.36 81.8 4.97 40.9 13.19 
240 129.5 4.85 117.6 29.55 102.3 8.38 139.1 21.39 133.1 8.53 102.2 7.42 63.0 8.33 
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Table 3.7. Summary of pharmacokinetic parameters determined from glucose data 
following the Intranasal (4 IU/kg) or subcutaneous (1 IU/k! ) administration of 
insulin with or without MVCSN or various other compounds In rats 
Mean ± SD 
Formulation or 
Group number 
No. rats 
in group 
Cmin 
(% glucose) 
Tmin 
(min) 
AOC 
(% glucose. min) 
Rate of decrease 
of glucose conc. 
(%/min) 
Pharmacological 
availability 
% 
1. Buffer control 3 96.5 t 3.09) 6 (t 5,2) 53 (t 65.2) 
2. Insulin control 5 85.9 (t 11.12) 20 f 7.2) 1172 t 1017.32) 0.44 t 0.350) 2.1 t 1.89) 
3. Insulin/ MVCSN 4 43.3 (t 7.46) 47 t 9.4) 7386 t 748.2) 1.58 t 0.134) 13.8 (t 1,37) 
4. Insulin / GDC 4 45.4 (t 14.59) 38 (t 8.7) 4556 (f 1800.3) 1.53 t 0.341) 8.5 (t 3.39) 
5. Insulin / Laureth-9 5 54.9 ± 17.66) 24 (± 0.0) 3661 (± 1601.7) 1.83 (± 0.707) 6.8 (± 3,04 
6. Insulin / LPC 4 31.8 t 6.18) 1 64 (t 18.9) 8680 t 837.1) 1 1.64 t 0.960 16.2 (± 1.59 
7. Subcut, insulin 3 28.9 (t 0.95) 110 t 45.8) 13379 (t 1396.0) 2.13 t 0.156) 100.0 
* Relative to subcutaneous 
One-way ANOVA 
Sig. dif, in values of Cmin, Tmin, AOC (P<0.001) and rate of decrease of glucose conc. (P<0.05) between the formulation groups. 
Tukey-Kramer Multiple Comparisons Test following ANOVA 
Cmin: sig. dif. between groups: lvs3, lvs4, lvs5, lvs6,2vs3,2vs4,2vs6 (P<0.001) and 2vs5 (P<0.01) 
Turin: sig. dif. between groups: lvs6,2vs6 (P<0.001), Ivs3,5vs6 (P<0.01) and Ivs4.2vs3.4vs6 (P<0.05) 
AOC: sig. dif. between groups: lvs3, lvs6,2vs3,2vs6,5vs6 (P<0.001), lvs4.2vs4,3vs5,4vs6 (P<0.01) and lvs5,3vs4 (P<0.05) 
Rate of decrease of glucose conc. : sig. dif. between groups: 2vs5 and 2vs6 (P<0.05). 
No sig. dif. (p>0.05) in values of Cmin, Tmin, AOC or rate of decrease of glucose conc. between other groups. 
Figure 3.2. Blood glucose concentrations versus time profiles following the 
intranasal (4 IU/kg) or subcutaneous (1 IU/kg) administration of insulin with or 
without MVCSN or various other compounds in rats 
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Figure 3.3. Values of pharmacokinetic parameters determined from glucose data 
following the intranasal (4 IU/kg) or subcutaneous (1 IU/ka) administration of 
insulin with or without MVCSN or various other compounds in rats 
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3.4 Conclusions 
The studies reported in this chapter have demonstrated that a relatively high dose of 
insulin (8 IU/kg) was substantially absorbed nasally in the anaesthetised rat model even 
in the absence of absorption promoting compounds although coadministration of a low 
viscosity chitosan glutamate (LVCSN) was shown to further improve nasal absorption. 
The efficacy of LVCSN was improved at acid pH and at higher concentrations. 
At a lower dose of insulin (4 IU/kg), insulin was not effectively absorbed via the nasal 
route without coadministration with absorption enhancing compounds. Medium 
viscosity chitosan glutamate (MVCSN) at 0.5% and at pH 4 was highly effective in 
enhancing insulin absorption ranking almost as well as LPC and better than either GDC 
or Laureth-9. A comparison of the performance of LVCSN and MVCSN is difficult 
since different concentrations of insulin were used in the respective studies. The results 
of the preliminary investigations of nasal delivery systems based on chitosan are 
encouraging in view of the reported low toxicity (Ilium et al., 1994, Aspden, 1996) of 
chitosan and thus it was concluded that chitosan would be further evaluated as an 
enhancer for nasal delivery. 
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buffer control Insulin control +MVCSN +GDC + Laureth-9 + LPC subcutaneous 
buffer control Insulin control + MVCSN + GDC + Laureth-9 + LPC subcutaneous 
CHAPTER 4 
INVESTIGATION OF FACTORS INFLUENCING THE NASAL 
ABSORPTION ENHANCING EFFICACY OF CHITOSAN IN THE RAT 
4.1 General Introduction 
In preliminary investigations, medium viscosity chitosan glutamate (MVCSN) was 
shown to effectively enhance the intranasal absorption of insulin in the anaesthetised rat 
model. In this chapter, investigations of a number of formulation factors which may 
influence the absorption enhancing efficacy of chitosan are reported along with additional 
studies which were performed to further elucidate the potential use of chitosan in nasal 
delivery systems. 
The tonicity of nasal formulations is an important consideration since this may influence 
the influx or efflux of water in the nasal cavity. Water transport through the numerous 
glands in the nasal cavity has been reported to influence nasal absorption through solvent 
drag (Kotani et al., 1983). Morimoto et al. (1985) reported that water absorption from a 
gel base applied nasally could improved nasal drug absorption through intracellular 
channels. Tonicity will also influence the potential irritant action of nasal formulations 
and to prevent or limit nasal irritancy formulations should be isotonic to physiological 
fluids. The tonicity of drug formulations has been reported to influence drug absorption 
(Ohwaki et al, 1987). Furthermore, in formulations incorporating MVCSN, ionic 
concentration will influence the conformation of chitosan in solution and hence the 
formulation viscosity. Pennington et al. (1988) suggested that the therapeutic efficacy of 
nasal preparations may be increased by increasing formulation viscosity since this will 
reduce the rate of clearance of the formulation from the nasal cavity. Thus, formulation 
viscosity may be an important factor for the absorption enhancing efficacy of chitosan. 
Thus, the effects of tonicity (adjusted using sodium chloride) on the nasal absorption of 
insulin in formulations with and without MVCSN was investigated. 
The effect of changing the concentration of chitosan in the nasal insulin formulation was 
also investigated. Chitosan concentration will influence both the viscosity (Filar and 
Wirick, 1977) and bioadhesive (Lehr et al., 1992) properties of the formulation as well as 
obviously determining the number of molecules of chitosan available to interact with the 
nasal mucosa. In Chapter 3, it was shown that the absorption enhancing efficacy of 
LVCSN was improved by increasing its concentration in a formulation with insulin from 
0.1%to0.5%. 
When developing nasal formulations containing absorption enhancers or excipients, it is a 
prerequisite that these compounds do not cause serious damage to the nasal mucosa or 
result in prolonged impairment of the normal physiology and function of the nasal cavity. 
Thus, the enhancer should have a transient effect in the nasal cavity following 
administration (Ilium et al., 1994). This is especially important for potential chronic 
nasal medication which may require once or multiple daily administrations. Many 
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compounds which have been demonstrated in the literature to enhance nasal peptide 
absorption have also been shown to cause severe damage to the nasal membrane which 
may also be the principal mode of action for these compounds. A study was performed 
to evaluate whether the effect of chitosan on nasal insulin absorption was transient which 
would provide a useful indication of the effect of chitosan on the nasal mucosal barrier. 
In previous studies reported in this project, low and medium viscosity grades of chitosan 
glutamate were tested. Since chitosan is commercially available in numerous grades and 
salt forms then investigation of the use of chitosan as a nasal absorption enhancer should 
focus on optimising the grade of chitosan employed. A study was performed to compare 
the absorption enhancing efficacy of four different grades of chitosan in the rat model. 
An important criteria for the selection of candidate nasal delivery systems is the 
reproducibility and predictability of intrasubject and intersubject drug absorption. 
Unreproducible and unpreditable nasal absorption are likely to prevent the application of 
the nasal delivery system on a commercial basis. Thus, a study was perfomed to 
investigate the inter-animal variations in nasal insulin absorption following nasal insulin/ 
MVCSN dose administration to different groups of rats on different study days. 
In the nasal absorption studies, the various formulations were administered intranasally 
to rats. Blood samples were collected pre- and post administration of the insulin 
formulations and blood glucose concentrations measured. Insulin absorption was 
assessed, indirectly, from the decrease in blood glucose concentrations following insulin 
dose administration. Materials and methods used were as described in Chapter 2/ 
Appendix 1. Additional details are given in the relevant sections. 
The studies are reported in the following sections: 
4.2. Effect of tonicity on intranasal insulin absorption of insulin from solution 
formulations with and without chitosan in rats 
4.3. Effect of different concentrations of chitosan on the intranasal absorption of 
insulin in rats 
4.4. Investigation of the transient effect of chitosan on the intranasal absorption of 
insulin in the rat 
4.5 Comparison of the efficacy of different grades of chitosan in enhancing the 
nasal absorption of insulin in the rat 
4.6 The reproducibility of insulin absorption from a formulation containing chitosan 
in the rat 
4.2 Effect of tonicity on intranasal insulin absorption from 
solution formulations with and without chitosan in rats 
4.2.1 Aims and objectives 
In studies in rats, the effect of osmolality on the intranasal absorption of insulin (4 IU/kg) 
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from solution formulations (pH 4.0) both with or without 0.5% w/v MVCSN was 
investigated. Sodium chloride (NaCl) was used to increase the osmolality of the insulin 
and insulin / MVCSN solutions. Nasal formulations were prepared for testing in rats 
containing various concentrations of NaCI (0.1125%, 0.225%, 0.45%, 0.9% and 
1.35%) and the osmolality of each formulation was measured using a cryoscopic 
osmometer prior to the study. 
4.2.2 Study outline 
4.2.2.1 Materials. 
Insulin (Semi-synthetic human sodium insulin, specific activity of pure insulin 28 
IU/mg), Novo-Nordisk, Gentofte, Denmark. Using spectrophotometry the purity of the 
material was determined to be 84.4%. Thus, the specific activity of the insulin was 
equivalent to 23.63 IU/mg and this value was used for all subsequent calculations. 
Medium viscosity chitosan glutamate (MVCSN), Pronova Biopolymer A/S, Drammen, 
Norway (refer to Table 2.1). 
4.2.2.2 Preparation of insulin formulations. 
Five nasal insulin-MVCSN solutions (Formulations 1-5) and five nasal insulin solutions 
(Formulations 6-10) were prepared for testing in rats. An outline composition of each of 
the formulations is given in Table 4.1. Formulations were prepared freshly on the 
morning of the study. Each formulation contained 40 IU/ml insulin and where 
appropriate 0.5%w/v (5 mg/ml) MVCSN. Formulations were prepared in aqueous media 
containing the appropriate concentration of sodium chloride (NaCl) as follows: 0.1125 %, 
0.225%, 0.45%, 0.9% and 1.35%. All formulations were adjusted to pH 4.0 during 
preparation using HCI. The osmolality of the final formulations was measured as an 
indication of the tonicity of the formulations and values are given in Table 4.1. 
Table 4.1. Outline composition of formulations 
Formulation No. Outline composition Osmolality (Osmol/kg) 
1 Insulin + MVCSN in 0.1125% NaCl, pH 4 0.070 
2 Insulin + MVCSN in 0.225% NaCl, pH 4 0.106 
3 Insulin + MVCSN in 0.45% NaCl, pH 4 0.183 
4 Insulin + MVCSN in 0.9% NaCl, pH 4 0.329 
5 Insulin + MVCSN in 1.35% NaCl, pH 4 0.467 
6 Insulin in 0.1125 % NaCl, pH 4 0.051 
7 Insulin in 0.225% NaCl, pH 4 0.088 
8 Insulin in 0.45% NaCl, pH 4 0.172 
9 Insulin in 0.9% NaCl, pH 4 0.335 
10 Insulin in 1.35% NaCl, pH 4 0.477 
* Concentration of MVCSN expressed as the concentration of chitosan glutamate 
4.2.2.3 Absorption study in the rat model 
Each rat was dosed with 4 IU/kg insulin in a volume of 0.1 ml/kg. From Formulations 
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1-5, MVCSN was dosed at 0.5 mg/kg expressed as the dose of chitosan glutamate. 
4.2.3 Results and Discussion 
The results are shown in Tables 4.2-4.4 and Figures 4.1-4.3). The results show that 
insulin was absorbed from each of the insulin / MVCSN and insulin solution 
formulations administered nasally to rats. As expected from previous studies, nasal 
insulin absorption was improved by coadministration with 0.5% MVCSN. Increasing 
the osmolality of the insulin solution formulations (without chitosan) (Formulations 6- 
10), over the range 0.051-0.477 osmol/kg, did not have an overall marked effect on the 
degree of insulin absorption (Tables 4.3-4.4, Figures 4.2-4.3). Mean blood glucose 
concentrations decreased to about 72-84% of basal values 30-90 minutes after dosing 
(Table 4.3, Figure 4.2). Values of the pharmacokinetic parameters determined from 
glucose data showed that decreases in blood glucose concentrations ranged from 
approximately 23-33%, values of Tmin from 42-90 minutes and values of AOC from 
746-3275 % gluocse. min (Table 4.4, Figure 4.3). The reason for the much lower value 
of AOC observed for Formulation 6 (insulin in 0.1125% NaCl) was not known. 
However, one of the three animals in this group died prematurely and hence an AOC 
value was not calculated for this animal. 
Following the administration of the insulin / MVCSN formulations (Formulations 1-5), 
increasing formulation osmolality over the range 0.070-0.329 osmol/kg (Formulations 1- 
4) had very little effect on the degree of absorption enhancement (Tables 4.2,4.4, 
Figures 4.1,4.3). For Formulations 1-4, mean blood glucose concentrations decreased 
to about 36-45% of basal values 45-60 after dose administration (Table 4.2, Figure 4.1). 
There was very little difference in pharmacokinetic values for Formulation Groups 1-4 
with decreases in blood glucose concentrations ranging from approximately 57-65%, 
values of Tmin from 47-60 minutes and values of AOC from 6668-7893 % glucose. min 
(Table 4.4, Figure 4.3). However, an insulin / MVCSN solution at 0.467 osmol/kg 
(Formulation 5) further improved nasal insulin absorption with mean blood glucose 
concentrations decreasing to about 20% of basal values at 60 mninutes. Following the 
nasal administration of Formulation 5, decreases in blood glucose concentrations and 
values of AOC were greater than those following administration of the other insulin / 
MVCSN formulations (approximately 19% and 12520 % gluocse. min, respectively). 
A one-way ANOVA (with a Tukey-Kramer multiple comparisons test) showed that there 
were significant differences in values of AOC between the insulin / MVCSN formulation 
groups and that the AOCs were significantly higher in animals dosed with Formulation 5 
compared to those dosed with Formulations 1,3 and 4 (Table 4.4). However, there were 
no significant differences in values of Cmin (and hence in the % decrease in glucose 
concentrations) between the insulin / MVCSN formulation groups. With the exception of 
animals dosed with Formulation 5, inter-animal variations in values of Cmin in each dose 
group tended to be high and probably accounted for the lack of significant differences. 
There were no statistically significant differences between the performance of the control 
insulin formulations (without chitosan) in terms of their pharmacokinetic parameters 
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(Table 4.4). 
Ohwaki et al (1987) reported that maximal absorption of the hormone secretin, 
administered nasally in rats, was observed at a sodium chloride solution molarity of 
0.462. This corresponds to a sodium chloride concentration of about 2.9% which will be 
hypertonic to physiological fluids. It was suggested that enhanced absorption was due to 
the interaction of sodium chloride with the nasal epithelium since microscopic 
examination of rat nasal mucosa exposed to 0.462 M sodium chloride showed shrinkage 
of the epithelial cells. However, structural changes in the rat nasal epithelium were not 
observed in tissue exposed to 0.924 M sorbitol, having almost the same osmolarity as 
0.462 M sodium chloride. The absorption of secretin was shown to decrease as the 
molar concentration of sorbitol increased. These observations were suggested to be due 
to the stronger action of the ionic species sodium chloride on the nasal epithelial cells than 
sorbitol. 
In this study, the maximum concentration of sodium chloride used was 1.35% which 
was less than half the concentration shown by Ohwaki et al (1987) to cause shrinkage of 
epithelial cells. Although a hypertonic medium containing 1.35% sodium choride may 
have some effect on the nasal epithelium, it was shown in this study that the structural 
integrity of the membrane was not breached since improved absorption of insulin alone 
was not observed following nasal administration of insulin in 1.35% sodium chloride. 
The marked improvement in insulin absorption following the administration of a 
formulation of insulin and MVCSN in 1.35% sodium chloride appears to be due to the 
combined effects of MVCSN and 1.35% sodium chloride on the structural integrity of the 
epithelial membrane. 
The viscosity of chitosan solutions is strongly influenced by the ionic concentration of the 
medium. The apparent viscosity of chitosan solutions has been shown to decrease 
dramatically with an increase in sodium chloride concentration (refer to Section 10.5). 
Although the viscosities of the chitosan formulations were not measured, based on the 
results presented in Section 10.5, it is likely that the formulation containing 0.1125% 
NaCl was marginally more viscous than the other formulations, yet this does not appear 
to have significantly influenced the degree of nasal absorption enhancement. 
Despite the apparent improved absorption of insulin by increasing the osmolality of the 
insulin / MVCSN formulation, this should not be considered as a feasible option for 
improving formulation efficacy. The nasal administration of strongly hyper- or 
hypotonic formulations are likely to cause irritation in the nasal cavity and may also cause 
cumulative damage to the nasal mucosa with chronic application. Furthermore, a 
hypertonic nasal formulation (adjusted with NaCl) was shown to improve the absorption 
enhancing efficacy of chitosan probably through a combined action on the nasal 
membrane. However, this potentially introduces an experimetal variable since the effect 
of NaCI on nasal absorption may not be consistent when other factors such as the 
concentration or grade of chitosan are altered. Thus, it was decided that in future nasal 
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absorption studies in the rat, formulations would be prepared in 0.9% NaCl. 
Table 4.2. Summary of mean blood glucose concentrations following the intranasal 
administration of insulin / MVCSN formulations of different tonicity in rats 
Mean ± SD n. 34blood glucose concentration % of basal) 
Time before or 
after dosing (min) 
0.1125% NaCI 
SD 
0.225% NaC1 
SD 
0.45% NaCl 
SD 
0.9% NaCI 
SD 
1.35% NaCI 
SD 
-10 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
-5 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
5 98.0 4.40 99.3 5.38 96.4 4.36 94.0 6.14 93.4 1.26 
10 87.4 4.32 85.8 10.32 86.2 3.04 84.0 6.27 86.7 4.57 
20 58.9 2.80 67.3 5.07 60.9 14.27 67.2 8.35 63.8 5.73 
30 47.5 6.34 55.7 12.81 44.6 13.49 51.5 18.83 44.6 10.07 
45 44.6 7.97 45.1 8.11 36.0 12.76 40.9 20.18 26.0 5.01 
60 47.7 9.13 40.8 9.05 40.2 13.16 40.6 19.10 19.9 3.06 
90 55.5 4.48 49.4 10.60 54.4 15.30 52.2 20.81 24.5 4.12 
120 64.0 4.85 58.1 11.17 64.9 14.59 69.5 14.12 37.0 3.56 
180 80.3 5.51 84.1 11.69 82.2 17.10 91.4 12.07 1 55.9 14.98 
240 102.3 8.38 90.2 18.45 111.5 18.62 118.7 12.23 1 77.5 13.94 
Table 4.3. Summary of 'mean blood glucose concentrations following the Intranasal 
administration of insulin formulations (without MVCSN) of different tonicity in 
rats 
Mean ± SD (n-3-5) blood glucose concentration (% of basal 
Time before or 
after dosing (min) 
0.1125% NaCI 
SD 
0.225% NaCl 
SD 
0.45% NaCI 
SD 
0.9% NaCl 
SD 
1.35% NaCl 
SD 
-10 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
100.0 0.00 
-5 100.0 0.00 100.0 0.00 100.0 0.00 100.0 
0.00 100.0 0.00 
5 97.0 5.12 87.9 5.42 91.9 7.27 100.5 6.34 94.1 5.45 
10 90.6 5.85 90.0 4.08 87.5 10.10 93.3 8.36 90.1 3.04 
20 85.4 8.33 92.1 4.31 85.4 13.74 86.9 9.91 83.0 10.03 
30 83.6 8.84 92.6 1.89 84.2 15.23 82.3 10.93 76.8 16.26 
45 85.0 18.81 90.6 6.13 92.2 14.66 77.8 13.79 75.9 17.43 
60 77.8 21.39 83.7 8.04 99.3 23.84 72.7 17.63 79.3 22.33 
90 82.3 21.07 74.1 8.07 103.1 31.43 71.9 21.87 78.4 20.09 
120 102.8 79.0 12.30 101.9 27.10 84.9 19.14 84.1 14.00 
180 125.3 103.5 20.07 96.8 5.82 110.8 28.49 109.5 25.53 
240 121.0 120.2 14.76 110.7 0.49 123.2 16.96 130.7 20.13 
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Table 4.4. Summary of pharmacokinetic parameters determined from glucose data 
following the intranasal administration of formulations of different tonicity 
containing insulin with and without MVCSN in rats 
Mean ± SID 
Formulation or 
Group number 
No. rats 
in group 
Cmin 
(% lucose) 
Decrease in 
% glucose conc. 
Tmin 
(min) 
AOC 
(% glucose. min 
1. Insulin / MVCSN / 0.1125% NaCI 4 43.3 (t 7.46) 56.7 (t 7.46) 47 (± 9 4) 7385.8 (t 748.23) 
2. Insulin / MVCSN / 0.225% NaCl 3 40.8 (t 9.08) 59.2 (t 9.08) 60 (t 0.0) 7892.7 (t 1788 00) 
3. Insulin / MVCSN / 0.45% NaCI 4 35.3 (t 13.13) 64.7 (t 13.13) 47 (t 9.4) 7622.5 t 2465.69) 
4. Insulin / MVCSN / 0.9% NaCI 4 38.7 (t 19.24) 61.3 (t 19.24) 54 (±7.2) 6667.7 (t 2789.52) 
5. Insulin / MVCSN / 1.35% NaCl 4 19.2 (t 2.25) 80.8 (t 2.25) 66 (t 16 6) 12520.0 t 1573.97) 
6. Insulin / 0.1125% NaCl 3 76.9 (t 20.53) 23.1 (t 20.53) 42 (t 16.1) 746.2 (24.96) 
7. Insulin / 0.225% NaCI 4 73.4 (±7.26) 26.6 (t 7.26) 90 (t 21.2) 2872.8 (t 1377.34) 
8. Insulin / 0.45% NaCI 4 79.2 (± 10.45) 20 9 (t 10 45) 43 (t 32.6) 1733.5 (t 823.86) 
9. Insulin/ 0.9% NaCI 5 67.4(±17.91) 32.6(±17.91) 64 (t 34.2) 3273.6 (t 1975.64) 
10. Insulin / 1.35% NaCI 5 70.6 (t 16.11) 29.4 (± 16.11) 49 (t 25.7) 3275.1 (t 2883.49) 
One-way ANOVA 
Formulation Groups 1-5: Sig. dif. (P<0.01) in values of AOC. No sig. dif. (P>0.05) in values of Cmin and Tmin. 
Formulation Groups 6-10: No sig. dif. (P>0.05) in values of Cmin, Tmin and AOC. 
Tukev-Kramer Multiple Comparison Test following ANOVA AOC (groups 1-5): Sig dif. between Groups 1 vs 5.3 vs 5 (P<0.05) and 4 vs 5 (P<0.01). 
No sig. dif. (P>0.05) between all other formulation groups. 
Fieure 4.1. Blood glucose versus time profiles following the intranasal 
administration of insulin / MVCSN formulations of different tonicity in rats 
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Figure 4.3. Selected pharmacokinetic parameters determined from glucose data 
following the intranasal administration of formulations of different tonicity 
containing insulin with and without MVCSN in rats 
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4.3 Effect of different concentrations of chitosan on the 
intranasal absorption of insulin in rats 
4.3.1 Aims and objectives 
Formulations for nasal administration should contain minimal concentrations of enhancer 
whilst retaining absorption enhancing efficacy so that possible irritant and toxicological 
effects or effects on the normal nasal physiology are prevented or at least limited. The 
aim of this study in rats was to investigate the effect of different concentrations of 
chitosan, ranging from 0 to 1.25%, on the intranasal absorption of insulin with a view to 
selecting a concentration of chitosan for further evaluation. 
4.3.2 Study outline 
4.3.2.1 Materials. 
Additional materials used were as given in Section 4.2. 
4.3.2.2 Preparation of insulin formulations. 
Solution formulations (Formulations 1-9) at pH 4.0 were prepared freshly on the 
morning of the study in 0.9% NaCI for nasal administration to rats. Each formulation 
contained 40 IU/ml insulin with different concentrations (% w/v) of MVCSN, expressed 
as the concentration of chitosan glutamate, as follows: 0% (Formulation 1), 0.1 % 
(Formulation 2), 0.2% (Formulation 3), 0.3% (Formulation 4), 0.4% (Formulation 5), 
0.5% (Formulation 6), 0.75% (Formulation 7), 1.0% (Formulation 8) and 1.25% 
(Formulation 9) (0,1.0,2.0,3.0,4.0,5.0,7.5,10.0 and 12.5 mg/ml, respectively). A 
summary of the formulations and dose groups is given in Table 4.5. 
4.3.2.3 Absorption study in the rat model 
Each rat was dosed with 4 IU/kg insulin in a volume of 0.1 ml/kg. The nasal doses of 
MVCSN are given in Table 4.5 
4.3.3 Results and Discussion 
The nasal absorption of insulin was apparently increased by increasing the formulation 
concentration of MVCSN (Table 4.6-4.7, Figures 4.3-4.4). However, the results 
showed that maximal insulin absorption was attained at a MVCSN concentration of 0.5 % 
(based on values of AOC) or 0.75% (based on values of Cmin or decrease in % glucose 
concentrations) (Table 4.7, Figure 4.4). Thus, maximal absorption enhancing efficacy 
was observed in the range 0.5-0.75% MVCSN and outside these concentrations there 
was a decrease in the degree of absorption enhancement attained. Mean blood glucose 
concentrations after administering insulin formulations containing 0,0.1,0.2,0.3,0.4, 
0.5,0.75,1.0 and 1.25 % MVCSN decreased to approximately 85%, 59%, 45%, 44%, 
40%, 34%, 53% and 57% of basal values, respectvely (20-120 minutes after dose 
administration) (Table 4.6, Figure 4.3). Pharmacokinetic parameters (Table 4.7, Figure 
4.4) showed that decreases in glucose concentrations after administration of the nasal 
insulin formulations ranged from about 33% with 0% MVCSN to a maximum of 70% 
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with 0.75% MVCSN. At concentrations above 0.75% MVCSN, decreases in glucose 
concentrations were gradually reduced reaching to about 45% at a concentrations of 
1.25% MVCSN. Values of Tmin ranged between 45-98 minutes although fluctuations in 
these values did not appear to follow a particular trend. Maximum values of AOC (- 
9251 % glucose-min), hence pharmacological availability (- 17%) were observed 
following the nasal administration of a formulation containing 0.5% MVCSN. As 
expected, minimum values of AOC (- 3274 % glucose. min) were observed after dosing 
the nasal control formulation (0% MVCSN). The lowest rate of decrease of glucose 
concentrations was observed after administering the nasal formulation containing 0.1 % 
MVCSN with a maximum rate at 0.5 % MVCSN. However, with the exception of the 
formulation containing 0.1 % MVCSN, there was little difference between the 
formulations tested. 
Statistical comparison of the dose groups using a one-way ANOVA showed that there 
were significant differences in values of Cmin and AOC but not in values Tmin or rate of 
decrease of glucose concentrations. The Tukey-Kramer multiple comparisons test 
following ANOVA showed that values of Cmin after dosing formulations containing 
0.2%, 0.5% and 0.75% MVCSN were significantly higher than values obtained after 
dosing a control solution (0% MVCSN). Values of AOC were shown to be significantly 
higher than those after administering the control solution. However, despite the apparent 
increased efficacy, in terms of values of Cmin or AOC, of formulations containing 0.5 % 
or 0.75% MVCSN, values obtained for these dose groups were not significantly 
different from those of the other formulation groups. Large inter-animal variations in the 
data probably accounted for the lack of significant differences between these formulation 
groups. 
The apparent increase in nasal absorption enhancing efficacy with increasing chitosan 
concentration may be attributed to a number of factors. Chitosan is a viscosity enhancing 
agent and hence, an increase in chitosan concentration will be accompanied by an 
increase in formulation viscosity (refer to Section 10.5) which may reduce the clearance 
of the formulation from the nasal cavity. Increasing the residence time of the formulation 
in the nasal cavity and hence increase in the contact time between the drug and the nasal 
mucosa may consequently enhance drug absorption (Pennington et al., 1988, Illum, 
1992). In the anaesthetised rat model, nasal mucociliary clearance mechanisms may be 
prevented or impaired (Mayor and Illum, 1994) and hence clearance of formulation from 
the nasal cavity by this route will probably not be as important as in conscious animals. 
However, spread and drainage of the formulation from the site of deposition in the nasal 
cavity, either posteriorly towards pharynx or anteriorly towards the nostrils may also 
decrease the residence time of the formulation in the main part of the nasal cavity where 
absorption is most likely to occur. The decrease in the efficacy of the formulation 
containing 1.0% and 1.25% MVCSN may be due to the viscosity characteristics of the 
formulation. Formulation viscosity increases with increase in chitosan concentration. 
The viscosity of the formulation may prevent or reduce the spread of the formulation 
from the site of deposition in the nasal cavity and hence reduce the surface area over 
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which contact between the formulation and the nasal cavity is made. Bioadhesive 
properties of chitosan (Lehr et al., 1992) may also contribute towards the absorption 
enhancing efficacy of chitosan. Interaction of the chitosan with the nasal mucosa, for 
example due to the interaction of the positively charged chitosan with the negatively 
charged surface of the nasal epithelium, will reduced the clearance of the formulation 
from the nasal cavity either by mucociliary clearance or by spread and subsequent 
drainage from the nasal cavity. 
Increase in chitosan concentration may increase the interaction of the formulation with the 
nasal membrane. The decreased effectiveness of the formulation containing 1% MVCSN 
may be due to inhibition of spread of the formulation in the nasal cavity reducing the 
surface area of the nasal mucosa over which the formulation is deposited. Furthermore, 
the release of insulin from relatively more viscous solutions may be slowed down which 
would also tend to reduce insulin absorption (Morimoto et al., 1985). Both the 
bioadhesive and viscosity enhancing properties of chitosan may increase the residence 
time of formulations in the nasal cavity although it is difficult to separate the importance 
of each of these properties. The direct action of chitosan on nasal epithelial tight 
junctions may be another factor leading to increased insulin absorption with increase in 
chitosan concentration (Arturrson et al., 1994). Thus, as chitosan concentration 
increases so too does the effect on tight junction. This could be in the degree of opening 
of the tight junctions or in the number of junctions opened or a combination of the two. 
Table 4.5. Summary of formulations and dose groups in the study to investigate the 
effect of MVCSN concentration on the intranasal absorption of insulin in the rat. 
Formulation or Group No. Insulin 
(IU/kg) 
MVCSN 
(mg/kg) 
Dose volume (ml/kg) 
1. Insulin + 0% MVCSN 4.0 0.0 0.1 
2. Insulin + 0.1% MVCSN 4.0 0.1 0.1 
3. Insulin + 0.2% MVCSN 4.0 0.2 0.1 
4. Insulin + 0.3% MVCSN 4.0 0.3 0.1 
5. Insulin + 0.4% MVCSN 4.0 0.4 0.1 
6. Insulin + 0.5% MVCSN 4.0 0.5 0.1 
7. Insulin + 0.75% MVCSN 4.0 0.75 0.1 
8. Insulin + 1.0% MVCSN 4.0 1.0 0.1 
8. Insulin + 1.25% MVCSN 4.0 1.25 0.1 
* Dose of MVCSN expressed as the dose of chitosan glutamate 
f 
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Table 4,6. Summary of mean blood glucose concentrations following the intranasal 
administration of insulin formulations containing different concentrations of 
MVCSN in rats 
Time before Mean ± SD n=3.3 blood locos. concentrodo (S of basal) 
or after 
dosin (min) 
0%MVCSN 
I SD 
0.1% MVCSN 
SD 
0.2% MVCSN 
SD 
0.3% MVCSN 
SD 
0.4% M VCSN 
SD 
0.3%M VCSN 
SD 
10.73% MVCS 
SD 
1.0% M VCSN 
SD 
1.23%MVCSN 
SD 
-10 100.0 0.00 100.0 0.00 1000 0.00 100.0 000 100.0, 1 0.00 100.0 0.00 100.0 0.00 100.0 000 100 0.00 
-3 1000 0.00 100.0 0.00 100.0 0.00 100.0 000 100.0 0.00 1000 0.00 1000 000 100.0 0.00 100 0.00 
5 93.1 6.34 93.7 10 01 96.8 1.64 99.6 2.43 101.8 3.13 97.6 3.63 996 3.80 946 3.96 96.7 4.33 
10 85.2 8.36 94.7 13.76 87.9 2.51 93.3 4.95 92.7 688 95.3 3.47 94.4 4.98 991 342 90.3 1027 
20 952 9.91 74.7 7.68 63.6 2.36 73.4 661 739 7.93 71.4 4.20 768 8.02 77.1 10.33 70.7 8.11 
30 85.2 10.93 70.2 6.52 53.9 9.53 59.0 10.80 62.1 12.77 55.7 8.84 59.2 10.50 66.1 13.83 64.6 9.2 
45 88.3 13.79 66.9 13.18 44.9 864 30.9 12.24 47.3 11.36 43.1 6.46 48.0 11.16 62.3 13.06 63.1 4.21 
60 995 17.63 61.4 1254 44.7 13.77 44.4 12.56 43.9 15.50 42.3 9.53 338 11.21 532 13.17 57.1 3 68 
90 101.6 21.87 58.7 13.20 31.0 16.74 53.1 14.85 49.7 21.64 39.3 9.86 341 407 33.0 11.96 60.2 4.99 
120 1148 1914 58.3 12.36 56.6 10.78 71.6 29.51 58,8 20.62 45.1 9.65 53.9 8.37 56.8 8 16 70 13 23 
180 160.7 28.49 72.9 8.56 912 24.21 98.3 23.51 80.9 8.78 74.3 15.32 75.2 1049 77.8 13.88 93.1 9.95 
240 150.8 16.96 87.9 9.74 1093 18 83 127.0 26.37 97.2 17.94 95.3 26.13 99.3 1704 1006 17.92 117.1 11.34 
Table 4.7. Summary of pharmacokinetic parameters determined from glucose data 
following the intranasal administration of insulin formulations containing different 
concentrations of MVCSN in rats 
Mean ± SD 
Formulation or 
Group number 
No. rats 
in group 
Cmin 
(% glucose) 
Decrease in 
glucose conc. 
(% lucose 
Tmin 
(min) 
AOC 
(% glucose. min) 
Rate of decrease 
of glucose conc. 
(%/min) 
Pharmacological 
availability 
(%) 
1.0% MVCSN 5 67.4 t 17.91) 32.6 17.91) 64 t 34.2 3274 ± 1975.6) 6.1 ± 3.69 
2.0.1 % MVCSN 4 53.9 (± 10.16) 46.2 (± 10.16) 98 (± 28.7) 7203 (± 1660.6) 1.12 (± 0.572) 13.3 ± 3.10 
3.0.2% MVCSN 4 40.7 (± 9.50) 59.4 (± 9.50) 60 t 21.2) 7505 t 2079.8) 1.72 (±0.542) 14.0 ±3.89 
4.0.3% MVCSN 4 43.6 (t 13.04) 56.4 t 13.04) 68 t 15.0 5753 t 2913.5) 1.40 (t 0.296) 10.8±5.44 
5.0.4% MVCSN 4 42.5 t 14.60) 57.5 t 14.60) 64 ± 18.87) 7610 t 2961.0) 1.37 f 0.222) 14.2 (± 5.53) 
6.0.5% MVCSN 4 37.0(±7.97) 63.0 (t 7.97) 73 t 15.5) 9251 t 1945.2) 1.87 (t 0.664) 17.3 ±3.63 
7.0.75% MVCSN 4 30.2 (± 4 64) 69.9 (t 4.64 71 t 14.4) 8805 t 1515.1) 1.46 (t 0.544) 16.5 ± 2.83 
8.1.0%MVCSN 3 47.6 (± 8.55) 52.4 (± 8.55 75 (± 26. 7179 ±1212.6 1.42 (± 0.944) 13.4 (± 2.2 
9.1.25% MVCSN 4 55.3 (± 2.26) 44.7 (± 2.26 45 (± 17.3 5383 t 840.7) 1.50 (± 0.464) 10.1(± 1.57 
Relative to subcutaneous 
One-way ANOVA 
Sig. dif. (P<0.01) in values of Cmin. No sig. dif. in values of Tmin and AOC. 
Tukey-Kramer Multiple Comparison Test following ANOVA 
Cmin: Sig. dif. between groups 1 vs 3,1 vs 6 (P<0.05) and 1 vs 7 (P<0.01). No sig dif (P>0.05) between all other groups. 
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Figure 4.5. Selected pharmacokinetic parameters determined from elucose data 
following the intranasal administration of insulin formulations containing different 
concentrations of MVCSN In rats 
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4.4 Investigation of the transient effect of chitosan on the 
intranasal absorption of insulin in the rat 
4.4.1 Aims and objectives 
Many compounds which have been demonstrated in the literature to enhance nasal 
peptide absorption have also been shown to have severe membrane damaging properties 
which may be the principal mode of action for these compounds. Clearly, severe damage 
to the nasal mucosa would be unacceptable in nasal delivery systems particularly for 
chronic application. The aim of this study was to evaluate whether chitosan had a 
transient effect on the nasal insulin absorption in rats. This would be a useful indication 
of any damaging effects to the nasal mucosa caused by chitosan and may also give a 
further clue to its mechanism of absorption enhancement. Chitosan has been reported to 
cause no histological damage to the rat nasal mucosa following exposure for 60 minutes 
(lllum et al., 1994). In the study, chitosan was administered to the nasal cavity of the rat 
and at certain fixed time intervals after chitosan administration, up to 60 minutes, the 
animal was dosed with a solution of insulin and absorption assessed. 
4.4.2 Study outline 
4,4.2 
,1 Materials. 
Additional materials used were as given in Section 4.2. 
4.4.2.2 Preparation of insulin and chitosan formulations. 
Solutions of 40 IU/ml insulin and 0.5% (5 mg/ml) MVCSN were prepared separately at 
pH 4 in 0.9% NaCI for nasal administration to rats. A summary of the formulation 
groups is given in Table 4.7. 
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4.4.2.3 Absorption study in the rat model 
The 0.5 % MVCSN solution was instilled into the nasal cavity of rats at 0.1 ml/kg, After 
a pre-determined time interval, a dose of 4 IU/kg insulin was administered into the same 
nostril (at 0.1 ml/kg from the 40 IU/kg solution) and insulin absorption assesssed. The 
time intervals between chitosan and insulin administrations were: 15,30,45 and 60 
minutes. The results were compared to previous results obtained following the nasal 
administration of a solution of 40 IU/kg insulin with 0.5% MVCSN (administered at 0.1 
ml/kg). The nasal dose of MVCSN was 0.5 mg/kg expressed as the dose of chitosan 
glutamate. 
4.4.3 Results and Discussion 
The results indicate that the effect of chitosan on the nasal absorption of insulin was 
transient. Following the nasal administration of insulin solution at 15,30,45 and 60 
minutes after MVCSN administration, mean blood glucose concentrations decreased to 
approximately 61%, 52%, 75% and 82% of basal values, respectively, compared to 
about 41 % when insulin and MVCSN were administered together (0 minutes) in the 
same formulation (Table 4.8, Figure 4.6). Values of the pharmacokinetic parameters 
showed that following the administration of insulin from 0 to 60 minutes post 
administration of MVCSN solution, values of % decrease in glucose concentrations and 
AOC were reduced from 63% to 22% and from 9251 to 2191 % glucose. min, 
respectively (Table 4.9, Figure 4.7). The values of AOC and decrease in glucose 
concentrations at 15 minutes post-administration appeared anomalously low compared to 
values at 0 and 30 minutes. Significant differences between the dose groups in terms of 
values of Cmin and AOC were shown with a one-way ANOVA (Table 4.9). However, 
the Tukey-Kramer multiple comparisons test showed that there were no significant 
differences in the values obtained when insulin was administered at 0,15 and 30 minutes 
post-administration of MVCSN. Thus, the apparently anomalous values obtained at 15 
minutes post administration were not significantly different from values obtained at 0 and 
30 minutes. 
It appears that the absorption enhancing effect of chitosan on the rat nasal membrane is 
transient and lasts about 30 minutes. The reduction in absorption when chitosan and 
insulin were administered at a 15 minute interval was probably due to some other factor 
rather than due to the recovery of the nasal membrane from the effects of chitosan pre- 
treatment. Previous studies in the rat have shown that the nasal absorption of insulin 
tends to occur within 5-10 minutes of insulin-chitosan dose administration. This 
suggests that the effect of chitosan on the nasal membrane is fairly rapid and occurs prior 
to or during this 5-10 minute period. Thus, the reduction at 15 minutes cannot be 
explained by an insufficient time allowed for chitosan to effect the nasal membrane. One 
possibility for the reduced absorption at 15 minutes is that the relatively viscous chitosan 
dose had not had sufficient time to spread and drain or be cleared from the site of 
deposition in the nasal cavity. Thus, insulin solution delivered at the same site as the pre- 
dosed chitosan solution in the nasal cavity may be partially displaced anteriorly or 
posteriorly in the nasal cavity by chitosan solution remaining at the site of deposition. 
137 
Consequently, the insulin solution will not be deposited over the exact same areas of the 
nasal cavity which have been affected by chitosan pre-treatment although insulin must be 
deposited on some regions which have been affected by chitosan since at 15 minutes 
absorption was greater than that previously observed for a control insulin solution. 
Similarly, this may contribute to the slight reduction in absorption observed at 30 
minutes. A greater spread of chitosan solution in the nasal cavity after 30 minutes pre- 
treatment, thus providing a larger surface area available for absorption may also 
contribute to the results obtained. It appears that after a 30 minute period, the effects of 
chitosan on the nasal membrane are reversed and the absorptive properties of the 
membrane are reduced. 
Hirai et al. (1981c) investigated the recovery of the nasal mucosa from the induced 
hyperabsorptive state by the surfactants sodium glycocholate and Laureth-9. In the study 
it was demonstrated that as the time interval between administration of surfactant and 
insulin solution increased, nasal absorption of insulin decreased. Thus, it was 
demonstrated that the effect of the surfactants on nasal absorption and hence on the nasal 
mucosa was transient. After administering sodium glycocholate, the time taken for 
insulin absorption to decrease to values similar to those obtained without surfactant was 
between 2-4 hours compared to between 6-24 hours for Laureth-9. In this study, 
following pre-dosing chitosan solution, nasal insulin absorption had decreased to values 
similar to those obtained without chitosan between 30-45 minutes. 
The results appear encouraging since they indicate that in the rat model, chitosan does not 
appear to cause serious damage to the nasal membrane otherwise the absorption 
enhancing capacity of the nasal membrane would probaby be retained for a much longer 
period of time than the 30 minutes demonstrated in this study. However, it would have 
been beneficial to include a control formulation such as Laureth-9 or LPC, which have 
both been reporpted in the literature (refer to Chapter 1) to have severe membrane 
disrupting properties, to allow direct comparison with chitosan. 
Table 4,7. Summary of formulations and dose groups in the study investigating the 
transient effect of MVCSN on the intranasal absorption of insulin in rats 
Formulation or Group No. 
Time interval between insulin and 
MVCSN administrations 
Insulin 
(IU/kg) 
MVCSN 
(mg/kg) 
Dose volume (ml/kg) 
1.0 (control) ** 4.0 0.5 0.1 (coadministered) 
2.15 minutes 4.0 0.5 0.1 each 
3.30 minutes 4.0 0.5 0.1 each 
4.45 minutes 4.0 0.5 0.1 each 
5.60 minutes 4.0 0.5 0.1 each 
* Dose of MVCSN expressed as dose of chitosan glutamate 
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Table 4.8. Summary of mean blood glucose concentrations following the Intranasal 
administration of insulin solution at various time intervals after nasally 
administering MVCSN solution in rats 
Mean ± SD (n=4.6) blood glucose concentration (% of basal) 
Time before or 
after dosing (min) 
0 minutes post 
SD 
15 min post 
SD 
30 min post 
SD 
45 min post 
SD 
60 min post 
SD 
-10 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
-5 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
5 94.0 6.14 95.3 9.22 97.5 7.88 97.5 2.76 99.5 7.35 
10 84.0 6.27 86.2 8.39 81.6 3.29 93.2 4.06 92.7 5.79 
20 67.2 8.35 72.4 13.75 64.3 4.84 82.3 7.02 88.9 5.13 
30 51.5 18.83 69.2 11.77 62.2 11.33 74.9 6.36 81.7 8.88 
45 40.9 20.18 61.3 13.62 51.3 12.90 84.7 14.30 81.6 8.95 
60 40.6 19.10 60.8 19.36 52.4 12.94 92.5 10.53 84.9 12.93 
90 52.2 20.81 65.8 16.41 55.9 15.23 99.1 6.25 88.7 16.47 
120 69.5 14.12 76.4 18.33 53.9 15.56 112.8 3.93 92.7 17.81 
180 91.4 12.07 92.4 14.56 76.9 9.94 140.5 10.14 108.2 16.04 
240 118.7 12.25 112.7 16.60 98.3 11.52 173.1 9.47 124.7 15.78 
Table 4,9. Summary ofpharmacokinetic parameters determined from glucose data 
following the intranasal administration of insulin solution at various time intervals 
after nasally administering MVCSN solution in rats 
Mean ± SD 
Formulation or 
Group number 
No. rats 
in ou 
Cmin 
(% glucose) 
Decrease in 
% glucose conc. 
Tmin 
(min) 
AOC 
(% glucose. min) 
1.0 min st 4 37.0 (t 7.97) 63.0 t 7.97) 73 (t 15.5) 9250.8 t 1945.20) 
2.15 min post 5 54.9 t 16.70 45.1 t 16.70) 60 (t 18.4) 5249.2 (t 2561.56) 
3.30 min post 5 45.2 (t 12.84) 54.8 (t 12.84) 59 (t 36.3) 7845.7 t 2015.49) 
4.45 min post 4 73.5 (t 8.08) 26.5 t 8.08) 33 t 8.7) 1052.0 t 620.64) 
5.60 min post 6 78.4 (t 9.62) 21.6 t 9.62) 50 t 22.6) 2190.7 (t 1734.05) 
One-way ANOVA 
Sig. dif. (P<0.001) in values of Cmin and AOC. 
No sig. dif. (P>0.05) in values of Tmin. 
Tukey-Kramer Multiple Comparisons Test following ANOVA 
Cmin: Sig. dif. between groups 1 vs 5 (P<0.001), 1 vs 4.3 vs 5 (P<0.0! ) and 2 vs 5,3 vs 4 (P<0.01). 
AOC: Sig. dif between groups 1 vs 4,1 vs 5,3 vs 4 (P<0.001), 3 vs 5 (P<0.01) and 2 vs 4 (P<0.05). 
No sig. dif. (P>0.05) between the other formulation groups. 
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Figure 4.6. Blood Qlucose versus time profiles following the Intranasal 
administration of insulin solution at various time intervals after nasally 
administering MVCSN solution in rats 
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Figure 4.7. Selected pharmacokinetic parameters determined from glucose data 
following the intranasal administration of insulin solution at various time intervals 
after nasally administering MVCSN solution in rats 
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4.5 Comparison of the efficacy of different grades of chitosan_ 
in enhancing the nasal absorption of insulin in the rat 
4.5.1 Aims and objectives 
The grade of chitosan employed may influence its absorption enhancing efficacy and thus 
should be fully evaluated when optimising systems for nasal drug delivery. Previously, 
low and medium viscosity grades of chitosan glutamate were shown to enhance the 
intranasal absorption of insulin in the rat model. In this study the efficacy of three 
different grades of chitosan in enhancing the nasal absorption of insulin (4 IU/kg) were 
compared. The grades investigated were low viscosity chitosan lactate (CSN lactate) 
medium viscosity chitosan glutamate (MVCSN) and high viscosity chitosan (HVCSN) 
which each had a similar degree of deacetylation (refer to Table 2.1). Since HVCSN was 
not water soluble but was readily soluble in dilute acid media to allow direct comparison 
of the grades, all formulations (pH 4) were prepared in dilute acid. As a control, an 
insulin solution (pH 4) in dilute acid was nasally administered to rats. 
4.5.2 Study outline 
4.5.2.1 Materials. 
Insulin (Semi-synthetic human sodium insulin, specific activity of pure insulin 28 IU/mg) 
Novo Biolabs, Novo-Nordisk, Denmark was used. Using spectrophotometry the purity 
of the material was determined to be 78.0%. Thus, the specific activity of the insulin was 
equivalent to 21.84 IU/mg and this value was used for all subsequent calculations. 
Low viscosity chitosan lactate (CSN lactate), medium viscosity chitosan glutamate 
(MVCSN) and high viscosity chitosan (HVCSN), Pronova Biopolymer A/S, Drammen, 
Norway (refer to Table 2.1). 
4.5.2.2 Preparation of insulin formulations. 
Four nasal formulations each containing 40 IU/ml insulin were prepared for testing in 
rats. The outline composition of the formulations is given in Table 4.10. One 
formulation was a control solution of insulin (no chitosan) and the remaining three 
formulations contained 0.5% of the appropriate grade of chitosan, expressed as the 
concentration of chitosan salt or with HVCSN as the concentration of the material 
supplied. The insulin control solution (Formulation 1) was prepared in water and 
adjusted to pH 4.0 with 10 M acetic acid. The chitosan formulations (Formulations 2-4) 
were prepared in 1% acetic acid and adjusted to pH 4.0 by the addition of 10 M acetic 
acid or 4M sodium hydroxide. 
4.5.2.3 Absorption study in the rat model 
Nasal doses of 4 IU/kg insulin were administered to rats in a volume of 0.1 ml/kg- 
Where appropriate, chitosan was dosed at 0.5 mg/kg. The dose of CSN lactate and 
MVCSN was expressed as the dose of chitosan salt. The dose of HVCSN was 
expressed as the dose of chitosan base. 
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Table 4.10. Outline composition of formulations 
Formulation 
No. 
Outline composition 
1 40 IU/ml insulin control solution, pH 4 
2 40 IU/ml insulin with 0.5% CSN lactate, pH 4 
3 40 IU/ml insulin with 0.5% MVCSN, pH 4 
4 40 IU/ml insulin with 0.5% HVCSN, pH 4 
* Concentration of CSN lactate and MVCSN expressed as the concentration chitosan salt. 
* Concentration of HVCSN expressed as the concentration of chitosan base. 
4.5.3 Results and Discussion 
Insulin was absorbed from each of the nasal formulations tested in rats (Tables 4.11- 
4.12, Figures 
. 
Insulin, dosed at 4 IU/kg, was absorbed from the control insulin 
solution at pH 4. However, insulin absorption was improved by coadministration with 
the different grades of chitosan. CSN lacate and MVCSN, at a concentration of 0.5 %, 
were equally effective in promoting nasal insulin absorption and these appeared to 
perform marginally better than the HVCSN. Values of Cmin for CSN lactate and 
MVCSN were about 34% compared to about 45% for HVCSN and 67% for the control 
insulin solution. Values of AOC for CSN lactate, MVCSN and HVCSN were 
approximately 12249,11046 and 9092 % gluocse. min, respectively, compared to about 
3415 % gluocse. min for the insulin control solution. 
A one-way ANOVA showed that there were significant differences in values of Cmin and 
AOC between the formulation groups. Further comparison of the formulation groups 
with a Tukey-Kramer multiple comparisons test showed that the values of Cmin were 
significantly lower and values of AOC significantly higher in animals dosed with each of 
the chitosan formulations than values obtained after administration of the control insulin 
solution. However, there were no significant differences between CSN lacate, MVCSN 
or HVCSN in terms of values of Cmin or AOC. 
Based on the results in rats, the low, medium and high viscosity grades of chitosan 
investigated in this study appeared to be effective for the intranasal delivery of insulin. 
The HVCSN was shown to be marginally less effective than LVCSN or HVCSN at 
concentrations of 0.5% which was speculated to be due to the increased viscosity of the 
formulation thereby reducing the spread of the formulation in the nasal cavity and hence 
reducing the absorptive area and also through inhibiting the release of insulin. The 
efficacy of the lactate (CSN lactate) and glutamate (MVCSN) salts of chitosan was 
interesting in view of the much lower content of chitosan in these grades compared to the 
high viscosity grade (HVCSN). The salt content of CSN lactate and MVCSN is between 
65-75% and 55-65%, respectively. Thus, the absorption enhancing efficacy of chitosan 
may be attributed to the complex interaction of a number of formulation factors such as 
the molecular weight / viscosity grade of chitosan and salt form used, buffer composition 
and fromulation concentrations of chitosan and drug. Aspden (1996) investigated a 
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number of different grades of chitosan, mainly hydrochloride salts, having different 
degrees of deacetylation and different molecular weights. However, no apparent 
difference between the grades in enhancing the nasal absorption of insulin in rat and 
sheep models was reported. 
Table 4.11. Summary of mean blood glucose concentrations following the Intranasal 
administration of insulin with different grades of chitosan in rats 
Mean ± SD (n=4) 
Time before or 
after dosing min 
Insulin control 
SD 
Insulin / CS N lactate 
SD 
Insulin /M VCSN 
SD 
Insulin / HVCSN 
SD 
-10 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
-5 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
5 111.3 9.88 96.2 5.92 100.9 4.42 103.2 9.56 
10 94.8 7.02 87.4 7.53 87.2 11.49 90.0 12.82 
20 98.3 12.53 67.8 16.73 55.4 4.72 71.7 6.21 
30 81.4 8.28 52.4 14.02 50.0 2.61 59.2 6.96 
45 77.4 16.71 44.5 13.61 39.1 8.67 48.5 4.73 
60 71.8 5.30 43.4 12.80 34.5 6.65 48.5 6.61 
90 72.0 15.88 34.4 5.44 40.5 3.77 46.0 4.69 
120 78.6 14.25 39.8 4.95 38.1 6.59 52.9 13.74 
180 103.7 16.60 44.9 12.04 54.2 16.80 64.9 16.25 
240 110.0 11.30 62.3 15.70 79.1 29.62 88.1 13.98 
Table 4.12. Summary of pharmacokinetic parameters determined from glucose data 
following the intranasal administration of insulin with different grades of chitosan 
in rats 
Mean ± SD (n=4 
Formulation or 
Group No. 
Cmin 
(% glucose) 
Tmin 
(min) 
AOC 
(% glucose. min) 
1. Insulin control 66.8 (±10.85) 68 (± 19.4) 3415.0 (t 1982.92) 
2. Insulin / CSN lactate 33.7 (±5.98) * 90 ±36.7) 12248.5 (f 1888.78) 
3. Insulin/ MVCSN 33.7 t 6.76) * 79 t 28.4 11046.2 (t 1400.83 
4. Insulin / HVCSN 44.7 t 3.54 ** 101 t 22.5) 9091.5 (± 2152.44) *" 
One-way ANOVA 
Sig. dif. (p<0.001) in values of Cmax and AOC between the formulation groups. 
No sig. dif. (p>0.05) in values of Tmin. 
Tukey-Kramer Multiple Comparisons Test following ANOVA 
* Values significantly different (p<O. 00l) to those in Formulation Group 1. 
** Values significantly different (p<0.01) to those in Formulation Group 1. 
No sig. dif. (p>0.05) in values of Cmäx or AOC between the other groups. 
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Figure 4,8, Blood glucose versus time profiles following the the intranasal 
administration of insulin with different grades of chitosan in rats 
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4.6 The reproducibility of insulin absorption from a 
formulation containing chitosan in the rat 
4.6.1 Aims and objectives 
In the development of nasal peptide and protein delivery systems for therapeutic 
application, an important criteria for the selection of candidate systems is the 
reproducibility and predictability in drug absorption. Intrasubject and intersubject 
variation in drug absorption are factors which may prevent the exploitation of nasal 
formulations commercially. The results presented in this section were not obtained from 
a study specifically designed to investigate intra- and inter-animal variations, hence 
reproducibility, in insulin absorption. The results were collated from studies in which a 
formulation of 40 IU/ml insulin with 0.5% MVCSN was dosed to different groups of 
rats on different study days. To investigate this further, the reproducibility in insulin 
absorption was compared in groups of rats which were dosed on different occasions with 
a formulation of insulin and MVCSN. 
4.6.2 Outline of study 
Materials and methods are as given in Section 4.2. A formulation of 40 IU/ml insulin 
with 0.5% MVCSN at pH 4.0, was prepared on three separate occasions and dosed to 
groups of rats on different study days. The doses of insulin and MVCSN administered 
on each study day were 4.0 IU/kg and 0.5 mg/kg, respectively (Dose volume was 0.1 
ml/kg). 
4.6.3 Results and Discussion 
The results indicate that nasal insulin absorption (i. e. the lowering of blood glucose 
concentrations) was reproducible in the groups of rats which were dosed on different 
study days. Similar blood glucose versus time profiles were obtained for each group of 
rats (Table 4.13, Figure 4.10). On study days 1,2 and 3, values of Cmin were 
approximately 37%, 41 % and 40%, respectively (corresponding values of Tmin were 73, 
68 and 75 minutes, respectively) (Table 4.14, Figure 4.11). Values of AOC were about 
9251,7061 and 8717 % glucose. min, respectively. There were no significant 
differences in values of Cmin, Tmin and AOC between the groups (Table 4.14). 
Calculation of values of pharmacological availability showed that for each of the three 
studies insulin absorption was about 17% (± 4.0), 13% (± 3.3) and 16% (± 2.5), 
respectively. These values are similar to the values reported previously for chitosan 
(Chapter 3). These results are encouraging showing that MVCSN consistently and 
reproducibly enhanced insulin absorption in the rat and that between-day variations in 
insulin absorption were low. The results also demonstrate the validity of the rat in 
intranasal absorption studies as a model for initial screening of candidate enhancers and 
show that the day-to-day variations in experimental conditions were negligible. 
145 
Table 4.11. Summary of mean blood glucose concentrations following the intranasal 
administration of an insulin / MVCSN formulation to rats on different occasions 
Mean ± SD n= 3-4 plasma glucose cone. (% of basal) 
Time before or 
after dosing (min) 
Insulin / MVCSN 
Day I 
SD 
Insulin / MVCSN 
Day 2 
SD 
Insulin / MVCSN 
Day 3 
SD 
-10 100.0 0.00 100.0 0.00 100.0 0.00 
-5 100.0 0.00 100.0 0.00 100.0 0.00 
5 97.6 3.65 99.0 2.87 96.7 3.10 
10 95.3 3.47 92.0 2.04 90.8 4.44 
20 71.4 4.20 72.6 4.36 68.8 7.09 
30 55.7 8.84 62.1 6.27 57.1 9.87 
45 43.1 6.46 44.0 11.65 45.3 16.05 
60 42.3 9.53 46.1 12.52 47.7 13.98 
90 39.5 9.86 44.8 13.64 41.9 11.45 
120 45.1 9.65 62.0 11.59 50.0 10.20 
180 74.3 15.32 86.2 9.91 73.8 2.48 
240 95.3 26.13 108.6 3.88 94.3 9.18 
Table 4.12. Summary of pharmacokinetic parameters determined from glucose data 
following the intranasal administration of an insulin / MVCSN formulation to rats 
on different occasions 
Mean ± SD 
Formulation or No. rats Cmin Tmin AOC Pharmacological 
Group number in group (% glucose min (% glucose. min availability 
1. Insulin / MVCSN 4 37.0 (t 7.97) 73 (± 15.5) 9250.8 (± 1943.20) 17.0 (± 4.04) 
Da 1 
2. Insulin / MVCSN 4 41.3 (t 12.33) 68 (±26.0) 7061.4 (± 1762.04) 13.2 (± 3.30) 
Day 2 
3. Insulin / MVCSN 3 39.8 (t 13.00) 75 (±26.0) 8716.7 (± 1323.94) 16.3 (t 2.50) 
3 Da 
* Relative to subcutaneous 
One-way ANOVA 
No sig. dif. (P>0.05) in values of Cmin. Tmin and AOC. 
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Figure 4.8. Blood glucose versus time profiles following the intranasal 
administration of an insulin / MVCSN formulation to rats on different occasions 
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Figure 4.9. Selected pharmacokinetic parameters determined from glucose data 
following the intranasal administration of an insulin / MVCSN formulation to rats 
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4.7 Conclusions 
Reported in this chapter are the results of various studies in rats which have further 
investigated the efficacy of chitosan (MVCSN) as a nasal absorption enhancer for insulin. 
It was shown that hypotonic and isotonic formulations (0.070-0.329 osmol/kg) 
containing 0.5% MVCSN were equally effective in promoting the nasal absorption of 
insulin. However, absorption enhancing efficacy was improved by administering a 
hypertonic formulation (0.467 osmol/kg) containing 0.5% MVCSN which was attributed 
to the combined effects of MVCSN and sodium chloride (used as the tonicity enhancing 
agent) on the structural integrity of the epithelial membrane. Despite the apparent 
improvement in absorption by increasing the osmolality of the insulin / MVCSN 
formulation, it was considered that this would not be a feasible option for improving 
absorption enhancement due to the likelihood of nasal irritation and potential toxicity with 
therapeutic use. Furthermore, since hypotonic solutions may also be irritant following 
nasal administration, it was decided that isotonic formulations of insulin and MVCSN 
would be used, wherever possible, in future studies. 
The nasal absorption of insulin was apparently improved by increasing the formulation 
concentration of MVCSN. The optimum concentration of MVCSN was between 0.5% 
and 0.75% (above or below which concentrations there was a decrease in the degree of 
absorption enhancement). This may be due to the optimal viscosity / bioadhesive 
properties of the formulation (with optimal interaction of the MVCSN with the nasal 
membrane). Since there was no apparent difference in the efficacy of formulations 
containing 0.5% or 0.75% MVCSN, then clearly the use of 0.5% chitosan would reduce 
potential adverse reactions and increase the acceptability of chitosan in commercial nasal 
preparations. It was decided that in future investigations in rats, formulations containing 
0.5% chitosan would be further investigated. Insulin absorption from isotonic nasal 
formulations containing 0.5% MVCSN was shown to be reproducible in groups of rats 
dosed on different study days. Furthermore interanimal variations in each study group 
and between the groups were low. Insulin absorption, relative to subcutaneous 
absorption, was estimated to be between 13-17% based on decreases in blood glucose 
concentrations. The absorption enhancing effect of MVCSN was shown to be transient, 
lasting about 30 minutes, which was encouraging since it indicated that MVCSN did not 
appear to cause serious damage to the nasal membrane. 
In a study comparing different grades of chitosan (0.5% concentrations) CSN lactate and 
MVCSN were equally effective in promoting nasal insulin absorption and these appeared 
to perform marginally better than HVCSN which may be attributable to the increased 
viscosity of the HVCSN formulation. Further comparison of the efficacy of the different 
grades of chitosan should be investigated in the sheep model since the rat does not appear 
to be a sufficiently sensitive model to allow subtle differences between the performance 
of nasal formulations to be evaluated. However, the rat model remains a useful model for 
the preliminary screening of candidate systems. 
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CHAPTER 5 
THE EFFECT OF CHITOSAN ON THE INTRANASAL ABSORPTION 
OF SALMON CALCITONIN IN THE RAT 
.1 Introduction 
In Chapters 3 and 4, chitosan was demonstrated to significantly enhance the intranasal 
absorption of insulin in the rat. Thus, chitosan may act as an absorption enhancer for 
other peptides applied nasally. Salmon calcitonin (S-CT) was selected as an alternative 
model peptide since it is readily available commercially and its absorption could be 
monitored indirectly from the lowering of plasma calcium concentrations. 
Salmon calcitonin is a synthetically manufactured peptide hormone composed of 32 
aminoacids and has a molecular weight of about 3500 (Azria, 1989). Human calcitonin 
and S-CT differ in 16 of the 32 aminoacids although the potency, in terms of its 
hypocalcaemic effect, of S-CT is much higher (4000-6000 IU/mg) than that of human 
calcitonin (100-200 IU/mg). In humans, endogenous calcitonin is secreted mainly in the 
thyroid parafollicular (C) cells. Its main physiological role is in the regulation of calcium 
homoestasis acting principally on the bone by protecting against bone resorption. 
Therapeutically, calcitonin can be used to treat a variety of diseases characterised by high 
bone turnover such as Paget's disease of bone and osteoporosis. Osteoporosis can be a 
major concern in postmenopausal women, since sex hormones such as oestrogen play a 
vital role in the maintenance of bone mass, and in the elderly (Raisz, 1995). In 
osteoporosis, los of bone mass and microarchitectural deterioration of the bone structure 
leads to an increase in the incidence of fractures. Calcitonin therapy is usually by 
intramuscular or subcutaneous injection although some have been administered nasally or 
rectally (Reynolds, 1996). 
This study investigated the effect of chitosan (MVCSN) on the intranasal absorption of 
salmon calcitonin (S-CT) in the rat. As a control, a buffer solution (without S-CT) was 
administered nasally. For reference, S-CT was administered by intramuscular injection. 
Blood samples were collected pre- and post administration of the formulations and 
plasma separated. The nasal absorption of S-CT was assessed, indirectly, by 
measurement of plasma calcium concentrations. 
5.2. Study outline 
Materials and methods used were as described in Chapter 2/ Appendix 1. Additional 
details are given below. 
5 
. 
2.1 Materials 
Salmon calcitonin acetate salt (S-CT) (S-CT. 4AcOH. 13H20, Bioactivity = 4730 IU/mg), 
Bachem Feinchemikalien AG, Switzerland. 
Dimethyldichlorosilane solution, FSA Laboratory Supplies, Fisons plc, Loughborough, 
Leicestershire, UK. 
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MSE Microcentaur centrifuge from Fisons Scientific Equipment, Fisons p1c. 
All other materials are as given in Section 4.2. 
5.2 
.2 Preparation of S-CT solutions 
To avoid adsorption losses of S-CT, all glassware (except Hamilton syringes used for 
nasal dose administration) that came into contact with S-CT formulations was pre-treated 
with dimethyldichlorosilane solution, a silicone water-repellent coating agent. Glassware 
was soaked in dimethyldichlorosilane solution for a minimum of 1 hour and then dried 
under a fume hood and then in a drying cabinet. All glassware was then washed 
thoroughly prior to use. Where contact between S-CT solutions and plastics (e. g. pipette 
tips, dosing cannula) was unavoidable, the plasticware was pre-flushed with some of the 
S-CT solution. The glass Hamilton syringe was also pre-flushed prior to dose 
administration. 
Three nasal solutions (Formulations 1-3) were prepared for testing in rats as detailed 
below. Each formulations was prepared in 50 mM acetate buffer solution at pH 4.0. The 
buffer solution was administered as a negative control (Formulation 1). The nasal S-CT 
solutions (Formulations 2 and 3) contained 10 IU/ml S-CT (sufficient to administer a 
dose of 1 IU/kg in a volume of 0.1 ml/kg). A solution for intramuscular injection 
(Formulation 4) was prepared in PBS, pH 7.4. The intramuscular solution contained 20 
IU/ml S-CT (sufficient to administer a dose of 0.5 IU/kg S-CT in a volume of 0.025 
ml/kg). 
Table 5.1. Outline composition of formulations 
Formulation No. Outline composition 
1 Buffer control solution, pH 4 
2 10 IU/ml S-CT control solution, pH 4 
3 10 IU/ml S-CT with 0.5% (5 mg/ml) MVCSN, pH 4 
4 20 IU/ml Intramuscular reference solution, pH 7.4 
* Concentration of MVCSN was expressed as the concentration of chitosan glutamate 
5.2.3 Absorption study in the rat model 
The rats were dosed nasally at 0.1 ml/kg and intramuscularly at 0.025 ml/kg. The nasal 
dose of S-CT from formulations 2 and 3 was 1 IU/kg. The intramuscular dose of S-CT 
was 0.5 IU/kg. A summary of the dose groups is given in Table 3.1. 
Blood samples of approximately 200 tl were collected from the cannulated carotid artery, 
pre- and post administration of the formulations and plasma separated by centrifugation 
at 13000 rpm for 10 minutes in a Microcentaur centrifuge. The plasma was collected 
(approximately 100 µl) and plasma calcium concentrations determined. 
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5.3 Results and Discussion 
The results as shown in Tables 5.2-5.3 and Figures 5.1-5.3. The results show that 
MVCSN significantly improved the nasal absorption of S-CT in the rat, as indicated 
indirectly from the lowering of plasma calcium concentrations. A Tukey-Kramer multiple 
comparisons test following one-way ANOVA showed that the values of Cmin were 
significantly lower and values of AOC significantly higher in animals dosed with the S- 
CT / MVCSN formulation compared to those dosed with the buffer control solution or 
the S-CT control solution. Despite apparent absorption from the control nasal solution of 
S-CT, values of Cmin and AOC were not significantly different from those of the buffer 
control group. 
After administering the buffer control solution basal calcium concentrations were 
observed to fluctuate in rats over the experimental period. Furthermore, there was 
considerable interanimal variation in the degree of fluctuation of calcium concentrations 
over the experimental period. With the assumption that the lowering of plasma calcium 
concentrations correlated with the absorption of S-CT (elevation in plasma S-CT 
concentrations), calculation of the values of pharmacological availability provided an 
estimate of the % absorption of S-CT administered nasally compared to the intramuscular 
route. However, Pontiroli et al. (1985) showed that plasma calcium concentrations were 
lowered to similar concentrations after intravenous and nasal administration of human 
calcitonin to healthy volunteers despite plasma calcitonin concentrations being higher after 
intravenous administration. Furthermore, the nasal administration of a higher dose of S- 
CT increased absorption although the hypocalcaemic response was not improved. 
Chierichetti et al. (1985) in a study in human volunteers, used changes in plasma 
concentrations of cAMP rather than the hypocalcaemic response to evaluate the 
absorption of calcitonin after intramuscular injection. Increases in plasma cAMP 
concentrations were shown to correlate well with increases in plasma calcitonin 
concentrations. In normal subjects, cAMP stimulation is suggested to be a more sensitive 
test for evaluating calcitonin absorption than its capacity to lower calcium concentrations 
(Gennari et al., 1990). Thus, the calcium data may be useful for comparing the efficacy 
of different nasal formulations, particularly when comparing the performance of enhancer 
formulations with those of a control, although these may not reliably mirror the overall 
bioavailability of the calcitonin. 
The values of pharmacological availability obtained after nasal administration of control 
S-CT and S-CT / MVCSN (16% and 63%, respectively) showed that absorption was 
increased almost 4-fold by the incorporation of MVCSN. Morimoto et al. (1985) 
reported that 10 U/kg [Asul, 7]-eel calcitonin was not absorbed nasally from a control 
solution (determined from the hypocalcaemic response). Coadministration of 0.1 % 
polyacrylic gel was shown to significantly improve nasal absorption of the calcitonin. 
Richardson et al. (1992) showed that a dose of 40 IU/kg S-CT (no enhancer) was 
absorbed nasally with plasma calcium concentrations decreasing to approximately 85% of 
basal values. Although the nasal absorption of the calcitonins have been demonstrated in 
the literature, few studies have reported the bioavailability of calcitonin, probably 
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reflecting the difficulty in determining plasma or serum calcitonin concentrations. 
Reginster et al. (1987) reported that in humans, based on measurements of plasma 
calcium concentration, the nasal absorption of S-CT (using a commercially available nasal 
spray formulation of S-CT developed by Sandoz, Basle, Switzerland) relative to an 
intramuscular injection was 40%. The bioavailability of a nasally administered synthetic 
analogue of eel calcitonin (Elcatonin), relative to the intramuscular route, was shown to 
be about 39% in dogs (Manzoni et al., 1989). In a study in patients with Paget's disease 
of bone, the bioequivalence of nasal S-CT (in a solution with NaCl and albumin to 
minimise adsorption to plastic syringes) relative to a subcutaneous injection was reported 
tobe 7.5 % (O'Doherty et al., 1990). 
Determination of S-CT concentrations would be advantageous when comparing the 
efficacy of nasal formulations. However, measurement of calcium concentrations would 
appear to be useful for screening purposes. This study has shown that the 
coadministration of MVCSN significantly increased the nasal absorption of S-CT in the 
rat. 
5.4 Conclusions 
The nasal absorption of S-CT, administered at 1 IU/kg, was significantly improved in 
rats by the incorporation of 0.5% MVCSN in a solution formulation. Compared to a 
control solution of S-CT, nasal absorption relative to the intramuscular route was 
improved from 16% to 63% by coadministration with MVCSN. These results 
demonstrate that MVCSN may be useful for the nasal delivery of other peptide and 
protein drugs 
Table 5.1. Summary of formulations and dose groups in the study to investigate the 
intranasal absorption of S-CT with and without chitosan relative to intramuscular 
absorption in rats 
Formulation or Group No. S-CT (IU/kg) 
MVCSN 
(mg g) 
Dose volume (fig) 
1. Buffer control solution 
- - 
0.1 
2. S-CT control solution 1.0 
- 
0.1 
3. S-CT / MVCSN solution 1.0 0.5 0.1 
4. Intramuscular S-CT 0.5 
- 
0.025 
* Dose of MVCSN expressed as dose of chitosan glutamate 
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Table 5.2. Summary of plasma calcium concentrations followine the intranasal 
administration of S-CT with and without chitosan or the intramuscula 
administration of S-CT in rats 
Meant SD (n=4) plasma calcium concentration (% of basal) 
Time before or 
after dosin (min) 
Buffer control 
SD 
S-CT control 
SD 
S-CT / 0.5% MVCSN 
SD 
S-CT intramuscular 
SD 
-10 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
-5 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
5 99.4 6.26 101.1 10.24 97.5 1.84 102.1 5.12 
10 101.3 6.19 99.6 10.31 89.4 2.00 92.8 5.33 
20 106.5 10.77 94.4 10.69 84.8 1.77 91.5 4.78 
40 101.7 3.45 88.5 8.01 74.0 13.37 88.6 7.30 
60 98.6 1.51 90.3 4.78 80.2 1.81 82.8 5.93 
90 100.7 3.24 100.6 14.15 79.3 4.49 83.0 10.27 
120 103.4 4.04 99.4 10.07 81.3 5.47 89.7 16.69 
180 104.2 4.58 103.3 7.46 93.9 9.88 92.3 9.68 
240 107.1 6.38 113.9 10.19 106.5 17.35 101.9 7.70 
300 103.1 12.65 117.6 15.19 103.9 6.76 106.3 20.67 
Table 5.3. Summary of pharmacokinetic parameters following the intranasal 
administration of S-CT with and without chitosan or the intramuscular 
administration of S-CT in rats 
Mean ± SD (n=4) 
Formulation or 
Group number 
Cmin 
(% calcium) 
Tmin 
(min) 
AOC 
(% calcium. min) 
Pharmacological 
availability 
1. Buffer control 92.8 (±4.72) 8 (t 2.9) 267.6 t 339.11) 
2.1 IU/kg S-CT nasal control 86.4 (±5.64) 40 (t 16.3) 1085.6 t 895.17) 16 t 17.9) 
3.1 IU/kg S-CT / 0.5% MVCSN 70.4 (± 10.99) " 58(±23.6) 3423.0(±l206.69)** 63 (t 24.2) 
4.0.5 TU/kg S-CT intramuscular 78.1 (± 5.66) 78 (± 35.0) 2763.6(±1589.67) 100 
* Relative to intramuscular 
One-way ANOVA 
Sig. diff. (p<0.01) in values of Crain and AOC between the formulation groups (Tukey-Krasner 
Multiple Comparisons Test Performed). No sig. diff. (p>0.05) in values of Tmin 
Tukey-Kramer Multiple Comparisons Test 
Cmin: * Sig. diff. to group I (P<0.01) and group 2 (P<0.05) 
AOC: *0 sig diff. to group I (P<0.01) and group 2 (P<0.05). 
No sig. diff. (p>0.05) in Cmin or AOC between groups 1&2 
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Figure 5.1. Plasma calcium concentration versus time profiles following the 
intranasal administration of S-CT with and without chitosan or the intramuscular 
administration of S-CT in rats 
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Figure 5.2. Selected pharmacokinetic parameters following the Intranasal 
administration of S-CT with and without chitosan or the intramuscular 
dministration of S-CT in rats 
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CHAPTER 
-6 
PRELIMINARY INVESTIGATION OF THE EFFICACY OF CHITOSAN 
AS A NASAL ABSORPTION ENHANCER FOR INSULIN IN THE 
SHEEP 
6.1 Introduction 
In this chapter a preliminary study investigating the efficacy of chitosan in enhancing the 
intranasal absorption of insulin in the sheep model is reported. In the study the 
performance of low and medium viscosity chitosan glutamate (LVCSN & MVCSN, 
respectively) were compared to that of lysophosphatidylcholine (LPC) which was shown 
to be marginally more effective than MVCSN in promoting the nasal absorption of insulin 
in rats. A nasal solution of insulin was administered without absorption enhancers as a 
control. Since subcutaneous insulin is used in standard preparations for the treatment of 
diabetes mellitus, a subcutaneous dose of insulin was administered for reference 
purposes. 
In the absorption studies, formulations were administered intranasally or subcutaneously 
to sheep. Blood samples were collected pre- and post administration of the insulin 
formulations, plasma separated and plasma glucose and insulin concentrations measured. 
Insulin absorption was assessed, indirectly, from the decrease in blood glucose 
concentrations and directly from the elevation in plasma insulin concentrations following 
insulin dose administration. 
6.2 Materials & Methods 
Materials and materials used were as described in Chapter 2/ Appendix 1. Additional 
details are given below. 
6.2.1.1 Materials 
Insulin (specific activity 24.22 IU/mg) was used as given in Section 3.2. Additional 
materials used were as given in Section 3.3. 
6.2.1.2 Preparation of insulin formulations 
Solution formulations were prepared for nasal (Formulations 1-6) and subcutaneous 
(Formulation 7) administration to sheep as listed below. Each nasal solution contained 
200 IU/ml insulin (sufficient to administer a dose of 2 IU/kg insulin in a volume of 0.01 
ml/kg). The solution for subcutaneous administration contained 4.2 IU/ml insulin 
(sufficient to administer a dose of 0.2 IU/kg insulin in a volume of 0.0476 ml/kg). All 
formulations were prepared in 14.65 mM phosphate buffer of pH 7.4. Formulations 
containing chitosan (Formulations 2-5) were adjusted to pH 4.0 during formulation 
preparation by the addition of HC1. Each formulation was freshly prepared on the day of 
the study. 
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Table 6.1. Outline composition of formulations 
Formulation No. Outline composition 
1 200 IU/ml insulin control solution, pH 7.4 
2 200 IU/ml insulin with 0.1 % (1 mg/ml) LVCSN, pH 4 
3 200 IU/mi insulin with 0.5% (5 mg/ml) LVCSN, pH 4 
4 200 IU/nil insulin with 0.1 % (1 mg/ml) MVCSN, pH 4 
5 200 IU/ml insulin with 0.5% (5 mg/ml) MVCSN, pH 4 
6 200 IU/ml insulin with 0.5% (5 mg/ml) LPC, pH 7.4 
7 4.2 IU/ml insulin subcutaneous reference solution, pH 7.4 
* Concentration of LVCSN / MVCSN expressed as the concentration of chitosan 
glutamate 
6.2.1.3 Absorption study in the sheep model 
Sheep were dosed nasally or subcutaneously with the appropriate insulin formulation. A 
summary of the dose groups is given in Table 6.2. Nasal doses of 2 IU/kg insulin were 
administered at a volume of 0.01 ml/kg. Each nasal dose was divided between both 
nostrils. The subcutaneous dose of 0.2 IU/kg was administered at 0.0476 ml/kg by 
injection into the flank. Insulin analysis was not performed on plasma samples collected 
from sheep dosed with 0.1% LVCSN or 0.5% LVCSN. 
6.3 Results & Discussion 
Results are presented in Tables 6 2-6.5 and Figures 6.1-6.3. Following subcutaneous 
insulin administration to sheep, sustained reductions of plasma glucose concentrations 
(Table 6.2, Figure 6.1) and elevations of plasma insulin concentrations (Table 6.3, Figure 
6.2) were observed and these values had not returned to basal values by the end of the 
study period. The insulin pharmacokinetic data of the subcutaneous dose group (Table 
6.5, Figure 6.3 ) showed that the values of Cmax and AUC (mean (± SD) of 
approximately 79 mU/l (± 26) and 9205 mU/l. min (± 2288), respectively) were in 
agreement with values reported in the literature after administering a similar subcutaneous 
dose of insulin to sheep. Farraj et al. (1990) reported mean values (± SEM) of Cmax and 
AUC of approximately 95 mU/1 (± 14) and 8615 mU/l. min (± 1297), respectively and 
Ilium et al. (1994) reported values of approximately 91 (± 18) and 10211 (± 837), 
respectively. Furthermore, values of Cm; n and AOC obtained from the glucose data in 
this study (mean (± SD) of approximately 44% (± 14.4) and 10176 % glucose. min (± 
2288), respectively) were in agreement with values reported by Illum et al. (1994) (mean 
values (± SEM) of approximately 37 ± 8.1 and 10040 ± 1062, respectively). 
The results show that insulin dosed at 2 IU/kg was not significantly absorbed following 
the nasal administration of a control solution (Tables 6.2-6.4, Figures 6.1-6.3). Values 
of bioavailability (Table 
. 
6.5, Figure 6.3) and pharmacological availability (Table 6.4, 
Figure 6.3), relative to subcutaneous, of the nasal control insulin dose were 0.20 % and 
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1.4%, respectively. The values of relative bioavailability and pharmacological availability 
are in good agreement indicating that a reasonable estimate of insulin absorption can be 
obtained from the glucose data. Slight discrepancies between the two values may be 
expected since basal fluctuations in glucose concentrations in sheep were not taken into 
account. Also, the elevation of insulin concentrations may not exactly mirror the fall in 
glucose concentrations which was apparent in one sheep in the group after subcutaneous 
administration where the insulin AUC was much lower than that of the other two animals 
in the group although the glucose AOC for the same animal was the second highest in the 
group (results not shown). The nasal bioavailablity of the control insulin solution was in 
agreement with values reported by Farraj et al. (1990) and Illum et al. (1994) of 1.8% 
and 1.2%, respectively. 
Intranasal insulin absorption was improved by coadministration of LVCSN, MVCSN or 
LPC compared to that obtained by administering a control insulin solution (Tables 6.3- 
6.6, Figures 6.1-6.3). However, it is evident from the plasma glucose concentration 
versus time curves (Table 6.3, Figure 6.1) that the extent and duration of hypoglycaemia 
was much more pronounced following the nasal administration of the formulation of 
insulin with 0.5% MVCSN compared to the other nasal formulations. The greater extent 
of the hyoglycaemia after administering the formulation containing 0.5% MVCSN was 
reflected in the lower mean value of Cmin (.. 43% of basal glucose concentration) 
obtained for this formulation compared to those obtained after dosing the other 
formulations (Table 6.5, Figure 6.3). For the other nasal enhancer formulations, values 
of Cmin were in the region of 71-84% compared to about 88% for the control insulin 
solution. The rate of decrease of % glucose concentrations (Table 6.4) after 
administering the insulin formulations (Table 6.4) was highest after administering the 
LPC formulation (- 1 %/min) closely followed by the 0.5% MVCSN formulation (- 0.9 
%/min), whereas for the other enhancer formulations rates were lower (0.37-0.49 
%/min). Comparing the chitosan (MVCSN & LVCSN) formulations, the rate of 
decrease of % glucose concentrations increased as chitosan concentration increased and at 
concentrations of 0.1% and 0.5%, respectively, values were lower for the LVCSN 
grade. The plasma glucose profile and values of Cmin for the 0.5% MVCSN formulation 
were similar to those following the subcutaneous dose. For the insulin / enhancer 
formulations, values of relative pharmacological availability of 2.4% (0.1 % LVCSN), 
3.2% (0.5% LVCSN), 4.0% (0.1% MVCSN), 8.7% (0.5% MVCSN), and 2.6% (0.5% 
LPC) were obtained compared to a value of 1.4% for the control solution. Thus, from 
the glucose data the compounds ranked in terms of absorption enhancing efficacy in the 
order: 0.5% MVCSN » 0.1% MVCSN > 0.5% LVCSN > 0.5% LPC -=0.1% 
LVCSN > control solution. 
The plasma insulin versus time curves (Table 6.4, Figure 6.2) show that prolonged 
elevation in insulin concentrations, indicating sustained insulin absorption, occurred after 
nasally dosing insulin / 0.5% MVCSN or following the subcutaneous dose. The mean 
value of Cmax (Table 6.6, Figure 6.3) for the 0.5% MVCSN formulation (-- 191 mU/1) 
was higher than that obtained for the other formulations (- 142,69,10 and 79 mU/I for 
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LPC, 0.1 % MVCSN, insulin control and subcutaneous formulations, respectively). The 
highest Tmax (40 minutes) was observed after administering the insulin / 0.5% MVCSN 
formulation indicating sustained absorption of insulin from this formulation compared to 
that from the other formulations. The rate of increase of insulin concentrations was 
highest for the LPC formulation (0.17 mU/l/min) with values of 0.09 and 0.05 mU/l. min 
for the formulation containing 0.5 % and 0.1 % MVCSN, respectively. Values of relative 
bioavailability of 1.8% (0.1% MVCSN), 8.4% (0.5% MVCSN), and 2.1% (0.5% LPC) 
were obtained compared to 0.20% for the control solution (no data for 0.2% or 0.5% 
LVCSN). Thus, from the insulin data the compounds ranked in terms of absorption 
enhancing efficacy in the order: 0.5% MVCSN » 0.5% LPC > 0.1 % MVCSN. 
Statistical analysis of the data with a one-way ANOVA showed that there were significant 
differences between the dose groups in the values of Cmin, AOC (hence relative 
pharmacological availability), Cmn and AUC (hence relative bioavailability). The 
Tukey-Kramer multiple comparisons test following ANOVA showed that only values of 
Cmin and AOC obtained for the 0.5% MVCSN dose group were significantly different to 
those of the insulin control group. Values of Cmin of 0.5% MVCSN group were also 
significantly lower than those in the 0.1 % LVCSN dose groups and values of AOC were 
significantly higher than those in all the other groups. The Tukey-Kramer multiple 
comparisons test showed that significantly higher values of Cmax were obtained for the 
0.5% MVCSN and 0.5% LPC dose groups compared to the insulin control group 
although there was no difference between the 0.1 % MVCSN and the control group. 
Values of Cmax were also significantly higher after administering the higher dose of 
MVCSN. Values of AUC of the 0.5% MVCSN dose group were significantly higher 
than those of the other dose groups although there were no differences between the other 
groups. 
The results show that the formulation containing 0.5% MVCSN, performed better than 
the other formulations in terms of enhancing nasal insulin absorption in the sheep model. 
Values of relative pharmacological availability obtained in the sheep (8.7% ± 2.39) after 
administering a solution of insulin with 0.5% MVCSN were of similar order of 
magnitude to those achieved in the rat (13.8% ± 1.37) after dosing insulin / 0.5% 
MVCSN. In contrast, after dosing a formulation of insulin and 0.5% LPC, values of 
relative pharmacological availability of 2.6% (± 2.16) and 16.2% (± 1.59) were obtained 
in the sheep and rat models respectively, indicating that the absorption enhancing efficacy 
of LPC was much lower in the sheep than in the rat. However, after nasal administration 
of a control insulin solution, values of relative pharmacological availability were of the 
same order of magnitude in the two species (1.4% ± 1.02 and 2.1% ± 1.89 in sheep and 
rats, respectively). 
Impaired mucociliary clearance in the rat model due to the effects of the anaesthetic, 
thereby increasing the contact time between the drug formulation and the nasal mucosa, 
may account for the increased absorption of insulin in this species. Mayor and Ilium 
(1994) showed that nasal insulin absorption was reduced in rats which were 
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anaesthetised compared to those which were sedated for dose administration or remained 
conscious. In the conscious sheep model, clearance of drug formulation from the nasal 
cavity due to mucociliary clearance mechanisms may reduce the contact time between the 
drug formulation and the nasal mucosa and this could explain the reduction in absorption 
for this species. Normal movements of the sheep after dose administration may also 
contribute to the drainage of the drug formulation from the nasal cavity and sneezing or 
snorting during the post-dose period may result in the physical loss of dose. In contrast 
to the LPC formulation, the nasal absorption enhancing efficacy of the formulation 
containing 0.5% MVCSN was not significantly reduced in the sheep. The reasons for 
this have not been elucidated. However, the bioadhesive and/or viscosity enhancing 
properites of chitosan may increase the residence time of the drug formulation in the nasal 
cavity, thus increasing the contact time between the drug and the nasal mucosa. 
The degree of enhancement of nasal insulin absorption in sheep by coadministering 
MVCSN was comparable with values reported by Aspden (1996). From plasma glucose 
data, Aspden reported a value of Cmi of about 55% and a Tmin of 54 minutes 
(concentration of 0.25% chitosan base) compared to values of about 43% and 85 
minutes, respectively in this study. Values of AOC could not be compared because of 
differences in the duration of the respective studies. 
The reasons for the apparently greater absorption enhancing efficacy of MVCSN 
compared to LVCSN has not been elucidated. However, differences in the performance 
of the two grades are probably due to differences in the viscosities, hence molecular 
weights, of the respective grades. The values of intrinsic viscosity of MVCSN and 
LVCSN are 1010 and 388 ml/g respectively (refer to Section 10.4). Thus, it is probable 
that the relatively less viscous formulations containing LVCSN is cleared more rapidly 
from the sheep nasal cavity than formulations containing MVCSN (at the same 
concentration). The viscosity grade may also influence the bioadhesive properties of 
chitosan. Furthermore, there may be an optimal molecular weight range of chitosan at 
which optimal absorption enhancing efficacy is exhibited. In view of the lack of 
differences in the performance of different grades of chitosan in the rat model, this should 
be evaluated in the sheep model. 
6.4 Conclusions 
The study showed that in the sheep model, insulin dosed at 2 IU/kg was not significantly 
absorbed without coadministration with absorption enhancers. Each of the compounds 
coadministered with insulin in solution formulations improved nasal insulin absorption 
although the formulation of insulin with 0.5% MVCSN performed significantly better 
than the other formulations tested. The relative bioavailability of insulin from the 0.5% 
MVCSN formulation was about 8% which was approximately a 40-fold improvement on 
absorption compared to the control solution and a 4-fold to that of the other enhancers. 
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Table 6.2. Summary of formulations and dose groups in the study to investigate the 
intranasal or subcutaneous absorption of insulin from various formulations in sheep 
Formulation or Group No. Insulin 
(IU/kg) 
Enhancer 
(mg/kg) 
Dose volume 
(ml/kg) 
1. Insulin control solution 2.0 
- 
0.01 
2. Insulin + 0.1% LVCSN 2.0 0.01 0.01 
3. Insulin + 0.5% LVCSN 2.0 0.05 0.01 
4. Insulin + 0.1% MVCSN 2.0 0.01 0.01 
5. Insulin + 0.5% MVCSN 2.0 0.05 0.01 
6. Insulin + 0.5% LPC 2.0 0.05 0.01 
7. Subcutaneous reference solution 0.2 
- 
0.0476 
* Dose of LVCSN / MVCSN expressed as dose of chitosan glutamate 
Table 6.3. Summary of_plasma glucose concentrations following the Intranasal 
administration of 2 IU/k! Insulin in combination with LVCSN MVCSN or LPC or 
the subcutaneous administration of 0.2 IU kg insulin In sheep 
Mean plasma glucose concentration (% of basal) (t SD) 
Time before or 
after dosin min 
insulin control 
SD 
0.1 % LVCSN 
I SD 
0.5%L CSN 
SD 
0.1% MVCSN 
SD 
0.5% MVCSN 
SD 
0.5% LPC 
SD 
Subcut insulin 
SD 
-15 100.0 
. 0.0 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
-5 100.0 0.0 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
1000 0.00 
5 100.0 3.4 103.3 3.43 95.8 2.37 96.0 1.73 95.2 2.92 100.0 1.54 97.6 9.74 
10 103.3 3.3 103.2 5.54 97.7 0.77 96.1 4.26 96.0 3.63 97.4 4.44 100.8 6.94 
15 104.6 4.0 102.2 6.52 98.6 1.39 949 1.85 97.8 0.76 98.3 1.73 95.3 8.67 
20 104.6 4.0 99.4 6.62 93.9 2.04 92.3 4.20 94.3 2.18 88.6 10.33 93.0 11.39 
30 105.3 2.6 97.4 8.27 90.1 1.41 88.3 0.83 84.7 5.52 78.0 14.23 76.4 14.59 
40 102.7 2.7 93.6 6.82 82.7 6.33 80.6 3.28 75.2 4.87 75.9 20.50 72.0 18.14 
50 101.2 4.4 87.9 7.02 77.1 6.19 76.8 4.48 64.9 5.13 76.9 16.00 58.9 16.61 
60 99.2 4.7 85.9 8.70 74.3 8.44 73.8 7.14 57.2 5.11 79.0 15.19 57.7 18.11 
75 98.7 3.8 86.9 7.84 71.5 10.04 71.8 8.63 47.9 14.66 82.2 12.56 49.9 16.14 
90 96.7 4.0 86.9 10.89 78.1 10.37 76.6 9.54 446 20.11 83.2 8.30 47.9 20.13 
120 94.1 8.1 86.9 8.14 84.6 7.57 76.9 4.38 47.2 19.98 91.8 10.47 49.0 15.46 
150 91.3 7.3 88.9 6.57 85.5 4.68 81.0 1.43 52.4 16.59 92.7 5.70 48.8 9.59 
180 90.6 9.7 88.0 5.15 89.3 3.34 85.0 490 59.2 13.99 94.0 8.77 47.8 10.26 
240 89.3 6.3 89.9 3.81 94.0 3.97 900 7.54 77.2 664 96.5 9.15 62.8 3.56 
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Table 64 Summary of plasma insulin concentrations following the intranasal 
administration of 2 IU/k Insulin In combination with 
subcutaneous administration of 02 IU 1kg insulin in shrPj 
Mean plasma Insulin concentration mUA 
Time before or 
after dosin(min) 
Insulin control 
SD 
Insulinl0.1% MVCSN 
SD 
Insulin/0,5% MVCSN 
SD 
Insulin/0.5% LPC 
SD 
Subcut. insulin 
SD 
-15 6.0 1.3 6.4 4.23 6.5 1.62 12.4 7.0 8.89 
-5 5.4 1.8 10.0 9.46 8.2 3.45 13.3 1.31 6.7 5.51 
5 5.9 1.1 14.6 5.58 24.2 22.08 104.1 51.33 57.7 45.08 
10 9.0 3.7 21.3 1.36 89.1 116.77 142.4 73.94 40.0 20.78 
15 9.4 5.1 42.9 8.65 110.7 34.82 74.3 21.82 48.7 16.04 
20 6.8 2.0 59.6 37.40 54.4 17.72 53.3 2.57 54.7 7.02 
30 5.4 0.5 55.2 35.95 59.7 47.47 30.7 9.06 71.7 16.17 
40 6.5 1.1 47.3 29.35 73.2 54.20 17.8 3.54 72.0 30.51 
50 5.3 1.5 17.0 12.10 87.8 8004 13.8 5.09 55.3 32.39 
60 5.5 1.5 9.3 6.34 100.8 85 69 8.3 1.10 60.3 29.70 
75 6.2 1.8 5.0 2.23 82.9 75.71 7.2 1.14 55.3 31.90 
90 5.7 1.8 3.7 0.81 52.6 45.78 7.2 3.08 43.0 17.00 
120 5.5 0.9 3.6 2.32 23.6 19.28 5.4 1.99 38.0 12.17 
150 6.7 2.0 2.9 1.40 11.7 6 90 5.9 2.40 35.3 11.02 
180 7.6 3.2 2.3 0 99 9.3 4.36 6.2 2.26 21.7 5.69 
240 5.3 2.3 3.2 2.06 7.8 3.96 6.2 3.10 19.7 11.59 
Table 6.5. Summary of pharmacokinetic paramenters determined from plasma 
glucose data followin! the Intranasal administration of 2 IU/k2 insulin in 
combination with LVCSN. MVCSN or LPC or the subcutaneous administration of 
0.2 IU. ke insulin in sheep 
Mean (± SD) 
Formulation or No sheep min Tmjp aQý Rate of decrease pharmaroloeical 
Grout) number 
. 
in smug (% slucose) fii41 I% glucose. min) of % elucose availability " 
1. Insulin control 4 88.0 (t 6.49) 105 (t 75.5) 1379 t 1032.6) 1.4 (t 1.02) 
2. Insulin / 0.1% LVCSN 3 84.0 (t 8.28) 133 t 93 8) 2486 (t 1427.9) 0.37 (t 0.032) 2.4 (t 1.40) 
3. Insulin / 0.5% LVCSN 3 70.6 (t 10.10) 70 t 8.7) 3295 (t 1166.5) 0.49 (t 0.171) 3.2 (t 1.14) 
4. Insulin/ 0.1%MVCSN 3 70.9 (± 8.50) 83(±27.0) 4065 (± 152.6) 0.46 (± 0.225) 40(±0.15) 
5. Insulin / 0.5% MVCSN 3 42.9 (± 17.05) 85 (t 22.9) 8815 (t 2433.7) 0.87 (t 0.055) 8.7 (t 2.39) 
6. Insulin / 0.5% LPC 3 74.9 (t 19.57) 48 (t 10.4) 2644 (t 2200.8) 0.95 t 0.384) 2.6 (t 2.16) 
7. Sucutaneous insulin 3 44.3 (± 14.40) 130 (t 56.8) 10176 (t 2794 8) 100.0 
0 Relative to subcutaneous 
One"wav ANOVA 
Sig. dif in values of Cmin (P<0.01), Rate of decrease of % glucose (P<0.05) and AOC (P<0.00I ). 
No sig. diff. in values of Tmin (P>0.05). 
Tukev- ramer M ultinl o a_ison Test following ANOVA 
Cmin: Sig. dif. between groups I vs 5,2 vs 5 (P<0.01). 
Rate of decrease of % glucose: Sig. dif. between group 2vs6 (P<0.05). 
AOC: Sig. dif. between groups 1 vs 5 (P<O. 001), 2 vs 5.3 vs 5,6 vs 5 (P<0.01) and 4 vs 5 (P<0.05). 
No sig. dif. (P>0.05y between all other formulation groups. 
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Table 6.6. Summary of pharmacokinetic paramenters determined from-plasma 
insulin data following the intranasal administration of 2 IU/kg insulin in 
combination with MVCSN or LPC or the subcutaneous administration of 0.2 IU. kg 
Insulin in sheep 
Mean (± SD 
Formulation or 
Group number 
No. sheep 
in group 
Cmax 
(mU/I) 
Tmax 
(min) 
AUC 
(mUA. min) 
Rate of increase 
of Insulin 
lo mU/I /min) 
Bloavailability " 
(%) 
1. Insulin control 4 10.4 (± 3.91) 20 (± 13.5) 169 (± 130.4) 0.2 (±0.14) 
4. Insulin/ 0.1% MVCSN 3 68.8 ±31.64) 22 t7.6) 1682 ±1189.3 0.05 (± 0.03 1.8 (t 1.29 
5. Insulin/0.5%MVCSN 3 191.1(±28 49) 40(±26.5) 7707(±4632.1) 0.09(±0.050) 8.4 ±5.03 
6. Insulin / 0.5% LPC 3 142.4 t 73.94) 10 3 0.0) 1942 t 610.0) 0.17 t 0.034) 2.1 t 0.66) 
7. Subcutaneous insulin 3 79.3 (± 26 06 25 t 18.0) 9205 t 2287.5) 100.0 
0 Relative to subcutaneous 
Statistical Analysis (Performed on nasal groups 1 4- &6 oni4 
One-way ANOVA 
Sig. dif in values of Cmax (P<0.001), rate of increase of insulin (P<0.05) and AUC (P<0.01). 
No sig. dif. in values of Tmax (P>0.05). 
Tukev-Kramer Multiple Comparison Test following ANOVA 
Cmax: Sig. dif. between groups I vs 5 (P<0.001). I vs 6 (P<0.0I) and 4 vs 5 (P<O. 05). 
Rate of increase of insulin: Sig. dif, between group 4vs6 (P<0.05). 
AUC: Sig. dif, between groups 1 vs 5 (P<0.01) and 4 vs S. 6 vs 5 (P<O. 05). 
No sig. dif. (P>0.05) in values of Cmax, Rate of increase of insulin conc. and AUC between other groups. 
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Fig 6.1 Plasma glucose concentration versus time profiles following the intranasal 
administration of2 IUfkg insulin in combination with LVCSN. MVCSN or LPC or 
the subcutaneous administration of 0.2 IU kg insulin In sheep- 
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Fig 6.2 Plasma insulin concentration versus time profiles following the intranasal 
administration of 2 IU/kg insulin in combination with MVCSN or LPC or the 
subcutaneous administration of 0.2 IU. kg insulin in sheep 
Legend as in Figure 6.1 
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Figure 6.3. Selected uharmacokinetic Parameters following 
-the 
Intranasal 
administration of 2 IU/ka insulin in combination with LVCSN. MVCSN or LPC or 
the subcutaneous administration of 0.2 UJ, kg insulin in sheen- 
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CHAPTER 7 
EVALUATION AND FURTHER OPTIMISATION OF NASAL INSULIN 
FORMULATIONS CONTAINING CHITOSAN IN SHEEP 
7 
.1 Introduction 
In Chapter 6 it was demonstrated that a formulation containing MVCSN was highly 
effective in enhancing the intranasal absorption of insulin in the sheep model. In further 
optimising chitosan solution formulations for the nasal delivery of insulin there are 
several factors relating to the formulation, such as the concentrations and doses of insulin 
and chitosan, the dose volume administered, the type of vehicle used and the 
characteristics of the grade of chitosan used, which should be considered. In this 
chapter, a number of these factors are investigated further details of which will be given 
in the appropriate section. The various studies are reported in the following sections: 
7.2 Effect of chitosan concentration on the intranasal absorption of insulin in sheep 
7.3 Effect of the dose of chitosan on the intranasal absorption of insulin in sheep 
7.4 Effect of the dose of insulin on the intranasal absorption of insulin in sheep 
7.5 Effect of dose volume on the intranasal absorption of insulin in sheep 
7.6 Effect of different vehicles on the absorption enhancing efficacy of chitosan in 
sheep 
7.7 Effect of different grades of chitosan on the intranasal absorption of insulin in 
sheep 
7.8 Reproducibility of the absorption enhancing efficacy of chitosan in sheep 
Many of the sheep studies were performed in parallel to the nasal absorption studies in 
rats. Despite the decision to use isotonic formulations in rat studies, in an early sheep 
study investigating the effect of chitosan concentration, hypotonic formulations were 
adinistered. Thus, for consistency throughout the sheep studies, it was decided that 
hypotonic fomulations would be administered. 
In the absorption studies, various insulin formulations were administered nasally to 
sheep. Blood samples were collected pre- and post administration of the insulin 
formulations and plasma separated. Plasma glucose and insulin concentrations were 
measured and insulin absorption was assessed, indirectly, from the decrease in blood 
glucose concentrations and directly from the elevation in plasma insulin concentrations 
following insulin dose administration. The efficacy of insulin absorption from the 
formulations used in each study were compared. For reference, the subcutaneous 
absorption data reported in Chapter 6 was used. 
Methods and materials used were as given in Chapter 2/ Appendix 1. Additional details 
are given in the relevant sections. 
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7.2 Effect of chitosan concentration on Intranasal insulin 
absorption in sheep 
7.2.1 Aims and Objectives 
In a previous study in rats (refer to Section 4.3), the absorption enhancing efficacy of 
chitosan was shown to increase with increasing concentration of chitosan in the 
formulation until an optimal range of concentrations was reached. In this study the effect 
of different concentrations of chitosan on the intranasal absorption of insulin was 
investigated in sheep. Five different concentrations of MVCSN, ranging from 0.1-1.0% 
were tested. 
7.2.2 Materials and Methods 
7.2 
. 
2.1 Materials 
Insulin (specific activity 24.22 IU/mg) was used as given in Section 3.2. Additional 
materials are given in Section 3.3. 
7.2.2.2 Preparation of insulin formulations 
Five solution formulations were prepared for nasal administration to sheep as listed 
below. Each nasal solution contained 200 IU/ml insulin (sufficient to administer a dose 
of 2 IU/kg insulin in a volume of 0.01 ml/kg). All formulations were prepared in 14.65 
mM phosphate buffer of pH 7.4. and were adjusted to pH 4 during preparation by the 
addition of HCI. Each formulation was freshly prepared on the day of the study. 
Table 7.1. Outline composition of formulations 
Formulation No. Outline composition 
1 200 IU/ml insulin with 0.10% (1.0 mg/ml) MVCSN, pH 4 
2 200 IU/ml insulin with 0.20% (2.0 mg/ml) MVCSN, pH 4 
3 200 IU/ml insulin with 0.35% (3.5 mg/ml) MVCSN, pH 4 
4 200 IU/ml insulin with 0.50% (5.0 mg/ml) MVCSN, pH 4 
5 200 IU/ml insulin with 1.00% (1.0 mg/ml) MVCSN, pH 4 
* Concentration of MVCSN expressed as the concentration of chitosan glutamate 
7.2.2.3 Absorption study in the sheep model 
Sheep were dosed nasally with the appropriate insulin formulation. A summary of the 
dose groups is given in Table 7.2. Nasal doses of 2 IU/kg insulin were administered at a 
volume of 0.01 ml/kg. Each nasal dose was divided between both nostrils. 
7.3 Results & Discussion 
The results show that insulin dosed at 2 IU/kg with chitosan was absorbed nasally from 
each of formulations administered to sheep (Tables 7.3-7.6, Figures 7.1-7.2). However, 
increasing the formulation concentration of chitosan improved insulin absorption. 
166 
The pharmacokinetic parameters determined from the glucose data (Table 7.5, Figure 7.2 
A-C) showed that decreases in plasma glucose concentrations and the rate of decrease in 
glucose concentrations reached a plateau at a chitosan concentration between 0.5% and 
1.0% (values of approximately 40% and 0.9 % glucose/min, respectively between 0.5- 
1.0% MVCSN). However, the effect on the overall extent and duration of the 
hypoglycaemia, reflected in the values of AOC and pharmacological availability, was 
marginally better at 1.0% (values of 4319 % glucose. min and 4.2%, respectively at 
1.0%). These findings were supported by the pharmacokinetic parameters determined 
from the insulin data (Table 7.6, Figure 7.2 D-F) which showed that increasing the 
formulation concentration of chitosan improved insulin absorption. Taking into account 
the inter-animal variations in the data, the absorption enhancing efficacy of chitosan in 
terms of values of Cmax and AUC (hence bioavailability) appeared to plateau at a 
concentration between 0.35-1.0% (At 0.35,0.5 and 1.0% MVCSN values of Cmax 
ranged between 76-99 mU/l and values of AUC between 2012-2370 mU/l. min). 
Values of pharmacological availability (3.6-4.2%) and bioavailability (2.2-2.6%), relative 
to a subcutaneous dose of insulin, showed that there was very little difference in insulin 
absorption from formulations containing between 0.35-1.0% chitosan (Tables 7.6 & 7.5, 
respectively). However, these values were much lower than those reported in Chapter 6 
following the intranasal administration of an insulin formulation containing 0.5% 
MVCSN (8.7% and 8.4%, respectively). Possible explanations for this are given below. 
There were no statistically significant differences between the formulation groups (Tables 
7.5 & 7.6) in terms of values of Cm; n and AOC obtained from the glucose data and 
values of Cmax, Tmax, rate of increase of insulin concentrations or AUC, hence 
bioavailability, obtained from the insulin data. There were, however, significant 
differences in values of Tmin and rates of decrease of glucose concentrations. Values of 
Tmin of Formulation Group 1 (0.1 % MVCSN) were higher than those of the other 
formulation groups. However, in view of glucose concentrations in this group of 
animals generally not decreasing to the same extent as those in the other formulation 
groups and since values of Tmax were not significantly different from those obtained in 
the other groups, the difference in values of Tm; n were not considered important and may 
in-part be due to a natural fluctuation in basal glucose concentrations. The rate of 
decrease of glucose concentrations after dosing the formulation containing 0.5 % chitosan 
although significantly higher than those obtained with the 0.1 % MVCSN formulation 
were not significantly different from values obtained for the other formulations. 
The results of this study show that the intranasal absorption of insulin was improved by 
increasing the concentration of chitosan in the formulation from 0.1 % to 0.35% although 
further increase in chitosan concentration did not appear to further increase insulin 
absorption. These findings support those from the previous study in rats (refer to 
Chapter 4) which showed that maximal insulin absorption was obtained at a chitosan 
concentration between 0.5-0.75%. The trend of increase in absorption with increasing 
chitosan concentration until reaching an optimal concentration suggests that the 
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mechanism (s) of action of chitosan on the nasal membrane, thereby promoting insulin 
absorption, reaches a maximum. As discussed in Chapter 4, increasing the concentration 
of chitosan may reduce mucociliary clearance or drainage of the formulation from the 
nasal cavity due to increased viscosity and/or bioadhesion. The viscosity of chitosan 
solutions increases with concentration (refer to Section 10.5). For MVCSN solutions 
prepared in 1% acetic acid, values of apparent viscosity measured at 5 rpm of MVCSN 
solutions in acetic acid at concentrations of 0.2,0.5 and 1.0 % (reported in Section 10.5) 
were 4.7,15.4 and 55.8 CPS, respectively. Interaction of chitosan with the nasal 
membrane and the effect on tight junctions may also increase by increase in chitosan 
concentration. 
The results obtained after nasally administering a dose of 2 IU/kg insulin from a 
formulation containing MVCSN generally agree with those reported by Aspden (1996). 
Aspden evaluated medium viscosity chitosan glutamate at concentrations of 0.25 % and 
0.5% w/v, expressed as the concentration of chitosan base, finding only marginal 
differences between the absorption enhancing efficacy of the two formulations. 
In this study the bioavailability, relative to subcutaneous, of insulin from the 0.5% 
MVCSN formulation was only 2% compared to about 8% in the study reported in 
Chapter 3. Furthermore, values of Cmax, pharmacological availability and reductions in 
glucose concentrations were lower in this study than values reported previously. The 
reasons for these discrepancies are not known but may be attributed to several factors. 
Inter-animal variations could be due to differences in the cross-breed of sheep used in the 
two studies. This may possibly influence absorption due to slight differences in the 
anatomy and physiology of the nasal cavity and differences in the homeostasis of blood 
glucose concentrations. Inter-animal variations in the anatomy and physiology of the 
nasal cavity will influence the exact site of deposition of the dosing solution in the nasal 
cavity which is likely to influence the subsequent spread and clearance of the dose from 
the nasal cavity. Differences do not appear to be related to the weight of the animals used 
since the weights of the sheep were similar in both studies. Differences in the ambient 
conditions. of temperature and humidity on different study days may also influence 
absorption and ideally experiments should be performed under standardised 
environmental conditions (Gizurarson, 1990). Due to a heavy wool coat for much of the 
year and low efficiency of the sweat glands, the sheep uses the surfaces of the respiratory 
system including the nasal cavity to dissipate heat through water vaporisation (May, 
1964). The rate of fluid production in the nasal cavity and the respiratory rate of sheep 
will help to regulate heat loss. Excess fluid production will also dilute the drug 
formulation which may subsequently affect the spread and clearance of the formulation 
from the'nasal cavity. Despite the lower values of bioavailability obtained in this study, 
the improvement in nasal absorption compared to a control solution was about 10-fold 
which for polypeptide drugs represents a substantial increase in absorption. 
From the results of this study it was decided to maintain the formulation concentration of 
chitosans at 0.5% for further investigations. Concentrations above 0.5% may cause 
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problems with nasal administration from spray devices which would be required for 
commercial application due to the increased viscosity of the solution. Lower 
concentrations of chitosan would also be favoured considering toxicological issues. In 
this study, the formulation containing 0.35% chitosan performed as well as that 
containing 0.5% chitosan. However, since a formulation concentration of 0.35% 
MVCSN was probably close to the start of the optimal range, it was decided to allow a 
margin of safety when selecting an optimal concentration. Thus, a concentration of 0.5% 
MVCSN was selcted for investigation in future studies. 
Table 7.2. Summary of formulations and dose groups in the study to investigate 
_ 
the 
effect of MVCSN concentration on the intranasal absorption of insulin in sheep 
Formulation or Group No. Insulin 
(IU/kg) 
MVCSN 
(m8/k8) 
Dose volume 
(ml/k8) 
1. Insulin + 0.10% MVCSN 2.0 0.01 0.01 
2. Insulin + 0.20% MVCSN 2.0 0.02 0.01 
3. Insulin + 0.35% MVCSN 2.0 0.035 0.01 
4. Insulin + 0.50% MVCSN 2.0 0.05 0.01 
5. Insulin + 1.00% MVCSN 2.0 0.1 0.01 
* Dose of MVCSN expressed as dose of chitosan glutamate 
Table 7.3. Summary of plasma glucose concentrations following the intranasal 
administration of 2 IU/kg insulin in combination with different concentrations of 
MVCSN in sheep 
Mean (± SD) plasma glucose concentration 
Time before or 
after dosing (mm' 
0.1% MVCSN 
SD 
0.2% MVCSN 
SD 
0.35% MVCSN 
SD 
0.5% MVCSN 
SD 
1.0% MVCSN 
SD 
-15 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
-5 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
5 97.4 2.17 93.6 1.03 979 2.00 97.9 3.86 97.1 2.03 
10 98.2 0.69 94.9 1.65 95.8 2.87 97.8 3.24 99.2 2.55 
15 95.6 3.16 92.2 0.79 944 2.44 93.4 6.52 94.3 2.19 
20 94.7 2.07 90.3 1.16 89.2 5.64 87.8 6.85 89.9 5.14 
30 91.2 3.45 84.0 2.15 80.0 14.20 77.1 11.01 79.8 8.81 
40 90.3 2.91 82.9 4.17 73.6 15.68 66.7 12.66 69.2 8.80 
50 87.7 7.21 79.9 6 67 70.9 19.29 61.2 12.80 63.7 7.61 
60 86.8 5.60 83.1 7.19 68.7 20.11 60.5 14.64 61.5 8.78 
75 83.3 8.09 84.3 6.07 69.6 20.77 65.1 14.27 61.5 8.81 
90 84.2 8.56 86.7 4.08 73.2 15.62 72.8 11.94 66.5 7.27 
120 84.2 13.09 87.3 3.14 82.3 7.17 84.2 6.81 77.8 6.57 
150 85.9 10.16 86.8 3.66 86.6 1.31 93.1 3.78 88.0 5.34 
180 85.0 9.70 85.4 2.85 90.8 4.11 93.0 0.70 90.9 7.48 
240 88.5 3.35 87.5 4.39 91.5 6.03 96.6 4.74 94.5 6.08 
i 
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Table 7 4. Summary of plasma insulin concentrations following the lntranasal 
administration of 2 IU/ka insulin in combination with different concentration of 
MVCSN in sheep 
Mean (± SD) plasma Insulin concentration 
Time before or 
after closing (min) 
0.1% MVCSN 
SD 
0.2% MVCSN 
SD 
0.33% MVCSN 
SD 
0.3% MVCSN 
SD 
1.0% MVCSN 
SD 
-15 7.1 2.32 12.0 1.22 11.7 5.49 6.9 2.13 8.2 3.36 
-5 7.4 1.99 8.7 0.86 10.9 6.25 6.0 0.94 8.0 3.33 
5 9.4 1.24 29.2 13.30 30.4 11.71 41.2 18.55 50.3 35.19 
10 36.2 11.09 47.3 18.48 81.0 68.07 74.3 11.11 54.5 29.18 
15 28.5 19.62 43.0 29.75 57.2 12.90 706 13.95 86.6 21.17 
20 23.0 17.29 29.5 10.85 52.9 19.13 45.1 3.12 69.0 23.79 
30 14.1 6.40 27.4 32.81 66.9 43.81 37.2 15.08 57.1 21.49 
40 8.7 1.60 10.0 4.54 43.3 28.81 27.4 17.00 33.0 8.49 
50 6.2 2.34 6.6 0.92 26.0 19.93 18.2 7.07 15.5 7.86 
60 6.3 0.28 6.3 0.27 21.6 20.71 15.7 13.10 23.4 16.94 
75 6.6 1.12 5.8 0.80 16.8 16.14 13.6 15.09 10.4 4.20 
90 5.7 1.71 5.4 0.89 8.8 6.28 5.6 4.03 7.8 1.84 
120 4.0 0.68 5.2 0.62 7.0 3.86 4.3 2.36 5.8 2.32 
150 3.7 1.30 4.1 1.11 7.6 3.37 44 1.95 5.6 1.27 
180 3.6 0.74 4.5 0.11 5.9 2.16 5.0 3.03 5.7 2.66 
240 4.3 0.85 5.8 2.27 5.6 1.43 4.1 1.01 5.0 1.86 
Table 7.5. Summary of pharmacokinetic paramenters determined from plasma 
glucose data following the intranasal administration of 2 IU/kg Insulin In 
combination with different concentrations of MVCSN in sheep 
Mean (± SD) 
Formulation or No sheep dip Decrease in imin AQC RatedclLcrease pharmacoiogirril 
Cron number (% e! ose (apI (% glucose. in) of % glucose ayaiyty " 
%/min) % 
1. Insulin with 3 80.6 (± 9.92) 119.4 (± 9.92) 123(156.3) 2980 (t 1661.3) 0.2340.0.121) 2.9 (t 1.63) 
0.1 % MVCSN 
2. Insulin with 4 79.9 (t 6.67) 20.1 (16.67) 50 (14.1) 3113 (t 759.3) 0.42 (± 0.148) 3.1 (± 0.75) 
0.2% MVCSN 
3. Insulin with 4 68.1(± 19.73) 31.9 (t 19.73) 65 (313.7) 3819 (t 1522.8) 0.64 (±0.338) 3.8 (t 1.50) 
0.35% MVCSN 
4. Insulin with 4 59.8 (t 14.43) 40.2 (t 14.43) 59 (17.8) 3699 (31143.3) 0.94 (10.208) 3.6 (t 1.13) 
0.5% MVCSN 
S. Insulin with 4 60.1(± 8.76) 39.9 (18.76) 68 (112.8) 4319 (t 1075.7) 0.87 (± 0.177) 4.2 (t 1.06) 
1.0% MVCSN 
* Relative to subcutaneous 
One-way ANOVA 
Sig. dif. in values of Tmin and rate of decrease of % glucose (P<0.05). 
No sig. dif. in values of Cmin & AOC (P>0.05). 
Tmin: Sig. dif. between groups I vs 2 (P<0.01) and lvs3, lvs4 (P<0.05) 
Rate of decrease of % glucose: Sig. dif. between groups 1 vs 4 (P<0.05) 
No sig. dif. (P>0.05) between all other formulation groups. 
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Table 7.6. Summary of pharmacokinetic paramenters determined from plasma 
Insulin data following the intranasal administration of-2-IU/kg insulin in 
combination with different concentrations of MVCSN In sheen 
Mun (3 SD) 
Formulation or 
Group number am= fmLL Lmjlu (mil/tmin) of Insulin M 
(n MU/11/min) 
1. Insulin + 3 39.3 (± 14.30) 12 (S 2.9) 351 (± 314.3) 0.08 (30.031) 0.5 (± 0.28) 
0.1 % MVCSN 
2. Insulin + 4 53.4 (t 26.22) 13 (t 2.9) 782 (t 666.3) 0.09 (±0.029) 0.9 (t 0.72) 
0.2% MVCSN 
3. Insulin + 4 99.2 (t 60.93) 16 (t 9.5) 2260 (t 1493.7) 0.08 (t 0.048) 2.5 (3 1.62) 
0.35% MVCSN 
4. Insulin+ 4 76.2(±11.16) 11(±23) 2012 (±773.6) 0.12(10.031) 2.2(10.84) 
0.3% MVCSN 
5. Insulin + 4 94.5 (t 13.77) 14 (t 2.5) 2370 (±962.3) 0.13 (t 0.098) 2.6 (± 1.05) 
1.0% MVCSN 
" Relative to subcutaneous 
Statistical Analysis 
One-way ANOVA 
No sig. dif. in values of Cmax, Tmax, AUC and rate of increase of insulin (P>0.05). 
Fie 7.1. Plasma glucose and insulin concentration versus time profiles following 
the intranasal administration of 2 IU/kg insulin in combination with different 
concentrations of MVCSN in sheep 
A. Glucose conc. versus time profiles 
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Figure 7.2. Values of pharmacokinetic parameters determined from Qlucose or 
Insulin data following the intranasal administration of--2- IU/kg insulin In 
combination with different concentrations of MVCSN in sheen 
A. Decrease in glucose conc. 
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7.3 Effect of chitosan dose on the intranasal absorption of 
insulin in sheep 
7.3.1 Aims and Objectives 
The previous study showed that increasing the concentration of MVCSN in the 
formulation improved nasal insulin absorption until an optimal concentration was 
reached. Increasing the concentration of chitosan in the formulation will inevitably 
increase the viscosity of the formulation which may in-part account for improved efficacy 
(refer to Section 10.5). Increasing chitosan concentration will also increase the dose of 
chitosan administered nasally to sheep. Thus, the aim of this study was to investigate the 
effect of the dose of chitosan on its nasal absorption enhancing efficacy. The dose of 
chitosan administered to sheep was adjusted by varying the dose volume administered. 
The use of a fixed concentration of chitosan in the formulations (0.5% MVCSN) ensured 
that any changes in the absorption enhancing efficacy of the formulations was not 
attributed to changes in the viscosity of the solutions. The insulin concentration of the 
formulations was appropriately adjusted to maintain a fixed dose of insulin at 2 IU/kg- 
The nasal dose of MVCSN was varied between 0.0125-0.2 mg/kg by varying dose 
volume between 0.0025-0.04 ml/kg. 
7.3.2 Materials and Methods 
7-3.2.1 Materials 
Materials used were as given in Section 7.2. 
7 3.2.2 Preparation of insulin formulations 
Five solution formulations were prepared for nasal administration to sheep as given in 
Table 7.8. Each formulation contained a sufficient concentration of insulin to administer 
a dose of 2 IU/kg at the appropriate dose volume (refer to Table 7.7). All formulations 
were prepared in 14.65 mM phosphate buffer of pH 7.4 and were adjusted to pH 4 
during preparation by the addition of HCI. Each formulation was freshly prepared on the 
day of the study. 
Table 7.7. Outline composition of formulations 
Formulation No. Outline composition 
1 50 IU/ml insulin with 0.5% (5.0 mg/ml) MVCSN, pH 4 
2 100 IU/ml insulin with 0.5% (5.0 mg/ml) MVCSN, pH 4 
3 200 IU/ml insulin with 0.5% (5.0 mg/ml) MVCSN, pH 4 
4 400 IU/ml insulin with 0.5% (5.0 mg/ml) MVCSN, pH 4 
5 800 IU/ml insulin with 0.5% (5.0 mg/ml) MVCSN, pH 4 
* Concentration of MVCSN is expressed as the concentration of chitosan glutamate 
7.3.2.3 Absorption study in the sheep model 
Sheep were dosed nasally with the appropriate insulin formulation. A summary of the 
dose groups is given in Table 7.8. Nasal doses of 2 IU/kg insulin were administered. 
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The dose volume was varied between 0.0025-0.04 ml/kg. Each nasal dose was divided 
between both nostrils. In view of the results obtained following glucose analysis, 
plasma insulin analysis was not performed. 
7.3.3 Results & Discussion 
The results showed that at a fixed dose of insulin (2 IU/kg), variations in the dose of 
MVCSN and the dose volume did not significantly influence the intranasal absorption of 
insulin in sheep (Tables 7.9-7.10, Figures 7.3-7.4). Furthermore, altering the 
concentration of insulin in the formulation over a wide range (50-800 IU/ml) had no 
apparent effect on the performance of the formulation. The plasma glucose versus time 
profiles of each group of sheep followed a similar trend (Figure 7.3). The return towards 
basal concentrations of plasma glucose appeared to be more rapid in sheep dosed with 
0.2 mg/kg MVCSN (0.04 ml/kg). However, the inter-animal variations for this group of 
animals were high (Table 7.9). A dose of 2 IU/kg insulin with 0.5% MVCSN 
administered at 0.01 ml/kg, did not perform as well as the other formulations in terms of 
the lowering of plasma glucose concentrations over the experimental period (Table 7.9, 
Figure 7.3). The reasons for this are not known but in view of the results from the other 
dose groups in which much higher and lower doses of chitosan and dose volumes were 
administered without apparently affecting glucose concentrations the results for this dose 
group were considered anomalous. 
The pharmacokinetic parameters determined from the glucose data (Table 7.10, Figure 
7.4) show that taking into account inter-animal variability there was little difference 
between the dose groups. Values of Cmin ranged between about 63-77 % glucose with 
values of Tmin of 70-105 minutes. The rates of decrease of glucose concentrations 
ranged from 0.5-0.9 % glucose/min, values of AOC from 2624-4532 % glucose. min and 
values of pharmacological availability from 2.6-4.5%. Statistical analysis of the data 
with a one-way ANOVA (Table 7.10) showed that there were no significant differences 
between the dose groups in values of Cmin, Tmin, AOC (hence pharmacological 
availability) and the rate of reduction of glucose concentrations. Values of 
pharmacological availability obtained for the different dose groups ranged between 2.6- 
4.5 % (Table 7.10). 
The intranasal absorption of insulin was not apparently affected by changes in the dose of 
MVCSN coadministered or by changes in the dose volume administered. In view of 
these results and those from the previous study which assessed different concentrations I 
doses of chitosan, at a fixed dose of insulin it appears that it is the concentration of 
chitosanin the formulation rather than the dose of chitosan coadministered which is the 
important factor influencing nasal absorption. This suggests that the effect of chitosan on 
the nasal membrane reaches a maximum. Increasing the dose volume administered 
should increase the surface area of the nasal cavity covered by the insulin formulation, 
thus, increase the absorptive surface area. This would be expected to increase insulin 
absorption. However, since the degree of absorption was not affected by varying the 
dose volume then absorption may be limited by the dose of insulin administered in the 
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formulation. Thus, it was decided that the effect of the nasal dose of insulin should be 
evaluated. 
Table 7.8. Summary of formulations and dose groups in the study to investigate the 
effect of chitosan concentration on the intranasal absorption of insulin in sheep 
Formulation or Group No. Insulin 
(IU/kg) 
MVCSN 
(mg/kg) 
Dose volume 
(mfg) 
1.50 IU/ml Insulin + 0.5% MVCSN 2.0 0.2 0.04 
2.100 IU/ml Insulin + 0.5% MVCSN 2.0 0.1 0.02 
3.200 IU/ml Insulin + 0.5% MVCSN 2.0 0.05 0.01 
4.400 IU/ml Insulin + 0.5% MVCSN 2.0 0.025 0.005 
5.800 IU/ml Insulin + 0.5% MVCSN 2.0 0.0125 0.0025 
* The dose of MVCSN was expressed as the dose of chitosan glutamate 
Table 7.9. Summary of plasma glucose concentrations following the intranasal 
administration of 2 IU/kg insulin with different doses of MVCSN and at various 
dose volumes in sheep 
Mean (± SD) plasma glucose concentration (% of basal) 
Time before or 0.2 mg/kg MVCSN 0.1 mg/kg MVCSN 0.05 mg/kg MVCSN 0.025 mg/kg MVCSN 0.0125 mg/kg MVCSN 
after dosing (min) SD SD SD SD SD 
Mean SD Mean SD Mean SD Mean SD Mean SD 
-15 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
-5 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
5 97.2 2.86 98.2 2.89 99.4 2.27 100.5 3.86 96.1 5.52 
10 96.5 2.21 100.0 3.26 99.5 3.69 101.3 1.91 98.6 6.22 
15 94.5 4.37 98.7 3.52 99.6 5.30 100.1 3.18 96.9 5.98 
20 91.7 5.93 95.1 6.43 97.1 6.02 95.6 2.46 94.4 7.86 
30 81.7 12.41 89.1 11.45 90.5 9.22 85.3 5.76 87.6 7.01 
40 72.3 15.01 81.9 16.97 85.5 9.05 76.2 9.54 80.3 9.00 
50 69.0 18.89 73.4 20.40 82.3 8.60 68.8 10.81 73.6 10.61 
60 65.9 20.33 69.2 20.41 78.4 4.20 63.3 14.16 68.9 12.74 
75 72.4 17.68 70.5 15.65 77.1 4.98 62.7 14.58 68.5 15.89 
90 80.0 8.45 71.2 12.31 80.6 6.33 64.6 15.38 69.8 19.38 
120 87.4 5.59 79.6 7.57 86.8 7.18 75.1 13.70 73.0 21.35 
150 90.2 4.96 86.2 5.82 92.3 9.94 82.5 12.21 81.9 15.88 
180 91.8 6.85 90.5 5.99 94.8 9.86 87.8 6.46 87.5 7.52 
240 91.3 7.83 90.4 5.22 96.2 10.19 93.1 2.59 91.3 6.25 
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Table 7.10. Summary of pharmacokinetic paramenters determined from plasma 
glucose data following the intranasal administration of 2 IU/kg insulin with 
different doses of MVCSN and at various dose-volumes in sheep 
Mean ± SID (n-4) 
Formulation or 
Group number 
Crain 
(% glucose) 
Train 
(min) 
AOC 
(% glucose. min) 
Rate of decrease 
of glucose 
9F/min) 
Pharmacological 
availability " 
9F 
1 64.9 (± 18.88) 105 (± 90.0) 3351 (± 1085.3) 0.90 ± 0.570 3.3 t 1.07) 
2 66.3 t 17.58) 86 (± 33.3) 3774 t 1576.1) 0.73 t 0.470) 3.7 t 1.55) 
3 76.5 (t 3.83) 73 (±13.7) 2624 t 1377.7) 0.50 t 0.136) 2.6 t 1.35) 
4 62.7 t 14.57) 70 t 61.3) 4532 t 1887.8) 0.85 t 0.228) 4.5 t 1.86 
S 65.4 t 17.27) 75 t 21.2) 4349 t 2525.3) 0.60 3 0.194 4.3 ± 2.48 
0 Relative to subcutaneous 
Statistical Analysis 
One-way ANOVA 
No sig. dif. in values of Cmin, Tmin, AOC and rate of decrease of glucose concentrations 
& pharmacological availability (P>0.05). 
Fie 7.3. Plasma glucose concentration versus time profiles following-the- intranasal 
administration of 2 IU/kg insulin with different doses of MVCSN and at various 
dose volumes in sheen 
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Figure 7.4. Values of pharmacokinetic parameters determined from glucose data 
following the intranasal administration of 2-TU/kg Insulin with different doses of 
MVCSN and at various dose volumes in sheer 
80 
5 70 
eo 
60 
50 
A. Values of Cmin 
90 
B. Values of AOC 
7000 1T 
6000 
5000 
4000 ö 
ýj 3000 
Oa 
2000 
40 1000 
-F 0 0.05 0.1 0.15 0.2 0 
MVCSN dose (mg/kg) 
C. Values of Pharmacological av 
8l 
* Relative to subcutaneous 
6T 
.ýI %IT 
12 11 
0 
7.4 
0 0.05 0.1 0.15 0.2 
MVCSN dose (mg/kg) 
Effect of insulin dose concentration on the nasal 
absorption enhancing efficacy of chitosan in sheep 
7.4.1 Aims and Objectives 
The previous study suggested that the absorption of insulin may be limited by the dose 
concentration of insulin administered rather than by the absorptive capacity of the nasal 
cavity. Thus, in this study the effect of varying the dose concentration of insulin on 
nasal absorption from an insulin / MVCSN formulation was assessed. The concentration 
of insulin in the formulation was varied between 50-400 IU/ml whereas the concentration 
of chitosan was fixed at 0.5%. Thus, by administering fixed volumes (0.01 ml/kg) of 
each solution formulation, doses of insulin between 0.5-4.0 IU/kg were administered. 
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0.05 0.1 0.15 0.2 
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7.4.2 Materials and Methods 
7-4,2.1 Materials 
Materials used were as given in Section 7.2. 
7.4-2.2 Preparation of insulin formulations 
Four solution formulations were prepared for nasal administration to sheep as given in 
Table 7.11. Each formulation contained an appropriate concentration of insulin to 
administer the insulin doses specified in Table 7.12 (dose volume 0.01 ml/kg). All 
formulations were prepared in 14.65 mM phosphate buffer of pH 7.4 and were adjusted 
to pH 4 during preparation by the addition of 1M HCI. Each formulation was freshly 
prepared on the day of the study. 
Table 7.11. Outline composition of formulations 
Formulation No. Outline composition 
1 50 IU/mi insulin with 0.5% (5.0 mg/ml) MVCSN, pH 4 
2 100IU/ml insulin with 0.5% (5.0 mg/ml) MVCSN, pH 4 
3 200 IU/ml insulin with 0.5% (5.0 mg/ml) MVCSN, pH 4 
4 400 IU/ml insulin with 0.5% (5.0 mg/m1) MVCSN, pH 4 
* Concentration of MCSN expressed as concentration of chitosan glutamate 
7.4.2.3 Absorption study in the sheep model 
Sheep were dosed nasally with the appropriate insulin formulation. A summary of the 
dose groups is given in Table 7.12. Nasal doses of 0.5-4.0 IU/kg insulin were 
administered at a dose volume of 0.01 ml/kg. Each nasal dose was divided between both 
nostrils. 
7.4.3 Results & Discussion 
The results showed that increasing the nasal dose of insulin increased both the reduction 
of plasma glucose concentrations and the elevation of plasma insulin concentrations 
(Tables 7.13-7.14, Figure 7.5). Values of Cmin and AOC obtained from the glucose data 
and Cmax and AUC obtained from the insulin data displayed a curvilinear relationship 
with increase in insulin concentration (Figure 7.6). Values of Cmin were approximately 
88,70,58 and 42 % glucose for doses of 0.5,1.0,2.0 and 4.0 IU/kg insulin, 
respectively. Corresponding values of AOC were 1087,3814,5211 and 6915 % 
glucose. min, respectively. Values of Cmax after dosing 0.5,1.0,2.0 and 4.0 IU/kg 
insulin were approximately 184,166,395 and 951 mU/1, respectively with values of 
AUC of 6296,7228,9926 and 33415 mU/l. min, respectively. 
Increase in the dose of insulin from 0.5-2.0 IU/kg had little affect on rates of reduction of 
glucose concentrations (Table 7.15) or rates of increase of insulin concentrations (Table 
7.16) although rates were increased following the administration of 4.0 IU/kg insulin. 
Considering interanimal variations, values of pharmacological availability were 
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approximately of the same order of magnitude for each dose group (3.4-7.5 %) (Table 
7.15). The slightly lower value (3.4%) after administering a higher nasal dose of insulin 
(4 IU/kg) could be due to saturation of the mechanisms which lower blood glucose 
concentrations during glucose homeostasis. In sheep glucose is not the main substrate of 
tissue metabolism and insulin secreting cells account for only about 12% of the pancreatic 
islet cells (Hecker, 1983) compared to about 75% of islet cells in man (Espinal, 1989). 
Thus, glucose homeostasis in the sheep is probably not as important as that in 
monogastric animals. Values of bioavailability for the dose groups ranged between 
approximately 11-27% (Table 7.16). Considering that in previous studies the values of 
pharmacological availability have provided a reasonable estimate of values of 
bioavailability, the values of bioavailability obtained in this study would appear to be 
anomalously high. However, no source of error in the analysis or in the processing of 
the data has been found although there were initial problems with the insulin 
radioimmunoassay. Thus, in this study, comparison of the performance of the 
formulations using values of bioavailability should be made with caution. 
There were statistically significant differences in values of Cmin, AOC and rates of 
reduction of glucose concentrations between the formulation groups although there were 
no significant differences between values of Tmin and pharmacological availability 
(Tables 7.15). Also, there were significant differences in values of Cmax, AUC and 
relative bioavailability but not in values of Tmax and rates of increase in insulin 
concentrations (Table 7.16). Differences in values of Cmin, AOC, Cmax and AUC are 
not unexpected considering the different doses of insulin administered in the study. 
Increase in the dose of insulin coadministered with MVCSN at a fixed dose volume will 
increase the concentration gradient of the drug across the nasal mucosa. This will 
increase the passsive absorption of insulin across the nasal membrane. The results 
indicated that the absorptive capacity of the nasal membrane was not saturated by an 
increase in the dose of insulin administered. The dose of insulin and/or its release 
appeared to be the factor limiting the overall absorption of insulin from the formulation. 
Table 7.12. Summary of formulations and dose groups in the study to investigate 
the effect of the dose of insulin on the intranasal absorption of insulin in sheep 
Formulation or Group No. Insulin 
(IU/kg) 
MVCSN 
(mg/kg) 
Dose volume 
(ml/k8) 
1.50 IU/ml Insulin + 0.5%MVCSN 0.5 0.05 0.01 
2.100 IU/ml Insulin + 0.5% MVCSN 1.0 0.05 0.01 
3.200 IU/ml Insulin + 0.5% MVCSN 2.0 0.05 0.01 
4.400 IU/ml Insulin + 0.5% MVCSN 4.0 0.05 0.01 
* Dose of MVCSN expressed as dose of chitosan glutamate 
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Table 7.13. Summary of plasma glucose concentrations followinr the intranasal 
administration of different doses of insulin with fixed doses of MV SN and fixed 
dose volumes in sheep 
Mean (± SD) glucose concentration (% of basal) 
Time before or 
after dosing (min) 
0.5 WAS insulin 
SD 
1.0IU/kg insulin 
SD 
2.01U/kg insulin 
SD 
4.0 lU/kg insulin 
SD 
-15 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
.5 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
5 99.3 1.82 96.2 2.00 100.0 1.97 97.0 1.63 
10 102.2 2.59 97.0 3.56 100.0 1.15 97.1 3.82 
15 101.0 6.90 95.5 5.07 98.0 1.74 94.4 4.28 
20 99.0 6.94 90.1 7.83 93.8 2.96 89.2 4.91 
30 95.5 6.88 83.9 10.25 86.9 2.05 74.5 6.19 
40 91.3 6.85 79.0 10.30 80.8 1.83 63.9 6.46 
50 92.0 7.35 74.8 8.81 74.6 2.41 55.2 5.34 
60 91.8 7.39 74.7 8.50 69.8 4.80 46.6 5.14 
75 91.6 6.08 77.3 10.43 65.7 12.96 41.9 5.17 
90 93.6 5.53 76.5 13.77 64.7 19.24 42.5 4.17 
120 96.7 3.25 79.9 14.10 69.3 25.99 49.4 6.62 
150 95.3 2.49 82.9 8.23 74.0 24.73 69.4 10.14 
180 95.2 2.71 86.5 2.98 79.5 20.45 87.8 4.33 
240 98.0 4.23 90.7 2.96 88.8 5.91 99.0 4.74 
Table 7.14. Summary of plasma insulin concentrations following the intranasal 
administration of different doses of insulin with fixed doses of MVCSN and fixed 
dose volumes in sheep 
Mean (t SD) Insulin concentration (% of basal) 
Time before or 
after dosing (min) 
0.5 WAS insulin 
SD 
1.0 WAS insulin 
SD 
2.0 WAS insulin 
SD 
4.0 lU/kg insulin 
SD 
-15 13.0 2.51 11.0 3.06 9.5 2.74 10.2 2.04 
-5 14.1 5.75 10.0 3.28 9.9 0.89 10.0 2.29 
5 111.6 78.61 67.2 32.57 62.6 46.45 158.9 40.15 
10 74.5 68.44 112.2 62.88 101.8 40.59 269.5 187.43 
15 71.8 75.17 100.9 65.61 241.6 174.41 649.8 307.55 
20 54.2 38.28 96.8 81.17 192.9 137.96 755.0 165.96 
30 92.8 60.96 87.6 31.27 256.2 195.69 848.5 324.88 
40 99.6 66.29 93.8 79.62 93.1 93.70 415.7 201.50 
50 52.4 31.80 95.1 62.41 98.0 71.90 328.9 201.29 
60 43.3 21.27 62.8 88.01 49.5 27.86 204.9 97.60 
75 33.7 4 86 47.5 37.70 43.6 9.07 98.2 40.30 
90 65.7 9.78 30.0 11.97 28.5 16.39 63.1 35.84 
120 25.6 13.28 17.1 8.28 16.9 9.18 29.0 21.22 
150 22.0 7.86 20.2 7.10 22.8 6.84 25.1 9.22 
180 20.1 5.66 24.6 8.84 17.4 5.71 28.4 13.03 
240 17.2 3.27 13.0 2.17 12.8 2.97 15.8 4.02 
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Fable 7.15. Summary of pharmacokinetic parnmenters determined from plasma 
glucose data following the intranasal administration of different doses of insulin 
with fixed doses of MVCSN and fixed dose volumes in sheep 
Meant SD n. 4 
Formulation or jpgyfin min imjp AQC Rate o(d ace Phnrmarnloeical 
Group number (ILAO (% g oce) jmjpl (% glucose- mini of alums avnilnbility a 
9F/min W 
1 0.5 88.4 f 3.02 88 3 63.9) 1087 ± 689.5 0.43 t 0.079 4.3 t 2.71 
2 1.0 69 8 (t 10.96) 67 t 22.7) 3814 t 1381.4) 0.63 (t 0.208) 7.5 (t 2.72) 
3 2.0 57.8 t 18.37) 85 (t 27.4) 5211 t 3282.2) 0.62 t 0.084) 5.1 t 3.23) 
4 4.0 41.5 t 4.72) 81 (t 7.2) 6915 t 1028.8) 0.90 (t 0.102 3.4 2 0.31 
* Relative to subcutaneous 
One-way ANOVA 
Sig. dif. in values of Cmin (P<0.001), AOC and rate of decrease of glucose concentration (P<0.01). 
No sig. dif. in values of Tmin & pharmacological availability (P>0.05). 
Tukey-Kramer Multiple Comparison test following one-way ANOVA 
Cmin: Sig. dif. between groups lvs4 (P<0.001) & lvs3,2vs4 (P<0.05). 
AOC: Sig. dif. between groups lvs4 (P<0.0 1) & lvs3 (P<0.05). 
Rate of decrease of glucose conc.: Sig. dif. between groups lvs4 (P<0.01) and 3vs4 (P<0.05). 
No sig. dif. (P>0.05) between other formulation groups. 
Table 7.16. Summary of pharmacokinetic paramenters determined from plasma 
insulin data following the intranasal administration of different doses of insulin 
with fixed doses of MVCSN and fixed dose volumes in sheep 
Mean ± SD (n. 4) 
Formulation or jpiy(ip anal imax AL IC Rate of increase Binavaiiability " 
Group mb LILLkg1 LmLfl lminl (mU/L mm) of inrulin L`ý1 ( lo mU/I min) 
1 0.5 184.0(±17.65) 15(±10.8) 6296(±867.4) 0.151±0.104) 27.4(±3.77) 
2 1.0 166(± 41.9) 24 (± 18.0) 7228 (±4178.8) 0.14 1± 0.067) 15.7 (t 9.08) 
3 2.0 394.5(±107.73) 23 (± 8.7) 99261±43094) 0.121±0069) 10.8(±468) 
4 4.0 931.1 1t 234.84) 24 (t 7.5) 33415 It 11232.6) 0.24 (± 0.028) 18.2 It 6.11) 
* Relative to subcutaneous 
One-way ANOVA 
Sig. dif. in values of Cmax, AOC (P<0.001) and Bioavailability (P<0.05). 
No sig. dif in values of Tmax and rate of increase of insulin (P>0.05). 
Tukey-Kramer Multiple Comparison test following one-way ANOVA 
Cmax: Sig. dif. between groups Ivs4,2vs4 & 3vs4 (P<0.001) 
AUC: Sig. dif. between groups Ivs4,2vs4 & 3vs4 (P<0.001) 
Bioavailability: Sig. dif between group lvs3 (P<0.05). 
No sig. dif. (P>0.05) between all other formulation groups 
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Figure 7.5. Plasma glucose and insulin concentration versus time profiles 
following the intranasal administration of different doses of insulin with fixed doses 
of MVCSN and fixed dose volumes in sheep 
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Figure 7.6. Values of pharmacokinetic parameters determined from glucose-and 
Insulin data following the Intranasal administration of different doses of Insulin 
with fixed doses of MVCSN and fixed dose volumes In sheep 
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75_ Effect of administration of different dose volumes of-the- 
same formulation on the intranasal absorption of insulin 
in sheep 
7.5.1 Aims and Objectives 
In the last of a series of studies to investigate the relationship between formulation 
concentrations and doses of insulin / chitosan and dose volumes on the efficacy of 
intranasal insulin absorption, the effect of nasally administering different volumes of a 
formulation containing fixed concentrations of insulin and MVCSN was investigated. 
This study also mimics a situation which may occur if an insulin / chitosan formulation is 
used therapeutically to treat diabetes. Poor patient compliance may inevitably lead to 
under or overdose of the formulation and hence the likely affects of this should be 
anticipated. 
7.5.2 Materials and Methods 
7.5.2 
.1 Materials 
Materials used were as given in Section 7.2. 
7. 
. 
2.2 Preparation of insulin formulation 
A solution formulation was prepared for nasal administration to sheep containing 200 
IU/ml insulin with 0.5% (5.0 mg/ml) MVCSN, expressed as the concentration of 
chitosan glutamate. The solution was prepared in 14.65 mM phosphate buffer of pH 7.4 
and was adjusted to pH 4 during preparation by the addition of HCI. The formulation 
was freshly prepared on the day of the study. 
7.5.2.3 Ab orption study in the sheep model 
The 200 IU/ml insulin with 0.5% (5.0 mg/ml) MVCSN solution formulation was 
administered at different dose volumes. By varying the dose volume administered 
(between 0.0025-0.03 ml/kg) 
, 
the insulin and chitosan doses were altered (0.5-6.0 
IU/kg and 0.0125-0.015 mg/kg, respectively). A summary of the dose groups is given 
in Table 7.17. The dose volume was varied between 0.0025-0.03 ml/kg. Each nasal 
dose was divided between both nostrils. 
7.5.3 Results & Discussion 
The results showed that the absorption of insulin, in-terms of deceases in plasma glucose 
concentrations and elevations of plasma insulin concentrations, increased with an increase 
in the volume administered of the 200 IU/ml insulin / 0.5% MVCSN formulation (Tables 
7.18-7.19, Figure 7.8). Thus, insulin absorption increased with increase in the doses of 
insulin and MVCSN administered. The relationship between dose volume and selected 
pharmacokinetic parameters is given in Tables 7.20-7.21 and Figure 7.9. Figure 7.9 
shows a curvilinear relationship between values of Cmin and AOC and the approximately 
linear relationship between values of Cmax and AUC. 
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Values of pharmacological availability were shown to decrease slightly at higher dose 
volumes which may reflect saturation of the mechanisms involved in lowering blood 
glucose concentrations. This is supported by values of Cmin and AOC which generally 
appear to be reaching a plateau towards the higher dose volume. Values of bioavailability 
show that, taking into account the high interanimal variability at low dose volume, values 
were similar for each dose group. Rates of reduction of plasma glucose concentrations 
and rates of increase of plasma insulin concentrations were shown to increase with 
increase in dose volume followed by a plateau between 0.02-0.03 ml/kg (Tables 7.20- 
7.21). 
As previously reported, the concentration of chitosan in the formulation rather than 
chitosan dose influenced the absorption of insulin. Thus, in this study the increase in 
insulin absorption with increase in dose volume is probably due to the increase in the 
dose of insulin rather than the increase in chitosan dose. Furthermore, increase in dose 
volume is likely to increase the spread of the formulation in the nasal cavity and hence the 
absorptive surface area. 
Table 7.17. Summary of formulations and dose groups in the study to investigate 
the effect of administering different dose volumes of the same formulation on the 
intranasal absorption of insulin in sheep 
Formulation 
or Group No. 
Insulin 
(IU/kg) 
MVCSN 
(mg/kg) 
Dose volume 
(ml/kg) 
1 0.5 0.0125 0.0025 
2 1.0 0.025 0.005 
3 2.0 0.05 0.01 
4 4.0 0.01 0.02 
5 6.0 0.015 0.03 
* Dose of MVCSN expressed as dose of chitosan glutamate 
Table 7.18. 
- 
Summary of plasma glucose concentrations following the Intranasal 
administration of different dose volumes of the same formulation in sheen 
Mean (t SD) glucose concentration (% of basal) 
Time before or 0.0025 g 0.005 ml/kg 0.01 nil/kg 0.02 ml/kg 0.03 ml/kg 
after dosing (min) 1S SD SD SD SD SD 
-13 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
-3 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
5 95.3 5.27 98.1 2.64 98.3 2.63 98.7 3.37 98.0 1.73 
10 96.7 4.84 98.1 2.64 100.4 4.35 98.6 4.07 98.5 2.06 
15 98.2 3.20 99.5 2.99 98.9 4.20 95.9 2.95 94.1 7.17 
20 95.3 5.13 98.7 2.56 93.9 3.39 93.0 2.00 88.8 10.23 
30 93.9 7.76 91.8 6.61 82.5 4.49 77.0 7.81 73.4 13.87 
40 893 13.16 85.8 5.78 73.2 7.74 69.3 8.32 64.0 16.65 
50 91.0 11.79 83.0 5.93 70.3 9.85 63.8 7.01 61.9 17.82 
60 91.7 12.49 78.4 7.08 68.8 12.05 62.5 2.03 58.5 13.51 
75 93.2 4.01 77.8 9.91 70.3 14.79 63.9 1.62 60.0 13.96 
90 96.0 5.91 83.1 10.08 75.3 16.06 73.1 9.10 69.9 18.63 
120 96.1 4.34 89.3 9.20 86.8 8.05 84.2 10.57 76.1 15.81 
150 98.3 2.16 91.4 6.81 93.3 8.06 91.1 6.94 88.6 7.39 
180 98.9 2.19 95.4 4.00 97.6 8.82 98.0 9.57 97.5 3.10 
240 99.6 2.49 99.5 3.77 103.3 7.43 106.3 8.45 106.4 3.71 
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Table 7.19. Summary of plasma Insulin-concentrations- following the intranasal 
administration of different dose volumes of the some formulation in sheep 
Mean (i SD) insulin concentration (mU/1) 
Time before or 
after dosing (min) 
0.0025 ml/kg 
SD 
0.005 mIkg 
SD 
0.01 mIkg 
SD 
0.02 mI/kg 
SD 
0.03 ml/kg 
SD 
-IS 18.2 6.54 13.8 3.93 12.6 4.29 10.2 2.34 15.6 5.98 
-5 20.6 5.18 15.4 2.63 11.8 2.31 16.8 4.76 22.0 6.34 
5 36.0 9.77 22.3 3.58 36.8 16.75 553 29.84 88.2 15.95 
10 56.6 32.98 46.2 9.60 62.8 19.51 141.8 102.91 202.8 97.45 
15 51.0 21.70 56.2 21.83 70.0 16.54 134.1 76.68 167.6 87.69 
20 59.1 47.45 50.3 12.64 81.0 26.53 129.6 64.06 183.7 109.14 
30 37.4 29.28 32.8 8.67 62.3 41.35 126.9 62.16 164.0 114.80 
40 39.1 16.59 31.8 8.60 79.8 81.01 98.9 51.51 157.8 119.58 
50 20.1 2.96 26.8 10.29 43.9 20.28 62.8 25.82 100.3 63.87 
60 33.4 16.67 26.0 11.93 33.1 8.20 54.0 13.31 76.3 53.10 
75 18.0 1.74 17.1 5.13 23.7 7.32 24.3 7.61 41.2 23.23 
90 24.0 7.56 14.2 2.63 16.5 1.91 183 5.39 32.3 11.69 
120 21.9 1.36 16.8 3.67 19.3 12.38 21.2 0.80 23.4 3.58 
ISO 16.1 6.31 11.4 3.03 13.7 1.99 15.8 3.64 17.0 4.20 
180 14.9 4.47 15.4 4.73 11.2 1.76 16.8 3.33 18.7 3.39 
240 16.0 8.98 15.4 2.11 14.8 2.18 12.0 2.48 17.1 5.42 
Table 7.20. Summary of pharmacokinetic uaramenters determined from plasma 
glucose data following the intranasal administration of different dose volumes of the 
same formulation in sheep 
Mean (t SD) 
Formulation or Dose vol. cmjp imilL AUC Rate of decrease Pharmacoloelcall 
Group number a) (% Qlucose) jijpl (% glucose_ min) ofyjppese availabili ^0 
9 /min 
1 0.0025 88.1 (± 11.83) 58 t 20.2) 887 (± 933.0) 0.32 t 0.389) 3.5 t 3.67) 
2 0.005 75.6 t 8.32) 69 t 11.3) 2197 (±1141.4) 0.48 t 0.208) 4.3 t 2.24) 
3 0.01 65.4 (± 10.32) 59 t 12.5) 2964 t 1435.6) 0.84 t 0.245) 2.9 (t 1.41) 
4 0.02 60.4 (±4.07) 62 t 10.3) 3453 t 1028.0) 1.01 t 0.548) 1.7 (± 0.51 
5 0.03 55.6 t 14.05) 58 t 11.9) 4012 t 1957.5) 1.11 (t 0.295) 1.31±0.64 
* Relative to subcutaneous 
One-way ANOVA 
Sig. dif. in values of Cmin (P<0.01) and AOC (P<0.05). 
No sig. dif. in values of Tmin, rate of decrease of glucose conc. & pharmacological availability (P>0.05). 
Tukey-Kramer Multiple Comparison test following ANOVA 
Cmin: Sig. dif. between groups Ivs5 (P<0.01) & lvs3, Ivs4 (P<0.05). 
AOC: Sig. dif. between group lvs5 (P<0.05). 
No sig. dif. (P>0.05) between other formulation groups. 
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Table 7.21, Summary of pharmacokinetic paramenters determined from plasma 
Insulin data following the intranasal administration of different dose volumes of the 
same formulation in sheep 
Mean SD n. 4 
Formulation or 
Group number 
Dose vol. 
(mllkg) 
Cmax 
(% glucose) 
Tmax 
(min) 
AUC 
(mUA. min) 
Rate of increase 
of Insulin 
o mUQ min) 
Bioaveilability " 
(%) 
1 0.0025 69.0 (t 41.12) 24 (t 25.0) 1539 (± 996.9) 0.04 ± 0.015) 6.7 (±4.33) 
2 0.005 60.7 t 18.17) 15 t 4.1) 1126(±399.9) 0.05(±0.014) 2.5 (t 0.87 
3 0.01 108.6 (t 64.61) 25 t 12.9) 3753(±2369.0) 0.08(±0.034) 4.1 (t 2.57 
4 0.02 178 0 (t 93.50) 25 t 12.9) 6079(±2887.9) 0-11(±0-060L 3.3 (t 1.57) 
5 0.03 240.0 110.56) 19 t 14.4) 8652(±5261.0) 0.10(±0.018) 3. I 1t 1.90 
* Relative to subcutaneous 
Statistical Analysis 
One-way ANOVA 
Sig. dif, in values of Cmax and AUC (P<0.05). 
No sig. dif. in values of Tmax, rate of increase of insulin conc. & Bioavailability (P>0.05). 
Tukey-Kramer Multiple Comparison test following one-way ANOVA 
Cmax: Sig. dif. between groups lvs5 & 2vs5 (P<0.05). 
AUC: Sig. dif. between group ivs5 & 2vs5 (P<0.05). 
No sig. dif. (P>0.05) between other formulation groups. 
Fig 7.7. Plasma glucose and insulin concentration versus time profiles following 
the intranasal administration of different dose volumes of the same formulation in 
sheep 
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Figure 7.8. Values of selected pharmacokinetic parameters following the intranasal 
administration of different dose volumes of the same formulation in sheep 
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7.6 Effect of different vehicles on the absorption enhancing 
efficacy of chitosan 
7.6.1 Aims and Objectives 
Previous studies in the rat showed that a hypertonic formulation of insulin / chitosan was 
shown to increase the nasal absorption of insulin relative to that obtained in hypotonic 
and isotonic media. There were no apparent differences in the performance of the 
formulation in hypotonic or isotonic media. In the previous studies performed in sheep, 
formulations were prepared in a hypotonic phosphate buffer. Thus, the aim of this study 
was to investigate the effect of hypotonic or isotonic vehicles on the absorption 
enhancing efficacy of MVCSN. A hypotonic solution prepared in 14.65 mM phosphate 
buffer was compared to a isotonic solution prepared in 0.85% sodium chloride (NaCI). 
As a control, an insulin solution without MVCSN was prepared in 14.65 mM phosphate 
buffer. All three formulations were prepared at pH 4.0. 
7.6.2 Materials and Methods 
7.6.2.1 Materials 
The materials used were as given in Section 7.2. 
7.6.2.2 Preparation of insulin formulation 
Three solution formulation, each containing 200 IU/ml insulin, were prepared for nasal 
administration to sheep. A summary of the formulations prepared is given in Table 7.21. 
Formulations were prepared in either 14.65 mM phosphate buffer of pH 7.4 or 0.9% 
NaC1 and each formulation was adjusted to pH 4 during preparation by the addition of 1 
M HCI. The formulations were freshly prepared on the day of the study. 
Table 7.22. Outline composition of the formulations 
Formulation Outline composition Osmolality 
No. (Osmol/kg) 
1 200 IU/ml insulin in phosphate buffer, pH 4 0.091 (control solution) 
2 200 IU/ml insulin with 0.5% (5.0 mg/ml) MVCSN 0.110 
in phosphate buffer, pH 4 
3 200 IU/ml insulin with 0.5% (5.0 mg/ml) MVCSN 0.310 
in 0.85% NaCl, pH 4 
* Concentration of MVCSN expressed as concentration of chitosan glutamate 
7.6.2.3 Absorption study in the sheep model 
Sheep were dosed with 2 IU/ml insulin from the appropriate insulin formulation at 0.01 
ml/kg. A summary of the dose groups is given in Table 7.22. Each nasal dose was 
divided between both nostrils. In view of the glucose results, plasma insulin 
concentrations were not measured. 
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7.6.3 Results & Discussion 
As expected from previous results, the nasal absorption of insulin was poor without 
coadministration with MVCSN (Tables 7.22-7.23, Figure 7.10). The pharmacological 
availability, relative to subcutaneous, for the control solution at pH 4.0 was about 0.7% 
compared to about 2.9% for the formulations containing MVCSN. There was no 
significant difference in the absorption enhancing efficacy of MVCSN in hypotonic or 
isotonic vehicles. The plasma glucose versus time profiles (Figure 7.10) and values of 
the pharmacokinetic parameters (Table 7.23) were similar for the two formulations. 
Thus, the two vehicles used did not appear to influence nasal insulin absorption. 
The values of relative pharmacological availability obtained for the control solution of 
insulin at pH 4 (0.7% ± 0.87) were slightly lower than those reported in Chapter 6 for 
the control solution at pH 7.4 (1.4% ± 1.02). There were also differences between 
values of Cmin and Tmin obtained for the control formulation. However, these 
differences were not significant. It must be taken into account that these studies were 
performed in different sheep and on different occasions where there may have been 
differences in experimental conditions. Also, subcutaneous dose administration was only 
performed on one occasion. Furthermore, measurement of a physiological parameter 
such as plasma glucose although giving a good indication of absorption is not as precise 
as measurement of plasma insulin concentrations. Intranasal insulin absorption has been 
shown to be pH dependent (Hirai et al., 1978). In a study in anaesthetised dogs, a high 
nasal dose of insulin (50 IU/kg) was shown to be poorly absorbed at a pH of about 6 
which is close to the isoelectric point of insulin. Insulin absorption was improved 
slightly in the pH range approximately 6 to 7.4 although dramatic increases in absorption 
were observed in the pH range pH 6 to 3.1 with maximum absorption occurring at the 
latter pH. The reduced absorption at the isoelectric point of insulin was attributed to the 
low solubility of insulin at this pH where it forms a suspension and the formation of 
isomers, particularly hexomers and octomers, compared to the predominance of 
monomers at acid pH. In the sheep studies reported in this project, insulin absorption 
was not shown to be pH dependent which may be attributed to differences in the two 
species and the much lower dose of insulin administered in the sheep studies. 
Furthermore, in contrast to the conscious sheep model used in this project, Hirai et al. 
used anaesthetised dogs in which mucociliary clearance mechanisms may be impaired. 
Although this study showed that the same degree of insulin absorption was obtained from 
both hypotonic and isotonic vehicles, for therapeutic application, particularly for chronic 
use, isotonic formulations are desirable to prevent or limit nasal irritation. Ilium et al 
(results not published), investigated the nasal irritancy of buffers prepared at pH 4 in two 
human volunteers finding that the nature of the bufffer, its buffering capacity and tonicity 
influenced the degree of nasal irritation. Generally, isotonic solutions tended to be less 
irritant than hypotonic solutions. The nature of the excipient used to adjust the tonicity of 
the formulation was also shown to influence the degree of- nasal irritancy. The pH of the 
buffer will also influence the degree of irritation to mucous membranes (Walz, 1985). 
Walz reported that the irritancy of isotonic solutions on mucous membranes was minimal 
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in the pH range approximately 4-11. 
Table 7.23. Summary of formulations and dose groups In the study to investigate 
the effect of two different vehicles on the intranasal absorption of insulin from a 
formulation containing MVCSN in sheep 
Formulation 
or Group No. 
Insulin 
(IU/kg) 
MVCSN 
(mg/kg) 
Dose volume 
(ml/kg) 
1. Control insulin solution, pH 4 2.0 0.01 
2. Insulin / MVCSN in phosphate buffer, pH 4 2.0 0.05 0.01 r3. Insulin / MVCSN in 0.85% NaCl, pH 4 2.0 0.05 0.01 
* Dose of MVCSN expressed as the dose of chitosan glutamate 
Table 7.24. Summary of plasma glucose concentrations following the Intranasal 
administration of an insulin / MVCSN formulation in two different vehicles in 
sheep. 
Mean (t SD) glucose concentration (% of basal) 
Time before or 
after dosing (min) 
Insulin control pH 4 
phosphate buffer 
SD 
Insulin + 0.5% MVCSN 
pH4 in phos. buffer 
SD 
Insulin + 0.5% MVCSN 
pH 4 in 0.85% NaCl 
SD 
-15 100.0 0.00 100.0 0.00 100.0 0.00 
-5 100.0 0.00 100.0 0.00 100.0 0.00 
5 99.2 2.87 100.5 4.45 101.2 3.20 
10 99.9 4.79 96.8 10.60 100.4 1.49 
15 100.0 6.86 95.8 7.82 97.3 3.41 
20 101.7 9.84 91.0 11.57 93.5 4.94 
30 99.2 9.83 81.3 13.19 83.4 8.10 
40 96.7 8.80 76.5 12.82 76.5 10.06 
50 97.5 10.33 71.5 10.85 74.1 11.33 
60 98.3 6.88 76.4 7.72 74.9 14.92 
75 99.2 6.18 84.4 5.53 78.7 16.93 
90 99.9 9.17 86.7 2.92 85.6 12.77 
120 98.2 738 93.9 0.56 93.4 3.99 
150 98.3 7.25 94.6 2.76 98.1 4.06 
180 101.7 4.93 99.7 1.99 98.9 3.16 
240 101.7 6.90 99.8 3.96 102.0 5.47 
Table 7.25. Summary of pharmacokinetic paramenters determined from plasma 
glucose data following the intranasal administration of an insulin / MVCSN 
formulation in two different vehicles in sheep. 
Mean t SD (n-4) 
Formulation or 
Group number 
ýn 
(% glucose) 
Inyp 
Imbal 
ýQS. 
(% vlucose. min) 
Rpte of Arrrc__ase 
of e(uoCsC 
Pharmacological 
availability " 
/min) 1%) 
1. Insulin control pH 4 
in phosphate buffer 
94.0 (t 8.03) 49 (t 35.2) 678 (f 797.5) 0.7 (t 0.87) 
2. Insulin + 0.5% MVCSN 
in phosphate buffer 
70.7 (t 9.67) 54 (± 8.8) 2638 (t 1574.4) 0.72 (t 0.128) 2.9 (t 1.71) 
3. Insulin +0.5% MVCSN 
in 0.85% NaCl 
71.0 (± 1lä8) 56 (± 11.6) 2667 (t 1392.7) 0.73 (t 0.247) 2.9 (t 1.51) 
Relative to subcutaneous 
Statistical Analysis 
One-way ANOVA 
Sig. dif. in values of Cmin (P<0.05). No sig. dif. in values of Tmin and AOC (P>0.05) 
Tukey 
-Kramer Multiple Comparisons Test following NOV, 
_A Cmin: Sig. dif between groups Ivs2 and lvs3 (P<0.05). No sig. dif. between groups 2vs3 (P>0.05). 
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Fig 7.9. Plasma glucose concentration versus time profiles following- the Intranusal 
administration of an insulin / MVCSN formulation In two different vehicles in 
sheep. 
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7.7 Effect of grade and molecular weight of chitosan 
on the intranasal absorption of insulin in sheep 
7.7 Aims and Objectives 
This project has predominantly investigated the absorption enhancing efficacy of a 
medium viscosity grade of chitosan glutamate (MVCSN). MVCSN was shown in a 
previous sheep study to perform better than a low viscosity grade in terms of enhancing 
nasal insulin absorption. However, there are many grades of chitosan available 
commercially and the characteristics of the chitosan utilised in the formulation, such as 
the degree of acetylation, molecular weight (related to the viscosity grade) and salt type, 
may influence insulin absorption via the nasal route. Thus, the chitosan employed in the 
nasal delivery system should be optimised. In this study, the effect of chitosan grade 
and salt type in promoting nasal insulin absorption was investigated. Each grade of 
chitosan used had a similar degree of deacetylation. The performance of a medium 
viscosity grade of chitosan hydrochloride (CSN HCL) and a low viscosity grade of 
chitosan lactate (CSN lacate) were compared to that of MVCSN. 
7.7.2 Materials and Methods 
7.7.2.1 Materials 
The characteristics of the chitosans used are given in Table 2.1 
7.2.2 Preparation of insulin formulation 
Solution formulation was prepared for nasal administration to sheep containing 200 
IU/ml insulin and either 0.5% (5.0 mg/ml) of MVCSN, CSN HCL or CSN lactate or 
1.0% (10.0 mg/ml) CSN lactate. A summary of the formulations prepared is given in 
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Table 7.26. All formulations were prepared in 14.65 mM phosphate buffer of pH 7.4 
and were adjusted to pH 4 during preparation by the addition of 1M HCI. The 
formulations were freshly prepared on the day of the study. 
Table 7.26. Outline composition of the formulation 
Formulation 
No. 
Outline composition Viscosity 
(CPS) 
1 200 IU/ml insulin with 0.5% (5.0 mg/ml) MVCSN, pH 4 9.4 
2 200 IU/ml insulin with 0.5% (5.0 mg/ml) CSN HCL, pH 4 17.8 
3 200 IU/ml insulin with 0.5% (5.0 mg/ml) CSN lacate, pH 4 2.7 
4 200 IU/ml insulin with 1.0% (10.0 mg/ml) CSN lactate, pH 4 5.5 
* Concentration of each chitosan expressed as the concentration of chitosan salt 
* Viscosity measured at 10 rpm / 25°C using a Brookfield DVIII rheometer with CP40 
cone and plate (refer to Section 10.5) 
7-7.23 Absorption study in the sheep model 
Sheep were dosed with 2 IU/ml insulin from the appropriate insulin formulation 
administered at 0.01 ml/kg. A summary of the dose groups is given in Table 7.22. Each 
nasal dose was divided between both nostrils. 
7.7.3 Results & Discussion 
The results showed that formulations containing 0.5% or 1.0% CSN lactate were less 
effective than those containing 0.5% of either MVCSN or CSN HCL in enhancing the 
intranasal absorption of insulin in sheep (Tables 7.24-7.27, Figures 7.10-7.11). Increase 
in the concentration of CSN lactate from 0.5% to 1.0% did not improve insulin 
absorption. 
The plasma glucose versus time profiles were similar following the nasal administration 
of formulations containing 0.5% MVCSN or CSN HCL (Figure 7.10 A) although with 
the MVCSN formulation the profile was shifted slightly to the right which was also 
indicated by the slightly lower rate of decrease of glucose concentrations for this 
formulation (Table 7.30). Despite the similarities in the plasma glucose profiles, there 
were differences in the plasma insulin versus time profiles for the MVCSN and CSN 
HCL formulations with higher peak plasma concentrations attained for the MVCSN 
formulation (Figure 7.10 B). The plasma insulin profiles were similar for the 0.5% and 
1.0% CSN lactate formulations although the latter did not perform as well in terms of 
lowering plasma glucose concentrations (Figure 7.10). 
The pharmacokinetic parameters determined from the glucose data (Table 7.30, Figure 
7.11 A-B) showed that values of Cmin and AOC (hence pharmacological availability) 
were similar for the MVCSN and CSN HCL formulations and values of Cmjn were lower 
and values of AOC higher than the values obtained for the CSN lactate formulations. The 
rate of decrease in glucose concentrations was marginally higher for the CSN HCL 
formulation compared to the MVCSN formulation although values in both these 
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formulations were higher than those obtained for the CSN lactate formulations (Table 
7.30). Pharmacokinetic parameters determined from the insulin data supports the glucose 
data in highlighting the differences in the performance of the medium viscosity and low 
viscosity grades of chitosan (Table 7.31, Figure 7.11 C-D). Values of Cmax and AUC 
(hence bioavailability) obtained for the MVCSN formulation were higher for those 
obtained for CSN HCL although the rates of increase in plasma insulin concentrations 
were similar for the two formulations. For the MVCSN and CSN HCL formulations 
these values were higher than those obtained for the CSN lactate formulations. 
Despite apparent differences in the pharmacokinetic parameters of the formulations, the 
only statistically significant differences between the formulation groups was in values of 
Cmin and Tmin (Table 7.30 ) and Cn, ax (Tables 7.31) which reflects the considerable 
inter-animal variations in the results. 
The grade of chitosan used in the formulations was shown to influence the degree of 
absorption enhancing efficacy with the low viscosity grade (lactate salt) being less 
effective than the medium viscosity grades (glutamate and hydrochloride salts) at the 
same concentration of chitosan salt. This may be a reflection of the different viscosities 
of the formulations since it was shown previously that increasing the concentration of 
MVCSN, thereby increasing solution viscosity improved the degree of nasal absorption 
enhancing efficacy. However, for the medium viscosity grades, the salt type also 
appeared to be of importance since the formulation containing the glutamate salt form was 
generally more effective than the hydrochloride salt despite the latter formulation being 
more viscous. The hydrochloride salt would be expected to be more viscous than the 
glutamate salt at the same concentration of chitosan salt since the hydrochloride salt form 
is composed of 80-90% chitosan compared to only 55-65% chitosan in the glutamate salt. 
An extensive study would be required to establish the relationship between salt type and 
viscosity or molecular weight. Evaluation of the performance of different molecular 
weight / viscosity fractions prepared from the same chitosan salt would be useful to 
establish the relationship between viscosity and absorption enhancing efficacy. 
Aspden (1996) showed that a medium viscosity glutamate salt of chitosan (42% salt) 
performed better, in terms of lowering plasma glucose concentrations, than low, medium 
and high viscosity grades of chitosan hydrochloride (9-16% salt), respectively at 
concentration of 0.25% and 0.5% chitosan base. Thus, in the above study, differences 
in absorption enhancing efficacy between the grades tested may have been observed if the 
salt content of the chitosans had been taken into account. 
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Table 7.27. Summary of formulations and dose groups-In-the study to investigate 
the effect of different grades of chitosan on the Intranasal absorption of insulin in 
sheep 
Formulation 
or Group No. 
Insulin 
(IU/kg) 
Chitosan 
(mg/kg) 
Dose volume 
(ml/kg) 
1. Insulin + 0.5% MVCSN 2.0 0.05 0.01 
2. Insulin + 0.5% CSN HCL 2.0 0.05 0.01 
3. Insulin + 0.5% CSN lactate 2.0 0.05 0.01 
4. Insulin + 1.0% CSN lactate 2.0 0.05 0.01 
* Dose of chitosan expressed as dose of chitosan salt 
Table 7.28. Summary of plasma glucose concentrations following the Intranasal 
administration of insulin with different grades of chitosan in sheep 
Mean (± SD) glucose concentration (% of basal) 
Time before or 0.5% MVCSN 0.5% CSN HCl 0.5% CSN lactate 1.0% CSN lactate 
after dosing (min) SD SD SD SD 
-15 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
-5 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
5 98.0 1.73 98.0 2.71 98.3 2.10 98.2 1.84 
10 98.7 2.43 97.1 3.04 97.6 2.84 101.2 2.46 
15 97.8 3.41 97.1 3.04 97.6 0.66 100.5 2.92 
20 94.0 1.32 90.8 3.14 92.7 1.97 99.0 0.71 
30 86.9 3.87 81.2 9.22 87.8 4.19 92.7 3.20 
40 75.5 3.19 70.6 9.61 82.2 4.03 89.8 4.72 
50 72.9 4.34 68.0 10.67 84.3 1.79 88.5 5.89 
60 69.4 3.23 69.5 11.61 84.4 4.08 89.2 7.32 
75 72.8 11.46 76.0 9.27 86.4 0.51 89.0 8.51 
90 76.9 10.55 78.3 12.28 87.1 1.85 90.3 8.40 
120 85.6 4.64 84.4 9.05 88.6 2.95 90.4 6.08 
150 87.6 4.64 85.1 7.02 90.6 2.82 92.7 3.10 
180 90.8 2.39 89.2 6.08 91.3 1.52 92.7 2.57 
240 92.4 4.59 91.2 6.05 95.5 2.51 93.4 1.79 
Table 7.29. Summary-of- plasma insulin concentrations following the intranasal 
administration of insulin with different grades of chitosan in sheep 
Mean (± SD) insulin concentration (mU/U) 
Time before or 0.5% MVCSN 0.5% CS N HCI 0.5% CSN lactate 1.0% CSN lactate 
after dosing (min) SD SD SD SD 
-15 21.9 6.07 14.9 2.87 24.7 7.16 17.8 
3.20 
-3 15.6 3.15 12.4 2.02 20.1 1.99 22.6 5.78 
5 51.9 33.09 51.7 21.78 42.6 14.86 40.1 25.95 
10 94.5 53.93 88.1 53.58 62.1 30.09 57.7 23.02 
15 159.9 68.73 92.5 34.74 58.6 17.61 60.0 28.04 
20 108.6 23.87 103.8 26.27 46.2 10.03 49.4 18.31 
30 76.0 24.28 66.0 29.36 47.9 18.31 37.2 20.11 
40 41.7 13.26 27.5 1.85 44.5 17.56 29.2 16.18 
50 45.3 22.98 33.0 17.06 34.4 8.84 20.2 4.78 
60 34.3 10.93 19.4 2.73 22.4 2.25 21.3 3.59 
75 24.6 15.73 14.3 4.33 24.6 7.21 20.2 6.86 
90 25.3 6.46 19.7 7.17 28.0 9.07 30.4 13.18 
120 18.2 0.36 15.2 4.21 19.0 3.66 21.6 8.24 
150 17.0 3.17 13.8 2.64 18.4 3.15 16.6 2.13 
180 17.1 5.60 15.6 2.00 20.6 7.28 12.8 2.59 
240 25.4 10.34 11.4 0.58 20.3 8.34 17.0 7.48 
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Table 7.30. Summary of pharmacokinetic paramenters determined from plasma 
glucose data following the intranasal administration of insulin with-different-2rades 
of chitosan in sheep 
Mean ± SD (n=4) 
Formulation or 
Group number 
Cmin 
(% glucose) 
Tmin 
(min) 
AOC 
(% glucose. min) 
Rate of decrease 
of glucose conc. 
%/min 
Pharmacokinetic 
availability * 
1.0.5% MVCSN 67.3 t 6.88) 63 t 8.7) 3403 (±901.4 0.67 t 0.093) 3.3 t 0.89 
2.0.5% CSN. HCI 66.5 (t 10.60) 55 t 12.2) 3671 (± 1544.7 0.86 t 0.252) 3.6 t 1.52 
3.0.5% CSN lactate 81.5 (t 3.24) 44 (t 7.5) 2314 t 454.9 0.50 t 0.152) 2.3 t 0.45) 
4.1.0% CSN lactate 85.6 t 6.25) 90 ± 36.3) 1819 t 771.1 0.43 t 0.207) 1.8 t 0.76 
* Relative to subcutaneous 
One-way ANOVA 
Sig. dif, in values of Cmin and Tmin (P<0.05). 
No sig. dif. in values of AOC and rate of fall of gluocse conc. (P>0.05). 
Tukey-Krmaer Multiple Comparisons Test following ANOVA 
Cmin: Sig. dif between groups lvs4 and 2vs4 (P<0.05). 
Train: Sig. dif between group 3vs4 (P<0.05). 
No sig. dif. (P>0.05) between other formulation groups. 
Table 7.31. Summary of pharmacokinetic paramenters determined from plasma 
insulin data following the intranasal administration of different grades of chitosan in 
sheep 
Mean ± SD (n=4) 
Formularion or y Izn AILC Rate of increase Bioavailabilnv " 
Group number (MUA) (Minl fmU/I. min) of insulin conc. 
(lo mU/I min) 
L21 
1.0.5%MVCSN 167.0(±34.85) 16 2.5) 4046(±1018.1) 0.10(±0.042) 4.4(±1.11) 
2.0.5% CSN. HCI 115.7 (± 37.85) 13 (t 6.5) 3032 (t 1492) 0.10 (±0.062) 3.3 (t 1.62) 
3.0.5% CSN lactate 70.9 (t 23.24) 26 (t 16.0) 2012 (t 1363.7) 0.07 1±0.040 2.2 (t 1.48) 
4.1.0% CSN lactate 68.3 (t 17.42) 15 (t 4.08) 1629 (t 1634.2) 0.06 (±0.049) 1.8 (t 1.78 
* Relative to subcutaneous 
One-way ANOVA 
Sig. dif. in values of Cmax (P<0.01). 
No sig. dif. in values of Tmax. AUC and rate of increase of insulin conc. (P>0.05). 
Tukey-Krmaer Multiple Comparisons Test following ANOVA 
Cmax: Sig. dif between groups lvs3 and lvs4 (P<0.05). 
No sig. dif. (P>0.05) between other formulation groups. 
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Pig 7.10. Plasma glucose and insulin concentration versus time profiles following 
the intranasal administration of insulin with different grades of chitosan in sheep 
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Figure 7.11. Values of selected pharmacokinetic parameters following the it rrý annsal 
administration of insulin with different grades of chitosan in sheep 
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7.8 Reproducibility of intranasal insulin absorption following 
theintranasal administration of an insulin / chitosan 
formulation on separate occasions in sheep 
7.8 Aims and Objectives 
In the studies reported previously in this chapter, following the nasal administration of a 
formulation containing 200 IU/ml insulin with 0.5% MVCSN (pH 4) there was 
considerable variation in insulin absorption between different groups of animals. This 
could be attributed to inter-animal variations in nasal absorption as well as differences in 
experimental conditions on different study days. The aim of this study was to investigate 
intra- and inter-animal variations in insulin absorption following the nasal administration 
of the same insulin / MVCSN formulation to the same group of sheep on separate 
occasions. 
7.8.2 Materials and Methods 
7.8.2.1 Materials 
Insulin of specific activity 21.84 IU/mg and MVCSN was used as given in Section 3.3. 
7.8.2.2 Preparation of insulin formulation 
A solution formulation containing 200 IU/ml insulin with 0.5% (5.0 mg/ml) MVCSN, 
was prepared freshly on each study day. Each formulation was prepared in 14.65 mM 
phosphate buffer of pH 7.4 and adjusted to pH 4 during preparation by the addition of 
HC1. 
7.8.2.3 Absorption study in the sheep model 
The study was performed in three sheep on three separate study days. There was a 
wash-out period of approximately 4 weeks between consecutive study days. Two of the 
sheep were used on all three study days. However, it was necessary to withdraw the 
third sheep from the study prior to the third study leg due to illness. A replacement sheep 
was used on the third study leg. On each study day sheep were dosed with the insulin / 
MVCSN formulation at 0.01 ml/kg. Each nasal dose was divided between both nostrils. 
A summary of the dose groups is given in Table 7.32. 
It was intended to analyse the glucose and insulin data obtained using a repeated 
measures analysis of variance which would allow both intra-animal variations, in sheep 
dosed on different study days, and inter-animal variations, in sheep dosed on each study 
day, to be evaluated. However, due one of the animal being withdrawn from the third 
study leg and since the replacement sheep, although a Suffolk and Texel cross-breed was 
a different strain cross-breed from the sheep previously used and differed in age / weight 
from the previous animals, repeated measures analysis of variance could not be used. In 
view of this, insulin analysis was not performed. 
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7.8.3 Results & Discussion 
The glucose data showed that on each study day the plasma glucose concentration versus 
time profiles followed a similar trend although there were inter-day variations in mean 
glucose concentrations (Table 7.33, Figure 7.12). The pharmacokinetic parameters 
further highlight the inter-day variation in the hypoglycaemic response to a2 IU/kg dose 
of insulin (Table 7.33, Figure 7.13). However, due to the inter-animal variations on each 
study day, there were no statistically significant differences between the groups dosed on 
different study days (Table 7.33). Generally on each study day, inter-animal variations in 
terms of the extent of the hypoglycaemia (values of Cmin) tended to be much less than 
variations in the overall extent and duration of the hypoglycaemia (values of AOC)(Table 
7.33). There was also less inter-day variation in values of Cmin than in values of AOC. 
There were intra-animal variations (sheep 1 and 2) in the plasma glucose versus time 
profiles and phanmcokinetic parameters following the nasal administration of insulin on 
different study days (Table 7.34-7.35, Figures 7.14-7.15). Generally, infra-animal 
variability of glucose concentration and pharmacokinetic data tended to be marginally less 
than inter-animal variability although there was not much difference between the two 
(Tables 7.32-7.35). A repeated measures analysis of variance would have allowed both 
intra- and inter-animal variations to be compared by statistical means although as 
previously mentioned this was not performed. 
Reproducibility of the hypoglycaemic response is a prerequisite for the therapeutic use of 
insulin (Lassmann-Vague, 1991). In the majority of insulin-dependent diabetics, day-to- 
day metabolic variability in glycaemic control occurs despite consistency in the parenteral 
dosing regimen (Pickup, 1991). Variability in subcutaneous insulin absorption may 
occur due to a number of factors. Inaccuracy in dose administration may account for 
day-to-day variations in a small minority of individuals particularly in elderly patients. 
The depth of subcutaneous injection may also influence insulin absorption. 
Perpendicular injection of the insulin dose using a 12 mm needle may inadvertantly lead 
to intramuscular injection depending on the thickness of the fat layer, hence, oblique 
injection into a fold of skin is recommended. Absorption from muscle tends to be faster 
than that following subcutaneous administration which may be due to the faster blood 
flow in muscle (Banerjee et al., 1991). The anatomical site of subcutaneous or 
intramuscular injection has a major influence on insulin and peptide absorption (Pickup, 
1991, B anerjee et al., 1991). Following subcutaneous injection, the rate of absorption of 
short-acting insulin preparations tends to be most rapid from the abdomen, particularly 
the upper abdomen, and slowest from the gluteal region with an intermediate rate in the 
arm. Thus, for consistency of absorption, the injection site should not be randomly 
altered. However, at each anatomical site the injection site should be rotated to prevent 
localised tissue damage or the development of lipohypertrophy which may reduce the rate 
of absorption of insulin. Within-site variability in insulin absorption may also occur due 
to the influences of a number of factors such as heat, massage at the site of injection and 
exercise. The rate of absorption of insulin following subcutaneous injection into a limb 
has been shown to increase during exercise. Massage at the subcutaneous site of 
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injection has also been shown to increase the rate of peptide absorption. Degradation or 
metabolism of insulin at the injection site may also account for variability in insulin 
absorption. Changes in the physical and chemical stability and biological potency of the 
insulin preparations are also factors which would influence subcutaneous absorption 
although these factors would be expected to remain constant within the normal shelf-life 
of the product 
Poor reproducibility in insulin absorption and in the resultant hypoglycaemic response 
would limit the delivery of insulin via the nasal route (Lassmann-Vague, 1991). In a 
study in healthy human volunteers, considerable inter-subject variation in serum insulin 
concentrations (103 ± 49 tU/1 at peak concentration) was observed following the 
intranasal administration of a solution of insulin with the bile salt sodium deoxycholate 
(Moses et al., 1983). However, there was much less variability in blood glucose 
concentrations (54 ± 14% of basal concentration) in these subjects. Intra-subject 
variations in peak serum insulin concentrations and blood glucose response were reported 
to be less than those between subjects. Paquot et al. (1988) also reported greater inter- 
subject than intra-subject variation in response to an intranasal formulation of insulin with 
Laureth-9. The coefficient of inter-subject variation in the maximal decrease in blood 
glucose concentrations was reported to be 52% compared to 88% for maximal plasma 
insulin increase. Sinay et al. (1990) investigated the reproducibility in nasal insulin 
absorption (solution with sodium glychcholate) and its biological effects in patients with 
insulin-dependent diabetes mellitus (IDDM). From the plasma glucose concentration 
data the inter-subject coefficient of variation in values of Cmin and AUC were reported to 
be 46% compared to intra-subject variability of 17% and 33%, respectively. Likewise, 
from the plasma insulin concentration data, the inter-subject coefficient of variation in 
values of Cmax and AUC were reported to be 48% and 77% compared to intra-subject 
variability of 31% and 33%, respectively. For therapeutic application inter-subject 
variations are less important than intra-subject variations since the regimen of insulin 
therapy should be tailored to the individuals needs (Lassmann-Vague, 1991). When 
addressing the reproducibility of intranasal insulin absorption and lowering of glucose 
concentrations, evaluation should be relative to subcutaneous insulin. Frauman et al. 
(1987) compared the efficacy of intranasal (coadministered with sodium glycocholate) 
and subcutaneous insulin in non-obese type II diabetics and reported that the inter-subject 
coefficient of variation in peak serum insulin concentrations was 41 % and 44%, 
respectively. The intra-subject coefficient of variation in peak serum insulin 
concentrations following the intranasal administration of insulin with meals was reported 
to be 55% although evaluation for subcutaneous insulin was not reported. The 
coefficients of variation in the glucose data was not reported. Lassmann-Vague (1991) 
suggests that in the same individual, the reproducibility of the action of intranasal insulin 
appears to be acceptable and at least comparable to that administered by subcutaneous 
injection. 
In this study in the sheep model, following the intranasal administration of a formulation 
of insulin containing 0.5% MVCSN, intra- and inter-animal variability would appear to 
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be reasonably low. From the glucose data, the coefficients of variation (over the 3 study 
days) of values of Cmin and AOC were 11.1-24.6% and 23.3-64.4%, respectively. In 
sheep 1, the coefficient of variation of values of Cmin and AOC were 13.3% and 34.3%, 
respectively. In sheep 2, the coefficient of variation of values of Cm; n and AOC were 
11.6% and 18.7%, respectively. 
Table 7.32. Summary of plasma glucose concentrations following the Intranasal 
administration of an insulin / MVCSN formulation to a group of 3 sheep on separate 
occasions (inter-day variability in hypoglycaemic response) 
Mean (t SD) plasma glucose cone. (% of basal) 
Time before or Day I Day 2 Day 3 
after dosing (min) SD SD SD 
-15 100.0 0.00 100.0 0.00 100.0 0.00 
.5 100.0 0.00 100.0 0.00 100.0 0.00 
5 104.3 0.31 100.0 3.15 103.2 6.00 
10 103.4 4.27 101.6 2.71 102.2 6.30 
15 102.6 4.62 97.6 4.31 102.2 8.91 
20 99.7 4.48 99.5 4.53 100.4 6.06 
30 92.9 4.86 86.0 6.35 92.4 9.96 
40 87.0 5.53 79.0 4.13 85.1 12.00 
50 82.0 12.24 72.3 7.03 79.7 17.40 
60 78.1 13.48 71.6 6.82 76.0 16.23 
75 80.1 11.44 71.1 8.98 70.5 15.38 
90 79.0 13.05 74.6 9.66 72.3 15.96 
120 90.8 4.93 79.1 6.20 81.3 9.45 
150 92.7 5.24 84.6 4.74 84.9 5.53 
180 95.5 5.46 85.6 5.89 88.6 5.07 
240 94.5 7.19 87.4 5.23 942 5.06 
Table 7.33. Summary of pharmacokinetic parameters following the intranasal 
administration of an insulin / MVCSN formulation to a group of 3 sheep on separate 
occasions (inter-day variability in hypoglycaemic response) 
Mean ± SD n. 4 
Formulation or 
Group number 
Cmm 
(% glucose) 
Tmm 
(min) 
AOC 
(% glucose. min) 
Rate of decrease 
of % glucose 
9F/min) 
pharmacological 
availability " 
*) 
1. Study Day 1 78.1 (± 13.48) 68 (± 6.6) 2260 (t 1454.7 0.66 (± 0.318) 2.2 (± 1.43) 
2. Study Day 2 69.2 (± 7.68) 69 t 18.4) 4078 951.9) 0.73 (± 0.193) 4.0 (t 0.94) 
3. Study Day 3 68.7 (± 16.91) 76 t 18.4) 3513 (± 1820.9) 0.66 (± 0.358) 3.5 (t 1.79) 
* Relative to subcutaneous 
Statistical Analysis 
One-way ANOVA 
No sig. dif. in values of Cmin, Tmin, rate of decrease of % glucose and AOC (P<0.05). 
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Table 7.34. Summary of plasma glucose concentrations following the- Intrannsal 
administration of an insulin / MVCSN formulation to individual sheep on separate 
occasions (intra-animal variability in hypoglycaemic response) 
Mean (t SD) plasma glucose conc. (% of basal) 
Time before or Shee I Shee 2 
after dosing (min) SD SD 
-15 100.0 0.00 100.0 0.00 
.5 100.0 0.00 100.0 0.00 
5 104.5 4.66 99.6 4.33 
10 107.0 2.30 100.6 3.69 
15 105.2 5.88 98.7 7.80 
20 102.4 5.80 98.7 5.24 
30 92.1 4.42 87.0 7.49 
40 83.7 2.06 79.1 5.39 
50 75.9 3.63 72.4 8.85 
60 72.4 0.67 69.3 8.07 
75 66.4 7.30 73.3 8.21 
90 65.7 10.06 75.0 8.53 
120 78.1 10.42 82.9 2.89 
150 83.1 6.11 86.8 2.76 
180 88.6 9.76 87.9 3.59 
240 90.2 8.61 896 2.99 
Table 7.35. Summary of pharmacokinetic parameters following the Intranasal 
administration of an insulin / MVCSN formulation to individual sheep on separate 
occasions (intra-animal variability in hypoglycaemic response) 
Shce 1 
Sheep 2 
Mean ± SD (n-3) 
Crain 
(% glucose) 
Tmin 
(min) 
AOC 
(% glucose. min) 
Rate of decrease 
of % glucose 
(%/min) 
pharmacological 
availability ' 
(%) 
64 8 (t 8.60) 81(t 15.6) 4036 (± 1385.8) 0.75 ± 0.05) 4.0 (± 1.36) 
69.3 (t 8.07) 62 (t 11.5) 3771(± 704.3) 0.80 (± 0.217) 3.7 (t 0.69) 
* Relative to subcutaneous 
Statistical Analysis 
One-way ANOVA 
No sig. dif. in values of Cmin, Train, rate of decrease of % glucose and AOC (P<0.05). 
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Figure 7.12. Plasma glucose concentration versus time profiles following the 
intranasal administration of an insulin / MVCSN formulation to a group of 3 sheep 
on separate occasions (inter-dom variability in bypoelycaemic response) 
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Figure 7.13. Values of selected pharmacokinetic parameters following the intranasal 
administration of an insulin / MVCSN formulation to a group of 3 sheep on separate 
occasions (inter-day variability in hypoglycaemic response) 
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Figure 7.14. Plasma glucose concentration versus time profiles following the 
intranasal administration of an insulin / MVCSN formulation to individual sheep on 
separate occasions fintra-animal variability in hypoglycaemic response) 
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Figure 7.15. Values of selected pharmacokinetic parameters following the intranasal 
administration of an insulin / MVCSN formulation to individual sheep on separate 
occasions (intra-animal variability in hypoglycaemic response) 
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7.9 Conclusions 
This chapter presents the results of several nasal absorption studies in sheep aimed at 
further investigating and optimising chitosan for the nasal delivery of insulin. Consistent 
with the nasal absorption study in rats reported in chapter 4, increasing the solution 
concentration of chitosan (MVCSN grade) was shown to improve the intranasal 
absorption of insulin. Optimal absorption enhancing efficacy was obtained between 0.35 
to 1.0 % w/v MVCSN. However, investigation of higher concentrations of chitosan 
would have been beneficial to establish if there was an upper limit to the optimal range of 
chitosan concentration above which absorption enhancing efficacy was reduced. Since 
increase in the solution concentration of MVCSN will not only increase the viscosity of 
the formulation but also the dose concentration of MVCSN administered, a study was 
performed to investigate the effect of the dose concentration of MVCSN on intranasal 
insulin absorption. 
At a fixed dose of insulin (2 IU/kg) increase in the dose concentration of MVCSN 
administered (by increasing the dose volume administered of formulations containing a 
fixed concentration of MVCSN, thereby altering chitosan dose without altering solution 
viscosity) did not appear to influence the performance of the formulation in terms of its 
nasal absorption enhancing efficacy. Thus, it appeared that it was the solution 
concentration of chitosan rather than dose concentration of chitosan which was important 
for the nasal absorption enhancement observed. This suggested that the effect of 
MVCSN in the nasal cavity reached a maximum for the formulations under investigation. 
The absorption enhancing efficacy of chitosan is proposed to be via a combination of 
increased residence time of the formulation in the nasal cavity, attributed to the viscosity 
enhancing and bioadhesive properties of chitosan and the transient effect of chitosan on 
epithelial tight junctions (Ilium et al., 1994). The absorption enhancing efficacy of 
chitosan due to its affect on tight junctions could be due to the degree of opening of tight 
junctions or due to the number of tight junctions opened. Increasing the dose 
concentration of chitosan administered by increasing the dose volume would be expected 
to increase the spread of chitosan in the nasal cavity, thus, increase the absorptive surface 
area. This could potentially increase the number of tight junctions opened. In a separate 
study, nasal insulin absorption was shown to be improved by increasing the dose 
concentration of insulin administered. Thus, in previous studies, nasal insulin 
absorption was limited by the dose concentration of insulin. Increasing the dose 
concentration of insulin increased insulin absorption in terms of the elevation in plasma 
insulin concentrations and decrease in plasma glucose concentrations although the 
bioavailability of nasal insulin absorption was not improved. A study was performed in 
which different volumes of a formulation of 200 IU/ml insulin with 0.5% w/v chitosan 
were administered. Thus, increasing the dose volume increased both the dose 
concentrations of insulin and chitosan administered nasally. Increasing the dose volume 
increased the elevation in plasma insulin concentrations and decreases in plasma glucose 
concentrations although the bioavailability of nasal insulin absorption was not improved. 
This study demonstrated that the efficacy of a nasal insulin / chitosan formulation was 
highly dependent on the volume administered nasally which is an important consideration 
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if the formulation is to be used therapeutically since poor patient compliance may lead to 
under- or overdosing. 
From the above studies, it appears that it is the formulation concentration of chitosan 
which is important for its absorption enhancing efficacy since increasing the 
concentration improved the degree of nasal absorption until an optimal concentration was 
attained. At the optimal concentration of chitosan, nasal insulin absorption was limited 
by the dose concentration of insulin. 
The efficacy of nasal absorption enhancement of MVCSN appeared to be the same from 
both hypotonic and isotonic formulations. Thus, differences in the conformation of 
chitosan in the respective solutions due to differences in ionic concentration (refer to 
Section 10.5) had no affect on its absorption enhancing efficacy. At chitosan 
concentrations lower than the optimal concentration, the tonicity of the formulation could 
be adjusted to regulate the viscosity of the formulation. This should allow the 
importance of viscosity to be evaluated since solutions containing a lower concentration 
of chitosan (e. g. 0.1 or 0.2% w/v) could be prepared having a similar viscosity to 
solutions containing an optimal concentration of chitosan (e. g. 0.5% w/v). The grade of 
chitosan used was shown to influence the degree of nasal absorption enhancement. Low 
viscosity chitosan lactate (CSN lactate), at concentrations of 0.5 and 1.0%, was shown 
to be less effective than medium viscosity chitosan glutamate (MVCSN) at a 
concentration of 0.5%. This could reflect the lower viscosity of the CSN lactate 
formulations. The performance of a formulation containing 0.5% MVCSN was shown 
to be improved compared to that of a formulation containing 0.5% medium viscosity 
chitosan hydrochloride (CSN HCL) despite the higher viscosity of the latter formulation. 
Thus, the grade of chitosan appeared to be important for the degree of absorption 
enhancement attained. It is difficult to compare the efficacy of the different grades of 
chitosan due to the differences in the chitosan content of the respective formulations. 
Investigation of the relationship between chitosan molecular weight and the efficacy of 
nasal absorption enhancement would best be achieved by the use of chitosan fractions of 
different molecular weights prepared from the same chitosan starting material. 
In the final study reported in this chapter, the degree of nasal absorption enhancement, in 
terms of the lowering of plasma glucose concentrations, was shown to be highly 
reproducible following the nasal administration of a formulation of insulin with 0.5% 
MVCSN. Inter- and infra-animal variations appeared to be reasonably low which was 
encouraging if a nasal delivery system incorporating chitosan is to find therapeutic 
application. 
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CHAPTER8 
INTRANASAL ABSORPTION OF SALMON CALCITONIN IN SHEEP 
8.1 Aims and objectives 
In Chapter 5 it was reported that a formulation containing 0.5% MVCSN enhanced the 
nasal absorption of salmon calcitonin (S-CT) in the rat model. In this study, the nasal 
absorption of S-CT from a formulation incorporating 0.5% MVCSN was investigated in 
the sheep. The performance of the nasal MVCSN formulation was compared to that of a 
nasal control solution of S-CT. In the study blood samples were collected pre- and post 
administration of the nasal S-CT formulations. Plasma was separated and plasma 
calcium concentrations measured. The absorption of S-CT was assessed, indirectly, 
from the decrease in plasma calcium concentrations following S-CT dose administration. 
8.2 Materials and Methods 
8.2.1 Materials 
Salmon Calcitonin acetate salt (S-CT. 4 AcOH. 13 H2O, specific activity 4730 IU/mg, 
Molecular weight 3431.9), Bachem Feinchemikalien AG, Switzerland. 
Chitosan (MVCSN) was used as described in Section 7.2. 
8.2.2 Preparation of S-CT formulations 
To avoid adsorption losses of S-CT, glassware and plasticware was treated as described 
in Section 5.2.2. Two solution formulations of S-CT for nasal administration were 
prepared as given in Table 8.1. Both solutions were prepared in 0.9% NaCl and adjusted 
to pH 4.0 during preparation by the addition of HCI. 
Table 8.1. Outline composition of formulations 
Formulation No. Outline composition 
1 2000 IU/ml S-CT control solution, pH 4 
2 2000 IU/ml S-CT with 0.5% (5 mg/ml) MVCSN, pH 4 
* Concentration of MVCSN expressed as the concentration of chitosan glutamate 
8.2.43 Absorption study in the sheep model 
Sheep were dosed nasally with the appropriate S-CT formulation. Nasal doses of 20 
IU/kg S-CT were administered at a volume of 0.01 ml/kg. MVCSN was administered 
(Formulation Group 2) at 0.05 mg/kg. 
8.3 Results and Discussion 
The results showed that nasal absorption of S-CT was poor following the administration 
of the control solution formulation of S-CT (Tables 8.2-8.3, Figures 8.1-8.2). The 
intranasal administration of the formulation of S-CT with 0.5% MVCSN appeared to 
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improve the nasal absorption of S-CT. From the plasma calcium concentration versus 
time profiles (Figure 8.1) it was observed that the extent and duration of the 
hypocalcaemia was much greater following the nasal administration of the formulation 
containing MVCSN. This was reflected in the lower values of Cmin and higher values of 
AOC for this formulation (Table 8.3, Figure 8.2). Statistical comparison of the 
formulation groups using a Student's unpaired T-test showed that values of Cmin were 
significantly lower and values of AOC significantly higher after dosing the S-CT 
formulation containing MVCSN than after dosing the control S-CT solution. 
This study demonstrated that a solution formulation containing 0.5% MVCSN improved 
the nasal absorption of S-CT in the sheep model, in terms of the lowering of plasma 
calcium concentrations, compared to a control solution of S-CT. Since a reference 
(parenteral) dose group was not included in the study then a relative etsimate of S-CT 
absorption via the nasal route was not obtained. The results support the findings of the 
nasal absorption study in rats (Chapter 5) by demonstrating that chitosan can potentially 
be used for the nasal delivery of other peptide drugs. Measurement of plasma S-CT 
concentrations and the inclusion of a subcutaneous, intramuscular or intravenous 
reference group in the study would enable values of bioavailability to be calculated. 
Values of bioavailability could also be compared to values of pharmacodynamic 
availability. The reference dose should be carefully selected when attempting to estimate 
nasal absorption from measurement of calcium concentrations to avoid satruation of the 
hypocalcaemic response (Sinko et al., 1995). Comparison of the performace of the S-CT 
/ MVCSN formulation with a commercially available nasal S-CT formulation would also 
be useful. 
8.4 Conclusions 
The study demonstrated that chitosan (MVCSN) enhanced the nasal absorption of S-CT, 
assessed indirectly from the lowering of plasma calcium concentrations, in the sheep 
model and thus warrants further investigation. 
Table 8.2. Plasma calcium concentration versus time profiles following the 
intranasal administration of a solution of S-CT. with and without MVCSN. in sheep 
Mean ± SD (n=4) 
plasma calcium concentration (% of basal) 
Time before or S-C T control S-CT / MVCSN 
after dosing (min) SD SD 
-15 100.0 0.00 100.0 0.00 
-5 100.0 0.00 100.0 0.00 
15 98.9 1.06 98.5 1.62 
30 98.5 1.47 97.6 0.52 
45 97.0 0.66 97.3 1.08 
60 97.4 1.03 96.6 2.88 
90 96.7 1.49 94.3 2.45 
120 96.6 0.65 92.6 2.52 
150 97.9 2.39 91.6 2.35 
180 97.1 2.84 91.4 1.61 
240 98.4 1.91 91.2 4.01 
300 98.3 2.37 91.2 4.05 
360 99.6 3.60 93.2 2.41 
420 97.6 1.74 94.5 1.79 
480 96.9 1.31 96.0 2.77 
600 100.6 2.20 98.4 3.96 
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Table 8.3. Summary of pharmacokinetic parameters following the intranasal 
administration of a solution of S-CT. with and without MVCSN. In sheep 
Meant SD n. 4) 
Formulation or 
Group number 
Cmjp 
(% calcium) 
1mia 
jmial 
AM 
1%calcium. min) 
1. S-C F control 95.9 t 1.53) 206 t 103.3) 1319 (± 710. 
2. S-C ! 0.5%MVCSN 89.7 ±2.01) 229 ±33.9 3215 ±1149.8) 
Statistical Analysis 
Student's unpaired t-Test 
Sig. dif. in values of Cmin (P<0.01). No sig. dif. in values of Tmin and AOC (P>0.05) 
Figure 8.1. Plasma calcium concentration versus time profiles following the 
intranasal administration of a solution of S-CT. with and without MVCSN. In sheep 
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Figure 8.2. Selected pharmacokinetic parameters following-the Intranasal 
administration of a solution of S-CT. with and without MVCSN. in sheep 
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CHAPTER 9 
IN VITRO INVESTIGATION OF THE HAEMOLYTIC EFFFECTS OF 
CHITOSAN AND VARIOUS ABSORPTION ENHANCERS 
9.1 General introduction 
Erythrocytes (red blood cells) have been frequently used to study the properties of 
biological membranes and membrane interactions (Cho and Proulx, 1969, Weltzien, 
1979). Erythrocytes provide a good natural biological membrane model which can be 
useful for screening the membrane damaging effects of potential nasal absorption 
enhancers in vitro (Gill et al., 1994a). Damage to the erythrocyte membrane resulting in 
cell rupture or haemolysis and thus release of haemoglobin can easily be detected 
spectrophotometrically. Blood from humans or animal models is readily available and the 
haemolysis assay is relatively easy to set up enabling many compounds to be screened 
over a short time period. Ultimately, enhancer induced damage to the nasal membrane 
should be verified by histopathological studies in animal models. However, because 
histopathology is time consuming and expensive, its application is usually limited to the 
most promising enhancers selected following screening in haemolysis assays. 
The haemolysis assay used in this project was based on that described by Gill et al.. 
(1994) using rat erythrocytes. In preliminary investigations, the effect of the osmolality 
and pH of the incubation media used in the assay were investigated prior to investigating 
the haemolytic effects of chitosan and various absorption enhancers (glycodeoxycholate 
(GDC), polyoxyethylene-9-lauryl ether (Laureth-9) L-a-lysophosphatidyl choline 
(LPC)). Following these initial studies, modification of the haemolysis assay was 
required to allow further investigation of the haemolytic effects of chitosan. The various 
haemolysis studies are reported in the following Sections: 
9.2 General materials and methods used in the haemolysis assays 
9.3 Investigation of the effect of osmolality and pH on the haemolysis assay 
9.4 Investigation of the haemolytic effects of chitosan and various absorption 
enhancers 
9.5 Effect of relative centrifugal field (RCF) and duration of centrifugation on 
the apparent haemolytic activity of MVCSN 
9.6 Further investigations of the haemolytic effects of chitosan 
9.2 General materials and methods used in the haemolysis 
_ 
assays 
9.2.1 Materials 
Citrate dextrose phosphate adenine anticoagulant (CDP-A anticoagulant, blood donor 
pack from Tuta Laboratories Pty Ltd., NSW, Australia) obtained, as a gift, from 
Department of Haematology, Queen's Medical Centre, Nottingham, UK. The 
composition of the CDP-A anticoagulant is given in Appendix 1. 
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Sodium chloride 0.9 % w/v solution (0.9 % NaCl, Steriflex®, 500 ml of 0.9 % sodium 
chloride intravenous infusion B P) Fresenius Health Care Group, Basingstoke, Hants, 
UK. 
Conical 12 ml polystyrene test tubes (12 ml test tubes), Sarstedt Ltd, Leicester, UK. 
MSE Mistral 2000 centrifuge and MSE Microcentaur centrifuge from Fisons Scientific 
Equipment, Loughborough, Leicestershire, UK. 
Water bath (W28) from Grant Instruments Ltd, Cambridge, UK. 
Hewlett Packard 845A diode array spectrophotometer (spectrophotometer), Hewlett 
Packard GmbH, Germany. 
Philips quartz cuvettes (matching pair) Unicam Analytical Supplies, Cambridge, UK. 
All other materials used are as previously given in previous chapeters. 
9.2.2 Methods 
Details of the reagents / buffers prepared in these studies are given in Appendix 1. 
9.2.2.1 Preparation of stock rat erythrocyte solution 
A stock erythrocyte solution was prepared from rat blood collected freshly on the day of 
the study in isotonic phosphate buffered saline (PBS) at pH 7. Blood was collected from 
male Wistar rats, of approximate weight 300-500g, under terminal anaesthesia. Rats 
were anaesthetised and the carotid artery cannulated, for the purpose of blood sample 
collection, as described in Section 2.2. A tracheotomy was not performed prior to 
cannulation of the carotid artery. From each rat used in this procedure, 2-3 aliquots of 
about 4.5 ml of blood were collected into 12 ml test-tubes containing 0.63 ml of CDP-A 
anticoagulant. Each tube was capped and inverted, gently, several times to ensure 
complete mixing of the blood and anticoagulant. The rats were killed by an overdose of 
pentobarbitone sodium 
Within approximately 30 minutes of collecting the blood, it was centrifuged at 1500 rpm 
for 5 minutes in a MSE Mistral 2000 centrifuge at room temperature. The supernatant 
was removed and discarded. The erythrocytes (pellet) were washed by resuspending 
them in PBS, centrifuging at 1500 for 5 minutes and discarding the supernatant. This 
washing procedure was repeated three more times. After the final wash, the supernatant 
was removed and the erythrocytes pooled in one tube. Erythrocyte stock solutions were 
prepared by adding 2 ml of pooled erythrocytes to 15.0 ml of PBS in polystyrene 
Universal bottles. These were mixed by gently inverting several times. The erythrocyte 
stock solutions were kept at room temperature prior to use. 
9 
. 
2.2.2 Erythrocyte lysis assay 
In the assay it was assumed that total (i. e. 100%) haemolysis occured following 
incubation of rat erythrocytes with water. Prior to performing the assay, the value of 
optical density at total haemolysis was tested by incubating erythrocytes with deionized 
water as described below. The assay required that the optical density at 540 nm was 
approximately 1.0, otherwise the stock solution was adjusted accordingly by the addition 
of PBS or pooled erythrocytes and the measurement of optical density at 100% 
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haemolysis repeated. 
The haemolysis assays were performed in triplicate. Since only one assay was done at a 
time then controls were incorporated in each assay. Each assay consisted of incubations 
of control media [water to indicate total i. e. 100% haemolysis and isotonic PBS or 
isotonic NaC1 (when testing some of the chitosan solutions) to indicate the basal 
haemolysis (haemolysis at zero concentration of enhancer solution) or test media [the 
solutions of enhancers] with erythrocyte stock solution. To 3.5 ml of the control or test 
media in a 12 ml test tube was added 0.25 ml of stock erythrocyte solution. The tubes 
were capped and inverted gently three times. The tubes were incubated in a water bath at 
37 °C for 5 minutes then centrifuged at 1800 rpm for 2 minutes. The optical density (OD) 
of the supernatant was measured at 540 nm (peak absorbance of haemoglobin in the test 
system) using the appropriate water, PBS or NaCI blank. For each assay, the 
haemolysis (%) was calculated as given below. The mean values of % haemolysis, with 
SD, were then calculated for each sample. 
% haemolysis 
= optical density (control or test) x 100 
optical density (Water) 
9.3 Investigation of the effect of osmolality and pH on the 
haemolysis assay 
9.3.1 Aims and objectives 
A preliminary study was performed to investigate the sensitivity of the haemolysis assay 
to fluctuations in the osmolality and pH of the incubation media. This enabled limits to 
be set for subsequent assay media in terms of their osmolality and pH. This was an 
important consideration when evaluating the haemolytic effects of various enhancer 
solutions since these may considerably alter the osmolality and pH of the diluent 
particularly at high concentration. The latter is of particular interest for the testing of 
chitosan solutions since these are prepared at pH 4. 
9.3.2 Materials and Methods 
The general materials used were as listed in Section 9.2. To investigate the effect of 
osmolality on erythrocyte haemolysis, solutions of PBS at pH 7.0 were prepared 
containing 0,0.05,0.10,0.30,0.50,0.70,0.85,0.90,0.95,1.20,1.50,1.80,2.25 
and 2.70 % w/v NaCl. The values of osmolality of these solutions ranged from 0.024 to 
0.855 Osmol/kg. The osmolality of `isotonic PBS' (containing 0.9% NaCI) was 0.302 
Osmol/kg. Values of osmolality are given in Table 9.1. To investigate the effect of pH 
on erythrocyte haemolysis, solutions of isotonic PBS were prepared at pH 8.5,8.0,7.5, 
7.0,6.5,6.0,5.5,5.0,4.5,4.0,3.5,3.0,2.5 and 2.0. The solutions of PBS of 
varying osmolality and pH were used as the test media. The haemolysis assay was 
performed as detailed in Section 9.2. 
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9.3.3 Results and Discussion 
In the haemolysis assays performed in this study, values of basal haemolysis (i. e. that 
caused by incubation with isotonic PBS) were in the region of 22% (Table 9.1. These 
values were much higher than the values of 5% basal haemolysis reported by Chandler 
(1992). Gillet al. (1994a) reported that basal values of haemolyssis were less than 20% 
although specific values were not given. Despite the relatively high values of basal 
haemolysis obtained, this study was still useful for evaluating the effect of tonicity and 
pH on the haemolysis of rat erythrocytes. 
PBS (pH 7) containing concentrations of NaCl of 0.3 % or lower (osmolality of 5 0.118 
Osmol/kg) resulted in total (100%) haemolysis of rat erythrocytes (Table 9.1, Figure 
9.1). Between concentrations of 0.3 and 0.5 % NaCl (0.118-0.181 Osmol/kg) the 
haemolytic effect was dramatically reduced. At 0.5 % NaCl the mean haemolysis was 
approximately 43 % (± 2.7). Increasing the NaCl concentration from 0.5 to 0.7 % NaCl 
(0.181-0.243 Osmol/kg), reduced the degree of haemolysis further. At 0.243 Osmol/kg 
values of haemolysis were similar to the values of basal haemolysis (isotonic PBS). 
Further increase in the concentration of NaCl in the lysate, up to 1.2 % (0.393 Osmolkg) 
did not greatly alter the degree of haemolysis from that of the basal value. Increasing 
osmolality above 0.393 Osmol/kg resulted in only small increases in the degree of 
haemolysis even at 0.855 Osmol/kg (2.7% NaCl). Thus, in the study, the degree of 
haemolysis was not affected by changes in lysate osmolality in the range 0.243-0.393 
Osmol/kg. 
For isotonic PBS between pH 3.5-8.5, values of % haemolysis were similar to basal 
values (Table 9.1, Figure 9.2). However, further reductions in the pH of the lysate 
increased erythrocyte haemolysis. Thus in this study, the degree of haemolysis was not 
affected by changes in lysate pH in the range pH 3.5 to 8.5. 
This study showed that rat erythrocytes are stable to a wide range of lysate osmolality and 
pH values. When evaluating the haemolytic effect of absorption enhancers, the solutions 
of enhancers should be maintained within these limits of osmolality and pH (0.243-0.393 
Osmol/kg and pH 3.5-8.5). Thus, haemolysis, above the basal values which are inherent 
for the haemolytic assay, can be attributed to the haemolytic effects of the compound 
under investigation and not due to osmolality or pH effects on erythrocytes. In this 
study, either osmolality or pH was maintained constant when evaluating the effects of 
changes in pH or osmolality respectively. However, the sensitivity of erythrocytes to 
changes in osmolality may be influenced by changes in pH and vice versa which should 
be kept in mind when performing haemolysis studies. The haemolytic activity of certain 
compounds may also be influenced by osmolality or pH. Senisterra et al (1988) showed 
that the haemolytic activity of lysophosphatidylcholine on mutilamellar liposomes (model 
lipid membrane) increased in hypertonic solutions and decreased in hypotonic solutions. 
Thus, this should also be considerd when designing experiments. 
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Table 9.1. 
. 
Summary of values of % haemolysis (lysis) obtained following-the 
incubation of rat erythrocytes with PBS solutions of different tonicity and nil 
Lysate Mean % 
haemolysis 
SD Lysate Mean % 
haemol sls 
SD 
Water 
PBS 
100.0 
21.7 
0.00 
4.11 
Water 
PBS 
100.0 
21.5 
0.00 
3.70 
PBS at different values of osmolality (pH 7) PBS at different values of pH (-0.300 Osmol/k 
NaC1 conc. 
(% w/v) 
Osmolality 
(Osmol/k ) 
% haemolysis SD pH % haemolysis SD 
0.00 0.024 102.0 2.00 8.5 14.3 1.27 
0.05 0.040 103.3 1.28 8.0 14.8 1.20 
0.10 0.056 103.4 1.91 7.5 16.0 3.88 
0.30 0.118 100.1 1.34 7.0 16.6 2.62 
0.50 0.181 43.4 2.73 6.5 14.1 4.51 
0.70 0.243 22.9 1.16 6.0 18.3 3.04 
0.85 0.293 22.5 3.22 5.5 16.7 1.64 
0.90 0.302 19.8 1.78 5.0 18.7 1.24 
0.95 0.316 20.4 1.47 4.5 16.0 0.56 
1.20 0.393 21.8 5.39 4.0 16.2 2.17 
1.50 0.486 28.4 2.17 3.5 22.0 1.81 
1.80 0.578 28.9 6.15 3.0 41.8 12.70 
2.25 0.717 24.7 2.04 2.5 31.7 9.94 
2.70 0.855 24.1 0.54 2.0 74.9 2.42 
Figure 9.1. Effect of osmolality on values of % haemolysis 
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9.4 Investigation of the haemolytic effects of chitosan and- 
various absorption enhancers 
9.4.1 Aims and objectives 
The nasal absorption enhancing efficacy of chitosan (MVCSN) and several other 
compounds (GDC, Laureth-9 and LPC) was evaluated in studies in the rat (Chapter 3). 
However, with the exception of chitosan, these compounds have been shown in various 
studies reported in the literature to cause damage to biological membranes which may, in- 
part, account for their absorption enhancing efficacy. The aim of this study, was to 
compare the haemolytic effects of MVCSN and the absorption enhancers GDC, Laureth- 
9 and LPC with a view to assessing the safety of chitosan. 
9.4.2 Methods 
The general materials used are as listed in Section 9.2. Additional materials are given in 
Section 3.3. Isotonic solutions of MVCSN, GDC, Laureth-9 and LPC were prepared in 
PBS (pH 7.0). MVCSN solutions in PBS were prepared at pH 4.0 by adjustment with 
HCI during preparation. MVCSN solutions at pH 4.0 were compared with solutions at 
pH about 5.3 which were prepared by dissolving / diluting MVCSN directly in PBS. 
Concentrations of MVCSN were expressed as the concentration of chitosan glutamate. 
The enhancer concentrations investigated are given in Table 9.2. The erythrocyte lysis 
assay was performed as described in Section 9.2. The assays were performed with 3.5 
ml of control or test media except those which used LPC solutions where the volume of 
control or test media was reduced to 1.75 ml. 
To directly compare the haemolytic activity of the enhancers, the concentration of 
enhancer at which 50% haemolysis occurred (L50) was estimated. In the calculation of 
L50, differences between the values of basal haemolysis (incubations with PBS) in each 
assay were taken in to account. Thus, the haemolysis was attributed solely to the effects 
of the enhancer. The calculation was performed as follows: 
% haemolysis =optical density (Test) - optical density (PBS) x 100 
optical density (Water) 
Values of mean % haemolysis were plotted against enhancer concentration (not shown) 
from which values of L50 were estimated. 
9.4.3 Results and Discussion. 
Table 9.2 shows that at enhancer concentrations of 0.0 mg/ml, indicating values of basal 
haemolysis, there was considerable variation in the values obtained (- 8-22%). The 
reasons for these variations are not known but may reflect an inherent sensitivity of rat 
erythrocytes to slight fluctuations in experimental conditions. The results for MVCSN 
were misleading, with values of haemolysis for a 0.5% solution at pH-6 calculated in 
excess of 100% (Table 9.2, Figure 9.3). Following centrifugation of the tubes 
containing MVCSN (both at pH-6 and pH4), aggregates of apparently intact erythrocytes 
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were observed in the supernatant and adhered to the walls of the tube especially in the 
tubes containing the higher concentrations of MVCSN. This was probably due to the 
relatively high viscosity of MVCSN solutions which prevented the sedimentation of intact 
erythrocytes. The effect appeared to be more pronounced with MVCSN at pH 5.3 than 
MVCSN at pH 4 which could have reflected differences in the viscosities of the 
respective solutions. Subsequently, the apparent viscosity of two 0.5% solutions of 
MVCSN, one at pH 4 and the second at pH 5.3 were measured using a Brookfield DV- 
III Programmable Rheometer (refer to Section 10.5 for further details of the method). At 
10 rpm, MVCSN at pH 5.3 had a viscosity of 9.78 cps (± 0.060, n=3) compared to 9.52 
cps (± 0.046, n=3) at pH 4. The higher viscosity of the solution at pH 5.3 may explain 
the reasons for the higher optical density readings obtained at this pH. The viscosity of 
chitosan in solution will usually increase as pH is reduced although at relatively high 
ionic concentration, such as in 0.9% NaCl, the effects of ionic concentration 
predominate. The increased viscosity at higher pH is probably due to the combined 
effects of pH and ionic concentration and the effects of the glutamate moiety of the 
chitosan salt. Since the centrifugation step employed in the assay appeared to be 
inadequate for the sedimentation of intact erythrocytes it was probable that the values of 
haemolysis calculated for chitosan solutions at the higher concentrations were 
anomalously high. Thus, this was kept in mind when assessing the haemolytic potency 
of chitosan in this study. Further investigations were performed to evaluate the effect of 
centrifugation on the values of % haemolysis obtained in the assay the details of which 
are given in Section 9.5. 
The results of this study show that the compounds investigated exhibited varying degrees 
of haemolytic potency (Tables 9.2-9.3, Figure 9.3). LPC had the greatest haemolytic 
activity with a value of L50 estimated at 4.5 x 10-4 % w/v compared to values of 4.1 x 
10-3,0.08,0.18 and 0.25 % w/v for Laureth-9, GDC, MVCSN pH-5.3 and MVCSN 
pH 4, respectively. The values obtained for LPC and Laureth-9 are in agreement with the 
values reported by Chandler (1995) of 5.2 x 10-4 % w/v and 4.1 x 10-3 % w/v, 
respectively. Thus, the compounds investigated in this study ranked in order of 
haemolytic potency as follows: LPC » Laureth-9 » GDC > MVCSN pH 5.3 > 
MVCSN pH 4 
The ranking of the compounds LPC, Laureth-9 and GDC was in agreement with results 
published by Gill et al. (1994a) (values of L50 were not reported). MVCSN was shown 
to have the lowest haemolytic activity despite suggestions of anomalously high values of 
haemolysis. 
Values of L50 used to rank the compounds in order of haemolytic potency will depend on 
the cell density used in the incubation media and thus depend on the experimental 
conditions (Weltzien et al., 1977). For lysophospholipids values of L50 are thought to 
reflect their binding affinities to erythrocytes. A more accurate measure of the actual 
membrane disruption may be obtained by determination of the cell-bound amounts of the 
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lysate at 50% haemolysis (A50) which is independent of experimental conditions. 
However, determination of values of A50 requires more complex assay procedures 
involving the use of radiolabelled compounds. In this study, since the haemolytic activity 
of the compounds was assessed using the same erythrocyte stock solution, thus the cell 
density of the incubation media was assumed to be identical, then values of L50 were 
considered appropriate for comparing the haemolytic activity of the various compounds. 
The fluctuations in basal values of haemolysis were taken into account during the 
calculation of values of L50. Haemolysis may be due to the disruption of the normal 
molecular organisation of the cell membrane, due to the removal of membrane lipids into 
mixed micelles with the lysate molecule (Helenius & Simons, 1975) or due to the binding 
and incorporation of the lysate into the lipid matrix of the membrane (Weltzien, 1979), 
which lead to permeability changes and leakage of haemoglobin. 
The order of haemolytic potency did not correlate with the order of nasal absorption 
enhancing potency demonstrated in Chapter 3 where the compounds were ranked in the 
order: LPC > MVCSN pH 4» GDC > Laureth-9. 
LPC was the most effective absorption enhancer but also had the greatest haemolytic 
activity. In contrast, the absorption enhancing efficacy of MVCSN pH 4 was only 
marginally less effective than that of LPC but its haemolytic activity was the lowest of the 
compounds tested. Laureth-9 was shown to be only moderately effective as an 
absorption enhancer despite being a potent haemolytic agent. GDC also showed 
moderate absorption enhancing efficacy although in contrast to Laureth-9 its haemolytic 
activity was relatively low. With the exception of MVCSN, the compounds investigated 
in this study, particularly LPC and Laureth-9, were shown to cause maximal haemolysis 
at concentrations which were much lower than the concentrations at which they 
effectively enhanced nasal insulin absorption in the rat. 
The haemolytic potency of LPC and Laureth-9 correlates with the severe damage that 
these compounds have been shown to cause to the rat nasal mucosa in vivo (Chandler et 
al., 1991a & 1991b). In this study the bile salt GDC was shown to exhibit similar 
haemolytic activity (L50 = 0.08 % w/v) to that of the bile salt derivative STDHF (L50 = 
0.045 % w/v) reported by Chandler et al (1995). Chandler et al. (199 lb) showed that 
STDHF caused less damage to the rat nasal mucosa than Laureth-9 at a similar 
concentration. The low haemolytic activity of MVCSN supports the histological studies 
of Ilium et al. (1994) which showed that exposure of the rat nasal mucosa to 0.5% 
chitosan for a period of 60 minutes did not result in any significant changes in nasal 
morphology. The results from the haemolysis studies results are encouraging since they 
suggest that MVCSN is relatively non-damaging to biological membranes. Furthermore, 
since the haemolytic activity of MVCSN recorded in this study was suspected to be 
anomalously high it was decided that this would be further investigated in haemolysis 
studies. 
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Table 9.2. Summary of values of % haemolysis (lysis) following the Incubation-of 
rat erythrocytes with solutions of MVCSN or various other absorption enhancers 
Lvsate Mean % haemolysis (t SD) 
water 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
Enhancer 
conc. (me/ml) 
MVCSN SD 
H4 
MVCSN SD 
H 5.3 
GDC SD Laureth-9 SD LPC SD 
0.0000 7.9 0.46 146 5.36 17.6 2.02 21.6 3.53 17.0 2.04 
0.0001 17.3 1.54 
0.0001 6.9 0.61 12.3 4.12 15.4 2.14 16.9 0.53 18.4 2.56 
0.0003 7.4 1.52 13.1 4.84 15.3 2.35 15.5 1.00 20.7 4.46 
0.0005 6.8 0.80 12.1 3.84 16.0 3.11 18.2 3.42 81.7 10.41 
0.0008 6.0 0.61 10.8 2.75 15.3 1.45 14.9 0.41 101.7 9.74 
0.0010 6.6 1.05 9.9 1.39 14.9 2.35 13.3 0.81 94.6 3.53 
0.0015 97.3 4.60 
0.0020 97.1 4.05 
0.0025 97.7 3.10 
0.0030 7.8 0.25 10.7 2.42 16.0 1.23 10.5 0.89 101.0 3.51 
00050 7.1 0.83 13.8 3.81 17.6 0.87 94.2 4.37 98.8 2.55 
0.0100 7.3 1.08 18.3 6.05 14.1 0.50 99.5 1.02 96.4 5.66 
0.0250 95.1 4.53 
0.0500 12.5 1.87 31.3 5.71 29.7 2.06 98.0 0.45 97.4 3.24 
0.1000 17.8 9.62 18.5 8.29 93.6 4.35 99.0 0.85 93.3 2.62 
0.3000 70.1 2.33 95.3 20.86 
0.5000 70.8 0.78 183.2 28.51 
Table 9.3. Haemolytic activity (values of Lyn) of MVCS and various other 
absorption enhancers 
Enhancer L50 (% w/v) 
MVCSN pH 4 0.25 
MVCSN pH 5.3 0.18 
GDC 0.08 
Laureth-9 4.5 x 10-3 
LPC 4.5 x 10-4 
* Concentration of MVCSN expressed as concentration of chitosan glutamate 
Figure 9.3. Effect of concentration of MVCSN or absorption enhancer on values of 
% haemolysis 
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2.5 Effect of relative centrifugal field (RCF) and duration of 
centrifugation on the apparent haemolytic activity of 
MVCSN 
9.5.1 Aims and objectives 
The values of % haemolysis calculated following the incubation of rat erythrocytes with 
viscous solutions of MVCSN may have been anomalously elevated due to insufficient 
centrifugation during the assay procedure. This could result in intact erythrocytes 
remaining in suspension in the lysate medium thus, producing anomalously high values 
of optical density. In this study the effect of the relative centrifugal field (RCF) and the 
duration of centrifugation on the apparent haemolytic activity of MVCSN was 
investigated. For this purpose solutions of 2% MVCSN were tested under different 
conditions of RCF and periods of centrifugation. In each assay incubations with water 
and PBS served as the positive and negative controls, respectively. 
9.5.2 Materials and Methods 
The general materials used are as listed in Section 9.2. Additional materials are given in 
Section 3.3. A solution of 2% MVCSN, expressed as the concentration of chitosan 
glutamate, was prepared in PBS. During preparation the pH of the solution was adjusted 
to pH 4.0 with 1M HCI. Each assay consisted of incubations with water, PBS and 2% 
MVCSN and these were performed in triplicate. Following the incubations the samples 
were centrifuged for 2,5,10 or 20 minutes at approximately 581 xg (1800 rpm), 1122 x 
g (2500 rpm) and 2198 xg (3500 rpm) in a MSE Mistral 2000 centrifuge or 2900 xg 
(6500 rpm) and 11600 xg (13000 rpm) in a MSE Microcentaur centrifuge. Other details 
of the assay were as given in Section 9.2. 
9.5.3 Results and Discussion 
Results are shown in Table 9.4 and Figure 9.5. The results show that the conditions of 
centrifugation (RCF and duration of centrifugation) greatly influence values of % 
haemolysis calculated for MVCSN solutions (Figure 9.5A). However, these conditions 
did not appear to markedly affect values of basal haemolysis (Figure 9.5B) or values of 
optical density at 100% haemolysis (not shown). For each of the assays performed, 
following incubation with water, the variation in values of optical density were low 
(mean ± SD = 1.046 ± 0.0534, n=60, CV = 5.1%). Variation in values of basal 
haemolysis were also reasonably low (0.117 ± 0.0267, n=60, CV = 22.8%). 
Following incubations with MVCSN solutions, values of mean % haemolysis generally 
decreased with increases in RCF and time of centrifugation indicating more efficient 
sedimentation of intact erythrocytes. Irrespective of RCF, centifugation for only 2 
minutes did not provide satisfactory sedimentation of erythrocytes. Centrifugation for 5 
minutes gave acceptable separation of erythrocytes from the supernatant at 11600 xg but 
not at any of the other values of RCF investigated. At 11600 x g, increasing the 
centrifugation time from 5 to 20 minutes did not significantly increase the values of mean 
% haemolysis obtained and these values were much lower than those obtained for all of 
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other combinations of RCF and centrifugation time. Thus, the study shows that without 
adequate centrifugation values of haemolysis of viscous solutions will be anomolously 
high. Centrifugation at 11600 xg for 5 minutes has been shown to be adequate for the 
sedimentation of intact erythrocytes in viscous solutions of MVCSN (2 % w/v) and thus, 
these conditions of centrifugation will be used to assess the haemolytic activity of 
chitosan solutions with greater accuracy. 
Table 9.4. Summary of values of % haemolysis (lysis) following the investigation 
of the effect of relative centrifugal field (RCF) and duration of centrifugation on the 
haemolytic activity of MVCSN 
Centrifugation Lysate Mean % haemolysis (t SD) 
time (minutes) 
Centrifugal Field 
581 xG SD 1122xG SD 2198x0 SD 2900xG SD 11600X0 SD 
2 water 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
PBS 4.3 0.14 12.6 0.93 12.9 1.35 9.3 0.22 12.1 0.14 
MVCSN 220.8 21.45 184.8 31.56 164.0 5.48 110.6 14.12 62.1 7.92 
5 water 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
PBS 7.4 0.79 12.8 0.72 12.9 0.94 11.0 0.06 10.1 0.34 
MVCSN 175.7 38.36 167.8 9.60 167.4 15.56 48.7 4.06 24.0 0.70 
10 water 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
PBS 8.9 0.62 13.8 0.37 13.1 0.22 14.4 0.35 11.1 0.23 
MVCSN 151.4 2.15 168.3 6.63 105.5 21.31 40.1 4.11 23.5 0.26 
20 water 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
PBS 9.7 0.99 10.0 0.45 12.8 1.47 14.3 0.29 10.8 0ä8 
MVCSN 127.3 5.69 110.3 10.46 56.7 1.09 38.3 1.82 23.1 0.32 
* MVCSN tested at 20 mg/ml (concentration expressed as concentration of chitosan glutamate) 
Figure 9.3. Effect of relative centrifugal field (RCF) and duration of centrifugation 
on the haemolytic activity of MVCSN 
A: Incubations with 2% MVCSN 
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9.6 Further investigations of the haemoloytic effects of 
chitosan 
9.6.1 Aims and objectives 
Based on the findings of the previous study (Section 9.5), the aim of this study was to 
re-evaluate the haemolytic activity of MVCSN. For comparison the haemolytic activities 
of CSN lactate, CSN HC1 and HVCSN were also assessed. 
9.6.2 Methods 
The general materials used are as listed in Section 9.2. Additional materials are as given 
in Sections 4.5 and 7.7. Isotonic solutions of MVCSN, CSN lactate and CSN HCl were 
prepared at pH 4.0 in 0.9 % NaCl. There were problems with the solution of CSN 
lactate which contained a fine suspension of insoluble material (different batch used from 
that used in nasal absorption studies). Attempt to filter the stock solution of LVCSN (2% 
CSN lactate) on 0.45 µm membrane filters was unsuccessful since the membrane quickly 
became blocked and hence filtration was performed on 5 µm membrane filters although 
particles were still observed in the filtrate. Due to the insolubility of HVCSN in NaCl at 
pH 4.0, isotonic solutions of HVCSN were prepared in 0.1 % acetic acid and for 
comparison a solution of MVCSN were also prepared in acetic acid. The concentration 
of MVCSN, CSN lacate and CSN HCL was expressed as the concentration of chitosan 
salt. The concentration of HVCSN was expressed as the concentration of chitosan base. 
During each assay centrifugation was performed at 13000 rpm (11600 x g) for 5 minutes. 
9.6.3 Results and Discussion 
The results are given in Table 9.5 and Figure 9.6. The haemolytic activity of MVCSN 
was shown to be extremely low at concentrations up to 2%. Values of % haemolysis up 
to concentrations of 1.0% MVCSN were less than those of the control incubations with 
PBS or with NaCl (0% MVCSN) which suggests that chitosan protects the cell 
membrane at these concentrations. At 2% MVCSN, values of haemolysis were 
comparable to those of the control incubations. CSN HCL was shown to have a higher 
haemolytic activity than that of MVCSN resulting in 50% haemolysis (basal haemolysis 
not taken into account) at a concentration of about 0.5%. CSN lactate was shown to be 
more haemolytic than MVCSN at all concentrations investigated and above a 
concentration of 0.5% the haemolytic activity of CSN lactate increased considerably. 
This was attributed to the suspension of insoluble material in the CSN lactate solutions 
having a direct effect on the integrity of the cell membrane and thus, it was concluded that 
the results of the haemolysis assay for CSN lactate were anomalously high. Since the 
assay of CSN lactate was not repeated (a different batch would have been used) then 
conclusions on the haemolytic activity of CSN lactate could not be made. Following the 
assay of the MVCSN and HVCSN solutions prepared in acetic acid the basal values of 
haemolysis were observed to be higher (approximately 30%) than those in previous 
studies. However, taking the basal haemolysis into account, the haemolytic activity of 
MVCSN was still shown to be low although results were marginally higher than those 
obtained previously (in 0.9% NaCl) which may reflect increased sensitivity of the cell 
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membrane to acetic acid. The haemolytic activity of MVCSN and HVCSN was shown to 
be comparable at concentrations up to 0.1 % although above these concentrations HVCSN 
was apparently a more potent lytic agent. Judging from the degree of haemolysis of the 
1.0% solution of HVCSN (values in excess of 100%), it is possible that the speed (RCF) 
and duration of centrifugation were insufficient to sediment intact erythrocytes in the high 
viscosity solutions and this should be kept in mind when reaching conclusions of the 
haemolytic activity of HVCSN. 
Table 9 
. 
5. Summary of values of % haemolysis (Iysis) following further 
investigation of the haemolytic activity of different grades of chitosan 
Lysate Mean % haemolysis (± SD) 
water 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 
PBS 8.3 0.31 11.1 2.09 8.9 2.21 11.3 1.26 14.7 3.21 
chitosan cons (% w/v MVCSN SD CSN HCI SD CSN lactate SD MVCSN * SD HVCSN * SD 
0.0 7.9 0.50 8.9 0.73 7.4 0.23 30.9 0.21 30.0 0.47 
0.05 5.5 0.33 5.7 0.35 8.8 0.07 33.3 0.80 32.9 0.46 
0.1 5.1 0.28 5.9 0.48 8.7 0.38 33.7 0.18 32.9 1.07 
0.3 3.9 0.19 36.7 3.00 11.9 0.20 39.0 1.41 43.5 2.95 
0.5 4.0 0.69 51.8 2.58 12.5 0.24 43.8 2.10 60.0 1.16 
0.75 5.6 1.66 68.8 3.27 30.4 1.47 48.4 0.48 83.4 2.71 
1.0 6.2 0.70 79.4 13.82 81.7 2.99 54.2 0.76 117.9 3.6 
1.5 10.2 0.73 
- - 
90.5 2.60 
- - 
ý 
2.0 16.0 1.42 
- 
92.9 4.62 
- - 
:ý 
* Solutions prepared in acetic acid 
Concentration of MVCSN. CVSN HCL and CSN lactate expressed as the concentration of chitosan salt 
Concentration of HVCSN expressed as the concentration of chitosan base 
Figure 9.6. 
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.7 Conclusions 
Erythrocytes were shown to be a useful model for screening the membrane damaging 
effects of chitosan and various other compounds and based on studies reported in the 
literature, the haemolytic activity obtained correlated well with the degree of membrane 
damage of these compounds in vivo. The values of basal haemolysis of the rat 
erythrocytes was shown to be variable and thus improved accuracy may be obtained if 
human erythrocytes are used in future studies (Ilium et al., Unpublished results). The 
haemolysis assay was shown to be stable over a wide range of values of osmolality 
(0.243-0.393 Osmol/kg) and pH (3.5-8.5). Thus, for test solutions within these limits 
of osmolality and pH, it was assumed that haemolysis above basal values, which are 
inherent for the haemolysis assay, is indicative of the haemolytic activity of the 
compound under investigation. For viscous chitosan solutions anomalously high optical 
density readings were obtained, hence corresponding values of % haemolysis were 
anomalously high, if both the relative centrifugal field (RCF) and duration of 
centrifugation were insufficient to sediment intact (un-haemolysed) erythrocytes. A RCF 
of 11600 xg (13000 rpm) for a minimum duration of 5 minutes was shown to be 
required when assaying most of the chitosan solutions. 
The haemolytic activity of MVCSN was shown to be extremely low compared to the 
other absorption enhancers investigated. The compounds investigated ranked in order of 
haemolytic potency as follows: LPC» Laureth-9» GDC > MVCSN. The haemolytic 
activity of a 0.5% solution of MVCSN was shown to be lower than that of basal values 
which implies that MVCSN protects the erythrocyte membrane, thus at this concentration 
MVCSN was shown to be non-toxic to the model membrane. In contrast, LPC, Laureth- 
9 and GDC caused maximal haemolysis at concentrations which were much lower than 
the concentration at which these compounds effectively enhanced nasal insulin absorption 
in the rat. 
The haemolytic activity of MVCSN was less than that of CSN HCl and HVCSN 
although with HVCSN at the higher concentrations investigated the solution viscosity 
may have prevented the sedimentation of intact erythrocytes at the RCF and period of 
centrfiugation used in the assay. The studies with CSN lactate were inconclusive since 
although they indicated that CSN lactate had a much higher haemolytic potency than 
MVCSN this was attributed to insoluble impurities in the batch of CSN lactate used. 
Overall, the studies demonstrated that MVCSN was relatively non-damaging to the 
erythrocyte model membrane up to concentrations of 2% w/v. From a safety perspective 
this further supports the potential application of MVCSN in nasal delivery systems. 
-1 
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CHAPTER 10 
PHYSICAL CHARACTERISATION OF CHITOSAN 
10.1 Introduction 
The chitosan predominantly used in this project, medium viscosity chitosan glutamate 
(MVCSN), was characterised in terms of its partial specific volume, apparent molecular 
weight, intrinsic viscosity and apparent viscosity. For some of these techniques, the 
physical properties of other grades of chitosan were also determined. A brief description 
of the techniques used is given in the following sections: 
10.2 Determination of partial specific volume, v 
10.3 Molecular weight determination by analytical ultracentrifugation 
10.4 Determination of intrinsic viscosity 
10.5 Determination of apparent viscosity 
Measurements of partial specific volume, molecular weight and intrinsic viscosity were 
performed at the National Centre for Macromolecular Hydrodynamics, Department of 
Applied Biochemistry and Food Science, University of Nottingham, UK. Reference is 
made in this text regarding the general theory behind the measurement of these parameters 
to the work of Van Holde (1985). Additional references are given in the text. 
10.2 Determination of partial specific volume. 7 
10.2.1 Theory 
Partial specific volume, 'v, is the volume increment when 1 gram of solute is dissolved in 
an infinite volume of solution. Knowledge of the value of V is required in the calculation 
of molecular weight by ultracentrifugation where the term (1-V. p) is encountered (p is the 
solution density). Errors in the measurement of v will be magnified in the determination 
of molecular weight. 
The value of v can be calculated from the equation given by Kratky et al. (1973): 
V=c 
Po 
Where dpldc is the change in solute density with concentration and po is the solvent 
(buffer) density. 
Density measurements were performed using a density meter which measures the period 
of oscillation, T, of a hollow glass oscillator filled with liquid sample. The principle of 
the measurement depends upon the variation of the natural frequency of the oscillator 
when filled with different liquids or gases. The mass and therefore density of the liquid 
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or gas changes this natural frequency because of the gross mass change of the oscillator 
caused by the introduction of the sample. For the difference of the densities of two 
samples, p1 and p2: 
PI-P2 = (1 /A) (T12-T22) 
where A is a predetermined density meter constant and Tl and T2 is the period of 
oscillation of the two samples respectively. The density meter constant is determined 
from calibration measurements with samples of caesium chloride of known density and is 
a function of the volume and the spring constant of the apparatus. The volume of liquid 
in the oscillator, which will influence its frequency, can always be accurately defined, as 
long as the oscillator is properly filled, since it is the volume which is between two fixed 
points. 
10.2.2 Method 
An Anton Paar digital DMA 02C precision density meter (Anton Paar, Graz, Austria) 
with a Techne thermostatically controlled water bath (TU-16A Tempunit) set at 25.00°C 
(± 0.05) was used to determine the densities of solvent or chitosan solutions. Water was 
circulated from the water bath to the density meter using a water pump. 
Chitosan solutions in the range 2.0 to 10.0 mg/ml were prepared in 0.05 M acetate buffer 
of pH 4.0. The chitosan solutions, the solvent (acetate buffer) and a sample of de- 
ionized distilled water were incubated at approximately 28°C in a water bath prior to 
injection into the density meter since this slight elevation of temperature helped to prevent 
air bubbles in the oscillator. An excess of sample (1.0 ml) was injected into the oscillator 
using a 1.0 ml disposable syringe. The capacity of the ocillatorwas about 0.7 ml. The 
oscillator was then viewed through a window in the instrument to check for complete 
filling and to ensure that it was free of air bubbles. After 10 minutes, allowed for thermal 
equilibration, the time lapse to complete 10,000 oscillations was measured and displayed 
by the instrument. This was repeated several times to obtain a reproducible value. In 
between samples the oscillator was washed with distilled water followed by absolute 
ethanol and dried with an air line. 
Using the equation given previously, (PI-P2 = (1/A) (T12-T22)), the density of the 
chitosan solutions were calculated. The slope of a plot of density versus chitosan 
concentration was used to determine dpldc from which 7 was calculated 
(v 
= (1-dp/dc)/ po). The units of 7 are ml/g. 
10.2.3 Results and Discussion 
The values of density at different solution concentrations of MVCSN are given in Table 
10.1 and Figure 10.1. The density of the buffer (p0) was 0.9988 g/ml and the slope 
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dpldc (± SE) was 0.4203 (± 0.01127). The value of partial specific volume, v, (t SE) 
was 0.58 mug (± 0.011) as given in Table 10.1. 
The value of v' obtained was in excellent agreement with that reported by Errington 
(1993) and Errington et al. (1993) using a similar grade of chitosan (0.580 ± 0.011 
ml/g). This value of v was subsequently used in the calculation of molecular weight of 
MVCSN by the technique of sedimentation equilibrium. 
Table 10.1. Values of density (p) of different solutions of MVCSN and value of 7 
; 1MVCSN solutions 
Concentration 
(m ml) 
p 
(g/mi) 
0.00 0.9988 
2.03 0.9996 
4.07 1.0004 
6.10 1.0015 
8.13 1.0022 
10.16 1.0030 
7 (tSE)=0.58 mug (±0.011) 
Figure 10.1. Plot of density (p) versus solution concentration of MVCSN used in 
the calculation of v 
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10.3 Determination of molecular weight 
10.3.1 Theory 
A macromolecular solution will often be polydispersed i. e. will not contain molecules of 
the same molecular weight, M, and hence average molecular weights are often 
considered. Sedimentation equilibrium in the analytical ultracentrifuge is an absolute 
method to determine the weight-average molecular weight, Mw, which can be defined as: 
Mw=7, ci"Mi/Ici 
in which ci is the weight concentration (g/ml) of all molecules having molecular weight 
A- 
The technique of sedimentation equilibrium uses relatively low speeds of rotation 
(typically 2000 to 15000 revs/min) so that a balance or equilibrium is established between 
the sedimentation of the molecules and their diffusion in the aqueous medium which is 
housed in a rotor cell. Sedimentation will tend to decrease the concentration of molecules 
at the meniscus and increase them at the cell base whereas diffusion tends to maintain the 
same concentration of molecules throughout the cell. In practical terms the molecules will 
sediment outwards from the centre of rotation. At equilibrium the concentration of the 
molecules will be lower at the meniscus and increased towards the cell base but there will 
be no net transport of matter i. e. sedimentation and diffusion are balanced. At 
equilibrium in an ideal two component system the concentration gradient for a single 
solute component can be given by: 
1/c. (d cl d r) = co2rM (1-vp)/ RT 
where: c= solute concentration (mass/volume), r= distance from the centre of 
rotation, co = angular velocity, M= molecular weight, v= partial specific volume, p= 
solution density, R= Gas constant (8.31 x 107 ergs/degree/mol. ), 
T= Absolute temperature. 
For a polydisperse and heterogeneous system M will be a weight average molecular 
weight, M. For a non-ideal system and at finite concentration, c, M will be an apparent 
molecular weight, Mw, app, although as c--)0, MW, app, -4 Mw, (Tanford, 1961). The 
events during sedimentation are most accurately followed by Rayleigh interference optics 
which detect the changes in the refractive index (n) of the sample and the solvent which 
are loaded into different compartments of a double sector cell (Harding and Rowe, 1988). 
The resultant fringe pattern produced can be readily observed and recorded 
photographically. Each fringe traces a curve of the refractive index versus radial distance 
in the cell. The displacement of the fringes can be related to the solute concentration (c) 
increments in the cell since dn/dc is assumed to be constant. Although the measured 
solute concentration increments are relative, absolute concentrations, in terms of fringe 
numbers, at the meniscus of the solute column can be determined and hence absolute 
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concentrations determined at all other radial positions in the cell. 
The absolute solute concentrations, in terms of fringe numbers, can be given by J such 
that J(r) is the absolute fringe concentration at radial position r and J(a) the absolute fringe 
concentration at the meniscus (a is the radial position at the meniscus). Mathematical 
processing of the fringe data can be used to determine weight average molecular weights 
(refer to Creeth and Harding, 1982, Harding et al., 1991). The (whole cell) apparent 
weight average molecular weight, Mw, app, measured over the whole distribution can be 
obtained from the limiting value at the cell base of the plot of M* (r) versus % (r) where 
M* (r) is an operational point average molecular weight, known as the "star" average, 
and 4 (r) is a function of the radial position as given below. 
4(r) 
= 
(r2 
- 
a2) / (b2 
- 
a2) 
where r= distance from centre of rotation, a= cell meniscus and b= cell base. 
At the cell base (4--ý 1) and M* (r)->MW, app(r) (Creeth and Harding, 1982). 
Alternatively, apparent point (local) weight average molecular weights, Mw, app(r), can 
be extrapolated to zero (fringe) concentration, J (r), by plotting Mw, app(r) versus J (r) to 
give Mw, app (J-40). 
10.3.2 Method 
Sedimentation equilibrium investigations were performed using a Beckman Model E 
analytical ultracentrifuge (Beckman Instruments UK Ltd) with an electonically controlled 
drive. Rayleigh interference optics were employed using a5 mW helium-neon laser and 
a mercury are light. A solution of MVCSN of 0.6 mg/ml was prepared in 0.05 M acetate 
buffer of pH 4, filtered on 0.45 pm syringe filters and dialysed overnight against the 
acetate buffer. A volume of 0.15 ml of the solution was loaded into the right-hand side 
and 0.15 ml of the dialysate (acetate buffer) loaded into the left-hand side of a 30 mm 
centrifuge cell (B 11-8). Centrifugation was performed in an evacuated chamber at 
approximately 10,000 rpm and 25°C. Rotor temperature throughout the procedure was 
maintained at 25°C. The photographic images of the Rayleigh interference pattern were 
recorded throughout the procedure in the form of photographic negatives on 35 mm black 
and white film. When superimposable images were obtained, indicating equilibrium of 
the system, final images were obtained and the centrifuge run stopped. The fringe pattern 
obtained on one of the final photographic negatives was enlarged and processed using a 
LKB 2202 laser densitometer (LKB Instruments, Bromma, Sweden). The resultant 
digitised pattern was then processed using a Fourier cosine series Pascal alogarithm 
`Analyser' to obtain data in the form of fringe concentrations, relative to the meniscus, 
versus radial distance in the centrifuge cell. Full molecular weight analysis of the data 
was performed using the mainframe IBM 3081 computer at Cambridge. Mw, app was 
obtained from the limiting value at the cell base (4-4 1) of the plot of M* (r) versus 4 (r). 
Mw, 
app(r) (J-*O) was obtained by extrapolation to zero (fringe) concentration of a plot of 
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Mw, 
app(r) versus J (r). At zero concentration the effects of non-ideality -40 and hence 
the apparent Mw app -4 the ideal Mw. 
10.3.3 Results and Discussion 
Plots of M* (r) versus 4 (r), MW, app(r) versus J (r) and Ln J (r) versus 4 (r) are shown in 
Figures 10.2-10.4. Values of MW, appp and Mw, app(r) (J-40) for MVCSN, at a loading 
concentration of 0.6 mg/ml, are given in Table 10.2. The plot of Ln J (r) versus 4 (r) 
exhibited considerable downward curvature which was indicative of strong 
thermodynamic non-ideality through exclusion volume and charge effects (Harding et al., 
1991). Thus, the thermodynamic effects of non-ideality outweigh the effects of 
polydispersity which would otherwise tend to produce upward curvature of the plot of Ln 
J (r) versus 4 (r). The values obtained for M. are much lower than expected for this 
grade of chitosan based on values quoted by Pronova Biopolymer A/S in the region of 
150,000-250,000. Errington (1993) and Errington et al. (1993) using the same batch of 
chitosan to the one used in this project reported a Mw of 162,000 g/mol (± 10,000) using 
sedimentation equilibrium. However, this was obtained by extrapolation, to zero 
concentration, of a plot of 1/Mw, app versus chitosan concentration. Also, lower 
concentrations of chitosan were also tested thereby minimising the effects of 
thermodynamic non-ideality (which tends to diminish measured molecular weights and 
mask heterogeneity (Harding et al., 1991)). Although the alternative method employed 
here of extrapolating point weight average molecular weights, Mw, app (r), to zero fringe 
concentration, (J-40), effectively eliminates non-ideality, it could possibly have the effect 
of biasing the results towards the lower end of the molecular weight distribution in the 
sample if there were any re-distribution of sample at the rotor speed used. Attempt was 
made to reanalyse MVCSN solutions at lower concentrations (0.1-0.3 mg/ml). 
However, the resultant fringe deviations were too small to be adequately interpreted. 
Table 10.2. Values of ýap and ý, ýapn 
(r) (J--* O) for MVCSN at a 
loading concentration of 0.6 mg/ml 
Mw, app f SE Mw, app (r) (J-+0) ± SE 
LVCSN 45000 ± 4000 65000 ± 4000 
Figure, 10.2. Example of Rayleigh interference optical fringe pattern 
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Figure 10.3. M* (r) versus t (g1 for MVCSN (loading concentration 0.6 
mg/ml) 
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10.4 Determination of Intrinsic viscosity, fnl. 
Additional sources of reference are Schott (1995) 
10.4.1 Theory 
Rheology is a term which describes the deformation and movement of matter under the 
influence of stresses and covers the topics of viscosity, elasticity and plasticity. In 
physiology, the rheology of blood and mucus is vitally important in blood circulation and 
mucus transport, respectively. In the development of pharmaceutical products for nasal 
delivery, rheology will influence the spray properties of the liquid drug formulation. 
Viscosity is a measure of the internal friction of a fluid (i. e. a measure of the resistance of 
a liquid to flow). The greater the friction, the greater is the shear or force required to 
move the liquid, thus, high viscosity fluids require more force to move than less viscous 
fluids. Shearing occurs whenever a liquid is physically moved or distributed. Values of 
viscosity are `absolute' when the value can be traced to the measurement of the test results 
in the absolute units of physics (unit of viscosity of: Pascal. second). Absolute values of 
viscosity are independent of the type or make of viscometer used. Capillary- and 
rotational cone and plate viscometers, both of which have been used in this project, can 
be used to measure values of absolute viscosity. The use of a cone and plate viscometer 
to measure the viscosity of a non-Newtonian fluid will yield `apparent' values of 
viscosity since values obtained will depend on the shear rate applied to the sample. Since 
the speed of revolution of the cone (rpm) will govern the shear rate, values of viscosity 
obtained will apply only to the particular rpm used. Thus, to directly compare the 
viscosity of two or more samples requires that the samples were `run' under identical 
conditions. Values of apparent viscosity will vary depending on the equipment used as 
well as on the run conditions. 
Intrinsic viscosity, [ri] 
, 
is a function of viscosity, rq measuring the resistance of a liquid 
to flow. Amacromolecular solution will have a viscosity, il 
, 
which will be higher than 
that of the solvent alone, i1o. The ratio of viscosities 11/rip yields the relative dynamic 
viscosity, rar, which can also be determined with knowledge of the flow times and 
densities of the solution (t and p, respectively) and solvent (to and r0, respectively) as 
follows: 
11r = '11110 = (t "P )/ (t0 " Pp) 
(For very dilute solutions this approximates to t/ to). Calculation of [1] using t/t0 gives 
the kinematic intrinsic viscosity [ii'] which can later be corrected to dynamic viscosity En]. 
An advantage of this method is that tedious determination of the density for each 
concentration of sample is not required. The following functions of il can then be 
calculated: 
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kinematic relative visosity =11'r =t/ to 
kinematic specific viscosity = rl'sp = h'r 
-1 
kinematic reduced specific viscosity = il'red = rI'sp /C 
where c is the solute concentration 
kinematic intrinsic viscosity = [ii'] = limit (c-. 0) il'sp /c 
where limit (c-ýo) is the limit of zero concentration 
[r1'] can be corrected to [q] using the correction factor of Tanford (1955) as follows: 
[Ti] = [(1-'v. Pp) / PO )] + I'll 
where v is the partial specific volume of the macromolecule as described previously. In 
practice [11] is determined by measuring ii'sp at several solute concentrations, plotting 
'1'red versus c (Huggins plot) and extrapolating to zero solute concentration. By 
extrapolation the intermolecular interactions in solution are removed and [11'] will depend 
on the properties of the isolated macromolecule. Alternatively, [71'] can be determined 
from a plot of In 11'r /c versus c (Kraemer plot) and extrapolating to zero solute 
concentration. If dilute solutions are used then the density corrections for the various 
solute concentrations are assumed to be negligible and hence the kinematic intrinsic 
viscosity [ri'] will be equal to the dynamic intrinsic viscosity [71]. The Huggins constant 
(k') can be determined from the equation: 
lisp/c = [ii'] + k'[11]2c 
10.4.2 Method 
Chitosan solutions (LVCSN and MVCSN) were prepared in the range 0.2 to 1.0 mg/ml 
in 0.05 M acetate buffer of pH 4.0. Determinations of [n] were performed using a 
Ubbelohde type micro-viscometer of capacity 3 ml (ref no. 537 13) in conjunction with a 
viscosity measuring system comprising an AVS 310 viscosity measuring unit, a CT 
050/2 transparent thermostatic water bath and an AVS/S measuring stand (Schott-Geräte, 
Hofheim, Germany). A 3.0 ml volume of solvent or chitosan solution was dispensed into 
the lower reservoir of the viscometer using a pipette to deliver 3x1.0 ml volumes into 
the barrel of a1 ml syringe, with its plunger removed, fitted with a 30 cm polypropylene 
cannula (Portex). The syringe plunger was then re-fitted and any droplets of sample in 
the syringe or cannula dispelled into the viscometer reservoir. Measurement of the flow 
times of sample liquids were fully automated. The viscosity measuring system was 
programmed to allow 10 minutes for the sample to reach thermal equilibrium following 
which it would perform and store 10 flow times per sample. The basis of the 
measurement is a follows: 
The sample is pumped up past two measuring levels (light barriers) M1 + M2 in the 
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timing bulb. When liquid has passed the upper level M1, the unit switches off the pump, 
the viscometer is vented and as the sample runs back time measurement starts when the 
meniscus of the sample passes M 1. The change in light intensity is converted to a digital 
electrical signal to start the internal crystal controlled clock with readout display. The 
acquisitioned flow time is then shown on the display and stored internally. In between 
samples the micro-viscometer was washed with 5% decon, 5% acetic acid, three times 
with de-ionized distilled water and finally with ethanol. The viscometer was dried with a 
vacuum line and then with nitrogen. 
For each chitosan, [il'] was determined by plotting 11'red versus c (Huggins plot) and 
extrapolating to zero solute concentration. Since the concentration of chitosan in the 
solutions was low then it was assumed that corrections for the density of the solutions 
was negligible (thus [ii'] was assumed to be equal to [11]). 
10.4.3 Results and Discussion 
The Plot of TT'red versus c (Huggins plot) is given in Figure 10.6. Values of [ii'] and k' 
for each chitosan are given in Table 10.3. The intrinsic viscosity of the medium viscosity 
grade of chitosan (MVCSN) was, as expected based on product specifications, higher 
than that of the low viscosity grade (LVCSN). The Huggins constants (k') for each 
chitosan system was low which is indicative of high asymmetry of the respective 
chitosans (Errington, 1993). For MVCSN, the value of intrinsic viscosity, [11'], 
obtained (1010 ± 11.2 ml/g) was considerably higher than the value reported by 
Errington et al. (1993). Errington et al. (1993) reported that the intrinsic viscosity of a 
SeaCure +210 medium viscosity grade of chitosan glutamate (Pronova Biopolymer A/S), 
similar to the grade used in this study was 540 ± 20 mug. Errington (1993) later reported 
that values of intrinsic viscosity of medium viscosity chitosan glutamate (SeaCure +210) 
varied with variations in the ionic strength of the acetate buffer solution. Increasing 
buffer ionic strength resulted in a decrease in values of intrinsic viscosity (ranging from 
401 ± 25 mug at 0.12 M to 590 ± 69 mug at 0.05 M. The composition of the buffer used 
by Errington at an ionic strength of 0.05 M was similar to that used in this study. There 
were slight differences in the pH of the buffers prepared in the respective studies with 
Errington using buffers at pH 4.3 compared to buffers of pH 4.0 used in this study. 
However, the discrepancies in the values of intrinsic viscosity do not appear to be 
explained by differences in the ionic strength and pH of the respective buffer systems. 
Aspden (1996) using a pH 4.3 acetate buffer of ionic strength 0.1 M reported a value of 
intrinsic viscosity of 930 mug for medium viscosity chitosan glutamate (SeaCure +210) 
and quoted a value obtained from Pronova Biopolymer for this batch of chitosan of 976 
mug. The values reported by Aspden (1996) are comparable with values obtained in this 
study taking into account differences in the ionic strength of the buffers used. The 
relatively large 
variations in results is most likely to be ascribable to the large variation in 
the materials. Degradation of chitosan samples could also account for wide variations in 
the values of intrinsic viscosity obtained. 
234 
Table 10.3. Intrinsic viscosity data for LVCSN and MVCSN 
Reduced viscosity (mV g) 
MVCSN LVCSN 
Concentration 
(me/ml) 
[n 
. red ] (ml/) 
Concentration 
(m ml) 
[TI 
'red ] 
mV 
0.205 1074.32 0.199 401.18 
0.410 1142.83 0.399 399.38 
0.615 1204.59 0.598 406.36 
0.820 1246.76 0.798 415.72 
1.025 1331.54 0.997 430.04 
Intrinsic viscos ity ± SE (mV g) 
[Huggins' constant, k' 
1010±11.2 388±5.7 
0.301 0.251 
Figure 10.6. Plot of tired versus chitosan concentration. c 
1400 
1200 
1000 
E 
800 
600 
400 
200 
G LVCSN 
  
MVCSN 
0 0.2 0.4 u. o W.. 
Chitosan concentration (mg/ml) 
235 
10.5 Measurement of values of apparent viscosity of chitosan 
solutions 
10.5.1 Theory 
Measurement of values of apparent viscosity using a rotational type cone and plate 
viscometer is a relatively rapid means of comparing the viscosities of different solutions. 
As mentioned in Section 10.4, the viscosity of non-Newtonian fluids can only be 
compared at a particular shear rate or rpm. The cone and plate viscometer consists of a 
rotating obtuse angled cone mounted on a spindle in close proximity to a stationary lower 
flat plate which is maintained at constant temperature. Liquid sample, filling a narrow 
triangular gap between the cone and plate, will cause viscous drag on the rotation of the 
cone which exerts a torque, proportional to the shear stress, on a dynamometer 
(calibrated spring). The low angle formed by the cone and plate and the narrow gap- 
width ensures that the shear rate throughout the sample is uniform. 
10.5.2 Methods 
In these studies, measurement of values of intrinsic viscosity was performed to 
investigate the effect of a number of formulation factors on the rheological behaviour of 
chitosan solutions and also to compare the values of viscosity of chitosan formulations. 
Formulation factors such as osmolality, pH and chitosan concentration were investigated. 
The effect of filtering chitosan solutions and the rate of shear applied during measurement 
of viscosity was also evaluated. The influence of temperature on the viscosity of chitosan 
solutions was not examined. However, viscosity measurements are highly temperature 
dependent. The apparent viscosity of chitosan solutions will tend to decrease with an 
increase in temperature although as shown below other factors will contribute to the 
viscosity of chitosan solutions. 
A Brookfield DV III programmable rheometer with CP40 cone and plate (cone angle 0.8°) 
and RHEOCALC software (Brookfield Engineering laboratories, Inc., Massachusetts, 
USA) was used to measure viscosity. The CP40 cone and plate had a sample volume of 
0.5 ml. A Grant thermostatic bath / circulator (Grant Instruments, Cambridge, UK) 
equilibrated at 25°C was used to circulate water throught the plate to maintain a constant 
temperature. The equipment was calibrated prior to use with a (Newtonian) 50 centipoise 
(CPS) (± 1%) Brookfield viscosity standard solution. After dispensing 0.5 ml of 
chitosan solution into the plate and assembling the plate at the pre-set, fixed, level, a 
period of 5 minutes was allowed for the chitosan to reach thermal equilibrium. The 
instrument was operated over a torque range of 10-100%. Wherever possible, viscosity 
measurements were performed towards the upper limits of the torque range to improve 
the accuracy of the instrument, hence the speed of revolution of the cone was 
appropriately adjusted during the studies. However, to directly compare the viscosities of 
two or more solutions required that measurements were performed at the same rpm. 
10.5.2.1 Effect of filtering on the viscosity of chitosan solution 
Solutions of chitosan prepared for use in the preparation of formulations for testing in 
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nasal absorption studies were filtered on 0.45 µm syringe filters prior to use. However, 
it was not known if filtering would alter the viscosity of the chitosan solutions. In this 
study, the viscosity of solutions filtered on 0.45 and 0.2 gm syringe filters and unfiltered 
solutions were compared. Solutions containing 0.5,1.0 and 2.0% MVCSN were 
prepared. All solutions were prepared at pH 4.0 in 0.9% NaCl (pH adjusted during 
formulation preparation using 1M HC1). Measurements of viscosity were performed in 
triplicate. Viscosity measurements of the 0.5,1.0 and 2.0% chitosan solutions were 
performed at 35.0,10.0, and 1.4 rpm, respectively. 
10.5.2.2 Effect of concentration of NaCl on the viscosity of chitosan solutions 
Solutions containing 0.5% MVCSN and different concentrations of sodium chloride 
(NaCl) were prepared at either pH 4.0 in water or at pH 3.4 in I% acetic acid. The 
concentration of NaCl of each system was adjusted between 0-3.0 %. The osmolality of 
each solution was measured prior to use. All measurements were performed at 35.0 rpm. 
10.5.2.3 Effect of pH on the viscosity of chitosan solutions 
Adjustments of the pH of chitosan solutions used in this project had been made using 
HC1 or acetic acid. In this study, the effect of adjusting the pH of chitosan solutions 
using either 1M HCl or 1M acetic acid on solution viscosity were evaluated. All 
solutions were prepared in 0.9% NaCl to which was added a fixed volume (0-150 µl) of 
the appropriate acid and filtered prior to use (0.45 gm). The pH of each solution was 
measured prior to use. All measurements were performed at 10 rpm. 
10.5.2.4 Effect of shear rate on the viscosity of chitosan solutions 
The effect of the shear rate applied to the chitosan solution, adjusted by altering the rpm 
of the cone, during measurement of viscosity was evaluated. Two solutions of 0.5% 
MVCSN at pH 4.0, one prepared in water and the second prepared in 0.9% NaCl, were 
used. Both solutions were filtered through 0.45 gm syringe filters prior to use. Shear 
rate was varied between 75.0-262.5 sec-t by altering rpm between 10.0-35.0 rpm. 
10.5.2.5 Effect of chitosan concentration 
The viscosity of MVCSN, CSN lactate and HVCSN solutions at different concentration 
were measured at 5 rpm. All solutions were prepared at pH 4.0 in 0.05 M acetate buffer 
and filtered (0.45 µm) prior to use. 
10.5.3 Results and Discussion 
10.5.3.1 Effect of filtering on the viscosity of chitosan solution 
The results showed that there was a marginal decrease in viscosity when solutions were 
filtered through 0.2 µm syringe filters (Table 10.4, Figure 10.7). Filtering through 0.45 
µm syringe filters had no effect on the viscosity of 0.5% and 1.0% MVCSN solutions 
although there was a marginal increase in viscosity with 2.0% MVCSN solution. 
However, a one-way ANOVA showed that there was no significant different between 
values of apparent viscosity of solutions filtered through 0.45 or 0.2 µm filters and 
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unfiltered solutions. 
Table 10.4 Effect of filtering on the apparent viscosity of MVCSN solutions 
Mean apparent viscosity (± SD) CPS) 
0.5% MVCSN 1.0% MVCSN 2.0% MVCSN 
5m 35 rpm 2 rpm 10 m 0.5 rpm 1.4 rpm 
Unfiltered 6.9 (t 0.29) 6.7 (±0.08) 27.3 (t 0.56) 26.9 t 0.15) 165.1 (t 2.76) 166.8 t 2.44) 
Filtered 0.45 m 6.9 (t 0.13) 6.7 (±0.07) 27.3 t 0.44) 26.9 (t 0.21) 168.1 t 2.54) 169.4 (t 2.45 
Filtered 0.2 m 6.6 t 0.11) 6.6 ±0.08 26.9 t 0.50) 26.6 t 0.30) 162.9 t 1.60) 165.3 (t 1.781) 
Figure 10.7 Effect of filtering on the apparent viscosity of MVCSN solutions 
A. 0.5% MVCSN B. 1.0% MVCSN C. 2.0% MVCSN 
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10.5.3.2 Effect of concentration of sodium chloride 
Increasing the sodium chloride concentration, hence osmolality, of solutions of MVCSN 
was shown to result in a dramatic decrease in values of apparent viscosity over the range 
0 to 0.3% NaCl (Table 10.5, Figure 10.8). Further increases in the concentration of 
NaCl produced only a small decrease in values of apparent viscosity between 0.3 to 1.1 % 
NaCl. Subsequent increases in NaCl concentration, between 1.1 to 3.0%, had very little 
effect on the apparent viscosity of MVCSN solutions. The apparent viscosity versus 
NaCl concentration profiles of MVCSN solutions prepared in water and 1% acetic acid 
were very similar (Figure 10.? ) despite considerable differences in the osmolalities of 
these solutions (Table 10.5). Thus, it appears that it is the ionic concentration of the 
solution, rather than solution osmolality, which influences the viscosity of chitosan 
solutions. 
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In solution at very low ionic strength, the chitosan molecule will tend to adopt an 
extended conformation due to the repelling effect of each positively charged deacetylated 
unit on neighbouring glucosamine units (Pronova Biopolymer A/S, 1992). An increase 
in ionic strength will tend to reduce the charge repelling effects in the chitosan molecule 
thus favouring a random coil conformation. This will significantly decrease solution 
viscosity due to a reduction in hydrodynamic volume (Muzzerelli, 1977) At low ionic 
strength the conformation of chitosan in solution, hence solution viscosity, is highly 
dependent on ionic strength. Above a certain ionic strength with the chitosan molecule in 
the `full'random coil confirmation, further increase in ionic strength will have little effect 
on molecular conformation, hence on solution viscosity. However, at higher 
concentrations of electroytes, a `salting-out' effect will occur due to the precipitation of 
chitosan out of solution resulting in a decrease in solution viscosity. 
Table 10.5 Effect of NaCl concentration on the apparent viscosity of MVCSN 
solutions 
MVCSN in water (H 4.0) MVCSN in I% acetic acid (H 3.4) 
NaCl Viscosity at 10 rpm Osmolality Viscosity at 10 rpm Osmolality 
conc. (% wtv) (CPS) (Osmol/kg) (CPS) OsmoVk ) 
0 24.5 0.018 24.1 0.181 
0.05 14.2 0.035 14.9 0.200 
0.1 12.3 0.051 12.0 0.216 
0.3 8.7 0.116 8.5 0.284 
0.5 7.8 0.180 8.3 0.340 
0.7 7.2 0.240 7.2 0.413 
0.9 6.8 0.304 7.0 0.477 
1.1 6.3 0.364 6.7 0.539 
1.3 6.3 0.426 6.8 0.601 
1.5 6.3 0.488 6.5 0.666 
1.8 6.1 0.582 6.6 0.764 
2.1 6.3 0.676 6.5 0.855 
2.4 6.3 0.770 6.6 0.951 
2.7 6.3 0.865 6.2 1.043 
3.0 6.3 0.958 6.4 1.141 
Figure 10 
.8 Effect of NaCl concentration on the apparent viscosity of MVCSN 
solutions 
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10.5.3.3 Effect of pH on the viscosity of chitosan solutions 
Altering solution pH, over the range pH 2.1 to 5.3 with 1M HCl or pH 4.1 to 5.3 with 
1M acetic acid, did not effect the apparent viscosity of MVCSN (Table 10.6, Figure 
10.9). However, the solution contained a relatively high concentration of NaCl which 
could have masked the effects on viscosity of changing solution pH. In the previous 
study, looking at the effects of NaCl concentration, at 0% NaCI there was very little 
difference between the MVCSN solutions at pH 4.0 and pH 3.4 (Table 10.5). Aspden 
(1996) showed that at lower NaCI concentration, increasing the pH of a solution of 
chitosan glutamate between pH 3-5 resulted in a decrease in apparent viscosity. Thus, 
the study should be repeated in media containing different concentrations of NaC1 to 
establish the relationship between ionic strength, pH and apparent viscosity. 
Table 10.6 Effect of pH on the apparent viscosity of MVCSN solutions 
H adjusted w ith IM HCl H adjusted with IM acetic acid 
Volume of acid Viscosity at 10 rpm pH Viscosity at 10 rpm pH 
added (1 CPS) (CPS) 
0.0 7 5.3 7.0 5.3 
10.0 7 5.0 6.9 5.0 
20.0 7 4.5 7.0 4.8 
40.0 7.1 4.0 7.0 4.6 
60.0 7 3.5 7.1 4.4 
80.0 7 3.0 7.0 4.3 
100.0 6.9 2.6 7.0 4.2 
150.0 6.9 2.1 7.0 4.1 
Figure 10.9 Effect of-pH on the apparent viscosity of MVCSN solutions 
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10.5.3.4 Effect of shear rate on the viscosity of chitosan solutions 
The apparent viscosities of MVCSN solutions prepared in water was shown to decease 
with an increase in shear rate which demonstrated the pseudoplastic or shear-thinning 
nature of chitosan (Table 10.7, Figure 10.10). However, a solution of MVCSN in 0.9% 
NaCl exhibited negligible pseudoplastic behaviour over the range of shear rates 
investigated. Pseudoplasticity, an example of non-Newtonian flow behaviour of fluids, 
results from the competition between the external forces, i. e. shear rate, and the 
intermolecular and intramolecular forces which influence the behaviour of chitosan in 
solution. At low shear rate, the rate of entanglement and randomisation of chitosan 
polymer chains and the rate of aggregation of particles which occur due to Brownian 
motion far outweigh the rate of disentanglement and alignment of polymer chains and the 
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breaking-up of aggregates and particles due to the application of shear. At very low shear 
rate (usually below lsec-1) the fluid will behave as a Newtonian liquid. However, as 
shear rate increases, progressive breakdown of the polymer structure in solution occurs 
and when this exceeds the rebuilding effect due to Brownian motion the viscosity will be 
dramatically reduced. At an optimal shear rate, the polymer chains will be completely 
disentangled and aligned in the direction of the applied shear and aggregates of particles 
will be fully broken up. Thus, since the residual structure of the polymer is fully broken, 
further increase in shear rate will not result in further decrease in solution viscosity. 
In this study at relatively low shear rate (sec-1), the observed differences in the apparent 
viscosity of the two chitosan solutions was attributable to the differences in the apparent 
viscosities of chitosan solutions at relatively low and high ionic strength (i. e. in water and 
0.9% NaCl, respectively). For chitosan solution in water, the decrease in viscosity will 
occur due to the progressive breakdown of the chitosan structure as outlined above. For 
chitosan in 0.9% NaCl, the random coil conformation of chitosan will significantly 
reduce values of apparent viscosity compared to solutions at low ionic strength. For 
chitosan solutions in 0.9% NaCl progressive increase in shear rate did not result in a 
shear thinning effect. This was presumably due to the viscosity reducing effects 
attributable to ionic strength reaching a maximum such that increase in shear rate did not 
cause further breakdown of chitosan structure. 
Table 10 
.7 Effect of shear rate on the apparent viscosity of MVCSN solutions 
Apparent viscosity (CPS) 
RPM Shear rate (I /sec) MVCSN in water MVCSN in 0.9% NaCl 
10.0 75.0 24.5 6.8 
15.0 112.5 23.2 6.7 
20.0 150.0 17.5 6.7 
25.0 187.5 14.0 6.6 
30.0 225.0 11.7 6.7 
35.0 262.5 10.0 6.6 
Figure 10.10 Effect of shear rate on the apparent viscosity of MVCSN solutions 
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10 5.3.5 Effect of chitosan concentration 
The concentration and viscosity grade of the chitosan used were shown to strongly 
influence the viscosity of chitosan solutions (Table 10.8, Figure 10.11). At equal 
concentration, as expected (refer to Table 2.1), the viscosity of HVCSN was higher than 
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that of MVCSN which in-turn was higher than that of LVCSN. An increase in the 
solution concentration of each grade of chitosan resulted in a non-linear increase in values 
of apparent viscosity. An increase in chitosan concentration will increase the 
hydrodynamic volume of chitosan molecules in solution chains thus increasing solution 
viscosity. 
Table 10.8 Effect of chitosan concentration on values of apparent viscosity 
Apparent viscosity (CPS) At Sm 
Chitosan conc. (% w/v) MVCSN LVCSN HVCSN 
0.1 4.4 
0.2 4.7 10.1 
0.3 19.1 
0.4 12.6 32.5 
0.5 15.4 53.5 
0.6 20.8 
0.8 35.7 
- 
1.0 55.8 6.1 
2.0 10.2 
3.0 26.4 
- 
4.0 62.2 
Figure 10.11 Effect of chitosan concentration on values of apparent viscosity 
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10.6 Conclusions 
The values of MW, app and MW, app(r) (J-+0) of 45,000 and 65,000, respectively have 
drammatically underestimated the molecular weight of MVCSN. Errington (1993) 
reported a molecular weight of 162,000 for the batch of MVCSN used in this project. 
Thus, any future measurement of molecular weights of chitosan should follow the 
procedures of Errington (1993). Intrinsic viscosity measurements showed that the 
intrinsic viscosity of MVCSN was much higher than that of LVCSN (1010 and 388 
mug, respectively). It would have been useful to measure the intrinsic viscosity of each 
grade of chitosan used in this project. Measurement of the apparent viscosities of 
chitosan solutions generally supports claims made in the literature regarding the effect of 
ionic concentration, pH, shear rate and chitosan concentration on values obtained. They 
also highlight the different viscosities of the grades of chitosan employed in this project. 
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CHAPTER 11 
PROJECT OVERVIEW AND SUGGESTED FURTHER STUDIES 
The findings of this project have added to the pool of information reported in the 
literature about the application of the nasal route for the delivery of insulin and other 
peptide drugs. The preliminary studies reported in this project were apparently the first 
studies performed to investigate the potential use of chitosan in nasal delivery systems 
and some of the results generated here were reported by Ilium et al. (1994). 
The efficacy of chitosan in enhancing the nasal absorption of insulin was demonstrated in 
rat and sheep models. In the rat model, insulin / chitosan formulations at pH 
-4 were 
more effective than formulations at pH 
-7 in enhancing intranasal insulin absorption. 
The reduced absorption in the latter formulation which was in the form of a suspension 
was attributed to complex formation between insulin and chitosan. Further investigation 
of the effect of pH on absorption enhancement was not evaluated since pH had to be 
lowered to below pH 5 to obtain solutions formulations of insulin and chitosan. 
However, this could be investigated using an alternative peptide such as salmon 
calcitonin where there does not appear to be a problem with complex formation. This 
may in part be due to the much higher potency of salmon calcitonin compared to insulin, 
thus solution formulations contain much lower concentrations of salmon calcitonin. At 
low ionic concentration, reduction in pH will increase the polycationic behaviour of 
chitosan. Thus, investigation of formulations at different pH would allow the influence 
of the polycationic properties of chitosan on nasal absorption enhancement to be further 
evaluated provided that the formulation components were in solution. 
In the rat model, the performance of chitosan, in terms of the degree of hypoglycaemia 
following dose administration, was second only to that of LPC. However, in the sheep 
model, a formulation incorporating chitosan was much more effective than a formulation 
containing LPC in promoting nasal insulin absorption. These differences were attributed 
to the animal models used to investigate nasal absorption. In the rat model, animals were 
anaesthetised which is likely to impair mucociliary clearance mechanisms. Thus, both 
the chitosan and LPC formulations remain pooled in the nasal cavity thereby increasing 
the residence time of both formulations in the nasal cavity and increasing the intimate 
contact between the formulation and the nasal mucosa. However, in the conscious sheep 
model, where mucociliary clearance mechanisms are not impaired, the relatively poor 
performance of the LPC formulation may be due to faster clearance of the LPC 
formulation from the nasal cavity compared to the clearance of the viscous / bioadhesive 
chitosan formulation. Thus, improved efficacy of chitosan formulations compared to 
LPC formulations in the sheep model are probably attributed to the increased residence 
time of the chitosan formulations in the nasal cavity. Gamma scintigraphic studies using 
radiolabelled chitosan or possibly insulin, would be useful to confirm the increased 
residence time of the formulation in the nasal cavity. 
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Further investigation of nasal delivery systems employing chitosan in the rat and sheep 
models showed that the degree of nasal absorption enhancement was improved by 
increasing the solution concentration of chitosan (MVCSN grade) until an optimal 
concentration was attained. In the rat studies, an optimal range of chitosan 
concentrations was demonstrated. A reduction in insulin absorption in rats at chitosan 
concentrations above the optimal range could be due to the increased viscosity of the 
formulation thereby preventing the spread of the formulation in the nasal cavity and/or 
reducing the rate of release of insulin from the formulation. In vitro studies to investigate 
the rate of insulin release from the insulin / chitosan formulations would be useful to 
evaluate the latter. It would also be useful to assess higher formulation concentrations of 
chitosan in the sheep model to establish if there was an upper limit to the optimal range of 
chitosan concentrations. Further evaluation of nasal insulin / chitosan formulations in 
sheep, suggested that the formulation concentration of chitosan was important for its 
absorption enhancing efficacy and at optimal chitosan concentration nasal insulin 
absorption was limited by the dose concentration of insulin. In both rat and sheep 
models, the nasal administration of hypotonic or isotonic formulations of insulin with 
chitosan did not influence the degree of nasal absorption enhancement attained. 
However, in rats, a hypertonic formulation was shown to further improve nasal insulin 
absorption which was attributed to the combined effects of the chitosan and the increased 
tonicity of the formulation on the nasal membrane. It would be useful to establish if a 
similar effect was observed in the sheep model. 
The grade of chitosan used in the nasal absorption studies appeared to influence the 
degree of absorption enhancement obtained. The rat model appeared to be of limited use 
for these investigations since differences in the absorption enhancing efficacy of a low 
viscosity grade of chitosan lactate and a medium viscosity grade of chitosan glutamate 
were not apparent. In contrast, in the sheep model differences between the two grades 
were observed with the medium viscosity grade performing better than the low viscosity 
grade. There was no difference in the performance of medium viscosity grades of 
glutamate and hydrochloride salts of chitosan (both tested at 0.5% w/v of chitosan salt) 
in sheep although considering the chitosan content of these salt forms (55-65 and 80- 
90% respectively), the glutamate salt form may potentially be the more effective. Aspden 
(1996) showed that in the sheep model, medium viscosity chitosan glutamate performed 
better than low, medium and high viscosity grades of chitosan hydrochloride, at 
concentrations of 0.25% w/v chitosan base. Increasing chitosan concentration to 0.5% 
w/v did not further improve the performance of chitosan glutamate but improved the 
performance of the hydrochloride salts. However, the glutamate salt still appeared to 
possess the greatest absorption enhancing efficacy. 
An elaborate study would be required to evaluate the relationship between the grade of 
chitosan and absorption enhancing efficacy. The use of different molecular weight, 
hence viscosity, fractions of chitosan prepared from the same parent material should be 
considered since it is difficult to directly compare different chitosan salts forms. 
Although the chitosan content of the different salt forms may be equated in terms of the 
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respective content of chitosan base, as in the studies by Aspden, the salt form used is 
likely to influence the behaviour of the chitosan in solution. Aspden (1996) reported that 
compared to medium viscosity chitosan hydrochloride, the intrinsic viscosity of medium 
viscosity chitosan glutamate was much greater than that predicted from its molecular 
weight. This was attributed to the greater influence of the glutamate moiety on molecular 
conformation and hence on solution viscosity than the hydrochloride moiety. Also the 
differences in viscosity observed could be attributed to the higher content of glutamate 
compared to hydrochloride. The importance of viscosity of the formulation should be 
further evaluated since the lower viscosity of the solutions prepared from low viscosity 
grades of chitosan may be the reason for the lower efficacy of nasal absorption 
enhancement. The effect of the degree of deacetylation of the chitosan on nasal 
absorption enhancement should also be fully evaluated. Aspden (1996) reported that 
there was no difference in the absorption enhancing efficacy of different grades of 
chitosan hydrochloride which were either 50% or approximately 85% deacetylated. 
However, these results would seem inconclusive in view of the high variability in values 
of intrinsic viscosity between the grades of chitosan used. Investigation of the effect of 
the degree of deacetylation on nasal absorption enhancing efficacy would best be 
achieved by preparing batches of chitosan of different degree of deacetylation from the 
same parent material. Careful control of the experimental conditions would be required 
since deacetylation can lead to depolymerisation of the chitosan. Depolymerisation 
should be avoided since this will decrease chitosan molecular weight, hence solution 
viscosity, thereby introducing another experimental variable. By optimisation of the 
degree of deacetylation and grade of chitosan employed in the nasal formulation, it may 
be possible to prepare stable formulations of chitosan at higher values of pH. This may 
be favourable if chitosan is to be used in nasal delivery systems for other peptide and 
non-peptide drugs. 
The degree of nasal absorption enhancement was shown to be reasonably reproducible in 
rat and sheep models, in terms of the hypoglycaemic responses following insulin I 
chitosan dose administration. The sheep model is probably better suited for these 
investigations since animals can be reused, thus intra- and inter-animal variability can be 
elucidated. The sheep model is also more likely to allow subtle differences between the 
performance of nasal delivery systems to be evaluated, thus, is better suited for 
optimisation studies. The study could be widened to investigate once daily or multiple 
daily dosing of the insulin /chitosan formulation in the same animals over a longer time 
period. Measurement of both plasma glucose and insulin concentrations should also be 
performed. It is important to establish if the nasal route for intranasal insulin delivery 
remains viable over longer time periods since the treatment of insulin dependent diabetes 
mellitus by this, route would require chronic therapeutic application. 
The demonstration of the transient effect of chitosan on the permeability of the nasal 
membrane in the rat model and the results of the in vitro haemolysis studies are highly 
encouraging and further support the view that chitosan is non-toxic and safe to use in 
nasal delivery systems. The transient nature of chitosan on nasal absorption 
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enhancement should be further evaluated in the rat model. A suitable positive control, 
such as Laureth-9 or LPC solutions which have both been shown in the literature to 
cause membrane damaging effects, should be included to allow the transient effects of 
potentially membrane damaging solutions to be compared with those of chitosan. 
Investigations could also be performed in the sheep model. In sheep, use of nasal sprays 
may be required to overcome difficulties in the delivery of chitosan and insulin 
formulations to the same region of the nasal cavity. However, pre-evaluation studies 
would be required to ensure that the distribution patterns of the viscous chitosan and 
non-viscous insulin solutions in the nasal cavity were similar from the spray devices. 
The sheep could also be anaesthetised during the dosing period and the dosing device left 
in-place in the nasal cavity to ensure that chitosan and insulin solutions were delivered to 
the same region of the nasal cavity. In conscious rats and /or sheep it would be 
interesting to assess the transient effect of chitosan on the nasal membrane following 
chronic administration. The haemolysis studies showed that MVCSN was non- 
damaging to rat erythrocyte membranes at concentrations which were higher than the 
concentrations used in nasal absorption studies. This was encouraging since most 
erythrocyte haemolysis studies reported in the literature (e. g. Chandler, 1992, Jabbal- 
Gill et al, 1994a) have demonstrated severe membrane damage by compounds at 
concentrations which were much lower than the concentrations which were effective for 
nasal absorption enhancement. The haemolysis assay appears to be effective for 
screening the membrane damaging effects of compounds. However, the studies 
performed in this project indicate that values of basal haemolysis are fairly high and thus 
the use of human erythrocytes is recommended (Ilium et al., Unpublished data). 
It would be useful to further investigate toxicological issues in parallel to the nasal 
absorption studies in animal models during the optimisation of nasal delivery systems. 
The appropriate negative (e. g. buffer solution) and positive (e. g. Laureth-9 or LPC 
solution which are known to cause cell damage) controls should be included in the 
studies. Perfusion studies could be performed in the rat to assess damage to the nasal 
mucosa indicated by the detection of concentrations of cellular markers (specific 
membrane bound and cytosolic enzymes) in the perfusate. Nasal washings could also be 
collected in sheep at pre-determined time intervals after dose administration and again 
concentrations of cellular markers measured. However, validation work would be 
required to establish if the concentrations of cellular markers can be detected in each 
system. Histological examination of the nasal mucosae of the rat and sheep models 
following chitosan dose administration should be performed on selected formulations. 
Histological examinations after both acute and chronic administrations of chitosan should 
be performed. Studies reported by Blum et al. (1994) and Aspden (1996) have 
investigated the acute effects of chitosan administration by histological examination but 
have not considered the effects after chronic application. Cilia beat frequency (CBF) 
studies would also be useful. Merkus et al. (1993) suggested that measurement of CBF 
is a valuable tool for evaluating the safety of nasal absorption enhancers. In frog palate 
studies, chitosan was shown to cause a transient slowing of mucociliary transport 
(Aspden et al., 1995a). This would also be expected following nasal administration of 
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chitosan to conscious animal models or humans and may account for the increased 
residence time of these formulations in the nasal cavity. Acute and chronic CBF studies 
are recommended. Toxicity studies in animal models or human subjects should also be 
supported by cell culture models. Artursson et al. (1994) suggested that chitosan 
affected the integrity of epithelial tight junctions in Caco-2 cell monolayers. Dodane et 
al. (1996), proposed that chitosan caused a transient modulation of the permeability and 
structure of the Caco-2 cell layer. Thus, extensive investigations are required to establish 
the precise effect on modulation of the permeability and structure of cell monolayers. 
Again, it is important to establish the effects of chitosan after acute and chronic 
application. The above toxicological investigations are useful for evaluating potential 
problems which may be associated with nasal delivery systems employing chitosan and 
also for evaluating the potential mechanisms of action of chitosan. The topical irritancy 
of chitosan applied to the nasal cavity should be assessed in human volunteers since 
irritant actions of compounds applied nasally may not correlate with the toxicological 
studies. 
Although this project was primarily concerned with the investigation of chitosan as a 
nasal delivery system for insulin, insulin could also be considered as a model peptide. 
Thus, investigation of the nasal absorption of insulin can be used as a general indicator 
of the nasal absorption of other peptide drugs. It was shown that MCSN enhanced the 
nasal absorption of salmon calcitonin (S-CT) in the rat and sheep models. However, the 
nasal absorption of S-CT was assessed indirectly from the hypocalcaemic response 
following nasal dose administration. These studies should be repeated and both plasma 
or serum S-CT and calcium concentrations measured to further evaluate nasal S-CT 
absorption. The nasal absorption of other peptides and proteins, and indeed other drugs, 
could also be investigated. 
This project has demonstrated that chitosan enhances the nasal absorption of insulin in rat 
and sheep models. In the sheep model the bioavailability of nasal insulin, relative to the 
subcutaneous route, was generally less than 5%. However, the hypoglycaemia which 
followed nasal insulin / chitosan dose administration was encouraging and a similar 
degree of efficacy in humans could be feasible for the therapeutic application of nasal 
insulin therapy. A nasal insulin / chitosan formulation could replace or complement 
subcutaneous insulin therapy. In insulin-dependent diabetics, nasal insulin could be 
used to replace injectable insulin before meal times for the control of post-prandial rises 
in glucose blood concentrations. In Type II diabetics, nasal administration of insulin 
could replace the absent early peak of insulin secretion. 
Clearly, full human clinical trial, toxicological and formulation stability evaluation would 
be required and furthermore economic factors associated with scaling-up procedures 
would have to be considered before nasal delivery systems became commercially viable. 
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Appendix 1 
Constituents of reagents used during this project 
14.65 mM phosphate buffer of pH 7.4 
1.904 g Na2HPO4.2H20 (M Wt 178.05)+ 0.616 g NaH2PO4.2H20 (M Wt 
156.01) made upto 1000 ml with water. 
Sodium chloride (NaCI) solutions 
Required concentrations prepared by dilution of 0.9% NaCI (details given in the 
relevant chapter) 
Phosphate buffered saline (PBS) 
Prepared by mixing solutions A and B (given below) until the appropriate pH was 
achieved 
A. In 250 ml water 
B. In 500 ml water 
0.39 g NaH2PO4.2H20 
2.25 g NaCl 
0.89 g Na2HPO4.2H20 
4.5 g NaCl 
Citrate phosphate dexrose adenine buffer (CPD-A) 
£mmol/1) 
Citric acid (monohydrate) 16 
Sodium citrate (dihydrate) 89 
Sodium acid phosphate (dihydrate) 16 
Dextrose (anhydrous) 129 
Adenine 2 
Acetate buffer for hydrodynamics 
(Gram % (w/v) 
0.327 
2.630 
0.251 
2.320 
0.027 
Prepared by mixing solutions of 13.609 g/1 CH3COONa. 3H20 and 5.728 MM 
glacial acetic acid to achieve a pH of 4.0 
